prednisone has been researched along with Disease Exacerbation in 750 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether 2 doses of dexamethasone is as effective as 5 days of prednisolone/prednisone therapy in improving symptoms and quality of life of children with asthma exacerbations admitted to the emergency department (ED)." | 9.24 | Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. ( Arana-Arri, E; Benito, J; Lopez, R; Mintegi, S; Mojica, E; Muñoz, N; Paniagua, N; Tames, M, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 9.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 9.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity." | 9.19 | Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014) |
| "In our initial double-blind, placebo-controlled trial, we randomly assigned patients who had idiopathic pulmonary fibrosis with mild-to-moderate impairment in pulmonary function to receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone; or placebo." | 9.19 | Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. ( Anstrom, KJ; de Andrade, JA; King, TE; Martinez, FJ; Raghu, G, 2014) |
| "To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis." | 9.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis." | 9.16 | Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. ( Anstrom, KJ; King, TE; Lasky, JA; Martinez, FJ; Raghu, G, 2012) |
| "The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT)." | 9.14 | "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. ( Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM, 2010) |
| "PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility." | 9.14 | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. ( Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H, 2009) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 9.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone." | 9.13 | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2008) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 9.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 9.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months, and substantially inhibits progression of radiologic joint damage in patients with early active rheumatoid arthritis and no previous treatment with disease-modifying antirheumatic drugs." | 9.10 | Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. ( Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002) |
| "To evaluate the effects of a 12 month, weight bearing, aerobic exercise program on disease activity, physical function, and bone mineral density (BMD) in women with rheumatoid arthritis (RA) taking low dose prednisone." | 9.09 | A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone. ( Berkowitz, J; Rangno, KK; Wade, JP; Westby, MD, 2000) |
| "The aim of this study was to evaluate the efficacy of fludarabine treatment in patients suffering from refractory rheumatoid arthritis." | 9.09 | Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 9.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| " All of the pediatric trials found that prednisone is not superior to dexamethasone in treating mild to moderate asthma exacerbations." | 8.90 | Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations? ( Biondi, E; Meyer, JS; Riese, J, 2014) |
| "Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy." | 7.91 | Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. ( Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES, 2019) |
| "Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry." | 7.88 | Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis. ( Bao, G; Conn, DL; Easley, KA; Li, S; Tiliakos, A, 2018) |
| "Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population." | 7.79 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. ( Bossuyt, X; Malemba, JJ; Mbuyi Muamba, JM; Mukaya, J; Verschueren, P; Westhovens, R, 2013) |
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 7.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 7.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "In a pilot project 10 patients with advanced cutaneous T-cell lymphomas, who had received a variety of previous treatments, were treated with bexarotene at the departments of dermatology in Münster, Minden and Charité Berlin, Germany." | 7.72 | Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. ( Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W, 2003) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 7.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Although pulse methylprednisolone therapy (PMT) has been used successfully in the management of children with steroid-resistant nephrotic syndrome (SRNS), the relationship between initial presenting findings and renal histological characteristics to the subsequent clinical response to PMT is unknown." | 7.71 | Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. ( Kim, MK; Kirpekar, R; Sibley, RK; Tune, BM; Yorgin, PD, 2002) |
| "Lenalidomide has response rates of 45% in relapsed transformed DLBCL." | 7.01 | Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 6.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer." | 6.27 | Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. ( Autio, K; Basch, E; Cleeland, C; Fizazi, K; Griffin, T; Hao, Y; Kheoh, T; Li, S; Logothetis, CJ; Mainwaring, PN; Meyers, ML; Molina, A; Mulders, P; Rathkopf, D; Ryan, CJ; Shore, N; Smith, MR, 2013) |
| "We hypothesise that early add-on IVIg leads to a greater clinical response after 12 weeks in patients with newly diagnosed myositis, in comparison to prednisone monotherapy." | 5.69 | Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial. ( Bogaards, JA; Colen-de Koning, JCA; de Borgie, C; de Visser, M; Eftimov, F; Evers, SW; Kamperman, RG; Maas, M; Raaphorst, J; van der Kooi, AJ; van Schaik, IN; Verhamme, C; Walter, HAW, 2023) |
| "- Bilirubin has strong anti-inflammatory and antioxidative stress action." | 5.46 | Serum Bilirubin Concentrations in Patients With Takayasu Arteritis. ( Deng, YB; Peng, YF, 2017) |
| "In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.41 | Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. ( Campbell, P; Cavo, M; Cook, M; Crepaldi, A; Dimopoulos, MA; Doyen, C; Fastenau, J; Fujisaki, T; Garg, M; Gries, KS; Grosicki, S; Jakubowiak, A; Knop, S; Kudva, A; Liberati, AM; Losava, G; Lucio, P; Mateos, MV; Nagy, Z; Pour, L; San-Miguel, J; Shelekhova, T; Suzuki, K; Usenko, G; Wang, J; Wroblewski, S; Yoon, SS, 2021) |
| " Secondary and exploratory endpoints will include changes in disease activity scores over time, prednisone dose and biomarkers of inflammation and bone turnover." | 5.34 | Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. ( Askanase, AD; Connolly-Strong, E; Furie, RA; Zhao, E; Zhu, J, 2020) |
| "The phase 3 FIRST trial demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) with an immune-stimulatory agent, lenalidomide, in combination with low-dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.34 | Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. ( Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D, 2020) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 5.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "Rhinocerebral mucormycosis is a rapidly progressive and often fatal infection frequently seen in patients with uncontrolled diabetes mellitus and hematologic malignancies." | 5.34 | Rhinocerebral mucormycosis acquired after a short course of prednisone therapy. ( Ferguson, AD, 2007) |
| "Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL." | 5.33 | Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005) |
| "Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms." | 5.32 | The effect of prednisone on the progression from ocular to generalized myasthenia gravis. ( Goldstein, JM; Knorr, AM; Lesser, RL; Monsul, NT; Patwa, HS, 2004) |
| "This phase II trial evaluated the efficacy of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were not candidates for rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 5.30 | Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. ( Berdeja, JG; Daniel, DB; Erter, J; Flinn, IW; Mace, JR, 2019) |
| "To determine whether 2 doses of dexamethasone is as effective as 5 days of prednisolone/prednisone therapy in improving symptoms and quality of life of children with asthma exacerbations admitted to the emergency department (ED)." | 5.24 | Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations. ( Arana-Arri, E; Benito, J; Lopez, R; Mintegi, S; Mojica, E; Muñoz, N; Paniagua, N; Tames, M, 2017) |
| "The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)." | 5.24 | Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. ( Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS, 2017) |
| "The present multicenter phase II trial evaluated the safety and efficacy of pegylated liposomal doxorubicin (PLD) instead of conventional doxorubicin in standard R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) therapy for elderly patients with diffuse large B-cell lymphoma." | 5.20 | Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. ( Astrow, AB; Durand, JB; Ewer, MS; Fanale, M; Fayad, LE; Fisch, MJ; Fowler, N; Hagemeister, FB; Huang, X; Kwak, LW; Lenihan, DJ; McLaughlin, P; Neelapu, SS; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Wang, M; Younes, A, 2015) |
| "Consolidation with high-dose melphalan and ASCT remains the preferred option in transplant-eligible patients with multiple myeloma, despite a better toxicity profile with chemotherapy plus lenalidomide." | 5.20 | Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. ( Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A, 2015) |
| "610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of prednisone." | 5.19 | A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. ( Allaart, CF; Bijkerk, C; de Buck, MP; de Sonnaville, PB; Goekoop, RJ; Grillet, BA; Harbers, JB; Heimans, L; Huizinga, TW; Speyer, I; van Oosterhout, M; Visser, K; Wevers-de Boer, KV, 2014) |
| "Plasma albuterol was significantly correlated with serum lactate concentration after adjusting for asthma severity." | 5.19 | Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma. ( Aubuchon, K; Ferguson, I; House, SL; Johnson, K; Lewis, LM; Matsuda, K; Schneider, J, 2014) |
| "In our initial double-blind, placebo-controlled trial, we randomly assigned patients who had idiopathic pulmonary fibrosis with mild-to-moderate impairment in pulmonary function to receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone; or placebo." | 5.19 | Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. ( Anstrom, KJ; de Andrade, JA; King, TE; Martinez, FJ; Raghu, G, 2014) |
| "To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis." | 5.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis." | 5.16 | Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. ( Anstrom, KJ; King, TE; Lasky, JA; Martinez, FJ; Raghu, G, 2012) |
| "Children with mild persistent asthma should not be treated with rescue albuterol alone and the most effective treatment to prevent exacerbations is daily inhaled corticosteroids." | 5.15 | Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. ( Bacharier, LB; Bade, E; Boehmer, SJ; Chinchilli, VM; Covar, RA; Friedman, NJ; Guilbert, TW; Heidarian-Raissy, H; Kelly, HW; Lemanske, RF; Malka-Rais, J; Martinez, FD; Mauger, DT; Mellon, MH; Morgan, WJ; Sorkness, CA; Strunk, RC; Szefler, SJ; Taussig, L; Zeiger, RS, 2011) |
| "The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous stem cell transplantation (ASCT)." | 5.14 | "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. ( Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM, 2010) |
| "PURPOSE To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility." | 5.14 | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. ( Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H, 2009) |
| " This trial evaluated the efficacy and safety of AA in combination with prednisone to reduce the symptoms of secondary hyperaldosteronism that can occur with AA monotherapy." | 5.14 | Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. ( Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME, 2010) |
| "This multicenter, open-label, non-comparative phase II trial evaluated the safety and efficacy of salvage therapy with lenalidomide, melphalan, prednisone and thalidomide (RMPT) in patients with relapsed/refractory multiple myeloma (MM)." | 5.14 | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. ( Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G, 2010) |
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| "The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone." | 5.13 | Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. ( Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H, 2008) |
| "To address early and late treatment failures in older patients with diffuse large B-cell lymphoma (DLBCL), we designed a two-stage randomized trial of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) versus rituximab plus CHOP (R-CHOP), with a second random assignment to maintenance rituximab (MR) or observation in responding patients." | 5.12 | Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. ( Cassileth, PA; Cohn, JB; Dakhil, SR; Fisher, RI; Gascoyne, RD; Habermann, TM; Horning, SJ; Morrison, VA; Peterson, BA; Weller, EA; Woda, B, 2006) |
| "We hypothesized that adding 5 days of prednisone to standard therapy for acute pulmonary exacerbations in patients with cystic fibrosis (CF) would result in a more rapid and greater increase in lung function." | 5.12 | Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. ( Aitken, ML; Dovey, M; Emerson, J; Gibson, RL; McNamara, S; Waltz, DA, 2007) |
| "Our previous analysis of patients with early active rheumatoid arthritis (RA) treated with prednisone or placebo revealed the following discrepancy: although a significant retardation of joint damage was observed in the prednisone group compared with the placebo group, no differences in clinical variables between the 2 groups were observed, due to greater use of additional therapy in the placebo group." | 5.11 | The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. ( Bijlsma, JW; Jacobs, JW; Siewertsz van Reesema, DR; van Everdingen, AA, 2004) |
| "To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma." | 5.11 | Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. ( Bosly, A; Bouabdallah, R; Christian, B; Coiffier, B; Fermé, C; Feugier, P; Gaulard, P; Gisselbrecht, C; Lepage, E; Morschhauser, F; Reyes, F; Salles, G; Sebban, C; Solal-Celigny, P; Tilly, H; Van Hoof, A, 2005) |
| "To evaluate the role of serum osteoprotegerin (OPG) as a biochemical marker for disease activity assessment and drug monitoring in patients with rheumatoid arthritis (RA) treated with cyclical etidronate." | 5.10 | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. ( Koivula, MK; Konttinen, YT; Laasonen, L; Mandelin, J; Risteli, J; Valleala, H, 2003) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 5.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "Prednisone, 10 mg/d, provides clinical benefit, particularly in the first 6 months, and substantially inhibits progression of radiologic joint damage in patients with early active rheumatoid arthritis and no previous treatment with disease-modifying antirheumatic drugs." | 5.10 | Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. ( Bijlsma, JW; Jacobs, JW; Siewertsz Van Reesema, DR; van Everdingen, AA, 2002) |
| "We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM)." | 5.09 | Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. ( Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; De Paoli, A; Delfini, C; Di Stasi, M; Giordano, M; Mora, O; Nicoletti, G; Piccinini, L; Riccardi, A; Rinaldi, E; Spanedda, R; Tinelli, C; Valentini, D, 2000) |
| "To evaluate the effects of a 12 month, weight bearing, aerobic exercise program on disease activity, physical function, and bone mineral density (BMD) in women with rheumatoid arthritis (RA) taking low dose prednisone." | 5.09 | A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone. ( Berkowitz, J; Rangno, KK; Wade, JP; Westby, MD, 2000) |
| "The aim of this study was to evaluate the efficacy of fludarabine treatment in patients suffering from refractory rheumatoid arthritis." | 5.09 | Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis. ( Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A, 2000) |
| " The study comprised 22 children (17 boys and 5 girls) with the nephrotic syndrome aged 4-12 years (the mean 9 years) treated with prednisone." | 5.09 | [Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and Helicobacter pylori infection in children with nephrotic syndrome]. ( Borzecka, H; Papierkowski, A; Szczepanowska, A; Zajaczkowska, M; Zbarańska, S; Zinkiewicz, Z, 2001) |
| "Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months." | 5.08 | [The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation]. ( Lacki, JK; Mackiewicz, SH, 1997) |
| " All of the pediatric trials found that prednisone is not superior to dexamethasone in treating mild to moderate asthma exacerbations." | 4.90 | Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations? ( Biondi, E; Meyer, JS; Riese, J, 2014) |
| "5 mg/day prednisone) in the treatment of rheumatoid arthritis is still controversial." | 4.90 | Glucocorticoid treatment in rheumatoid arthritis. ( Rau, R, 2014) |
| "The authors report a 40-year-old Caucasian man with relapsing muscle and skin involvement of dermatomyositis treated with high-dose corticosteroids, taken orally, and methotrexate and human gamma globulin, both administered intravenously." | 4.83 | Acute dermatomyositis with subcutaneous generalized edema. ( Appenzeller, S; Bértolo, MB; Costallat, LT; Werner de Castro, GR, 2006) |
| "Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy." | 3.91 | Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. ( Choi, CW; Choi, H; Kang, KW; Kim, BS; Kim, DS; Lee, BH; Lee, SR; Park, Y; Sung, HJ; Yu, ES, 2019) |
| "Evidence supports using dexamethasone for mild-to-moderate asthma exacerbations in the emergency department, but the effectiveness of dexamethasone versus prednisone for asthmatic patients who are hospitalized is unclear." | 3.91 | Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol. ( Cotter, JM; Dempsey, A; Hoch, H; Moss, A; Reese, J; Szefler, S; Topoz, I; Tyler, A, 2019) |
| "Determine the effect of daily low divided or single daily dose of prednisone on the longitudinal change in the number of tender and swollen joints and HAQ scores in African Americans (AA) with early rheumatoid arthritis (RA) from the Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) 1 Registry." | 3.88 | Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis. ( Bao, G; Conn, DL; Easley, KA; Li, S; Tiliakos, A, 2018) |
| "There is a lack of data on the effect of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy on brain glucose metabolism of diffuse large B-cell lymphoma (DLBCL) patients, as measured by 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)." | 3.83 | Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects. ( Adams, HJ; de Klerk, JM; Dubois, SV; Fijnheer, R; Heggelman, BG; Kwee, TC; Nievelstein, RA, 2016) |
| " Combined immunosuppressive therapy with prednisone and cyclophosphamide might be needed to treat recurrent thrombosis due to Behçet disease." | 3.80 | Recurrent right atrial thrombosis due to Behçet disease. ( Fukuda, K; Kuno, T; Kuwana, M; Murata, M; Ono, T; Satoh, T; Tamura, Y, 2014) |
| "Long-term observation has identified a pattern of continuing relapse in limited stage diffuse large B-cell lymphoma (DLBCL) treated by three cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus involved-field irradiation." | 3.79 | R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. ( Fujimaki, K; Fujisawa, S; Fujita, A; Hagihara, M; Hashimoto, C; Ishigatsubo, Y; Kishimoto, K; Koharazawa, H; Kuwabara, H; Matsuura, S; Miyashita, K; Numata, A; Ogusa, E; Ohshima, R; Sakai, R; Taguchi, J; Takasaki, H; Takemura, S; Tomita, N; Yamazaki, E, 2013) |
| "Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA) but data concerning the effectiveness of treatment with this compound are lacking in the Congolese population." | 3.79 | Treatment of rheumatoid arthritis with methotrexate in Congolese patients. ( Bossuyt, X; Malemba, JJ; Mbuyi Muamba, JM; Mukaya, J; Verschueren, P; Westhovens, R, 2013) |
| "The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents." | 3.78 | Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012) |
| " Despite intensive therapies including corticosteroids and azathioprine, marked progression of the ulcers was noted and large areas of necrosis appeared." | 3.78 | [Cutaneous polyarteritis nodosa--is it really benign?]. ( Berman, E; Halevy, S; Horev, A; Shavit, E, 2012) |
| "The proportion of intravenous drug abusers (IVDA) in HIV-HD (38%) is higher than in French HIV-infected population as a whole (20." | 3.78 | Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. ( Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM, 1995) |
| "The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as a first-line treatment." | 3.77 | A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. ( Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS, 2011) |
| "We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan." | 3.75 | The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. ( Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Ishimaru, F; Kataoka, I; Kiguchi, T; Maeda, Y; Makita, M; Matsuo, K; Nawa, Y; Nishimori, H; Sezaki, N; Shinagawa, K; Sugiyama, H; Sunami, K; Tabayashi, T; Tabuchi, T; Takeuchi, M; Takimoto, H; Tanimoto, M; Togitani, K; Yamane, H; Yamasuji, Y; Yano, T; Yoshino, T, 2009) |
| "We previously reported that prednisone reduced the frequency of generalized myasthenia (GMG) and controlled diplopia without major adverse effects at 2 years in patients with ocular myasthenia gravis (OMG)." | 3.75 | Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. ( Kupersmith, MJ, 2009) |
| "The authors studied a 72-year-old man with polymyalgia rheumatica who, after taking 100 mg of prednisone for 3 months, developed a psychosis followed by dementia." | 3.73 | Steroid dementia: an overlooked diagnosis? ( Sacks, O; Shulman, M, 2005) |
| " Of 33 SL cases, 14 consecutive diffuse large B-cell lymphomas were treated with CHOP (adriamycin, cyclophosphamide, vincristine and prednisone) or CHOP-like chemotherapy regimen." | 3.73 | Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. ( Assaf, E; Azoulay, R; Bosq, J; Cainap, C; Jabbour, E; Koscielny, S; Lapusan, S; Oprea, C; Ribrag, V; Vanel, D, 2005) |
| "To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis." | 3.72 | Development of generalized disease at 2 years in patients with ocular myasthenia gravis. ( Homel, P; Kupersmith, MJ; Latkany, R, 2003) |
| "In a pilot project 10 patients with advanced cutaneous T-cell lymphomas, who had received a variety of previous treatments, were treated with bexarotene at the departments of dermatology in Münster, Minden and Charité Berlin, Germany." | 3.72 | Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. ( Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W, 2003) |
| "Several trials have shown the activity of thalidomide (THAL) in relapsed multiple myeloma (MM) patients failing PBSCT or conventional chemotherapy." | 3.71 | Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. ( Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D, 2002) |
| "Although pulse methylprednisolone therapy (PMT) has been used successfully in the management of children with steroid-resistant nephrotic syndrome (SRNS), the relationship between initial presenting findings and renal histological characteristics to the subsequent clinical response to PMT is unknown." | 3.71 | Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. ( Kim, MK; Kirpekar, R; Sibley, RK; Tune, BM; Yorgin, PD, 2002) |
| " Three of them occurred during pregnancy in prednisone-treated patients with active sarcoidosis." | 3.70 | [Sarcoidosis and pregnancy. A retrospective study of 11 cases]. ( Biousse, V; Chapelon Abric, C; Darbois, Y; de Gennes, C; Ginsburg, C; Godeau, P; Janse Marec, J; Piette, JC; Wechsler, B, 1998) |
| "Despite receiving high-dose intravenous methylprednisolone and oral prednisone for biopsy-proven giant cell arteritis that presented as a severe anterior ischemic optic neuropathy in the right eye, a patient developed progressive ocular ischemia in that eye as well as an ocular ischemic syndrome in the fellow eye." | 3.70 | Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment. ( Girkin, CA; Hellmann, DB; Hwang, JM; Lai, JC; Miller, NR; Perry, JD, 1999) |
| "A case of acute nonlymphocytic leukemia (ANLL) occurring 2 years after the diagnosis of multiple myeloma (MM) that had been treated by only one course of melphalan/prednisone chemotherapy is reported." | 3.69 | Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia. ( Hossfeld, DK; Junge, I; Seeger, D; Weh, HJ, 1996) |
| "Facial swelling, pain, and trismus are the most common postoperative sequelae after mandibular third molar (M3M) surgery." | 3.30 | Three-dimensional facial swelling evaluation of pre-operative single-dose of prednisone in third molar surgery: a split-mouth randomized controlled trial. ( Antonelli, A; Barone, S; Bennardo, F; Giudice, A, 2023) |
| "Lenalidomide has response rates of 45% in relapsed transformed DLBCL." | 3.01 | Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. ( Ansell, SM; Desai, SH; Habermann, TM; Inwards, DJ; Johnston, PB; King, RL; LaPlant, B; Macon, WR; Micallef, I; Nowakowski, GS; Porrata, LF; Wang, Y; Witzig, TE, 2021) |
| "The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis." | 3.01 | Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. ( Appleby, N; Cabes, M; Campo, E; Dreau, H; Ehinger, M; Eyre, TA; Klintman, J; Knight, SJL; Månsson, R; Martín-Subero, JI; Pascua, LL; Popitsch, N; Ridout, K; Robbe, P; Rossi, D; Schuh, A; Stamatopoulos, B; Taylor, JC; Vavoulis, DV, 2021) |
| " Physician-reported incidences of adverse events (AEs) for Cushingoid appearance, hirsutism, weight gain, and behavior change were less for vamorolone than published incidences for prednisone and deflazacort." | 2.94 | Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. ( Arrieta, A; Castro, D; Clemens, PR; Conklin, LS; Damsker, JM; Dang, UJ; Finkel, RS; Gordish-Dressman, H; Guglieri, M; Hagerty, L; Hoffman, EP; Jaros, M; Kerchner, L; Kuntz, NL; Mah, JK; McDonald, CM; Mengle-Gaw, LJ; Morgenroth, LP; Nevo, Y; Ryan, MM; Schwartz, BD; Shale, P; Shimony, M; Smith, EC; Tulinius, M; Webster, R, 2020) |
| "Chronic obstructive pulmonary disease (COPD) is a major public health issue affecting approximately 4% to 7% of the Swiss population." | 2.90 | Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial). ( Abig, K; Bachler, H; Boesing, M; Cattaneo, M; Dieterle, T; Essig, S; Leuppi, JD; Markun, S; Merlo, C; Rutishauser, J; Schuurmans, MM; Senn, O; Ullmer, E; Urwyler, P; Zeller, A, 2019) |
| "The cumulative incidences of visceral metastases were calculated by the Kaplan-Meier method and compared using log-rank testing." | 2.90 | Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. ( Antonarakis, ES; Carducci, MA; Denmeade, SR; Qiu, F; Teply, BA, 2019) |
| " The most common treatment-emergent adverse events were fatigue (32%), decreased appetite (25%), asthenia (18%), back pain (17%), and arthralgia (16%)." | 2.87 | Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. ( Baron, B; Chowdhury, S; de Bono, JS; Elliott, T; Feyerabend, S; Fizazi, K; Grande, E; Hirmand, M; Melhem-Bertrandt, A; Werbrouck, P, 2018) |
| "Median time to radiographic evidence of disease progression was not reached but on sensitivity analysis in 15 patients it was estimated to be 41." | 2.87 | The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. ( Crawford, ED; Francis, PSJ; Kantoff, PW; Londhe, A; McGowan, T; Phillips, J; Ryan, CJ; Shore, ND; Taplin, ME; Underwood, W, 2018) |
| " Long-term use of prednisone has been suggested as one of the mechanisms driving resistance, which may be reversed by switching to another steroid." | 2.87 | Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). ( Attard, G; Castro, E; Cendón, Y; Correa, R; Cruz, JJ; Garcés, T; Grau, G; Gutierrez-Pecharoman, A; Herrera, B; Jayaram, A; López, PP; López-Campos, F; Lorente, D; Lozano, R; Montesa, A; Nombela, MP; Olmos, D; Pacheco, MI; Rivera, L; Romero-Laorden, N; Rosero, A; Saez, MI; Van de Poll, F; Villatoro, R, 2018) |
| "Men with metastatic prostate cancer who have a poor response to initial androgen-deprivation therapy (ADT), as reflected by a prostate-specific antigen (PSA) level higher than 4." | 2.84 | Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. ( Agarwal, N; Deshpande, HA; Flaig, TW; Hussain, MHA; Mitsiades, N; Plets, M; Thompson, IM; Vaishampayan, UN, 2017) |
| "Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) compromise physical activity and quality of life and contribute significantly to health care costs." | 2.84 | Predictors of re-exacerbation after an index exacerbation of chronic obstructive pulmonary disease in the REDUCE randomised clinical trial. ( Engel, B; Leuppi, JD; Rutishauser, J; Schindler, C, 2017) |
| " The aim of the SYNERGY trial was to investigate the effect of custirsen in combination with docetaxel and prednisone on overall survival in patients with metastatic castration-resistant prostate cancer." | 2.84 | Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. ( Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P, 2017) |
| " This analysis of the pivotal phase 3 FIRST trial examined the impact of renally adapted dosing of lenalidomide and dexamethasone on outcomes of patients with different degrees of renal impairment." | 2.82 | Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. ( Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R, 2016) |
| "Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM)." | 2.82 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. ( Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB, 2016) |
| "Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production." | 2.80 | Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. ( Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A, 2015) |
| "Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor." | 2.80 | Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ( Agarwal, N; Agus, D; Bellmunt, J; Borgstein, N; Carcano, F; Cruz, FM; De Bono, J; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fountzilas, G; Jones, R; Lee, SY; Oudard, S; Petrylak, DP; Saad, F; Tejura, B; Ulys, A; Webb, IJ, 2015) |
| "Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer." | 2.80 | Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. ( Akaza, H; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fong, PC; Hart, LL; Jinga, V; Jones, R; MacLean, DB; McDermott, R; Nelson, J; Saad, F; Scher, HI; Suzuki, K; Wang, L; Webb, IJ; Wirth, M, 2015) |
| " Specific adverse events with abiraterone-prednisone were similar between the age subgroups." | 2.80 | Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. ( Carles, J; Griffin, TW; Kheoh, T; Li, J; Molina, A; Mulders, PF; Rathkopf, DE; Ryan, CJ; Smith, MR; Van Poppel, H, 2015) |
| "30 patients presenting to ED with AECOPD were included." | 2.80 | Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. ( Armstrong, P; Clayton-Smith, B; Hardy, M; Marchant, G; Marsh, E; Mukerji, S; Shahpuri, B; Smith, N, 2015) |
| "Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr." | 2.79 | Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). ( Beer, TM; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; Fradet, Y; Griffin, TW; Hainsworth, JD; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mulders, PF; North, S; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, ND; Small, EJ; Smith, MR; Taplin, ME; Todd, MB; Van Poppel, H; Yu, EY; Yu, MK, 2014) |
| "The aim of the present study was to evaluate the efficacy of cyclosporine A (CsA) combined with medium/low dose prednisone in the treatment of progressive immunoglobulin A nephropathy (IgAN)." | 2.79 | Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. ( Guan, GJ; Liu, ZC; Luo, Q; Lv, XA; Xu, L, 2014) |
| " Neutropenia (48%) was the most frequent grade 3 to 4 adverse event (AE); no grade 3 to 4 cardiac AEs were observed." | 2.76 | Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. ( Ardizzoni, A; Boggiani, D; Franciosi, V; Musolino, A; Panebianco, M; Salvagni, S; Vasini, G, 2011) |
| "Chemotherapy was administered until disease progression or unacceptable toxicity." | 2.76 | Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. ( Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R, 2011) |
| "Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy." | 2.75 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. ( Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010) |
| "slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF)." | 2.74 | Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. ( Behr, J; Boissard, G; Buhl, R; Costabel, U; De Vuyst, P; Dekhuijzen, RP; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B, 2009) |
| "Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone." | 2.70 | Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. ( Asmar, L; Berry, W; Dakhil, S; Gregurich, M; Modiano, M, 2002) |
| "The chief clinical characteristics of Graves' disease are hyperthyroidism and ophthalmopathy." | 2.69 | Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. ( Bartalena, L; Bartolomei, MP; Bogazzi, F; Bruno-Bossio, G; Dell'Unto, E; Lepri, A; Manetti, L; Marcocci, C; Martino, E; Nardi, M; Pinchera, A; Rossi, G; Tanda, ML, 1998) |
| "Although chlorambucil slowed disease progression, there was no effect on overall survival." | 2.69 | Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. ( Binet, JL; Cazin, B; Desablens, B; Dighiero, G; Dreyfus, B; Jaubert, J; Leblay, R; Lepeu, G; Leporrier, M; Maloum, K; Navarro, M; Travade, P, 1998) |
| " On the basis of comparisons with other data sets, we hypothesize a dose-response relationship between glucocorticoid dose and PSA decline." | 2.69 | Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. ( Figg, WD; Li, A; Moore, A; Sartor, O; Weinberger, M, 1998) |
| "Osteoporosis has been recognized as an important side effect of long-term and of pulsed steroid application after heart transplantation." | 2.69 | Progression of steroid-associated osteoporosis after heart transplantation. ( Abraham, C; Cremer, J; Demertzis, S; Graeter, T; Haverich, A; Nischelsky, J; Strüber, M; Wagenbreth, I, 1999) |
| "Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone." | 2.69 | Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. ( Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999) |
| " No toxic deaths have occurred." | 2.69 | Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. ( Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000) |
| " Despite increased hematotoxicity, moderate dose escalation is safe for the majority of the patients with G-CSF assistance and standard supportive treatment." | 2.69 | Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). ( Diehl, V; Engel, C; Loeffler, M; Schmitz, S; Tesch, H, 2000) |
| "Twenty eligible patients with NHL and chronic lymphatic leukemia (CLL), resistant to or relapsed after previous protocols of polychemotherapy were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle." | 2.68 | Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia. ( Bairey, O; Blickstein, D; Hadar, H; Lahav, M; Prokocimer, M; Shaklai, M; Shaklai, S; Sulkes, J, 1996) |
| "In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis." | 2.68 | Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. ( Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B, 1996) |
| "In contrast, in four patients with polycystic kidney disease, progression accelerated by 99% +/- 63%." | 2.68 | Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. ( Hill, S; Walser, M, 1997) |
| "Deflazacort-treated patients experienced significantly lower functional decline over 48 weeks." | 2.66 | Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. ( Cox, DA; Darras, BT; Elfring, G; Landry, J; McDonald, CM; McDonnell, E; Peltz, SW; Sajeev, G; Shieh, PB; Signorovitch, J; Souza, M; Yao, Z, 2020) |
| " (iii) Evaluation of the relative risk (RR) and risk difference of serious toxicity defined as adverse events (AEs) with grade ≥ 3 specific AEs." | 2.66 | Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. ( Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M, 2020) |
| "Abiraterone has been proven to be an effective agent used in the management of metastatic castration-resistant prostate cancer, significantly improving overall and progression-free survival." | 2.61 | Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. ( Dubinsky, S; Emmenegger, U; McFarlane, TRJ; McLeod, AG; Thawer, A, 2019) |
| "BACKGROUND Chronic intake of high-dose corticosteroids is associated with multiple adverse clinical effects, including hypertension, insulin resistance, impaired wound healing, immunosuppression, myopathy, and osteoporosis." | 2.58 | Glucocorticoid-Induced Myopathy in a Patient with Systemic Lupus Erythematosus (SLE): A Case Report and Review of the Literature. ( Ochoa, W; Silver, EM, 2018) |
| "While skin rashes are a common presentation of neonatal LCH, other systems or organs may also be involved." | 2.55 | Delayed Treatment Response in a Neonate with Multisystem Langerhans Cell Histiocytosis Case report and review of literature. ( Mandal, A; Mishra, S; Patel, A; Singh, A; Singh, L, 2017) |
| "The volume of metastases, as defined in the CHAARTED study for instance, could be an interesting predictive factor." | 2.55 | Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. ( Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S, 2017) |
| "Pyoderma gangrenosum is an unusual cause of skin ulcerations that wound specialists must be prepared to recognize." | 2.53 | Pyoderma Gangrenosum:Recognition and Management. ( Pompeo, MQ, 2016) |
| "The uncertainty as to whether Langerhans cell histiocytosis is a reactive or a neoplastic disease has resulted in a long-standing debate on this question, and the limited understanding of the pathogenesis of the disease has impeded clinical improvement for patients." | 2.53 | Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications. ( Allen, CE; Chakraborty, R; Zinn, DJ, 2016) |
| "Acute exacerbations of chronic obstructive pulmonary disease (COPD)--characterized by shortness of breath, increased sputum production, increased purulence, or a combination of these signs--are costly and can have major impacts on the patient's health." | 2.53 | Treating and preventing acute exacerbations of COPD. ( Aboussouan, LS; Hatipoglu, US, 2016) |
| "was diagnosed with chronic lymphocytic leukemia (CLL)." | 2.52 | Richter syndrome: an aggressive transformation. ( Streu, E, 2015) |
| "Here we report two cases of follicular lymphoma that transformed to CD30 positive diffuse large B cell lymphoma and review the literature on this topic." | 2.52 | CD 30-positive transformed follicular lymphoma: two case reports and literature review. ( Batlle, A; Climent, F; Colorado, M; Conde, E; Espiga, CR; González Barca, EM; González de Villambrosía, S; Insunza, A; Martin-Sánchez, G; Montes-Moreno, S; Pané-Foix, M; Piris, MA, 2015) |
| "A prednisone-treated systemic flare occurred during the first trimester without later complication." | 2.50 | Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. ( Broussolle, C; Durieu, I; Gerfaud-Valentin, M; Hot, A; Huissoud, C; Seve, P, 2014) |
| "One patient experienced disease progression." | 2.50 | [Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review]. ( Ma, H; Wan, B; Wang, JY; Wu, PJ; Zhu, G, 2014) |
| "In patients with exacerbations of chronic obstructive pulmonary disease (COPD) requiring hospitalisation, 5 days of corticosteroid therapy appears to be as effective as 14 days of corticosteroid therapy for preventing recurrences." | 2.50 | COPD exacerbations: 5 days of corticosteroid therapy. ( , 2014) |
| " The choice of initial prednisone dosage (from 0." | 2.49 | [Treatment of giant cell arteritis]. ( Bienvenu, B; Pugnet, G; Sailler, L, 2013) |
| "Prednisone treatment is often used as the first-line treatment and studies suggest response to treatment in 50-66% of cases." | 2.49 | Common variable immunodeficiency-associated granulomatous and interstitial lung disease. ( Kayser, G; Prasse, A; Warnatz, K, 2013) |
| "Lupus nephritis was present in two cases." | 2.49 | [Three cases of bullous lupus erythematosus]. ( Elomri, N; Elqatni, M; Ghafir, D; Jira, M; Mekouar, F; Sekkach, Y, 2013) |
| "Castration-resistant prostate cancer (CRPC) has historically presented significant challenges to both clinicians and patients in regard to disease progression and consequent management." | 2.49 | Challenges in treating advanced disease. ( Petrylak, DP, 2013) |
| "Drug-induced vasculitis is an inflammation of blood vessels caused by the use of various pharmaceutical agents." | 2.48 | Drug-induced vasculitis: a clinical and pathological review. ( Martinović Kaliterna, D; Radić, J; Radić, M, 2012) |
| "A pathological diagnosis of follicular lymphoma (FL), grade 3A, was made based on a biopsy specimen from the right inguinal lymph node." | 2.47 | CD5-positive follicular lymphoma: a case report and literature review. ( Ichikawa, K; Imai, H; Komatsu, N; Noguchi, M; Sawada, T; Sekiguchi, Y; Wakabayashi, M, 2011) |
| "Acute or progressive sensorineural hearing loss, with or without vertigo and tinnitus, has a considerable impact upon an individual's quality of life." | 2.45 | Idiopathic sensorineural hearing disorders in adults--a pragmatic approach. ( George, DL; Pradhan, S, 2009) |
| "The treatment of autoimmune hepatitis is evolving as the pathogenic pathways that underlie the disease are defined, new immunosuppressive agents are tested, and site-specific molecular interventions become feasible." | 2.44 | Current therapy for autoimmune hepatitis. ( Czaja, AJ; Montano Loza, AJ, 2007) |
| "Although no cure exists for multiple myeloma, current treatments, such as oral melphalan and prednisone, can slow disease progression and prolong overall survival." | 2.44 | Clinical updates and nursing considerations for patients with multiple myeloma. ( Faiman, B, 2007) |
| "The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges between 1% and 37%." | 2.43 | Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. ( Caruso, V; de Gaetano, G; Di Castelnuovo, A; Donati, MB; Iacoviello, L; Mariani, G; Storti, S, 2006) |
| "Autoimmune hepatitis is a chronic inflammatory liver disease that responds well to prednisone alone or in combination with azathioprine." | 2.42 | Autoimmune hepatitis. Making sense of all those antibodies. ( Luxon, BA, 2003) |
| " In case of steroid responsiveness, the risk is the relapse when the steroid dosage is tapered or stopped and the complications related to the treatment which is given to maintain remission." | 2.42 | [Lipoid nephrosis in childhood]. ( Niaudet, P, 2003) |
| "Disease progression was significantly more frequent in patients presenting an immunological event or an M component." | 2.41 | Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. ( Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C, 2002) |
| "Nephrotic patients with primary focal segmental glomerulosclerosis (FSGS) have a poor prognosis with 50% progressing to end stage renal disease (ESRD) over 3 to 8 years." | 2.41 | The treatment of primary focal segmental glomerulosclerosis. ( Korbet, SM, 2000) |
| "Treatment with melphalan and prednisone results in an objective response in 50%-60% of patients." | 2.41 | Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. ( Kyle, RA, 2001) |
| "Acute myelofibrosis (AMF), as defined by an acute panmyelopathy associated with marked megakaryocytic hyperplasia and marrow fibrosis, appears to be a stem cell disorder." | 2.39 | Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature. ( Dunphy, CH; Kitchen, S; Saravia, O; Velasquez, WS, 1996) |
| " Longitudinal changes in outcomes, progression to key disease milestones, and dosing and body composition metrics were analyzed descriptively and in multivariate models." | 1.91 | Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1. ( Frean, M; Freimark, J; Goemans, N; Henricson, EK; Hor, KN; Koladicz, K; Lane, H; Marden, JR; Mayer, OH; McDonald, CM; Miller, D; Signorovitch, J; Trifillis, P; Zhang, A, 2023) |
| "Oral prednisone was gradually tapered off by a diminished dose according to a relatively strict protocol." | 1.91 | HIGH LONG-TERM DRUG-FREE REMISSION RATE FOR ACUTE VOGT-KOYANAGI-HARADA DISEASE WITH AN APPROPRIATE IMMUNOSUPPRESSIVE REGIMEN. ( Cheng, Z; Li, H; Li, X; Liu, T; Tao, Q; Wang, K; Zhang, M; Zhang, X; Zhao, G; Zheng, C, 2023) |
| "Langerhans cell Histiocytosis is a rare neoplastic disease, which occurs mainly in children and adolescents." | 1.91 | [Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents]. ( Ahlmann, M; Albert, M; Barnbrock, AE; Beutel, K; Bochennek, K; Classen, CF; Holzhauer, S; Hutter, C; Lakatos, K; Lehrnbecher, T; Meisel, R; Minkov, M; Porto, L; Vokuhl, C; Vraetz, T, 2023) |
| "The neurologic manifestations of coronavirus disease 2019 (COVID-19) are wide-ranging, including various cranial neuropathies, beyond anosmia and dysgeusia, the exact neuropathological mechanism of which are yet unknown." | 1.62 | Stridor Due to Cranial Nerve X Palsy Progressing to Polyneuropathy in a Teenager With COVID-19. ( Chelius, D; Dean, A; Marri, K; Said, A, 2021) |
| "Although the standard treatment for relapsed DLBCL is high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), the efficacy of this approach for primary refractory DLBCL is not well understood." | 1.62 | Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. ( Fukuhara, S; Hatta, S; Ito, Y; Izutsu, K; Kobayashi, Y; Makita, S; Maruyama, D; Miyagi-Maeshima, A; Munakata, W; Nomoto, J; Suzuki, T; Tajima, K; Taniguchi, H; Tobinai, K; Yuda, S, 2021) |
| "Crescent formation in immunoglobulin A nephropathy (IgAN) has been demonstrated to be a risk factor for worse outcomes." | 1.56 | Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents. ( Chen, J; Li, C; Lin, L; Liu, S; Peng, Z; Xu, H; Zhu, X, 2020) |
| "Remission in systemic lupus erythematosus (SLE) is defined through a combination of 'clinical SLE Disease Activity Index (cSLEDAI)=0', 'physician's global assessment (PGA) <0." | 1.56 | Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. ( Afeltra, A; Bortoluzzi, A; Ceccarelli, F; Conti, F; Dall'Ara, F; Doria, A; Frigo, AC; Frontini, G; Gatto, M; Govoni, M; Iaccarino, L; Margiotta, DPE; Moroni, G; Mosca, M; Saccon, F; Signorini, V; Tincani, A; Zen, M, 2020) |
| "BACKGROUND Most patients with chronic lymphocytic leukemia (CLL) are asymptomatic at diagnosis, but 10% present with B symptoms." | 1.56 | Subcutaneous Masses as an Unusual Manifestation of Relapse in a Case of Atypical Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation and Complex Karyotype: A Diagnostic Dilemma and Treatment Challenge. ( Abdulla, MAJ; Aldapt, MB; Sharaf Eldean, MZ; Shwaylia, HM; Soliman, D; Szabados, L; Yassin, MA, 2020) |
| "Disease activity (per Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)), SLE exacerbations, emergency room visits, hospitalisations, disease damage (per Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), corticosteroids exposure, prednisone dose and immunosuppressive drugs exposure were determined before and after HCQ dose change." | 1.56 | Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. ( Arroyo-Ávila, M; González-Sepúlveda, L; Medina-Cintrón, N; Vázquez-Otero, I; Vilá, LM, 2020) |
| "Treatment with abiraterone acetate or enzalutamide is one of the approved approaches in men with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting." | 1.56 | Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. ( Eterović, D; Omrčen, T; Vrdoljak, E, 2020) |
| "Highest contributors were infections (30%) and medications that may worsen MG (19%), with 24% unattributed." | 1.51 | Factors associated with acute exacerbations of myasthenia gravis. ( Deroche, CB; Govindarajan, R; Gummi, RR; Kukulka, NA, 2019) |
| "Effective inpatient chronic obstructive pulmonary disease (COPD) exacerbation management is critical to appropriately manage health care resources." | 1.51 | Systemic Corticosteroid and Antibiotic Use in Hospitalized Patients With Chronic Obstructive Pulmonary Disease Exacerbation. ( Murphy, JA; Petite, SE, 2019) |
| "Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality." | 1.51 | Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. ( Abrahamowicz, M; Arbillaga, H; Avina-Zubieta, A; Chédeville, G; Fortin, PR; Hitchon, CA; Huber, AM; Hudson, M; Iczkovitz, S; Levy, D; Peschken, CA; Pineau, C; Pope, J; Ross, J; Sayani, A; Silverman, E; Smith, CD; Tucker, L; Wang, Y; Wynant, W; Zummer, M, 2019) |
| "To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender." | 1.48 | Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( Altmann, B; Hohloch, K; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trümper, L; Zettl, F; Ziepert, M, 2018) |
| "Enteric duplication (ED) cysts are rare congenital anomalies of the alimentary canal that present in childhood." | 1.48 | Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst. ( Nair, R; Scialla, W; Sreedhar, A, 2018) |
| "Our EHS-based "COPD PowerPlan" order set included admission, laboratory, pharmacy, and radiology orders for managing AECOPD." | 1.48 | The use of a standardized order set reduces systemic corticosteroid dose and length of stay for individuals hospitalized with acute exacerbations of COPD: a cohort study. ( Bhatt, SP; Davison, PN; Dransfield, MT; Gulati, S; Kalehoff, JP; Kirkpatrick, DP; Wells, JM; Wren, CS; Zouk, AN, 2018) |
| "More than half of patients with Crohn's disease [CD] develop disease complications requiring aggressive medical therapy or surgery over time." | 1.46 | Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course. ( Drylewicz, J; Groenen, MJM; Horjus Talabur Horje, CS; Nierkens, S; Smids, C; van Lochem, EG; Wahab, PJ, 2017) |
| "- Bilirubin has strong anti-inflammatory and antioxidative stress action." | 1.46 | Serum Bilirubin Concentrations in Patients With Takayasu Arteritis. ( Deng, YB; Peng, YF, 2017) |
| "Median proteinuria was 145,05 ± 85,54 mg/kg/24 hours." | 1.46 | [Idiopathic nephrotic syndrome (INS) in children in Dakar: about 40 cases]. ( Dial, CM; Diouf, B; Ka, EHF; Keita, Y; Lemrabott, AT; Moreira, C; Ndiaye, O; Ndongo, AA; Niang, A; Niang, B; Sall, MG; Sow, A; Sylla, A, 2017) |
| "Langerhans cell histiocytosis is a rare systemic disease characterized by the abnormal overproduction of histiocytes that tend to infiltrate single or multiple organ systems leading to significant tissue damage." | 1.46 | Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report. ( Fares, E; Maddah, J; Mansour, MJ; Mokbel, E; Nasr, F, 2017) |
| "To evaluate the effectiveness and safety of mycophenolate mofetil (MMF) as first-line therapy combined with systemic corticosteroids in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease." | 1.46 | Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. ( Abu El-Asrar, AM; Al-Muammar, A; Dosari, M; Gikandi, PW; Hemachandran, S, 2017) |
| "Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients." | 1.43 | Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. ( Binder, M; Hillman, DW; Kohli, M; Kohli, R; Kohli, T; Lee, A; Zhang, BY, 2016) |
| "Abiraterone acetate (AA) has demonstrated improved outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)." | 1.42 | Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. ( Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T, 2015) |
| "Patients with Duchenne muscular dystrophy exhibit progressive cardiac and skeletal muscle dysfunction." | 1.42 | Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. ( Benson, DW; Fleck, RJ; Gao, Z; Hor, KN; Jefferies, JL; Mazur, W; Sticka, JJ; Tandon, A; Taylor, MD; Towbin, JA; Villa, CR; Wong, BL, 2015) |
| "Patients with chronic lymphocytic leukemia or non-Hodgkin’s lymphoma are at risk of infectious diseases of respiratory system because of immunodeficiency." | 1.42 | Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report. ( Maksymiuk, B; Opoka, L; Polaczek, MM; Roszkowski-Sliż, K; Zych, J, 2015) |
| " Details regarding the natural course of this disorder, the effects of specific therapies on its progression, and the optimal therapeutic dosage and duration of prednisone are limited." | 1.42 | Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. ( Amato, AA; Arnold, WD; Barohn, RJ; Dimachkie, MM; Gwathmey, K; Heatwole, CR; Hebert, D; Johnson, NE; Kissel, J; McDermott, MP; McVey, AL; Pasnoor, M, 2015) |
| "Approximately 80% of patients with ulcerative colitis (UC) have intermittently active disease and up to 20% will require a colectomy, but little data available on predictors of poor disease course." | 1.42 | Predictors of Outcome in Ulcerative Colitis. ( Cohen, Z; Croitoru, K; Dinani, A; Greenberg, GR; Knight, J; McLeod, RS; Nguyen, GC; Silverberg, MS; Steinhart, AH; Stempak, JM; Waterman, M; Xu, W, 2015) |
| "Among these abnormalities, minimal change nephrotic syndrome (MCNS) is the most common." | 1.42 | The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome. ( Dinçel, N; Hacıkara, Ş; Kaplan Bulut, İ; Mir, S; Yılmaz, E, 2015) |
| "We describe a patient with metastatic renal cell carcinoma and a history of Crohn's disease who was treated with sunitinib and developed a severe exacerbation of Crohn's disease." | 1.40 | Severe exacerbation of Crohn's disease during sunitinib treatment. ( Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ, 2014) |
| "Rituximab is used for the treatment of granulomatosis with polyangiitis (GPA), historically known as Wegener's granulomatosis." | 1.40 | Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. ( Kim, J; Kim, YJ; Malm, IJ; Mener, DJ; Seo, P, 2014) |
| "Pauci-immune glomerulonephritis is rare in African Americans (AA) and the clinical presentation and treatment outcomes of vasculitis have not been well described." | 1.40 | Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. ( Falk, RJ; Geetha, D; Hogan, SL; Hu, Y; McGregor, JA; Poulton, CJ; Seo, P, 2014) |
| "Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel." | 1.40 | Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014) |
| "Both acute pancreatitis and diffuse alveolar haemorrhage are rare conditions associated with systemic lupus erythematosus (SLE)." | 1.40 | Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. ( Gonzalez-Echavarri, C; Pernas, B; Ruiz-Irastorza, G; Ugarte, A, 2014) |
| "People living with HIV/AIDS (PLWHA) are at a higher risk of developing non-Hodgkin lymphoma (NHL)." | 1.40 | Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era. ( Adamski, M; Gunthel, C; Mosunjac, M; Nguyen, ML; Silverton, A, 2014) |
| "Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules." | 1.40 | Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. ( Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H, 2014) |
| "Histoplasmosis is an endemic mycosis with most cases of clinical illness reported in North and Central America." | 1.40 | The intricate relationship of histoplasmosis and sarcoidosis: a case report. ( Crook, TJ; Mathur, P; Zurlo, JJ, 2014) |
| "Treatment with prednisone or/and immunosuppressive drugs significantly reduced the frequency of CD4(+)CXCR5(+), CD4(+)CXCR5(+)PD-1(+) TFH cells and serum IL-21 level, but increased IL-4 and IL-10 levels in the patients." | 1.40 | Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy. ( Ayana, DA; Jiang, Y; Liu, Y; Qu, Z; Zhao, P, 2014) |
| "Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0." | 1.40 | Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. ( Alba, MA; Butjosa, M; Cid, MC; Corbera-Bellalta, M; Espígol-Frigolé, G; García-Martínez, A; Hernández-Rodríguez, J; Planas-Rigol, E; Prieto-González, S; Tavera-Bahillo, I, 2014) |
| "Epidemiologically, COPD exacerbations exhibit seasonal patterns peaking at year-end." | 1.39 | Detection of COPD Exacerbations and compliance with patient-reported daily symptom diaries using a smart phone-based information system [corrected]. ( Coyle, PV; de Verdier, MG; Higenbottam, T; Hussack, P; Jenkins, M; Johnston, NW; Lambert, K; Lewis, J; McIvor, RA; Newbold, P; Norman, GR, 2013) |
| "Eighty patients with pemphigus vulgaris, 47 with pemphigus foliaceus, and 7 with paraneoplastic pemphigus were included." | 1.39 | Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. ( Almugairen, N; Bedane, C; D'incan, M; Duvert-Lehembre, S; Hospital, V; Houivet, E; Joly, P; Picard, D; Tronquoy, AF, 2013) |
| "The progression from DLE to systemic lupus erythematosus has been reported in up to 28% of patients." | 1.39 | Pulmonary hemorrhage in a patient initially presenting with discoid lupus. ( Jiménez-Encarnación, E; Vilá, S; Vilá-Rivera, K, 2013) |
| "Primary pulmonary MALT lymphoma exhibited an indolent clinical course." | 1.39 | Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population. ( Hattori, Y; Ishigatsubo, Y; Ishii, Y; Matsumoto, C; Ogusa, E; Takasaki, H; Tomita, N, 2013) |
| "We document a high incidence of aseptic bone necrosis, possibly related to prednisolone." | 1.38 | Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. ( Aurlien, E; Blystad, AK; Fiskvik, IH; Fosså, A; Hole, KH; Holte, H; Ikonomou, IM; Kolstad, A; Lauritzsen, GF, 2012) |
| "Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP." | 1.38 | Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. ( Berkahn, L; Child, N; O'Carroll, M, 2012) |
| "Oral prednisone was administered to all 5 patients (median starting dose, 60 mg/d; range, 25-80 mg/d)." | 1.37 | Vasculitis of the gastrointestinal tract in chronic periaortitis. ( Calamia, KT; Hunder, GG; Matteson, EL; Miller, DV; Pipitone, N; Salvarani, C; Warrington, KJ, 2011) |
| "There were 70 IgA nephropathy patients of whom 46 were men." | 1.37 | Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran. ( Broomand, B; Najafi, I; Salimi, BH; Soleymanian, T, 2011) |
| "There were no CNS recurrences in the three patients who received CNS prophylaxis." | 1.37 | Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. ( Fukuhara, S; Kim, SW; Kobayashi, Y; Maeshima, AM; Maruyama, D; Matsuno, Y; Mori, M; Munakata, W; Taniguchi, H; Tanosaki, R; Tobinai, K; Watanabe, T, 2011) |
| "Renal sarcoidosis is rare and may lead to renal failure in less than 3% of patients." | 1.37 | [Renal failure in sarcoidosis]. ( Al Hamany, Z; Bayahia, R; Benamar, L; Ouzeddoun, N; Sadek, BH; Sqalli, Z, 2011) |
| "Adult Langerhans cell histiocytosis (LCH) is a rare disease." | 1.36 | MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. ( Agostinelli, C; Baccarani, M; Broccoli, A; Castellucci, P; Derenzini, E; Fanti, S; Fina, MP; Gandolfi, L; Lopci, E; Pellegrini, C; Pileri, S; Stefoni, V; Venturini, F; Zinzani, PL, 2010) |
| "Eight patients died due to disease progression, and the median overall survival was 70." | 1.36 | Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. ( Kim, K; Kim, SJ; Kim, WS; Ko, YH; Won, YW, 2010) |
| "In patient B, progression of renal cell carcinoma was found more than a half year later." | 1.36 | [Sweet syndrome in underlying malignancy]. ( Dercksen, MW; Nijziel, MR; Prins, M; ten Oever, J; van Hirtum, PV; Vreugdenhil, G, 2010) |
| "Pyoderma gangrenosum is a rare, chronic, progressive and noninfectious necrosis of skin with an unclear etiology." | 1.35 | [Pyoderma gangrenosum--an interdisciplinary diagnostic problem]. ( Dziankowska-Bartkowiak, B; Jurałowicz, P; Kondras, K; Kondras, M; Modzelewski, B; Torzecka, JD; Waszczykowska, E, 2008) |
| " Optimal dosing for infliximab in PUK has not been established, and increasing dose frequency to every 4 weeks may be necessary." | 1.35 | Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. ( Keystone, EC; Ma, JJ; Odorcic, S, 2009) |
| "Patients with orthostatic intolerance, anhidrosis, constipation, urinary dysfunction, sicca syndrome and pupillary dysfunction had higher antibody titers than subjects that did not (P<0." | 1.35 | Antibody titers predict clinical features of autoimmune autonomic ganglionopathy. ( Freeman, R; Gibbons, CH, 2009) |
| "In this case, adult-onset nemaline myopathy was probably the primary disease process." | 1.35 | Adult nemaline myopathy with trabecular muscle fibers. ( de Armond, SJ; Irodenko, VS; Layzer, RB; Lee, HS, 2009) |
| "Prednisone was started during the ambulant phase at age 3." | 1.35 | Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. ( de Groot, IJ; Overweg-Plandsoen, WC; Straathof, CS; van den Burg, GJ; van der Kooi, AJ; Verschuuren, JJ, 2009) |
| "Extraintestinal manifestations of Crohn's disease such as erythema nodosum and pyoderma gangrenosum are well recognized and appreciated." | 1.35 | Clinical spectrum of vulva metastatic Crohn's disease. ( Buchman, AL; Collyer, J; Leu, S; Mirowski, GW; Schlosser, B; Smidt, A; Stika, CS; Sun, PK; Vanagunas, A, 2009) |
| "Maintenance therapy of severe pediatric systemic lupus erythematosus (SLE) usually consists of azathioprine and prednisone ." | 1.35 | Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. ( Amann, K; Benz, K; Dittrich, K; Dötsch, J; Ross, S, 2009) |
| "Patients who developed renal and CNS disease more than 1 year after diagnosis had higher SLEDAI scores at disease onset." | 1.35 | Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. ( Benseler, SM; Harvey, E; Hebert, D; Hiraki, LT; Silverman, ED; Tyrrell, PN, 2008) |
| "Celiac disease is the most common severe food intolerance in the Western world and is due to gluten ingestion in genetically susceptible children and adults." | 1.35 | [Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]. ( Belda, O; Garrido, A; Giráldez, A; Márquez, JL; Trigo, C; Verdejo, C, 2008) |
| "Elephantiasis is a very unusual presentation of pretibial myxoedema and its occurrence doesn't depend to the intensity of thyrotoxicosis and its evolution." | 1.34 | [Elephantiasic pretibial myxoedema: study of five cases]. ( Bocoum, TI; Diallo, M; Dieng, MT; Kane, A; Ndiaye, B; Niang, SO, 2007) |
| "Lipid abnormalities in patients with systemic lupus erythematosus (SLE) are common and are likely to be one of the causes of premature atherosclerosis in these patients." | 1.34 | Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. ( Beyene, J; Feldman, B; McCrindle, B; Sarkissian, T; Silverman, ED, 2007) |
| "The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications." | 1.34 | [Our experiences in treating patients with Hodgkin disease in the last decade]. ( Gergely, L; Illés, A; Keresztes, K; Miltényi, Z; Ress, Z; Simon, Z; Vadász, G; Váróczy, L, 2007) |
| "Thalidomide is a promising agent that may exert a therapeutic benefit in HS." | 1.34 | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. ( Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I, 2007) |
| "Treatment with prednisone and azathioprine may lead to a rapid improvement in aminotransferase levels." | 1.34 | Development of autoimmune hepatitis in primary biliary cirrhosis. ( Gossard, AA; Lindor, KD, 2007) |
| "Rhinocerebral mucormycosis is a rapidly progressive and often fatal infection frequently seen in patients with uncontrolled diabetes mellitus and hematologic malignancies." | 1.34 | Rhinocerebral mucormycosis acquired after a short course of prednisone therapy. ( Ferguson, AD, 2007) |
| "This case demonstrates that lymphomatoid granulomatosis is still a chemotherapy-resistant disease in some patients despite addition of rituximab." | 1.34 | Failure of CHOP with rituximab for lymphomatoid granulomatosis. ( Oosting-Lenstra, SF; van Marwijk Kooy, M, 2007) |
| "Susac syndrome is a rare disorder with a clinical triad of encephalopathy, branch retinal artery occlusions, and hearing loss." | 1.34 | [Susac syndrome and ocular manifestation in a 14-year-old girl]. ( Laroche, L; Momtchilova, M; Pelosse, B; Saliba, M, 2007) |
| "Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL." | 1.33 | Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. ( Best, JH; Hornberger, JC, 2005) |
| "Treatment of Takayasu's arteritis remains a demanding challenge to clinicians." | 1.33 | Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. ( Hoffmann, U; Rieger, J; Tatò, F, 2005) |
| "A total of 49 boys with Duchenne muscular dystrophy, between the age of 12 and 15 yrs, who were observed over a 7-yr period were reviewed retrospectively." | 1.33 | Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. ( Balaban, B; Carry, T; Clayton, GH; Matthews, DJ, 2005) |
| "Two of the patients died of disease progression." | 1.33 | Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. ( Ishikura, S; Kitadai, Y; Kobayashi, Y; Matsuno, Y; Mera, K; Nakamura, S; Ochiai, A; Oda, I; Ohtsu, A; Suzumiya, J; Tobinai, K; Yokoi, T; Yoshino, T, 2006) |
| "Fibrillary glomerulonephritis is a rarely diagnosed disease with clinical manifestations such as proteinuria, microscopic haematuria, nephrotic syndrome and impairment of renal function." | 1.33 | Fibrillary glomerulonephritis in a patient with type 2 diabetes mellitus. ( Gielen, GA; Mudde, AH; Steenbergen, EJ; Wetzels, JF, 2006) |
| " There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors." | 1.33 | Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. ( Belkacémi, Y; Bolla, M; Castelain, B; Knobel, D; Landmann, C; Oner, FD; Ozsahin, M; Poortmans, P; Tsang, RW; Zouhair, A, 2006) |
| "Reactive hemophagocytic syndrome (HS) occurs mainly in the setting of serious infections and lymphomas." | 1.33 | Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. ( Amoura, Z; Bader-Meunier, B; Delfraissy, JF; Godeau, B; Goujard, C; Harmouche, H; Khellaf, M; Lambotte, O; Manceron, V; Piette, JC, 2006) |
| "Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group." | 1.33 | Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. ( Choi, CW; Jung, KY; Kim, BS; Kim, CY; Kim, IS; Kim, JS; Kim, SJ; Seo, HY; Seol, HR; Sung, HJ, 2006) |
| "Sclerosing cholangitis is a potential complication of Langerhans'cell histiocytosis, mainly in its multivisceral form." | 1.32 | [Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis]. ( Hayem, G; Meyer, O; Pagnoux, C; Palazzo, E; Roux, F, 2003) |
| "Treatment strategies in Hodgkin's disease have an impact on different risk factors." | 1.32 | Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90. ( Dieckmann, K; Heinzl, H; Hofmann, J; Pötter, R; Schellong, G; Wagner, W, 2003) |
| "Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with systemic lupus erythematosus, as well as in adults." | 1.32 | Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. ( Lindsley, CB; Samad, AS, 2003) |
| "Prednisone was used by 87." | 1.32 | Accrual of organ damage over time in patients with systemic lupus erythematosus. ( Gladman, DD; Ibañez, D; Rahman, P; Tam, LS; Urowitz, MB, 2003) |
| "Association with an optic neuropathy is uncommon." | 1.32 | [Bilateral optic neuropathy in a case of primary Gougerot Sjögren's syndrome]. ( El Afrit, MA; Kraiem, A; Lamloum, M; Loukil, I; Mazlout, H; Trojet, S, 2003) |
| "Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms." | 1.32 | The effect of prednisone on the progression from ocular to generalized myasthenia gravis. ( Goldstein, JM; Knorr, AM; Lesser, RL; Monsul, NT; Patwa, HS, 2004) |
| " Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab." | 1.32 | Safety of rituximab therapy during the first trimester of pregnancy: a case history. ( Elinder, G; Kimby, E; Sverrisdottir, A, 2004) |
| "IgA nephropathy is one of the most common causes of glomerulonephritis in the world and is characterized histologically by the deposition of polymeric forms of IgA within the mesangium and in some cases along the glomerular capillary wall." | 1.32 | Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy. ( Hennigar, RA; Tumlin, JA, 2004) |
| "A diagnosis of seronegative Wegener's granulomatosis was made and the patient received a combination of prednisone and cyclophosphamide with clinical improvement and clearance of the radiological lesions in the lungs." | 1.32 | Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis. ( Amariglio, N; Amir, G; Cohen, Y; Polliack, A; Schibi, G, 2004) |
| "A final diagnosis of acute lymphoblastic leukemia (ALL) was established in a fourth, repeated bone marrow biopsy performed more than 2 months after the first presenting symptom appeared." | 1.32 | Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia. ( Goldschmidt, N; Gural, A; Kornberg, A; Paltiel, O; Shopen, A; Spectre, G, 2004) |
| "In B-cell chronic lymphocytic leukemia (CLL) a high Bcl-2/Bax ratio contributes to death defiance." | 1.31 | Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. ( Moshynska, O; Sankaran, K; Saxena, A; Sheridan, DP; Viswanathan, S, 2002) |
| "Myasthenia gravis is a life-threatening disease as evidenced by the death of one of our patients." | 1.31 | The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. ( Buncic, JR; Mullaney, P; Smith, R; Vajsar, J, 2000) |
| "Supradiaphragmatic MALT lymphoma is less common and its natural history is not well defined." | 1.31 | Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. ( Cabanillas, F; Cox, JD; Ha, CS; Hess, M; Liao, Z; Manning, JT; McLaughlin, P, 2000) |
| "Serpiginous choroiditis is a very rare ocular disease with an unknown etiology." | 1.31 | [Serpiginous choroiditis--the diagnostic problems]. ( Dragomir, M; Selaru, D; Stângu, C, 2000) |
| "Disease progression was arrested with systemic prednisone and methotrexate before eyelid reconstruction was performed." | 1.31 | Destructive eyelid lesions in sarcoidosis. ( Bernardini, F; Kersten, RC; Kulwin, DR; Moin, M, 2001) |
| "Responses to treatment and disease progression were determined by comparing scores with baseline scores." | 1.31 | Oral lichen planus: patient profile, disease progression and treatment responses. ( Chainani-Wu, N; Lozada-Nur, F; Mayer, P; Silverman, S; Watson, JJ, 2001) |
| " In order to obtain a corticosteroid-sparing effect, new studies are necessary to evaluate a reduced initial dosage of corticosteroids." | 1.31 | [Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose]. ( Barrier, JH; Chevalet, P; de Wazières, B; Duhamel, E; el Kouri, D; Glémarec, J; Hamidou, M; Jégo, P; Maugars, Y; Planchon, B; Rodat, O, 2001) |
| "Dapsone was the most commonly used drug (51 patients), followed by methotrexate (24 patients), azathioprine (23 patients), and cyclophosphamide (15 patients); prednisone, always given as adjunctive treatment, was used in 17 patients." | 1.31 | The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. ( Ahmed, AR; Baltatzis, S; Foster, CS; Miserocchi, E; Roque, MR, 2002) |
| "Proptosis and 6th nerve palsy is very uncommon presentation." | 1.31 | Multiple myeloma presenting as proptosis and sixth nerve palsy. ( Multani, LS; Neki, NS; Sharma, N; Sharma, RK, 2001) |
| "Precursor B cell lymphoblastic lymphoma has not been previously reported as a form of posttransplant lymphoproliferative disease." | 1.31 | Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease. ( Borges, E; Ferry, JA; Friedmann, AM, 2002) |
| "The major risk factors for disease progression were late stage of disease (Stage III) at presentation and radiographic extent of the lesion (>200 degrees), regardless of diagnosis." | 1.30 | Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. ( Fairbank, AC; Hungerford, DS; Mont, MA; Petri, M, 1997) |
| "From 536 patients with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasis), seven were identified as having peripheral neuropathy not attributable to another cause." | 1.30 | A case-control and nerve biopsy study of CREST multiple mononeuropathy. ( Dyck, PJ; Hunder, GG, 1997) |
| "Multiple myeloma was the cause of death in four patients; one patient died of systemic amyloidosis." | 1.30 | Primary systemic amyloidosis with delayed progression to multiple myeloma. ( Gertz, MA; Kyle, RA; Rajkumar, SV, 1998) |
| "One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved." | 1.30 | Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. ( Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE, 1999) |
| "Patients with types I and III MPGN did not differ in age at apparent onset, age at diagnosis, or interval from apparent onset of symptoms to diagnosis (biopsy)." | 1.30 | Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. ( Braun, MC; Strife, CF; West, CD, 1999) |
| "Forty-eight patients with syphilitic labyrinthitis have been treated and followed up for periods of six months to 25 years; interpretation of the hearing results must be in the light of the natural history of this condition which is perceived to be progression of hearing loss to profound deafness." | 1.29 | Syphilitic labyrinthitis--an update. ( Adams, DA; Chan, YM; Kerr, AG, 1995) |
| "Among children with lupus nephritis, those with Class IV disease, hypertension, high creatinine levels, and low C3 complement levels at the time of diagnosis are at increased risk for ESRD." | 1.29 | Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. ( Ahmad, H; Balachandra, S; Baqi, N; Moazami, S; Singh, A; Tejani, A, 1996) |
| " Two patients developed exacerbation of hepatitis when the dosage of prednisolone was reduced after they had ten weeks of high dose prednisolone." | 1.29 | Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. ( Chong, R; Goh, YT; Lee, LH; Ng, HS; Tan, P; Wong, GC, 1996) |
| "Prednisone dosage was lower in diabetics with EOD at 6 months, but did not differ among the three groups at 12 months." | 1.29 | Heart transplantation in patients with diabetic end-organ damage before transplantation. ( Aleksic, I; Blanche, C; Czer, LS; Dalichau, H; Freimark, D; Nessim, S; Nusser, P; Takkenberg, JJ; Trento, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.13) | 18.7374 |
| 1990's | 71 (9.47) | 18.2507 |
| 2000's | 260 (34.67) | 29.6817 |
| 2010's | 348 (46.40) | 24.3611 |
| 2020's | 70 (9.33) | 2.80 |
| Authors | Studies |
|---|---|
| Desai, SH | 1 |
| LaPlant, B | 1 |
| Macon, WR | 1 |
| King, RL | 1 |
| Wang, Y | 4 |
| Inwards, DJ | 2 |
| Micallef, I | 1 |
| Johnston, PB | 1 |
| Porrata, LF | 1 |
| Ansell, SM | 2 |
| Habermann, TM | 2 |
| Witzig, TE | 2 |
| Nowakowski, GS | 1 |
| Chieng, H | 1 |
| Hafner, JP | 1 |
| Mccarthy, L | 1 |
| Ibrahim, A | 1 |
| Itty, R | 1 |
| Chong, WH | 1 |
| Saha, B | 1 |
| Conuel, E | 1 |
| Bachy, E | 1 |
| Camus, V | 1 |
| Thieblemont, C | 2 |
| Sibon, D | 1 |
| Casasnovas, RO | 1 |
| Ysebaert, L | 1 |
| Damaj, G | 1 |
| Guidez, S | 1 |
| Pica, GM | 1 |
| Kim, WS | 3 |
| Lim, ST | 1 |
| André, M | 1 |
| García-Sancho, AM | 1 |
| Penarrubia, MJ | 1 |
| Staber, PB | 1 |
| Trotman, J | 1 |
| Hüttmann, A | 2 |
| Stefoni, V | 3 |
| Re, A | 1 |
| Gaulard, P | 2 |
| Delfau-Larue, MH | 1 |
| de Leval, L | 1 |
| Meignan, M | 1 |
| Li, J | 9 |
| Morschhauser, F | 2 |
| Delarue, R | 2 |
| Dean, A | 1 |
| Said, A | 1 |
| Marri, K | 1 |
| Chelius, D | 1 |
| Li, Y | 4 |
| Fu, R | 1 |
| Gao, J | 1 |
| Wang, L | 4 |
| Duan, Z | 1 |
| Tian, L | 1 |
| Ge, H | 1 |
| Ma, X | 2 |
| Zhang, Y | 3 |
| Li, K | 1 |
| Xu, P | 1 |
| Tian, X | 1 |
| Chen, Z | 1 |
| Zhou, X | 1 |
| Li, X | 2 |
| Ting, CY | 1 |
| Tan, SY | 1 |
| Gan, GG | 1 |
| Zain, SM | 1 |
| Pung, YF | 1 |
| Ong, DB | 1 |
| Bee, PC | 1 |
| Solli, E | 1 |
| Doshi, H | 1 |
| Elze, T | 1 |
| Pasquale, LR | 1 |
| Branco, J | 1 |
| Wall, M | 1 |
| Kupersmith, M | 1 |
| Ugarte-Gil, MF | 3 |
| Hanly, J | 1 |
| Urowitz, M | 1 |
| Gordon, C | 1 |
| Bae, SC | 1 |
| Romero-Diaz, J | 2 |
| Sanchez-Guerrero, J | 2 |
| Bernatsky, S | 1 |
| Clarke, AE | 2 |
| Wallace, DJ | 1 |
| Isenberg, DA | 1 |
| Rahman, A | 1 |
| Merrill, JT | 2 |
| Fortin, PR | 2 |
| Gladman, DD | 3 |
| Bruce, IN | 1 |
| Petri, M | 2 |
| Ginzler, EM | 1 |
| Dooley, MA | 1 |
| Ramsey-Goldman, R | 1 |
| Manzi, S | 1 |
| Jönsen, A | 1 |
| van Vollenhoven, RF | 1 |
| Aranow, C | 1 |
| Mackay, M | 1 |
| Ruiz-Irastorza, G | 3 |
| Lim, S | 1 |
| Inanc, M | 1 |
| Kalunian, K | 1 |
| Jacobsen, S | 1 |
| Peschken, C | 1 |
| Kamen, DL | 1 |
| Askanase, A | 1 |
| Pons-Estel, BA | 2 |
| Alarcón, GS | 3 |
| Bi, Z | 2 |
| Cao, Y | 2 |
| Gui, M | 2 |
| Lin, J | 4 |
| Zhang, Q | 2 |
| Ji, S | 2 |
| Bu, B | 2 |
| McDonald, CM | 3 |
| Mayer, OH | 2 |
| Hor, KN | 2 |
| Miller, D | 1 |
| Goemans, N | 1 |
| Henricson, EK | 1 |
| Marden, JR | 1 |
| Freimark, J | 1 |
| Lane, H | 1 |
| Zhang, A | 1 |
| Frean, M | 1 |
| Trifillis, P | 1 |
| Koladicz, K | 1 |
| Signorovitch, J | 2 |
| Rimner, A | 1 |
| Moore, ZR | 1 |
| Lobaugh, S | 1 |
| Geyer, A | 1 |
| Gelblum, DY | 1 |
| Abdulnour, RE | 1 |
| Shepherd, AF | 1 |
| Shaverdian, N | 1 |
| Wu, AJ | 1 |
| Cuaron, J | 1 |
| Chaft, JE | 1 |
| Zauderer, MG | 1 |
| Eng, J | 1 |
| Riely, GJ | 1 |
| Rudin, CM | 1 |
| Els, NV | 1 |
| Chawla, M | 1 |
| McCune, M | 1 |
| Li, H | 5 |
| Jones, DR | 1 |
| Sopka, DM | 1 |
| Simone, CB | 1 |
| Mak, R | 1 |
| Weinhouse, GL | 1 |
| Liao, Z | 2 |
| Gomez, DR | 1 |
| Zhang, Z | 1 |
| Paik, PK | 1 |
| Wang, K | 1 |
| Zheng, C | 1 |
| Zhao, G | 1 |
| Zhang, M | 1 |
| Liu, T | 3 |
| Tao, Q | 1 |
| Cheng, Z | 1 |
| Zhang, X | 2 |
| Kamperman, RG | 1 |
| Bogaards, JA | 1 |
| Evers, SW | 1 |
| Walter, HAW | 1 |
| de Visser, M | 1 |
| de Borgie, C | 1 |
| Colen-de Koning, JCA | 1 |
| Verhamme, C | 1 |
| Maas, M | 1 |
| Eftimov, F | 1 |
| van Schaik, IN | 1 |
| van der Kooi, AJ | 2 |
| Raaphorst, J | 1 |
| Kooistra, EJ | 1 |
| Dahm, K | 1 |
| van Herwaarden, AE | 1 |
| Gerretsen, J | 1 |
| Nuesch Germano, M | 1 |
| Mauer, K | 1 |
| Smeets, RL | 1 |
| van der Velde, S | 1 |
| van den Berg, MJW | 1 |
| van der Hoeven, JG | 1 |
| Aschenbrenner, AC | 1 |
| Schultze, JL | 1 |
| Ulas, T | 1 |
| Kox, M | 1 |
| Pickkers, P | 1 |
| Antonelli, A | 1 |
| Barone, S | 1 |
| Bennardo, F | 1 |
| Giudice, A | 1 |
| Lehrnbecher, T | 1 |
| Ahlmann, M | 1 |
| Albert, M | 1 |
| Barnbrock, AE | 1 |
| Beutel, K | 1 |
| Bochennek, K | 1 |
| Classen, CF | 1 |
| Holzhauer, S | 1 |
| Hutter, C | 1 |
| Lakatos, K | 1 |
| Meisel, R | 1 |
| Porto, L | 1 |
| Vokuhl, C | 1 |
| Vraetz, T | 1 |
| Minkov, M | 1 |
| Burke, JM | 1 |
| Masaquel, A | 1 |
| Wang, R | 1 |
| Hossain, F | 1 |
| Zhou, SQ | 1 |
| Ng, CD | 1 |
| Matasar, M | 1 |
| Gummi, RR | 1 |
| Kukulka, NA | 1 |
| Deroche, CB | 1 |
| Govindarajan, R | 2 |
| de Meel, RHP | 1 |
| Tannemaat, MR | 1 |
| Verschuuren, JJGM | 1 |
| Harper, LJ | 1 |
| McCarthy, M | 1 |
| Ribeiro Neto, ML | 1 |
| Hachamovitch, R | 1 |
| Pearson, K | 1 |
| Bonanno, B | 1 |
| Shaia, J | 1 |
| Brunken, R | 1 |
| Joyce, E | 1 |
| Culver, DA | 1 |
| Weiss, M | 1 |
| Vignon, MD | 1 |
| Lepelletier, C | 1 |
| Macaux, L | 1 |
| Jachiet, M | 1 |
| de Masson, A | 1 |
| Bagot, M | 1 |
| Bouaziz, JD | 1 |
| Sajeev, G | 1 |
| Yao, Z | 1 |
| McDonnell, E | 1 |
| Elfring, G | 1 |
| Souza, M | 1 |
| Peltz, SW | 1 |
| Darras, BT | 1 |
| Shieh, PB | 1 |
| Cox, DA | 1 |
| Landry, J | 1 |
| Chen, J | 3 |
| Xu, H | 1 |
| Peng, Z | 1 |
| Lin, L | 2 |
| Li, C | 1 |
| Zhu, X | 1 |
| Liu, S | 1 |
| Xu, L | 2 |
| Castro, D | 2 |
| Reisch, JS | 1 |
| Iannaccone, ST | 1 |
| Walewski, J | 2 |
| Goulabchand, R | 1 |
| Perrochia, H | 1 |
| Aubert-Bringer, E | 1 |
| Do Trinh, P | 1 |
| Guilpain, P | 1 |
| Batta, N | 1 |
| Shukla, M | 1 |
| Pandey, M | 1 |
| Urwyler, P | 1 |
| Boesing, M | 1 |
| Abig, K | 1 |
| Cattaneo, M | 1 |
| Dieterle, T | 1 |
| Zeller, A | 1 |
| Bachler, H | 1 |
| Markun, S | 1 |
| Senn, O | 1 |
| Merlo, C | 1 |
| Essig, S | 1 |
| Ullmer, E | 1 |
| Rutishauser, J | 3 |
| Schuurmans, MM | 1 |
| Leuppi, JD | 3 |
| Chen, RX | 1 |
| Cao, SS | 1 |
| Zhao, LD | 1 |
| Yang, HX | 1 |
| Bravo-Perez, C | 1 |
| Pajares, I | 1 |
| Muiña, B | 1 |
| Escobar, H | 1 |
| Amigo, ML | 1 |
| Garcia-Malo, MD | 1 |
| Garcia, J | 1 |
| Rodriguez-Pinilla, SM | 1 |
| Piris, MA | 3 |
| Ortuño, FJ | 1 |
| Park, SSE | 1 |
| Akella, S | 1 |
| Kumthekar, A | 1 |
| Barmettler, A | 1 |
| Batlevi, CL | 1 |
| Sha, F | 1 |
| Alperovich, A | 1 |
| Ni, A | 1 |
| Smith, K | 1 |
| Ying, Z | 1 |
| Gerecitano, JF | 1 |
| Hamlin, PA | 1 |
| Horwitz, SM | 1 |
| Joffe, E | 1 |
| Kumar, A | 2 |
| Matasar, MJ | 1 |
| Moskowitz, AJ | 1 |
| Moskowitz, CH | 1 |
| Noy, A | 2 |
| Owens, C | 1 |
| Palomba, LM | 1 |
| Straus, D | 1 |
| von Keudell, G | 1 |
| Zelenetz, AD | 1 |
| Seshan, VE | 1 |
| Luminari, S | 1 |
| Marcheselli, L | 2 |
| Federico, M | 2 |
| Younes, A | 2 |
| Di Nunno, V | 1 |
| Santoni, M | 1 |
| Mollica, V | 1 |
| Conti, A | 1 |
| Montironi, R | 1 |
| Battelli, N | 1 |
| Ardizzoni, A | 2 |
| Massari, F | 1 |
| Ungaro, RC | 1 |
| Yzet, C | 1 |
| Bossuyt, P | 1 |
| Baert, FJ | 1 |
| Vanasek, T | 1 |
| D'Haens, GR | 1 |
| Joustra, VW | 1 |
| Panaccione, R | 1 |
| Novacek, G | 1 |
| Reinisch, W | 1 |
| Armuzzi, A | 1 |
| Golovchenko, O | 1 |
| Prymak, O | 1 |
| Goldis, A | 1 |
| Travis, SP | 1 |
| Hébuterne, X | 1 |
| Ferrante, M | 1 |
| Rogler, G | 1 |
| Fumery, M | 1 |
| Danese, S | 1 |
| Rydzewska, G | 1 |
| Pariente, B | 1 |
| Hertervig, E | 1 |
| Stanciu, C | 1 |
| Serrero, M | 1 |
| Diculescu, M | 1 |
| Peyrin-Biroulet, L | 1 |
| Laharie, D | 1 |
| Wright, JP | 1 |
| Gomollón, F | 1 |
| Gubonina, I | 1 |
| Schreiber, S | 1 |
| Motoya, S | 1 |
| Hellström, PM | 1 |
| Halfvarson, J | 1 |
| Butler, JW | 1 |
| Petersson, J | 1 |
| Petralia, F | 1 |
| Colombel, JF | 1 |
| Saccon, F | 2 |
| Zen, M | 2 |
| Gatto, M | 2 |
| Margiotta, DPE | 1 |
| Afeltra, A | 1 |
| Ceccarelli, F | 1 |
| Conti, F | 1 |
| Bortoluzzi, A | 1 |
| Govoni, M | 1 |
| Frontini, G | 1 |
| Moroni, G | 1 |
| Dall'Ara, F | 1 |
| Tincani, A | 1 |
| Signorini, V | 1 |
| Mosca, M | 1 |
| Frigo, AC | 1 |
| Iaccarino, L | 2 |
| Doria, A | 2 |
| Fenando, A | 1 |
| Firn, K | 1 |
| Louissa, S | 1 |
| Hussain, A | 1 |
| Aldapt, MB | 1 |
| Soliman, D | 1 |
| Szabados, L | 1 |
| Sharaf Eldean, MZ | 1 |
| Shwaylia, HM | 1 |
| Abdulla, MAJ | 1 |
| Yassin, MA | 1 |
| Askanase, AD | 1 |
| Zhao, E | 1 |
| Zhu, J | 1 |
| Connolly-Strong, E | 1 |
| Furie, RA | 1 |
| Jiang, S | 1 |
| Qin, Y | 2 |
| Jiang, H | 1 |
| Liu, B | 1 |
| Shi, J | 1 |
| Meng, F | 1 |
| Liu, P | 3 |
| Yang, J | 1 |
| Yang, S | 2 |
| He, X | 1 |
| Zhou, S | 1 |
| Gui, L | 1 |
| Liu, H | 1 |
| Han-Zhang, H | 1 |
| Shi, Y | 2 |
| Jelinek, T | 1 |
| Zuchnicka, J | 1 |
| Sortais, C | 1 |
| Lok, A | 1 |
| Tessoulin, B | 1 |
| Gastinne, T | 1 |
| Mahé, B | 1 |
| Dubruille, V | 1 |
| Blin, N | 1 |
| Touzeau, C | 1 |
| Moreau, A | 1 |
| Bossard, C | 1 |
| Peterlin, P | 1 |
| Garnier, A | 1 |
| Guillaume, T | 1 |
| Le Bourgeois, A | 1 |
| Chevallier, P | 1 |
| Moreau, P | 1 |
| Leux, C | 1 |
| Le Gouill, S | 1 |
| Vázquez-Otero, I | 1 |
| Medina-Cintrón, N | 1 |
| Arroyo-Ávila, M | 1 |
| González-Sepúlveda, L | 1 |
| Vilá, LM | 2 |
| Jurado, LF | 1 |
| Pinzón, B | 1 |
| De La Rosa, ZR | 1 |
| Mejía, M | 1 |
| Palacios, DM | 1 |
| Bergstra, SA | 3 |
| Van Der Pol, JA | 1 |
| Riyazi, N | 1 |
| Goekoop-Ruiterman, YPM | 1 |
| Kerstens, PJSM | 1 |
| Lems, W | 1 |
| Huizinga, TWJ | 3 |
| Allaart, CF | 16 |
| Janikova, A | 2 |
| Michalka, J | 1 |
| Bortlicek, Z | 2 |
| Chloupkova, R | 2 |
| Campr, V | 3 |
| Kopalova, N | 2 |
| Klener, P | 3 |
| Benesova, K | 1 |
| Hamouzova, J | 2 |
| Belada, D | 5 |
| Prochazka, V | 2 |
| Pytlik, R | 3 |
| Pirnos, J | 3 |
| Duras, J | 2 |
| Mocikova, H | 2 |
| Trneny, M | 3 |
| Omrčen, T | 1 |
| Eterović, D | 1 |
| Vrdoljak, E | 1 |
| Zukotynski, KA | 1 |
| Jadvar, H | 1 |
| Potvin, K | 1 |
| Cho, SY | 1 |
| Kim, CK | 1 |
| Winquist, E | 3 |
| Ugarte, A | 2 |
| Ruiz-Arruza, I | 1 |
| Khamashta, M | 1 |
| Voelker, D | 1 |
| Almodallal, Y | 1 |
| Scrodin, MD | 1 |
| Lim, K | 1 |
| Keogh, K | 1 |
| Patel, A | 2 |
| Iyer, V | 1 |
| Pelaia, C | 1 |
| Busceti, MT | 1 |
| Crimi, C | 1 |
| Carpagnano, GE | 1 |
| Lombardo, N | 1 |
| Terracciano, R | 1 |
| Vatrella, A | 1 |
| Pelaia, G | 1 |
| Singh, S | 1 |
| Persky, DO | 2 |
| Stephens, DM | 2 |
| Park, SI | 1 |
| Bartlett, NL | 1 |
| Swinnen, LJ | 1 |
| Barr, PM | 1 |
| Winegarden, JD | 1 |
| Constine, LS | 1 |
| Fitzgerald, TJ | 1 |
| Leonard, JP | 1 |
| Kahl, BS | 2 |
| LeBlanc, ML | 1 |
| Song, JY | 1 |
| Fisher, RI | 6 |
| Rimsza, LM | 3 |
| Smith, SM | 3 |
| Miller, TP | 2 |
| Friedberg, JW | 3 |
| André, MPE | 1 |
| Carde, P | 3 |
| Viviani, S | 2 |
| Bellei, M | 1 |
| Fortpied, C | 1 |
| Hutchings, M | 1 |
| Gianni, AM | 2 |
| Brice, P | 4 |
| Casasnovas, O | 2 |
| Gobbi, PG | 1 |
| Zinzani, PL | 4 |
| Dupuis, J | 1 |
| Iannitto, E | 1 |
| Rambaldi, A | 2 |
| Brière, J | 1 |
| Clément-Filliatre, L | 1 |
| Heczko, M | 1 |
| Valagussa, P | 3 |
| Douxfils, J | 1 |
| Depaus, J | 1 |
| Mounier, N | 1 |
| Wang, H | 1 |
| Su, T | 1 |
| Kang, L | 1 |
| Yang, L | 2 |
| Wang, S | 1 |
| Wang, WT | 1 |
| Liang, JH | 1 |
| Zhu, HY | 1 |
| Xia, Y | 2 |
| Fan, L | 1 |
| Li, JY | 1 |
| Xu, W | 3 |
| Mohty, M | 1 |
| Holler, E | 1 |
| Jagasia, M | 2 |
| Jenq, R | 1 |
| Malard, F | 1 |
| Martin, P | 1 |
| Socié, G | 1 |
| Zeiser, R | 1 |
| Tomazoni, SS | 1 |
| Casalechi, HL | 1 |
| Ferreira, CSB | 1 |
| Serra, AJ | 1 |
| Dellê, H | 1 |
| Brito, RBO | 1 |
| de Melo, BL | 1 |
| Vanin, AA | 1 |
| Ribeiro, NF | 1 |
| Pereira, AL | 1 |
| Monteiro, KKDS | 1 |
| Marcos, RL | 1 |
| de Carvalho, PTC | 1 |
| Frigo, L | 1 |
| Leal-Junior, ECP | 1 |
| Freeman, CL | 1 |
| Savage, KJ | 3 |
| Villa, DR | 1 |
| Scott, DW | 2 |
| Srour, L | 1 |
| Gerrie, AS | 1 |
| Brown, MJ | 1 |
| Slack, GW | 1 |
| Farinha, P | 1 |
| Skinnider, B | 1 |
| Morris, J | 1 |
| Bénard, F | 1 |
| Aquino-Parsons, C | 1 |
| Lo, A | 1 |
| Pickles, T | 1 |
| Wilson, DC | 1 |
| Tonseth, P | 1 |
| Connors, JM | 4 |
| Sehn, LH | 3 |
| Jurgens, MS | 1 |
| Safy-Khan, M | 1 |
| de Hair, MJH | 1 |
| Bijlsma, JWJ | 1 |
| Welsing, PMJ | 1 |
| Tekstra, J | 1 |
| Lafeber, FPJG | 1 |
| Sasso, EH | 1 |
| Jacobs, JWG | 1 |
| Schmitz, C | 1 |
| Rekowski, J | 1 |
| Müller, SP | 1 |
| Farsijani, N | 1 |
| Hertenstein, B | 1 |
| Franzius, C | 1 |
| von Verschuer, U | 1 |
| La Rosée, P | 1 |
| Freesmeyer, M | 1 |
| Wilop, S | 1 |
| Krohn, T | 1 |
| Raghavachar, A | 1 |
| Ganser, A | 1 |
| Bengel, FM | 1 |
| Prange-Krex, G | 1 |
| Kroschinsky, F | 1 |
| Kotzerke, J | 1 |
| Giagounidis, A | 1 |
| Dührsen, U | 3 |
| Wu, J | 1 |
| He, Z | 1 |
| Zhu, Y | 2 |
| Jiang, C | 1 |
| Deng, Y | 1 |
| Wei, B | 1 |
| Smith, EC | 1 |
| Conklin, LS | 1 |
| Hoffman, EP | 1 |
| Clemens, PR | 1 |
| Mah, JK | 1 |
| Finkel, RS | 1 |
| Guglieri, M | 1 |
| Tulinius, M | 1 |
| Nevo, Y | 1 |
| Ryan, MM | 1 |
| Webster, R | 1 |
| Kuntz, NL | 1 |
| Kerchner, L | 1 |
| Morgenroth, LP | 1 |
| Arrieta, A | 1 |
| Shimony, M | 1 |
| Jaros, M | 1 |
| Shale, P | 1 |
| Gordish-Dressman, H | 1 |
| Hagerty, L | 1 |
| Dang, UJ | 1 |
| Damsker, JM | 1 |
| Schwartz, BD | 1 |
| Mengle-Gaw, LJ | 1 |
| George, J | 1 |
| Ganoff, M | 1 |
| Lipari, M | 1 |
| Goss, MB | 1 |
| Munoz, FM | 1 |
| Ruan, W | 1 |
| Galván, NTN | 1 |
| O'Mahony, CA | 1 |
| Rana, A | 1 |
| Cotton, RT | 1 |
| Moreno, NF | 1 |
| Heczey, AA | 1 |
| Leung, DH | 1 |
| Goss, JA | 1 |
| Pelka, K | 1 |
| Stec-Polak, M | 1 |
| Wojas-Pelc, A | 1 |
| Pastuszczak, M | 1 |
| Belch, A | 2 |
| Bahlis, N | 1 |
| White, D | 1 |
| Cheung, M | 1 |
| Chen, C | 1 |
| Shustik, C | 2 |
| Song, K | 2 |
| Tosikyan, A | 2 |
| Dispenzieri, A | 1 |
| Anderson, K | 1 |
| Brown, D | 1 |
| Robinson, S | 1 |
| Srinivasan, S | 1 |
| Facon, T | 5 |
| Klintman, J | 1 |
| Appleby, N | 1 |
| Stamatopoulos, B | 2 |
| Ridout, K | 1 |
| Eyre, TA | 3 |
| Robbe, P | 1 |
| Pascua, LL | 1 |
| Knight, SJL | 1 |
| Dreau, H | 1 |
| Cabes, M | 2 |
| Popitsch, N | 1 |
| Ehinger, M | 1 |
| Martín-Subero, JI | 1 |
| Campo, E | 2 |
| Månsson, R | 1 |
| Rossi, D | 1 |
| Taylor, JC | 1 |
| Vavoulis, DV | 1 |
| Schuh, A | 3 |
| Dudiak, GJ | 1 |
| Popyack, J | 1 |
| Grimm, C | 1 |
| Tyson, S | 1 |
| Solic, J | 1 |
| Ishmael, FT | 1 |
| Fisher, KS | 1 |
| Gill, J | 1 |
| Todd, HF | 1 |
| Yang, MB | 1 |
| Lopez, MA | 1 |
| Abid, F | 1 |
| Lotze, T | 1 |
| Shah, VS | 1 |
| Adatia, A | 1 |
| Allen, CJ | 1 |
| Wald, J | 1 |
| Richards, CD | 1 |
| Waserman, S | 1 |
| Nair, P | 2 |
| Knop, S | 1 |
| Mateos, MV | 6 |
| Dimopoulos, MA | 5 |
| Suzuki, K | 2 |
| Jakubowiak, A | 1 |
| Doyen, C | 2 |
| Lucio, P | 1 |
| Nagy, Z | 1 |
| Usenko, G | 1 |
| Pour, L | 2 |
| Cook, M | 1 |
| Grosicki, S | 1 |
| Crepaldi, A | 1 |
| Liberati, AM | 2 |
| Campbell, P | 2 |
| Shelekhova, T | 1 |
| Yoon, SS | 3 |
| Losava, G | 1 |
| Fujisaki, T | 1 |
| Garg, M | 1 |
| Wang, J | 2 |
| Wroblewski, S | 1 |
| Kudva, A | 1 |
| Gries, KS | 1 |
| Fastenau, J | 1 |
| San-Miguel, J | 1 |
| Cavo, M | 1 |
| Suzuki, T | 3 |
| Maruyama, D | 2 |
| Miyagi-Maeshima, A | 1 |
| Nomoto, J | 1 |
| Tajima, K | 1 |
| Ito, Y | 3 |
| Hatta, S | 1 |
| Yuda, S | 1 |
| Makita, S | 1 |
| Fukuhara, S | 2 |
| Munakata, W | 2 |
| Taniguchi, H | 3 |
| Izutsu, K | 1 |
| Kobayashi, Y | 3 |
| Tobinai, K | 5 |
| Lolli, G | 1 |
| Casadei, B | 1 |
| Pellegrini, C | 2 |
| Argnani, L | 1 |
| Cocito, F | 2 |
| Amin, K | 1 |
| Choksi, V | 1 |
| Farouk, SS | 1 |
| Sparks, MA | 1 |
| Castillo, JJ | 1 |
| LaMacchia, J | 1 |
| Flynn, CA | 1 |
| Sarosiek, S | 1 |
| Pozdnyakova, O | 2 |
| Treon, SP | 1 |
| Yang, Z | 1 |
| Ni, Y | 1 |
| Zhao, D | 1 |
| Jiang, L | 1 |
| Chen, D | 1 |
| Wu, Z | 1 |
| He, L | 1 |
| Zhou, F | 1 |
| Zeng, H | 1 |
| Smith, MR | 9 |
| Saad, F | 11 |
| Rathkopf, DE | 4 |
| Mulders, PFA | 1 |
| de Bono, JS | 10 |
| Small, EJ | 4 |
| Shore, ND | 4 |
| Fizazi, K | 10 |
| Kheoh, T | 8 |
| De Porre, P | 4 |
| Todd, MB | 2 |
| Yu, MK | 4 |
| Ryan, CJ | 8 |
| Flaig, TW | 4 |
| Plets, M | 1 |
| Hussain, MHA | 1 |
| Agarwal, N | 2 |
| Mitsiades, N | 1 |
| Deshpande, HA | 1 |
| Vaishampayan, UN | 1 |
| Thompson, IM | 1 |
| Smids, C | 1 |
| Horjus Talabur Horje, CS | 1 |
| Nierkens, S | 1 |
| Drylewicz, J | 1 |
| Groenen, MJM | 1 |
| Wahab, PJ | 1 |
| van Lochem, EG | 1 |
| Grammatico, S | 1 |
| Bringhen, S | 2 |
| Vozella, F | 1 |
| Siniscalchi, A | 2 |
| Boccadoro, M | 4 |
| Petrucci, MT | 6 |
| Peng, YF | 1 |
| Deng, YB | 1 |
| Iriyoda, TMV | 1 |
| Stadtlober, N | 1 |
| Lozovoy, MAB | 1 |
| Delongui, F | 1 |
| Costa, NT | 1 |
| Reiche, EMV | 1 |
| Dichi, I | 1 |
| Simão, ANC | 1 |
| Martin, PJ | 1 |
| Storer, BE | 1 |
| Inamoto, Y | 1 |
| Flowers, MED | 1 |
| Carpenter, PA | 1 |
| Pidala, J | 1 |
| Palmer, J | 1 |
| Arora, M | 1 |
| Arai, S | 1 |
| Cutler, CS | 1 |
| Lee, SJ | 3 |
| Xiao, J | 1 |
| Du, S | 1 |
| Dai, G | 1 |
| Gao, G | 1 |
| Yang, D | 1 |
| Zhao, H | 2 |
| Keita, Y | 1 |
| Lemrabott, AT | 1 |
| Sylla, A | 1 |
| Niang, B | 1 |
| Ka, EHF | 1 |
| Dial, CM | 1 |
| Ndongo, AA | 1 |
| Sow, A | 1 |
| Moreira, C | 1 |
| Niang, A | 1 |
| Ndiaye, O | 1 |
| Diouf, B | 1 |
| Sall, MG | 1 |
| Skoetz, N | 1 |
| Will, A | 1 |
| Monsef, I | 1 |
| Brillant, C | 1 |
| Engert, A | 9 |
| von Tresckow, B | 1 |
| Ramírez, J | 1 |
| Narváez, JA | 1 |
| Ruiz-Esquide, V | 1 |
| Hernández-Gañán, J | 1 |
| Cuervo, A | 1 |
| Inciarte-Mundo, J | 1 |
| Hernández, MV | 1 |
| Sampayo-Cordero, M | 1 |
| Pablos, JL | 1 |
| Sanmartí, R | 1 |
| Cañete, JD | 1 |
| Hamada, T | 1 |
| Miyake, T | 1 |
| Otsuka, M | 1 |
| Iwatsuki, K | 1 |
| Engel, B | 1 |
| Schindler, C | 2 |
| Singh, A | 2 |
| Mandal, A | 1 |
| Singh, L | 1 |
| Mishra, S | 1 |
| Piatopoulou, D | 1 |
| Avgeris, M | 1 |
| Marmarinos, A | 1 |
| Xagorari, M | 1 |
| Baka, M | 1 |
| Doganis, D | 1 |
| Kossiva, L | 1 |
| Scorilas, A | 1 |
| Gourgiotis, D | 1 |
| Chowdhury, S | 1 |
| Feyerabend, S | 3 |
| Elliott, T | 1 |
| Grande, E | 1 |
| Melhem-Bertrandt, A | 1 |
| Baron, B | 1 |
| Hirmand, M | 1 |
| Werbrouck, P | 1 |
| Bhutani, M | 1 |
| Yang, WH | 1 |
| Hébert, J | 1 |
| de Takacsy, F | 1 |
| Stril, JL | 1 |
| Chhabra, A | 1 |
| Lam, JM | 1 |
| Rhemus, W | 1 |
| Wojdyla, D | 1 |
| Pons-Estel, GJ | 1 |
| Catoggio, LJ | 1 |
| Drenkard, C | 1 |
| Sarano, J | 1 |
| Berbotto, GA | 1 |
| Borba, EF | 1 |
| Sato, EI | 2 |
| Tavares Brenol, JC | 1 |
| Uribe, O | 1 |
| Ramirez Gómez, LA | 1 |
| Guibert-Toledano, M | 1 |
| Massardo, L | 1 |
| Cardiel, MH | 1 |
| Silveira, LH | 1 |
| Chacón-Diaz, R | 1 |
| Mansour, MJ | 1 |
| Mokbel, E | 1 |
| Fares, E | 1 |
| Maddah, J | 1 |
| Nasr, F | 1 |
| Landewé, RBM | 1 |
| Akdemir, G | 2 |
| Heimans, L | 4 |
| Goekoop, RJ | 3 |
| van Oosterhout, M | 3 |
| van Groenendael, JHLM | 1 |
| Peeters, AJ | 3 |
| Steup-Beekman, GM | 1 |
| Lard, LR | 1 |
| de Sonnaville, PBJ | 1 |
| Grillet, BAM | 1 |
| Larosa, M | 1 |
| Ghirardello, A | 1 |
| Punzi, L | 1 |
| Roswarski, J | 1 |
| Roschewski, M | 1 |
| Lucas, A | 1 |
| Melani, C | 1 |
| Pittaluga, S | 1 |
| Jaffe, ES | 2 |
| Steinberg, SM | 1 |
| Waldmann, TA | 1 |
| Wilson, WH | 2 |
| Garje, R | 1 |
| Chau, JJ | 1 |
| Chung, J | 1 |
| Wanat, K | 1 |
| Zakharia, Y | 1 |
| Garval, E | 1 |
| Pennaforte, JL | 1 |
| Jaussaud, R | 1 |
| Servettaz, A | 1 |
| Bernard, P | 2 |
| Reguiai, Z | 2 |
| Schrappe, M | 1 |
| Bleckmann, K | 1 |
| Zimmermann, M | 1 |
| Biondi, A | 1 |
| Möricke, A | 1 |
| Locatelli, F | 1 |
| Cario, G | 1 |
| Rizzari, C | 1 |
| Attarbaschi, A | 1 |
| Valsecchi, MG | 1 |
| Bartram, CR | 1 |
| Barisone, E | 1 |
| Niggli, F | 1 |
| Niemeyer, C | 2 |
| Testi, AM | 1 |
| Mann, G | 1 |
| Ziino, O | 1 |
| Schäfer, B | 1 |
| Panzer-Grümayer, R | 1 |
| Beier, R | 1 |
| Parasole, R | 1 |
| Göhring, G | 1 |
| Ludwig, WD | 1 |
| Casale, F | 1 |
| Schlegel, PG | 1 |
| Basso, G | 1 |
| Conter, V | 1 |
| Namiki, T | 1 |
| Hashimoto, T | 1 |
| Nishida, M | 1 |
| Ugajin, T | 1 |
| Miura, K | 1 |
| Yokozeki, H | 1 |
| Paniagua, N | 1 |
| Lopez, R | 1 |
| Muñoz, N | 1 |
| Tames, M | 1 |
| Mojica, E | 1 |
| Arana-Arri, E | 1 |
| Mintegi, S | 1 |
| Benito, J | 1 |
| Rogers, KA | 1 |
| Huang, Y | 1 |
| Ruppert, AS | 1 |
| Salem, G | 1 |
| Heerema, NA | 1 |
| Andritsos, LA | 1 |
| Awan, FT | 1 |
| Byrd, JC | 1 |
| Flynn, JM | 1 |
| Maddocks, KJ | 1 |
| Jones, JA | 1 |
| Hohloch, K | 1 |
| Altmann, B | 1 |
| Pfreundschuh, M | 7 |
| Loeffler, M | 7 |
| Schmitz, N | 7 |
| Zettl, F | 1 |
| Ziepert, M | 4 |
| Trümper, L | 2 |
| Proença, NG | 1 |
| Sreedhar, A | 1 |
| Nair, R | 1 |
| Scialla, W | 1 |
| Conn, DL | 1 |
| Tiliakos, A | 1 |
| Bao, G | 1 |
| Li, S | 2 |
| Easley, KA | 1 |
| Pease, DF | 1 |
| Morrison, VA | 2 |
| Silver, EM | 1 |
| Ochoa, W | 1 |
| Thakur, MK | 1 |
| Heilbrun, L | 2 |
| Dobson, K | 1 |
| Boerner, J | 1 |
| Stark, K | 2 |
| Smith, D | 2 |
| Heath, E | 3 |
| Fontana, J | 2 |
| Vaishampayan, U | 2 |
| Crawford, ED | 1 |
| Underwood, W | 1 |
| Taplin, ME | 4 |
| Londhe, A | 2 |
| Francis, PSJ | 1 |
| Phillips, J | 1 |
| McGowan, T | 1 |
| Kantoff, PW | 1 |
| Soto-Cabrera, E | 1 |
| Villamil-Osorio, LV | 1 |
| Garcia-Luna, RC | 1 |
| Carrera-Pineda, R | 1 |
| Lorente, D | 2 |
| Olmos, D | 2 |
| Mateo, J | 1 |
| Dolling, D | 1 |
| Bianchini, D | 2 |
| Seed, G | 1 |
| Flohr, P | 1 |
| Crespo, M | 1 |
| Figueiredo, I | 1 |
| Miranda, S | 1 |
| Scher, HI | 5 |
| Terstappen, LWMM | 1 |
| Zhang, WH | 1 |
| Li, GY | 1 |
| Ma, YJ | 1 |
| Li, ZC | 1 |
| Chang, J | 1 |
| Hao, SG | 1 |
| Tao, R | 1 |
| Umakanathan, M | 1 |
| P'ng, CH | 1 |
| Varikatt, W | 1 |
| Kwok, F | 1 |
| Lin, MW | 1 |
| Vucak-Dzumhur, M | 1 |
| Vale, CL | 1 |
| Fisher, DJ | 1 |
| White, IR | 1 |
| Carpenter, JR | 1 |
| Burdett, S | 1 |
| Clarke, NW | 1 |
| Gravis, G | 4 |
| James, ND | 1 |
| Mason, MD | 1 |
| Parmar, MKB | 1 |
| Rydzewska, LH | 1 |
| Sweeney, CJ | 1 |
| Spears, MR | 1 |
| Sydes, MR | 1 |
| Tierney, JF | 1 |
| Bang, SP | 1 |
| Jun, JH | 1 |
| Fenioux, C | 1 |
| Louvet, C | 1 |
| Charton, E | 1 |
| Rozet, F | 2 |
| Ropert, S | 1 |
| Prapotnich, D | 1 |
| Barret, E | 1 |
| Sanchez-Salas, R | 1 |
| Mombet, A | 1 |
| Cathala, N | 1 |
| Joulia, ML | 1 |
| Molitor, JL | 1 |
| Henriques, J | 1 |
| Bonnetain, F | 1 |
| Cathelineau, X | 1 |
| Bennamoun, M | 1 |
| Gulati, S | 1 |
| Zouk, AN | 1 |
| Kalehoff, JP | 1 |
| Wren, CS | 1 |
| Davison, PN | 1 |
| Kirkpatrick, DP | 1 |
| Bhatt, SP | 1 |
| Dransfield, MT | 1 |
| Wells, JM | 1 |
| Romero-Laorden, N | 1 |
| Lozano, R | 1 |
| Jayaram, A | 1 |
| López-Campos, F | 1 |
| Saez, MI | 1 |
| Montesa, A | 1 |
| Gutierrez-Pecharoman, A | 1 |
| Villatoro, R | 1 |
| Herrera, B | 1 |
| Correa, R | 1 |
| Rosero, A | 1 |
| Pacheco, MI | 1 |
| Garcés, T | 1 |
| Cendón, Y | 1 |
| Nombela, MP | 1 |
| Van de Poll, F | 1 |
| Grau, G | 1 |
| Rivera, L | 1 |
| López, PP | 1 |
| Cruz, JJ | 1 |
| Attard, G | 2 |
| Castro, E | 1 |
| Petite, SE | 1 |
| Murphy, JA | 1 |
| Li, T | 1 |
| Ito, T | 1 |
| Diels, J | 1 |
| Van Sanden, S | 1 |
| Roiz, J | 1 |
| Abogunrin, S | 1 |
| Koufopoulou, M | 1 |
| Peschken, CA | 1 |
| Abrahamowicz, M | 1 |
| Pope, J | 1 |
| Silverman, E | 1 |
| Sayani, A | 1 |
| Iczkovitz, S | 1 |
| Ross, J | 1 |
| Zummer, M | 1 |
| Tucker, L | 1 |
| Pineau, C | 1 |
| Levy, D | 1 |
| Hudson, M | 1 |
| Hitchon, CA | 2 |
| Huber, AM | 1 |
| Smith, CD | 1 |
| Avina-Zubieta, A | 1 |
| Arbillaga, H | 1 |
| Chédeville, G | 1 |
| Wynant, W | 1 |
| Emamekhoo, H | 1 |
| Barata, PC | 1 |
| Edwin, NC | 1 |
| Woo, KM | 1 |
| Grivas, P | 1 |
| Garcia, JA | 1 |
| Coomes, EA | 1 |
| Heendeniya, A | 1 |
| Bunce, PE | 1 |
| Lee, SR | 1 |
| Choi, H | 1 |
| Lee, BH | 1 |
| Kang, KW | 1 |
| Yu, ES | 1 |
| Kim, DS | 1 |
| Park, Y | 1 |
| Choi, CW | 3 |
| Kim, BS | 2 |
| Sung, HJ | 2 |
| Kawamoto, K | 1 |
| Kasami, T | 1 |
| Kiryu, M | 1 |
| Sone, H | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takizawa, J | 1 |
| Tselios, K | 1 |
| Urowitz, MB | 2 |
| Tyler, A | 1 |
| Cotter, JM | 1 |
| Moss, A | 1 |
| Topoz, I | 1 |
| Dempsey, A | 1 |
| Reese, J | 1 |
| Szefler, S | 1 |
| Hoch, H | 1 |
| Flores-Terry, MA | 1 |
| Prado, MD | 1 |
| Romero-Aguilera, G | 1 |
| Garcia-Arpa, M | 1 |
| Villasanti-Rivas, N | 1 |
| Franco-Munoz, M | 1 |
| Pons-Estel, G | 1 |
| Reveille, JD | 1 |
| McGwin, G | 1 |
| Çağlayan, Ç | 1 |
| Terawaki, H | 1 |
| Ayer, T | 1 |
| Goldstein, JS | 1 |
| Rai, A | 1 |
| Chen, Q | 1 |
| Flowers, C | 2 |
| Goldschmidt, N | 3 |
| Horowitz, NA | 1 |
| Heffes, V | 1 |
| Darawshy, F | 1 |
| Mashiach, T | 1 |
| Shaulov, A | 1 |
| Gatt, ME | 1 |
| Dann, EJ | 1 |
| Voortman, M | 1 |
| Hendriks, CMR | 1 |
| Elfferich, MDP | 1 |
| Bonella, F | 1 |
| Møller, J | 1 |
| De Vries, J | 1 |
| Costabel, U | 2 |
| Drent, M | 1 |
| Vähämurto, P | 1 |
| Mannisto, S | 1 |
| Pollari, M | 1 |
| Karjalainen-Lindsberg, ML | 1 |
| Mäkitie, AA | 1 |
| Leppä, S | 1 |
| Yamada, T | 1 |
| Hara, T | 1 |
| Goto, N | 1 |
| Iwata, H | 1 |
| Tsurumi, H | 1 |
| Gourd, E | 1 |
| Hansen, AR | 1 |
| Tannock, IF | 4 |
| Templeton, A | 1 |
| Chen, E | 1 |
| Evans, A | 1 |
| Knox, J | 1 |
| Prawira, A | 1 |
| Sridhar, SS | 2 |
| Tan, S | 1 |
| Vera-Badillo, F | 2 |
| Wouters, BG | 1 |
| Joshua, AM | 2 |
| Sawnani, H | 1 |
| Horn, PS | 1 |
| Wong, B | 3 |
| Darmahkasih, A | 1 |
| Rybalsky, I | 1 |
| Shellenbarger, KC | 1 |
| Tian, C | 1 |
| Rutter, MM | 1 |
| Simakajornboon, N | 1 |
| Amin, R | 1 |
| Gurbani, N | 1 |
| Pascoe, J | 1 |
| Burrows, C | 1 |
| Khirani, S | 1 |
| Amaddeo, A | 1 |
| Fauroux, B | 2 |
| Ginsberg, S | 1 |
| Rosner, I | 2 |
| Slobodin, G | 2 |
| Rozenbaum, M | 2 |
| Kaly, L | 1 |
| Jiries, N | 1 |
| Boulman, N | 2 |
| Awisat, A | 1 |
| Hussein, H | 1 |
| Novofastovski, I | 1 |
| Silawy, A | 1 |
| Rimar, D | 1 |
| Teply, BA | 1 |
| Qiu, F | 1 |
| Antonarakis, ES | 1 |
| Carducci, MA | 1 |
| Denmeade, SR | 2 |
| Mayer, J | 1 |
| Flinn, IW | 1 |
| Erter, J | 1 |
| Daniel, DB | 1 |
| Mace, JR | 1 |
| Berdeja, JG | 1 |
| Dubinsky, S | 1 |
| Thawer, A | 1 |
| McLeod, AG | 1 |
| McFarlane, TRJ | 1 |
| Emmenegger, U | 1 |
| Liebowitz, J | 1 |
| Hellmann, DB | 2 |
| Schnappauf, O | 1 |
| Ricciuti, B | 1 |
| Dahlberg, SE | 1 |
| Adeni, A | 1 |
| Sholl, LM | 1 |
| Nishino, M | 1 |
| Awad, MM | 1 |
| Tomita, N | 2 |
| Takasaki, H | 2 |
| Miyashita, K | 1 |
| Fujisawa, S | 2 |
| Ogusa, E | 2 |
| Matsuura, S | 1 |
| Kishimoto, K | 1 |
| Numata, A | 2 |
| Fujita, A | 1 |
| Ohshima, R | 1 |
| Kuwabara, H | 1 |
| Hagihara, M | 2 |
| Hashimoto, C | 1 |
| Takemura, S | 1 |
| Koharazawa, H | 1 |
| Yamazaki, E | 1 |
| Fujimaki, K | 1 |
| Taguchi, J | 2 |
| Sakai, R | 1 |
| Ishigatsubo, Y | 2 |
| Johnston, NW | 1 |
| Lambert, K | 1 |
| Hussack, P | 1 |
| de Verdier, MG | 1 |
| Higenbottam, T | 1 |
| Lewis, J | 1 |
| Newbold, P | 1 |
| Jenkins, M | 1 |
| Norman, GR | 1 |
| Coyle, PV | 1 |
| McIvor, RA | 1 |
| Keating, GM | 1 |
| Sailler, L | 1 |
| Pugnet, G | 1 |
| Bienvenu, B | 1 |
| Gerfaud-Valentin, M | 1 |
| Hot, A | 1 |
| Huissoud, C | 1 |
| Durieu, I | 1 |
| Broussolle, C | 1 |
| Seve, P | 1 |
| Malemba, JJ | 1 |
| Mbuyi Muamba, JM | 1 |
| Mukaya, J | 1 |
| Bossuyt, X | 1 |
| Verschueren, P | 1 |
| Westhovens, R | 1 |
| Schuetz, P | 1 |
| Bingisser, R | 1 |
| Bodmer, M | 1 |
| Briel, M | 1 |
| Drescher, T | 1 |
| Duerring, U | 1 |
| Henzen, C | 1 |
| Leibbrandt, Y | 1 |
| Maier, S | 1 |
| Miedinger, D | 1 |
| Müller, B | 1 |
| Scherr, A | 1 |
| Stoeckli, R | 1 |
| Viatte, S | 1 |
| von Garnier, C | 1 |
| Tamm, M | 1 |
| Watanabe-Okada, E | 1 |
| Inazumi, T | 1 |
| Matsukawa, H | 1 |
| Ohyama, M | 1 |
| Lee, E | 1 |
| Kim, TM | 1 |
| Lim, Y | 1 |
| Jeon, YK | 1 |
| Go, H | 1 |
| Kim, CW | 1 |
| Heo, DS | 1 |
| Wevers-de Boer, KV | 2 |
| Visser, K | 4 |
| Harbers, JB | 2 |
| Bijkerk, C | 2 |
| Speyer, I | 2 |
| de Buck, MP | 2 |
| de Sonnaville, PB | 4 |
| Grillet, BA | 4 |
| Huizinga, TW | 12 |
| Mangiacavalli, S | 1 |
| Pochintesta, L | 1 |
| Pompa, A | 1 |
| Bernasconi, P | 1 |
| Cazzola, M | 1 |
| Corso, A | 1 |
| Ozsan, N | 1 |
| Cagirgan, S | 2 |
| Saydam, G | 2 |
| Gunes, A | 1 |
| Hekimgil, M | 2 |
| Abroug, F | 1 |
| Ouanes-Besbes, L | 1 |
| Fkih-Hassen, M | 1 |
| Ouanes, I | 1 |
| Ayed, S | 1 |
| Dachraoui, F | 1 |
| Brochard, L | 1 |
| Elatrous, S | 1 |
| Schuster, S | 1 |
| Diethelm, M | 1 |
| Chen, MB | 1 |
| Zhou, XY | 1 |
| Hong, XN | 1 |
| Almugairen, N | 1 |
| Hospital, V | 1 |
| Bedane, C | 1 |
| Duvert-Lehembre, S | 1 |
| Picard, D | 1 |
| Tronquoy, AF | 1 |
| Houivet, E | 1 |
| D'incan, M | 1 |
| Joly, P | 2 |
| Patil, P | 1 |
| Chandan, S | 1 |
| Singh, V | 1 |
| Gadre, K | 1 |
| Halli, R | 1 |
| Gadre, P | 1 |
| Prasse, A | 1 |
| Kayser, G | 1 |
| Warnatz, K | 1 |
| Aggarwal, R | 1 |
| Halabi, S | 1 |
| Kelly, WK | 2 |
| George, D | 1 |
| Mahoney, JF | 1 |
| Millard, F | 1 |
| Stadler, WM | 1 |
| Morris, MJ | 2 |
| Kantoff, P | 1 |
| Monk, JP | 1 |
| Carducci, M | 1 |
| Lewis, LM | 1 |
| Ferguson, I | 1 |
| House, SL | 1 |
| Aubuchon, K | 1 |
| Schneider, J | 2 |
| Johnson, K | 1 |
| Matsuda, K | 1 |
| Steurer, J | 1 |
| Binder, C | 1 |
| Eimermacher, H | 1 |
| Aldaoud, A | 1 |
| Rosenwald, A | 2 |
| Truemper, L | 1 |
| Jurczak, W | 1 |
| Szmit, S | 1 |
| Sobociński, M | 1 |
| Machaczka, M | 1 |
| Drozd-Sokołowska, J | 1 |
| Joks, M | 1 |
| Dzietczenia, J | 1 |
| Wróbel, T | 1 |
| Kumiega, B | 1 |
| Zaucha, JM | 2 |
| Knopińska-Posłuszny, W | 1 |
| Spychałowicz, W | 1 |
| Prochwicz, A | 1 |
| Drohomirecka, A | 1 |
| Skotnicki, AB | 1 |
| Caffo, O | 1 |
| Palermo, A | 1 |
| Veccia, A | 1 |
| Maines, F | 1 |
| Chierichetti, F | 1 |
| Berruti, A | 1 |
| Galligioni, E | 1 |
| Boers-Sonderen, MJ | 1 |
| Mulder, SF | 1 |
| Nagtegaal, ID | 1 |
| Jacobs, JF | 1 |
| Wanten, GJ | 1 |
| Hoentjen, F | 1 |
| van Herpen, CM | 1 |
| Velez de Mendizabal, N | 1 |
| Hutmacher, MM | 1 |
| Troconiz, IF | 1 |
| Goñi, J | 1 |
| Villoslada, P | 1 |
| Bagnato, F | 2 |
| Bies, RR | 1 |
| Du, J | 2 |
| Yang, Q | 1 |
| Chen, XS | 1 |
| Tian, J | 1 |
| Yao, X | 1 |
| Basch, E | 1 |
| Autio, K | 1 |
| Mulders, P | 1 |
| Shore, N | 1 |
| Logothetis, CJ | 4 |
| Rathkopf, D | 2 |
| Mainwaring, PN | 1 |
| Hao, Y | 1 |
| Griffin, T | 1 |
| Meyers, ML | 1 |
| Molina, A | 6 |
| Cleeland, C | 1 |
| Martínez-Villaescusa, M | 1 |
| López-Montes, A | 1 |
| López-Rubio, E | 1 |
| de la Vara-Iniesta, L | 1 |
| Méndez-Molina, M | 1 |
| Donate-Ortiz, D | 1 |
| Nam-Cha, H | 1 |
| Gómez-Roldán, C | 1 |
| Guillet, S | 1 |
| Stokkermans, J | 1 |
| Vergier, B | 1 |
| Doutre, MS | 1 |
| Beylot-Barry, M | 1 |
| Malm, IJ | 1 |
| Mener, DJ | 1 |
| Kim, J | 1 |
| Seo, P | 2 |
| Kim, YJ | 2 |
| Keklik, M | 1 |
| Sivgin, S | 1 |
| Kontas, O | 1 |
| Abdulrezzak, U | 1 |
| Kaynar, L | 1 |
| Cetin, M | 1 |
| Kälvesten, J | 1 |
| Steup-Beekman, M | 1 |
| Sonpavde, G | 2 |
| Pond, GR | 2 |
| Armstrong, AJ | 3 |
| Galsky, MD | 1 |
| Leopold, L | 1 |
| Wood, BA | 1 |
| Wang, SL | 3 |
| Paolini, J | 3 |
| Chen, I | 3 |
| Chow-Maneval, E | 2 |
| Mooney, DJ | 1 |
| Lechuga, M | 2 |
| Michaelson, MD | 3 |
| Jira, M | 1 |
| Elqatni, M | 1 |
| Sekkach, Y | 1 |
| Elomri, N | 1 |
| Mekouar, F | 1 |
| Ghafir, D | 1 |
| Lévy-Sitbon, C | 1 |
| Durlach, A | 1 |
| Goeldel, AL | 1 |
| Grange, F | 1 |
| Oudard, S | 5 |
| Ou, YC | 1 |
| Sengeløv, L | 1 |
| Houede, N | 1 |
| Ostler, P | 1 |
| Stenzl, A | 2 |
| Daugaard, G | 1 |
| Jones, R | 3 |
| Laestadius, F | 1 |
| Ullèn, A | 1 |
| Bahl, A | 1 |
| Castellano, D | 1 |
| Gschwend, J | 1 |
| Maurina, T | 1 |
| Chow Maneval, E | 1 |
| Lechuga, MJ | 1 |
| Geetha, D | 1 |
| Poulton, CJ | 1 |
| Hu, Y | 1 |
| McGregor, JA | 1 |
| Falk, RJ | 1 |
| Hogan, SL | 1 |
| Vilá-Rivera, K | 1 |
| Jiménez-Encarnación, E | 1 |
| Vilá, S | 1 |
| Cao, XX | 1 |
| Zhang, W | 1 |
| Duan, MH | 1 |
| Shen, T | 1 |
| Zhou, DB | 1 |
| Guirguis, HR | 1 |
| Cheung, MC | 2 |
| Piliotis, E | 1 |
| Spaner, D | 1 |
| Berinstein, NL | 2 |
| Imrie, K | 1 |
| Zhang, L | 2 |
| Buckstein, R | 1 |
| Leibowitz-Amit, R | 1 |
| Templeton, AJ | 2 |
| Omlin, A | 1 |
| Pezaro, C | 1 |
| Atenafu, EG | 1 |
| Keizman, D | 1 |
| Seah, JA | 1 |
| Knox, JJ | 1 |
| Rios, AL | 1 |
| Kamath, V | 1 |
| Heidenreich, A | 1 |
| Bracarda, S | 1 |
| Mason, M | 1 |
| Ozen, H | 1 |
| Sengelov, L | 1 |
| Van Oort, I | 1 |
| Papandreou, C | 1 |
| Fossa, S | 1 |
| Hitier, S | 1 |
| Climent, MA | 1 |
| Petrylak, DP | 5 |
| Harada, K | 1 |
| Murakami, N | 1 |
| Kitaguchi, M | 1 |
| Sekii, S | 1 |
| Takahashi, K | 1 |
| Yoshio, K | 1 |
| Inaba, K | 1 |
| Morota, M | 1 |
| Sumi, M | 1 |
| Suzuki, S | 1 |
| Uno, T | 1 |
| Itami, J | 1 |
| Gonzalez-Echavarri, C | 1 |
| Pernas, B | 1 |
| Chen, Y | 2 |
| Bao, H | 1 |
| Liu, Z | 4 |
| Zhang, H | 2 |
| Zeng, C | 1 |
| Hu, W | 2 |
| Imamura, Y | 1 |
| Zhou, ZR | 1 |
| Liu, SX | 1 |
| Zhang, TS | 1 |
| Xia, J | 1 |
| Li, B | 2 |
| Baguley, C | 1 |
| Brownlow, A | 1 |
| Yeung, K | 1 |
| Pratt, E | 1 |
| Sacks, R | 1 |
| Harvey, R | 1 |
| Zaky, AH | 1 |
| Bakry, R | 1 |
| El-sayed, MI | 1 |
| Elwanis, MA | 1 |
| Nabih, O | 1 |
| Kubáčková, K | 1 |
| Vášová, I | 1 |
| Kozák, T | 2 |
| Bolomská, I | 1 |
| Matuška, M | 1 |
| Přibylová, J | 1 |
| Burešová, L | 1 |
| Sýkorová, A | 1 |
| Berková, A | 1 |
| de Souza, P | 2 |
| Mulders, PF | 3 |
| Mainwaring, P | 2 |
| Hainsworth, JD | 2 |
| Beer, TM | 1 |
| North, S | 3 |
| Fradet, Y | 1 |
| Van Poppel, H | 2 |
| Carles, J | 3 |
| Efstathiou, E | 4 |
| Yu, EY | 1 |
| Higano, CS | 4 |
| Griffin, TW | 3 |
| Park, YC | 2 |
| Silverton, A | 1 |
| Gunthel, C | 1 |
| Adamski, M | 1 |
| Mosunjac, M | 1 |
| Nguyen, ML | 1 |
| Dabaja, BS | 1 |
| Hess, K | 1 |
| Shihadeh, F | 1 |
| Podoloff, DA | 1 |
| Medeiros, LJ | 2 |
| Mawlawi, O | 1 |
| Arzu, I | 1 |
| Oki, Y | 2 |
| Hagemeister, FB | 3 |
| Fayad, LE | 2 |
| Reed, VK | 1 |
| Kedir, A | 1 |
| Wogan, CF | 1 |
| Rodriguez, A | 1 |
| Richardson, PG | 3 |
| Lahuerta, JJ | 3 |
| Larocca, A | 2 |
| Oriol, A | 3 |
| García-Sanz, R | 4 |
| Di Raimondo, F | 1 |
| Esseltine, DL | 3 |
| van de Velde, H | 4 |
| Desai, A | 1 |
| San Miguel, JF | 5 |
| Palumbo, A | 4 |
| Kamath, S | 2 |
| Vaccaro, SA | 1 |
| Rea, TH | 1 |
| Ochoa, MT | 1 |
| Meyer, JS | 1 |
| Riese, J | 1 |
| Biondi, E | 1 |
| Clarke, SJ | 1 |
| Vardy, JL | 1 |
| Martinez, FJ | 2 |
| de Andrade, JA | 1 |
| Anstrom, KJ | 2 |
| King, TE | 2 |
| Raghu, G | 2 |
| Rau, R | 1 |
| Malek, A | 1 |
| Raeeskarami, SR | 1 |
| Ziaee, V | 1 |
| Aghighi, Y | 1 |
| Moradinejad, MH | 1 |
| Fujimoto, N | 1 |
| Kito, K | 1 |
| Yoshida, T | 1 |
| Tanaka, T | 1 |
| Mathur, P | 1 |
| Zurlo, JJ | 1 |
| Crook, TJ | 1 |
| Liu, Y | 1 |
| Zhao, P | 1 |
| Qu, Z | 1 |
| Ayana, DA | 1 |
| Jiang, Y | 1 |
| Liu, ZC | 1 |
| Guan, GJ | 1 |
| Lv, XA | 1 |
| Luo, Q | 1 |
| Cheng, J | 1 |
| Talamo, G | 1 |
| Malysz, J | 1 |
| Ochmann, M | 1 |
| Lamy, T | 1 |
| Loughran, TP | 1 |
| Ma, H | 1 |
| Zhu, G | 1 |
| Wan, B | 1 |
| Wu, PJ | 1 |
| Wang, JY | 1 |
| Kuno, T | 1 |
| Tamura, Y | 1 |
| Ono, T | 1 |
| Murata, M | 1 |
| Kuwana, M | 1 |
| Satoh, T | 1 |
| Fukuda, K | 1 |
| Alba, MA | 1 |
| García-Martínez, A | 1 |
| Prieto-González, S | 1 |
| Tavera-Bahillo, I | 1 |
| Corbera-Bellalta, M | 1 |
| Planas-Rigol, E | 1 |
| Espígol-Frigolé, G | 1 |
| Butjosa, M | 1 |
| Hernández-Rodríguez, J | 1 |
| Cid, MC | 1 |
| Makiyama, J | 1 |
| Imaizumi, Y | 1 |
| Tsushima, H | 1 |
| Moriwaki, Y | 1 |
| Sawayama, Y | 1 |
| Imanishi, D | 1 |
| Hata, T | 1 |
| Tsukasaki, K | 1 |
| Miyazaki, Y | 1 |
| Markusse, IM | 2 |
| de Vries-Bouwstra, JK | 5 |
| Han, KH | 7 |
| van der Lubbe, PA | 3 |
| Schouffoer, AA | 1 |
| Kerstens, PJ | 9 |
| Lems, WF | 5 |
| Li, W | 1 |
| Cai, L | 2 |
| Zhang, J | 1 |
| Auchus, RJ | 1 |
| Nguyen, S | 1 |
| Mundle, SD | 1 |
| Kalisch, A | 1 |
| Wilhelm, M | 2 |
| Erbguth, F | 1 |
| Birkmann, J | 2 |
| Shin, HC | 1 |
| Seo, J | 1 |
| Kang, BW | 1 |
| Moon, JH | 2 |
| Chae, YS | 3 |
| Lee, YJ | 1 |
| Han, S | 1 |
| Seo, SK | 1 |
| Kim, JG | 2 |
| Sohn, SK | 3 |
| Park, TI | 2 |
| Arkader, A | 1 |
| Jubran, RF | 1 |
| Kim, S | 2 |
| Campbell, KA | 1 |
| Fox, DJ | 2 |
| Matthews, DJ | 2 |
| Valdez, R | 1 |
| Wevers-deBoer, KV | 1 |
| Ronday, HK | 7 |
| Collée, G | 1 |
| Ewer, MS | 1 |
| Lenihan, DJ | 1 |
| Fisch, MJ | 1 |
| Fanale, M | 1 |
| Romaguera, J | 1 |
| Pro, B | 2 |
| Fowler, N | 1 |
| Astrow, AB | 1 |
| Huang, X | 1 |
| Kwak, LW | 1 |
| Samaniego, F | 1 |
| McLaughlin, P | 3 |
| Neelapu, SS | 1 |
| Wang, M | 1 |
| Durand, JB | 1 |
| Rodriguez, MA | 3 |
| Gandhi, JG | 1 |
| Clark, WR | 1 |
| Oh, WK | 1 |
| Agus, DB | 1 |
| Carthon, B | 1 |
| Moran, S | 1 |
| Kong, N | 1 |
| Suri, A | 1 |
| Bargfrede, M | 1 |
| Liu, G | 2 |
| Silvariño, R | 1 |
| Noboa, O | 1 |
| Cervera, R | 1 |
| Bonciani, D | 1 |
| Bonciolini, V | 1 |
| Antiga, E | 1 |
| Verdelli, A | 1 |
| Caproni, M | 1 |
| Senetta, R | 1 |
| Sternberg, CN | 3 |
| Miller, K | 1 |
| Naini, V | 1 |
| Shah, D | 1 |
| Mohan, G | 1 |
| Flueckiger, P | 1 |
| Corrigan, F | 1 |
| Conn, D | 1 |
| de Wit, R | 4 |
| De Bono, J | 1 |
| Cruz, FM | 1 |
| Fountzilas, G | 1 |
| Ulys, A | 1 |
| Carcano, F | 1 |
| Agus, D | 1 |
| Bellmunt, J | 1 |
| Lee, SY | 1 |
| Webb, IJ | 2 |
| Tejura, B | 1 |
| Borgstein, N | 1 |
| Dreicer, R | 2 |
| Ataya, A | 1 |
| Faruqi, I | 1 |
| Salgado, JC | 1 |
| Marton, A | 1 |
| Kezouh, A | 1 |
| Petrogiannis-Haliotis, T | 1 |
| Assouline, S | 1 |
| Jinga, V | 1 |
| Fong, PC | 1 |
| Hart, LL | 1 |
| McDermott, R | 1 |
| Wirth, M | 2 |
| MacLean, DB | 1 |
| Akaza, H | 1 |
| Nelson, J | 1 |
| Ganesan, P | 1 |
| Rajendranath, R | 1 |
| Kannan, K | 1 |
| Radhakrishnan, V | 1 |
| Ganesan, TS | 1 |
| Udupa, K | 1 |
| Lakshmipathy, KM | 1 |
| Mahajan, V | 1 |
| Sundersingh, S | 1 |
| Rajaraman, S | 1 |
| Krishnakumar, R | 1 |
| Sagar, TG | 1 |
| Xu-Monette, ZY | 1 |
| Deng, L | 1 |
| Shen, Q | 1 |
| Manyam, GC | 1 |
| Martinez-Lopez, A | 1 |
| Montes-Moreno, S | 2 |
| Visco, C | 2 |
| Tzankov, A | 1 |
| Yin, L | 1 |
| Dybkaer, K | 1 |
| Chiu, A | 1 |
| Orazi, A | 1 |
| Zu, Y | 1 |
| Bhagat, G | 1 |
| Richards, KL | 1 |
| Hsi, ED | 1 |
| Choi, WW | 2 |
| van Krieken, JH | 1 |
| Huh, J | 3 |
| Ponzoni, M | 1 |
| Ferreri, AJ | 3 |
| Zhao, X | 1 |
| Møller, MB | 1 |
| Farnen, JP | 1 |
| Winter, JN | 1 |
| Pham, L | 1 |
| Young, KH | 1 |
| Zhang, T | 1 |
| Dhawan, MS | 1 |
| Healy, P | 1 |
| George, DJ | 2 |
| Harrison, MR | 1 |
| Oldan, J | 1 |
| Chin, B | 1 |
| Diamond, E | 1 |
| Garcias, Mdel C | 1 |
| Karir, B | 1 |
| Tagawa, ST | 2 |
| van der Pol, CB | 1 |
| Chakraborty, S | 1 |
| Côté, I | 1 |
| Humphrey-Murto, S | 1 |
| Michaud, J | 1 |
| Streu, E | 1 |
| Tandon, A | 1 |
| Villa, CR | 1 |
| Jefferies, JL | 1 |
| Gao, Z | 1 |
| Towbin, JA | 1 |
| Wong, BL | 1 |
| Mazur, W | 1 |
| Fleck, RJ | 1 |
| Sticka, JJ | 1 |
| Benson, DW | 1 |
| Taylor, MD | 1 |
| Kelly, JL | 1 |
| Salles, G | 3 |
| Goldman, B | 1 |
| Press, O | 1 |
| Maloney, DG | 1 |
| Soubeyran, P | 1 |
| Rimsza, L | 1 |
| Haioun, C | 1 |
| Xerri, L | 1 |
| LeBlanc, M | 3 |
| Tilly, H | 2 |
| Baker, JF | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Haroldsen, C | 1 |
| Caplan, L | 1 |
| Mikuls, TR | 1 |
| Gil, B | 1 |
| Merav, L | 1 |
| Pnina, L | 1 |
| Chagai, G | 1 |
| Climent, F | 1 |
| González de Villambrosía, S | 1 |
| González Barca, EM | 1 |
| Batlle, A | 1 |
| Insunza, A | 1 |
| Pané-Foix, M | 1 |
| Colorado, M | 1 |
| Martin-Sánchez, G | 1 |
| Espiga, CR | 1 |
| Conde, E | 1 |
| Polaczek, MM | 1 |
| Zych, J | 1 |
| Opoka, L | 1 |
| Maksymiuk, B | 1 |
| Roszkowski-Sliż, K | 2 |
| Yoon, JH | 1 |
| Kim, JW | 1 |
| Jeon, YW | 1 |
| Lee, SE | 1 |
| Eom, KS | 1 |
| Lee, S | 1 |
| Kim, HJ | 3 |
| Min, CK | 2 |
| Lee, JW | 1 |
| Min, WS | 1 |
| Park, CW | 1 |
| Cho, SG | 1 |
| Johnson, NE | 1 |
| Arnold, WD | 1 |
| Hebert, D | 2 |
| Gwathmey, K | 1 |
| Dimachkie, MM | 1 |
| Barohn, RJ | 1 |
| McVey, AL | 1 |
| Pasnoor, M | 1 |
| Amato, AA | 1 |
| McDermott, MP | 1 |
| Kissel, J | 1 |
| Heatwole, CR | 1 |
| Sato, M | 1 |
| Furuta, M | 1 |
| Hirayanagi, K | 1 |
| Nagamine, S | 1 |
| Makioka, K | 1 |
| Ikeda, Y | 1 |
| Vitale, A | 1 |
| Rigante, D | 1 |
| Caso, F | 1 |
| Franceschini, R | 1 |
| Cantarini, L | 1 |
| Feld, J | 2 |
| Shupak, A | 1 |
| Zisman, D | 1 |
| Kawano, N | 1 |
| Yoshida, S | 1 |
| Kuriyama, T | 1 |
| Tahara, Y | 1 |
| Yamashita, K | 1 |
| Nagahiro, Y | 1 |
| Kawano, J | 1 |
| Koketsu, H | 1 |
| Toyofuku, A | 1 |
| Manabe, T | 1 |
| Beppu, K | 1 |
| Ono, N | 1 |
| Himeji, D | 1 |
| Yokota-Ikeda, N | 1 |
| Inoue, S | 1 |
| Ochiai, H | 1 |
| Sonoda, KH | 1 |
| Shimoda, K | 1 |
| Ishikawa, F | 1 |
| Ueda, A | 1 |
| Hussain, M | 1 |
| Armstrong, A | 1 |
| Ferrari, A | 1 |
| Hainsworth, J | 1 |
| Joshi, A | 1 |
| Hozak, RR | 1 |
| Schwartz, JD | 1 |
| Andreiana, I | 1 |
| Stancu, S | 1 |
| Avram, A | 1 |
| Taran, L | 1 |
| Mircescu, G | 1 |
| Waterman, M | 1 |
| Knight, J | 1 |
| Dinani, A | 1 |
| Stempak, JM | 1 |
| Croitoru, K | 1 |
| Nguyen, GC | 1 |
| Cohen, Z | 1 |
| McLeod, RS | 1 |
| Greenberg, GR | 1 |
| Steinhart, AH | 1 |
| Silverberg, MS | 1 |
| Wark, PA | 1 |
| McDonald, VM | 1 |
| Gibson, PG | 1 |
| Yang, KW | 1 |
| Yu, W | 1 |
| Song, Y | 1 |
| Huang, LH | 1 |
| Han, WK | 1 |
| He, ZS | 1 |
| Jin, J | 1 |
| Zhou, LQ | 1 |
| Adams, HJ | 1 |
| de Klerk, JM | 1 |
| Fijnheer, R | 1 |
| Heggelman, BG | 1 |
| Dubois, SV | 1 |
| Nievelstein, RA | 1 |
| Kwee, TC | 1 |
| Dinçel, N | 1 |
| Yılmaz, E | 1 |
| Kaplan Bulut, İ | 1 |
| Hacıkara, Ş | 1 |
| Mir, S | 1 |
| Shevrin, D | 1 |
| Stein, M | 1 |
| Land, S | 1 |
| Dickow, B | 1 |
| Seashore, JB | 1 |
| Silbiger, JJ | 1 |
| Epelbaum, O | 1 |
| Till, BG | 1 |
| Bernstein, SH | 1 |
| Burack, WR | 1 |
| Floyd, JD | 1 |
| DaSilva, MA | 1 |
| Moore, DF | 1 |
| Gay, F | 1 |
| Oliva, S | 1 |
| Conticello, C | 1 |
| Catalano, L | 1 |
| Corradini, P | 1 |
| Magarotto, V | 2 |
| Carella, A | 1 |
| Malfitano, A | 1 |
| Petrò, D | 1 |
| Evangelista, A | 1 |
| Spada, S | 1 |
| Pescosta, N | 1 |
| Omedè, P | 1 |
| Offidani, M | 1 |
| Ria, R | 1 |
| Pulini, S | 1 |
| Patriarca, F | 1 |
| Hajek, R | 1 |
| Spencer, A | 1 |
| Advani, RH | 1 |
| Lechowicz, MJ | 1 |
| Beaven, AW | 1 |
| Loberiza, F | 1 |
| Carson, KR | 1 |
| Evens, AM | 1 |
| Foss, F | 1 |
| Horwitz, S | 1 |
| Pinter-Brown, LC | 1 |
| Shustov, AR | 1 |
| Vose, JM | 2 |
| Roussel, M | 1 |
| Gamberi, B | 1 |
| Kolb, B | 1 |
| Derigs, HG | 1 |
| Eom, H | 1 |
| Belhadj, K | 1 |
| Lenain, P | 1 |
| Van der Jagt, R | 1 |
| Rigaudeau, S | 1 |
| Dib, M | 1 |
| Hall, R | 1 |
| Jardel, H | 1 |
| Jaccard, A | 1 |
| Karlin, L | 1 |
| Bensinger, W | 1 |
| Schots, R | 3 |
| Leupin, N | 2 |
| Chen, G | 3 |
| Marek, J | 1 |
| Ervin-Haynes, A | 3 |
| Paiva, B | 1 |
| Corchete, LA | 1 |
| Vidriales, MB | 1 |
| Puig, N | 1 |
| Maiso, P | 1 |
| Rodriguez, I | 1 |
| Alignani, D | 1 |
| Burgos, L | 1 |
| Sanchez, ML | 1 |
| Barcena, P | 1 |
| Echeveste, MA | 1 |
| Hernandez, MT | 2 |
| Ocio, EM | 1 |
| Gironella, M | 1 |
| Palomera, L | 2 |
| De Arriba, F | 2 |
| Gonzalez, Y | 1 |
| Johnson, SK | 1 |
| Epstein, J | 1 |
| Barlogie, B | 1 |
| Blade, J | 2 |
| Orfao, A | 1 |
| Pompeo, MQ | 1 |
| Demiselle, J | 1 |
| Sayegh, J | 1 |
| Cousin, M | 1 |
| Olivier, A | 1 |
| Augusto, JF | 1 |
| Posadas, EM | 1 |
| Bruce, J | 1 |
| Lim, EA | 1 |
| Peng, W | 1 |
| Maul, S | 1 |
| Smit, JW | 1 |
| Gonzalez, MD | 1 |
| Tran, N | 1 |
| Nanus, DM | 1 |
| Zinn, DJ | 1 |
| Chakraborty, R | 1 |
| Allen, CE | 1 |
| Mukerji, S | 1 |
| Shahpuri, B | 1 |
| Clayton-Smith, B | 1 |
| Smith, N | 1 |
| Armstrong, P | 1 |
| Hardy, M | 1 |
| Marchant, G | 1 |
| Marsh, E | 1 |
| Ishii, Y | 2 |
| Itabashi, M | 1 |
| Yamamoto, W | 1 |
| Motohashi, K | 1 |
| Matsumoto, K | 1 |
| Pilon, D | 1 |
| Queener, M | 1 |
| Lefebvre, P | 1 |
| Ellis, LA | 1 |
| Hatipoglu, US | 1 |
| Aboussouan, LS | 1 |
| Decker, ML | 1 |
| Emery, DJ | 1 |
| Smyth, PS | 1 |
| Lu, JQ | 1 |
| Lacson, A | 1 |
| Yacyshyn, E | 1 |
| Dirven, L | 3 |
| Goekoop-Ruiterman, YP | 5 |
| van Groenendael, JH | 3 |
| Molenaar, TH | 1 |
| Le Cessie, S | 1 |
| Stijnen, T | 1 |
| Ten Wolde, S | 1 |
| Restuccia, G | 1 |
| Boiardi, L | 1 |
| Cavazza, A | 1 |
| Catanoso, M | 1 |
| Macchioni, P | 1 |
| Muratore, F | 1 |
| Cimino, L | 2 |
| Aldigeri, R | 1 |
| Crescentini, F | 1 |
| Pipitone, N | 2 |
| Salvarani, C | 2 |
| Martínez, C | 1 |
| Díaz-López, A | 1 |
| Rodriguez-Calvillo, M | 1 |
| Terol, MJ | 2 |
| Pérez-Ceballos, E | 1 |
| Jiménez, MJ | 1 |
| Cantalapiedra, A | 1 |
| Domingo-Domenech, E | 1 |
| Rodriguez, MJ | 1 |
| Sampol, A | 1 |
| Espeso, M | 1 |
| López, FJ | 1 |
| Briones, J | 1 |
| García, JF | 1 |
| Sureda, A | 2 |
| Ikeda, S | 1 |
| Ohtani, K | 1 |
| Uwatoku, T | 1 |
| Higo, T | 1 |
| Hulin, C | 2 |
| Lu, J | 2 |
| Rodon, P | 1 |
| Pégourié, B | 1 |
| Garderet, L | 1 |
| Hunter, H | 1 |
| Azais, I | 2 |
| Eek, R | 1 |
| Gisslinger, H | 1 |
| Macro, M | 1 |
| Dakhil, S | 2 |
| Goncalves, C | 1 |
| LeBlanc, R | 1 |
| Romeril, K | 1 |
| Royer, B | 1 |
| Leleu, X | 1 |
| Offner, F | 1 |
| Houck, V | 1 |
| Clifford, R | 1 |
| Bloor, A | 1 |
| Boyle, L | 1 |
| Roberts, C | 1 |
| Collins, GP | 1 |
| Devereux, S | 1 |
| Follows, G | 1 |
| Fox, CP | 1 |
| Gribben, J | 1 |
| Hillmen, P | 1 |
| Hatton, CS | 1 |
| Littlewood, TJ | 1 |
| McCarthy, H | 1 |
| Murray, J | 2 |
| Pettitt, AR | 1 |
| Soilleux, E | 1 |
| Love, SB | 1 |
| Wotherspoon, A | 2 |
| Zeynalova, S | 1 |
| Nickelsen, M | 1 |
| Kansara, R | 1 |
| Villa, D | 1 |
| Glass, B | 3 |
| Gascoyne, RD | 4 |
| Binder, M | 1 |
| Zhang, BY | 1 |
| Hillman, DW | 1 |
| Kohli, R | 1 |
| Kohli, T | 1 |
| Lee, A | 1 |
| Kohli, M | 1 |
| Sundararajan, S | 1 |
| Puvvada, S | 1 |
| Ding, Y | 1 |
| Smetak, M | 1 |
| Reimer, P | 1 |
| Geissinger, E | 1 |
| Ruediger, T | 1 |
| Metzner, B | 2 |
| Schaefer-Eckart, K | 1 |
| Tanyildiz, HG | 1 |
| Dincaslan, H | 1 |
| Yavuz, G | 1 |
| Unal, E | 1 |
| Ikinciogulları, A | 1 |
| Dogu, F | 1 |
| Tacyildiz, N | 1 |
| Eren, R | 1 |
| Nizam, N | 1 |
| Doğu, MH | 1 |
| Mercan, S | 1 |
| Erdemir, AV | 1 |
| Suyanı, E | 1 |
| Abu El-Asrar, AM | 1 |
| Dosari, M | 1 |
| Hemachandran, S | 1 |
| Gikandi, PW | 1 |
| Al-Muammar, A | 1 |
| Martusewicz-Boros, MM | 1 |
| Piotrowska-Kownacka, D | 1 |
| Wiatr, E | 1 |
| Elahi, HA | 1 |
| Bertorini, TE | 1 |
| Igarashi, M | 1 |
| Mays, WH | 1 |
| Whitaker, JN | 1 |
| Cabanillas, F | 4 |
| Rivera, N | 1 |
| Pardo, WI | 1 |
| Audenet, F | 1 |
| Irani, J | 1 |
| Timsit, MO | 1 |
| Barthelemy, P | 1 |
| Beuzeboc, P | 2 |
| Fléchon, A | 2 |
| Linassier, C | 2 |
| Rebillard, X | 1 |
| Richaud, P | 1 |
| Rouprêt, M | 1 |
| Thiery Vuillemin, A | 1 |
| Vincendeau, S | 1 |
| Albiges, L | 1 |
| Song, MK | 2 |
| Chung, JS | 2 |
| Shin, DY | 1 |
| Lim, SN | 1 |
| Lee, GW | 1 |
| Choi, JC | 1 |
| Park, WY | 1 |
| Oh, SY | 1 |
| Staveri, C | 1 |
| Karokis, D | 1 |
| Liossis, SC | 1 |
| Tsang-A-Sjoe, MW | 1 |
| Bultink, IE | 1 |
| Heslinga, M | 1 |
| Voskuyl, AE | 1 |
| Ceriani, L | 1 |
| Martelli, M | 1 |
| Gospodarowicz, MK | 1 |
| Ricardi, U | 1 |
| Chiappella, A | 1 |
| Stelitano, C | 1 |
| Balzarotti, M | 1 |
| Cabrera, ME | 1 |
| Cunningham, D | 2 |
| Guarini, A | 1 |
| Giovanella, L | 1 |
| Johnson, PW | 2 |
| Zucca, E | 1 |
| Lee, JH | 3 |
| Huang, SY | 1 |
| Qiu, L | 1 |
| Lee, JJ | 2 |
| Kim, K | 2 |
| Shen, ZX | 1 |
| Eom, HS | 2 |
| Chen, WM | 1 |
| Lee, JO | 1 |
| Kwak, JY | 2 |
| Yiu, W | 1 |
| Chi, KN | 2 |
| Blumenstein, B | 1 |
| Ferrero, JM | 2 |
| Reeves, J | 1 |
| Merseburger, AS | 1 |
| Bergman, AM | 1 |
| Mukherjee, SD | 1 |
| Zalewski, P | 1 |
| Jacobs, C | 1 |
| Gleave, M | 1 |
| Cho, SF | 1 |
| Liu, YC | 1 |
| Hsiao, HH | 1 |
| Huang, CT | 1 |
| Tsai, YF | 1 |
| Wang, HC | 1 |
| Lin, SF | 1 |
| Liu, TC | 1 |
| Deschênes, G | 1 |
| Vivarelli, M | 1 |
| Peruzzi, L | 1 |
| Ruether, D | 1 |
| Ernst, S | 1 |
| Cheng, T | 2 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Verzegnassi, F | 1 |
| Torzecka, JD | 1 |
| Kondras, K | 1 |
| Dziankowska-Bartkowiak, B | 1 |
| Waszczykowska, E | 1 |
| Modzelewski, B | 1 |
| Jurałowicz, P | 1 |
| Kondras, M | 1 |
| van der Kooij, SM | 4 |
| Güler-Yüksel, M | 4 |
| Zwinderman, AH | 2 |
| de Beus, WM | 1 |
| Breedveld, FC | 2 |
| Dijkmans, BA | 7 |
| Fu, K | 2 |
| Weisenburger, DD | 2 |
| Perry, KD | 1 |
| Smith, LM | 1 |
| Shi, X | 1 |
| Hans, CP | 1 |
| Greiner, TC | 2 |
| Bierman, PJ | 1 |
| Bociek, RG | 1 |
| Armitage, JO | 2 |
| Chan, WC | 2 |
| Ahmadzadeh, A | 2 |
| Derakhshan, A | 1 |
| Schlag, R | 2 |
| Khuageva, NK | 2 |
| Shpilberg, O | 2 |
| Kropff, M | 2 |
| Spicka, I | 1 |
| Samoilova, OS | 1 |
| Dmoszynska, A | 1 |
| Abdulkadyrov, KM | 1 |
| Jiang, B | 1 |
| Anderson, KC | 1 |
| Liu, K | 2 |
| Cakana, A | 2 |
| Durie, BG | 1 |
| Schütt, P | 1 |
| Zimmermann, K | 1 |
| Derks, C | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Poser, M | 1 |
| Hense, J | 1 |
| Metz, K | 1 |
| Anhuf, J | 1 |
| Sandmann, M | 1 |
| Neise, M | 1 |
| Moritz, T | 1 |
| Stuschke, M | 1 |
| Niederle, N | 1 |
| Seeber, S | 1 |
| Nowrousian, MR | 1 |
| Machiels, JP | 2 |
| Mazzeo, F | 1 |
| Clausse, M | 1 |
| Filleul, B | 1 |
| Marcelis, L | 1 |
| Honhon, B | 1 |
| D'Hondt, L | 1 |
| Dopchie, C | 1 |
| Verschaeve, V | 1 |
| Duck, L | 1 |
| Verhoeven, D | 1 |
| Jousten, P | 1 |
| Bonny, MA | 1 |
| Moxhon, AM | 1 |
| Tombal, B | 1 |
| Kerger, J | 1 |
| Gottlieb, K | 1 |
| Anders, K | 1 |
| Kaya, H | 1 |
| Lenz, G | 1 |
| Wright, G | 1 |
| Dave, SS | 1 |
| Xiao, W | 1 |
| Powell, J | 1 |
| Tan, B | 1 |
| Iqbal, J | 1 |
| Vose, J | 1 |
| Bast, M | 1 |
| Kyle, A | 1 |
| May, L | 1 |
| Troen, G | 1 |
| Holte, H | 3 |
| Kvaloy, S | 1 |
| Dierickx, D | 1 |
| Verhoef, G | 1 |
| Delabie, J | 2 |
| Smeland, EB | 1 |
| Jares, P | 1 |
| Martinez, A | 1 |
| Lopez-Guillermo, A | 1 |
| Montserrat, E | 1 |
| Braziel, RM | 1 |
| Cook, JR | 1 |
| Pohlman, B | 1 |
| Sweetenham, J | 1 |
| Tubbs, RR | 1 |
| Hartmann, E | 1 |
| Ott, G | 1 |
| Muller-Hermelink, HK | 3 |
| Wrench, D | 1 |
| Lister, TA | 1 |
| Staudt, LM | 1 |
| Eng, C | 1 |
| Tanaka-Kitajima, N | 1 |
| Iwata, N | 1 |
| Ando, Y | 1 |
| Sakurai, H | 1 |
| Iwami, M | 1 |
| Tsuzuki, K | 1 |
| Kondo, M | 1 |
| Kimura, H | 1 |
| Avshovich, N | 1 |
| Ben-Arieh, Y | 2 |
| Avvisati, G | 1 |
| Odorcic, S | 1 |
| Keystone, EC | 2 |
| Ma, JJ | 1 |
| Niang, SO | 1 |
| Diallo, M | 1 |
| Kane, A | 1 |
| Bocoum, TI | 1 |
| Dieng, MT | 1 |
| Ndiaye, B | 1 |
| Park, JA | 1 |
| Park, SS | 1 |
| Park, SE | 1 |
| Gibbons, CH | 1 |
| Freeman, R | 1 |
| Kawaguchi, T | 1 |
| Horie, S | 1 |
| Bouchenaki, N | 1 |
| Ohno-Matsui, K | 1 |
| Mochizuki, M | 1 |
| Herbort, CP | 2 |
| Shin, DH | 1 |
| Seol, YM | 1 |
| Shin, HJ | 1 |
| Choi, YJ | 1 |
| Cho, GJ | 1 |
| Horakova, D | 5 |
| Dwyer, MG | 4 |
| Havrdova, E | 5 |
| Cox, JL | 4 |
| Dolezal, O | 5 |
| Bergsland, N | 4 |
| Rimes, B | 1 |
| Seidl, Z | 5 |
| Vaneckova, M | 5 |
| Zivadinov, R | 4 |
| Markova, J | 1 |
| Kobe, C | 1 |
| Skopalova, M | 1 |
| Klaskova, K | 1 |
| Dedeckova, K | 1 |
| Plütschow, A | 1 |
| Eich, HT | 2 |
| Dietlein, M | 1 |
| Irodenko, VS | 1 |
| Lee, HS | 1 |
| de Armond, SJ | 1 |
| Layzer, RB | 1 |
| Straathof, CS | 1 |
| Overweg-Plandsoen, WC | 1 |
| van den Burg, GJ | 1 |
| Verschuuren, JJ | 1 |
| de Groot, IJ | 1 |
| Nishimori, H | 1 |
| Matsuo, K | 1 |
| Maeda, Y | 1 |
| Nawa, Y | 1 |
| Sunami, K | 1 |
| Togitani, K | 1 |
| Takimoto, H | 1 |
| Hiramatsu, Y | 1 |
| Kiguchi, T | 1 |
| Yano, T | 1 |
| Yamane, H | 1 |
| Tabayashi, T | 1 |
| Takeuchi, M | 1 |
| Makita, M | 1 |
| Sezaki, N | 1 |
| Yamasuji, Y | 1 |
| Sugiyama, H | 1 |
| Tabuchi, T | 1 |
| Kataoka, I | 1 |
| Fujii, N | 1 |
| Ishimaru, F | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Hara, M | 1 |
| Yoshino, T | 3 |
| Tanimoto, M | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Balgera, R | 1 |
| Agostoni, E | 1 |
| Kupersmith, MJ | 3 |
| Marneros, AG | 1 |
| Grossman, ME | 1 |
| Silvers, DN | 1 |
| Husain, S | 1 |
| Nuovo, GJ | 1 |
| MacGregor-Cortelli, B | 1 |
| Neylon, E | 1 |
| Patterson, M | 1 |
| O'Connor, OA | 1 |
| Zain, JM | 1 |
| Berenson, JR | 1 |
| Leu, S | 1 |
| Sun, PK | 1 |
| Collyer, J | 1 |
| Smidt, A | 1 |
| Stika, CS | 1 |
| Schlosser, B | 1 |
| Mirowski, GW | 1 |
| Vanagunas, A | 1 |
| Buchman, AL | 1 |
| Abasq, C | 1 |
| Mouquet, H | 1 |
| Gilbert, D | 1 |
| Tron, F | 1 |
| Grassi, V | 1 |
| Musette, P | 1 |
| Krasensky, J | 3 |
| Novakova, I | 1 |
| Ticha, V | 1 |
| Dusek, L | 1 |
| Houzvickova, E | 1 |
| Hussein, S | 3 |
| Svobodnik, A | 1 |
| Eccersley, LR | 1 |
| Hoffbrand, AV | 1 |
| Rustin, MH | 1 |
| McNamara, CJ | 1 |
| Cabras, MG | 1 |
| Mamusa, AM | 1 |
| Vitolo, U | 1 |
| Freilone R, R | 1 |
| Dessalvi, P | 1 |
| Orsucci, L | 1 |
| Tonso, A | 1 |
| Levis, A | 1 |
| Liberati, M | 1 |
| Lay, G | 1 |
| Angelucci, E | 1 |
| Shefrin, AE | 1 |
| Goldman, RD | 1 |
| Zhen, ZJ | 1 |
| Ling, JY | 1 |
| Tong, GL | 1 |
| Cai, Y | 1 |
| Sun, XF | 1 |
| Kim, SN | 1 |
| Lee, MH | 1 |
| Telles, RW | 1 |
| Ferreira, GA | 1 |
| da Silva, NP | 1 |
| George, DL | 1 |
| Pradhan, S | 1 |
| Conrad, AL | 1 |
| Go, RS | 1 |
| Gasparetto, C | 1 |
| Gockerman, JP | 1 |
| Diehl, LF | 1 |
| de Castro, CM | 1 |
| Moore, JO | 1 |
| Long, GD | 1 |
| Horwitz, ME | 1 |
| Keogh, G | 1 |
| Chute, JP | 1 |
| Sullivan, KM | 1 |
| Neuwirth, R | 1 |
| Davis, PH | 1 |
| Sutton, LM | 1 |
| Anderson, RD | 1 |
| Chao, NJ | 1 |
| Rizzieri, D | 1 |
| Lieberman, SM | 1 |
| Sherry, DD | 1 |
| Rodenburg, EM | 1 |
| Maartense, E | 1 |
| Posthuma, EF | 1 |
| Anoop, P | 1 |
| Ravindranathan, G | 1 |
| Osuji, N | 1 |
| Dearden, CE | 1 |
| Bain, BJ | 1 |
| Matutes, E | 1 |
| Sartor, O | 2 |
| Witjes, JA | 1 |
| Demkow, T | 1 |
| Eymard, JC | 1 |
| Falcon, S | 1 |
| Calabrò, F | 1 |
| James, N | 1 |
| Bodrogi, I | 2 |
| Harper, P | 1 |
| Berry, W | 2 |
| Petrone, ME | 1 |
| McKearn, TJ | 1 |
| Noursalehi, M | 1 |
| George, M | 1 |
| Rozencweig, M | 1 |
| Iványi, JL | 1 |
| Marton, E | 1 |
| Plander, M | 1 |
| Gyánó, G | 1 |
| Czumbil, L | 1 |
| Tóth, C | 1 |
| Kastritis, E | 1 |
| Delforge, M | 1 |
| Alexeeva, J | 1 |
| Masszi, T | 1 |
| Deraedt, W | 1 |
| Behr, J | 1 |
| Demedts, M | 1 |
| Buhl, R | 1 |
| Dekhuijzen, RP | 1 |
| Jansen, HM | 1 |
| MacNee, W | 1 |
| Thomeer, M | 1 |
| Wallaert, B | 1 |
| Laurent, F | 1 |
| Nicholson, AG | 2 |
| Verbeken, EK | 1 |
| Verschakelen, J | 1 |
| Flower, CD | 1 |
| Petruzzelli, S | 1 |
| De Vuyst, P | 1 |
| van den Bosch, JM | 1 |
| Rodriguez-Becerra, E | 1 |
| Lankhorst, I | 1 |
| Sardina, M | 1 |
| Boissard, G | 1 |
| Derenzini, E | 1 |
| Fina, MP | 1 |
| Venturini, F | 1 |
| Broccoli, A | 1 |
| Gandolfi, L | 1 |
| Pileri, S | 1 |
| Fanti, S | 1 |
| Lopci, E | 1 |
| Castellucci, P | 1 |
| Agostinelli, C | 1 |
| Baccarani, M | 2 |
| Sinno, H | 1 |
| Thibaudeau, S | 1 |
| Coughlin, R | 1 |
| Chitte, S | 1 |
| Williams, B | 1 |
| Allen, JA | 1 |
| Scala, S | 1 |
| Jones, HR | 1 |
| Kost Al, M | 1 |
| Kost Alová, M | 1 |
| Laco, J | 1 |
| Rush, DN | 1 |
| Cockfield, SM | 1 |
| Nickerson, PW | 1 |
| Arlen, DJ | 1 |
| Boucher, A | 1 |
| Busque, S | 1 |
| Girardin, CE | 1 |
| Knoll, GA | 1 |
| Lachance, JG | 1 |
| Landsberg, DN | 1 |
| Shapiro, RJ | 1 |
| Shoker, A | 1 |
| Yilmaz, S | 1 |
| Dittrich, K | 1 |
| Ross, S | 1 |
| Benz, K | 1 |
| Amann, K | 1 |
| Dötsch, J | 1 |
| Sparano, JA | 1 |
| Lee, JY | 1 |
| Kaplan, LD | 1 |
| Levine, AM | 1 |
| Ramos, JC | 1 |
| Ambinder, RF | 1 |
| Wachsman, W | 1 |
| Aboulafia, D | 1 |
| Henry, DH | 1 |
| Von Roenn, J | 1 |
| Dezube, BJ | 1 |
| Remick, SC | 1 |
| Shah, MH | 1 |
| Leichman, L | 1 |
| Ratner, L | 1 |
| Cesarman, E | 1 |
| Chadburn, A | 1 |
| Mitsuyasu, R | 1 |
| Karmon, Y | 1 |
| Blum, S | 1 |
| Levite, R | 1 |
| Barenboim, E | 1 |
| Gadoth, N | 2 |
| He, C | 1 |
| Zhang, SL | 1 |
| Hu, CJ | 1 |
| Tong, DW | 1 |
| Li, YZ | 1 |
| Nguyen, DL | 1 |
| Carmona, EM | 1 |
| Edson, RS | 1 |
| Danila, DC | 1 |
| Bubley, GJ | 1 |
| Haqq, C | 1 |
| Anand, A | 1 |
| Koscuiszka, M | 1 |
| Larson, SM | 1 |
| Schwartz, LH | 1 |
| Fleisher, M | 1 |
| Olin, RL | 1 |
| Kanetsky, PA | 1 |
| Ten Have, TR | 1 |
| Nasta, SD | 1 |
| Schuster, SJ | 1 |
| Andreadis, C | 1 |
| Davis, M | 1 |
| Auh, S | 1 |
| Riva, M | 1 |
| Richert, ND | 1 |
| Frank, JA | 1 |
| McFarland, HF | 1 |
| Hildebrand, BA | 1 |
| Arroyo, R | 1 |
| Bowen, DA | 1 |
| Call, TG | 1 |
| Shanafelt, TD | 1 |
| Kay, NE | 2 |
| Schwager, SM | 1 |
| Reinalda, MS | 1 |
| Rabe, KG | 1 |
| Slager, SL | 1 |
| Zent, CS | 1 |
| Wolfe, KC | 1 |
| Poma, R | 1 |
| Falco, P | 1 |
| Sanpaolo, G | 1 |
| Falcone, AP | 1 |
| Federico, V | 1 |
| Canepa, L | 1 |
| Crugnola, M | 1 |
| Genuardi, M | 1 |
| Ghdifan, S | 1 |
| Couderc, L | 1 |
| Michelet, I | 1 |
| Leguillon, C | 1 |
| Masseline, B | 1 |
| Marguet, C | 1 |
| Hasenclever, D | 4 |
| Kuhnt, E | 1 |
| Eitner, F | 1 |
| Floege, J | 1 |
| Won, YW | 1 |
| Kim, SJ | 3 |
| Ko, YH | 1 |
| Klarenbeek, NB | 4 |
| Gerards, AH | 2 |
| Ueda, K | 1 |
| Yokoyama, M | 1 |
| Asai, H | 1 |
| Koudaira, M | 1 |
| Yamada, S | 1 |
| Katsube, A | 1 |
| Mishima, Y | 1 |
| Sakajiri, S | 1 |
| Takeuchi, K | 1 |
| Saotome, T | 1 |
| Terui, Y | 1 |
| Takahashi, S | 1 |
| Hatake, K | 1 |
| Seys, PE | 2 |
| Halbsguth, TV | 1 |
| Nogová, L | 1 |
| Mueller, H | 1 |
| Sieniawski, M | 1 |
| Eichenauer, DA | 1 |
| Schober, T | 1 |
| Nisters-Backes, H | 1 |
| Borchmann, P | 2 |
| Diehl, V | 8 |
| Josting, A | 3 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Moxley, RT | 1 |
| Pandya, S | 1 |
| Ciafaloni, E | 1 |
| Campbell, K | 1 |
| Mouthon, L | 4 |
| Bérezné, A | 2 |
| Guillevin, L | 4 |
| Valeyre, D | 3 |
| Ozguroglu, M | 1 |
| Hansen, S | 1 |
| Kocak, I | 1 |
| Mackenzie, MJ | 1 |
| Shen, L | 1 |
| Roessner, M | 1 |
| Gupta, S | 1 |
| Sartor, AO | 1 |
| Musolino, A | 1 |
| Boggiani, D | 1 |
| Panebianco, M | 1 |
| Vasini, G | 1 |
| Salvagni, S | 1 |
| Franciosi, V | 1 |
| van Hirtum, PV | 1 |
| Prins, M | 1 |
| ten Oever, J | 1 |
| Nijziel, MR | 1 |
| Vreugdenhil, G | 1 |
| Dercksen, MW | 1 |
| Berenguer, M | 2 |
| Aguilera, V | 2 |
| San Juan, F | 2 |
| Benlloch, S | 2 |
| Rubin, A | 1 |
| López-Andujar, R | 1 |
| Moya, A | 1 |
| Pareja, E | 1 |
| Montalva, E | 1 |
| Yago, M | 1 |
| de Juan, M | 1 |
| Mir, J | 1 |
| Prieto, M | 2 |
| Peces, R | 1 |
| Vega-Cabrera, C | 1 |
| Peces, C | 1 |
| Pobes, A | 1 |
| Fresno, MF | 1 |
| Rocha Araújo, FD | 1 |
| Brandão, KN | 1 |
| Araújo, FA | 1 |
| Vasconcelos Severiano, GM | 1 |
| Alves Meira, ZM | 1 |
| Calamia, KT | 1 |
| Matteson, EL | 2 |
| Hunder, GG | 2 |
| Miller, DV | 1 |
| Warrington, KJ | 1 |
| Pérez-Crespo, M | 1 |
| Moragón, M | 1 |
| Onrubia, J | 1 |
| Sevila, A | 1 |
| Alfonso, R | 1 |
| Miralles, J | 1 |
| Requena, L | 1 |
| Dreyling, M | 2 |
| Polliack, A | 3 |
| Tadmor, T | 1 |
| Petrioli, R | 1 |
| Pascucci, A | 1 |
| Conca, R | 1 |
| Chiriacò, G | 1 |
| Francini, E | 1 |
| Bargagli, G | 1 |
| Fiaschi, AI | 1 |
| Manganelli, A | 1 |
| De Rubertis, G | 1 |
| Barbanti, G | 1 |
| Ponchietti, R | 1 |
| Francini, G | 1 |
| Kýr, M | 1 |
| Lelková, P | 1 |
| Pospíšilová, L | 1 |
| Martinez, FD | 1 |
| Chinchilli, VM | 1 |
| Morgan, WJ | 1 |
| Boehmer, SJ | 1 |
| Lemanske, RF | 2 |
| Mauger, DT | 1 |
| Strunk, RC | 1 |
| Szefler, SJ | 2 |
| Zeiger, RS | 1 |
| Bacharier, LB | 1 |
| Bade, E | 1 |
| Covar, RA | 1 |
| Friedman, NJ | 1 |
| Guilbert, TW | 1 |
| Heidarian-Raissy, H | 1 |
| Kelly, HW | 1 |
| Malka-Rais, J | 1 |
| Mellon, MH | 1 |
| Sorkness, CA | 2 |
| Taussig, L | 1 |
| Moumine, M | 1 |
| Sabani, H | 1 |
| Qamous, W | 1 |
| Nassih, M | 1 |
| Al Bouzidi, A | 1 |
| Rzin, A | 1 |
| Ramos, A | 1 |
| García, R | 2 |
| Sanz, J | 1 |
| Daza, RM | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Sekiguchi, Y | 1 |
| Imai, H | 1 |
| Wakabayashi, M | 1 |
| Sawada, T | 1 |
| Ichikawa, K | 1 |
| Komatsu, N | 1 |
| Noguchi, M | 1 |
| Minami, Y | 1 |
| Hirabayashi, Y | 1 |
| Nagata, C | 1 |
| Ishii, T | 1 |
| Harigae, H | 1 |
| Sasaki, T | 1 |
| Cicero, G | 1 |
| De Luca, R | 1 |
| Rexer, H | 1 |
| Chu, L | 1 |
| Jones, RJ | 1 |
| Goodman, OB | 1 |
| Staffurth, JN | 1 |
| Harland, S | 1 |
| Hutson, TE | 1 |
| Patterson, H | 1 |
| Ellard, SL | 1 |
| Saleh, M | 1 |
| Scholz, M | 1 |
| Zivi, A | 1 |
| Loriot, Y | 1 |
| Chieffo, N | 1 |
| Haqq, CM | 1 |
| Soleymanian, T | 1 |
| Najafi, I | 1 |
| Salimi, BH | 1 |
| Broomand, B | 1 |
| Marcheselli, R | 1 |
| Bari, A | 1 |
| Liardo, EV | 1 |
| Morabito, F | 1 |
| Baldini, L | 1 |
| Brugiatelli, M | 1 |
| Merli, F | 1 |
| Di Renzo, N | 1 |
| Sacchi, S | 1 |
| Hashimoto, N | 1 |
| Sasaki, R | 1 |
| Nishimura, H | 1 |
| Yoshida, K | 1 |
| Miyawaki, D | 1 |
| Nakayama, M | 1 |
| Uehara, K | 1 |
| Okamoto, Y | 1 |
| Ejima, Y | 1 |
| Azumi, A | 1 |
| Matsui, T | 1 |
| Sugimura, K | 1 |
| Hui-Yuen, JS | 1 |
| Imundo, LF | 1 |
| Avitabile, C | 1 |
| Kahn, PJ | 1 |
| Eichenfield, AH | 1 |
| Levy, DM | 1 |
| Felipez, LM | 1 |
| Gokhale, R | 1 |
| Tierney, MP | 1 |
| Kirschner, BS | 1 |
| Watanabe, T | 1 |
| Mori, M | 1 |
| Kim, SW | 2 |
| Maeshima, AM | 1 |
| Tanosaki, R | 1 |
| Matsuno, Y | 2 |
| Patel, M | 1 |
| Perrin, K | 1 |
| Beasley, R | 1 |
| Berger, G | 1 |
| Hardak, E | 1 |
| Shaham, B | 1 |
| Avitan, E | 1 |
| Yigla, M | 1 |
| Yhim, HY | 1 |
| Kim, JS | 2 |
| Kang, HJ | 1 |
| Kim, JA | 1 |
| Won, JH | 1 |
| Shim, H | 1 |
| Lee, DH | 1 |
| Suh, C | 2 |
| Meskin, SW | 1 |
| Carlson, EM | 1 |
| Lim, SH | 1 |
| Fosså, A | 1 |
| Fiskvik, IH | 1 |
| Kolstad, A | 1 |
| Lauritzsen, GF | 2 |
| Aurlien, E | 1 |
| Blystad, AK | 1 |
| Hole, KH | 1 |
| Ikonomou, IM | 1 |
| van de Schans, SAM | 1 |
| Wymenga, ANM | 1 |
| van Spronsen, DJ | 1 |
| Schouten, HC | 1 |
| Coebergh, JWW | 1 |
| Janssen-Heijnen, MLG | 1 |
| Bousquet, G | 1 |
| Alexandre, J | 1 |
| Le Tourneau, C | 1 |
| Goldwasser, F | 1 |
| Faivre, S | 1 |
| de Mont-Serrat, H | 1 |
| Kaiser, R | 1 |
| Misset, JL | 1 |
| Raymond, E | 1 |
| Stauder, MC | 1 |
| Zhang, YJ | 1 |
| Poortmans, P | 2 |
| Li, YX | 2 |
| Constantinou, N | 1 |
| Thariat, J | 1 |
| Kadish, SP | 1 |
| Nguyen, TD | 1 |
| Kirova, YM | 1 |
| Ghadjar, P | 1 |
| Weber, DC | 1 |
| Bertran, VT | 1 |
| Ozsahin, M | 2 |
| Mirimanoff, RO | 1 |
| Ewals, JA | 1 |
| Lu, DF | 1 |
| Moon, M | 1 |
| Lanning, LD | 1 |
| McCarthy, AM | 1 |
| Smith, RJ | 1 |
| Benbouazza, K | 1 |
| Benchekroun, B | 1 |
| Rkain, H | 1 |
| Amine, B | 1 |
| Bzami, F | 1 |
| Benbrahim, L | 1 |
| Atouf, O | 1 |
| Essakalli, M | 1 |
| Abouqal, R | 1 |
| Dougados, M | 1 |
| Hajjaj-Hassouni, N | 1 |
| Sadek, BH | 1 |
| Sqalli, Z | 1 |
| Al Hamany, Z | 1 |
| Benamar, L | 1 |
| Bayahia, R | 1 |
| Ouzeddoun, N | 1 |
| Chang, HJ | 1 |
| Do, YR | 1 |
| Bae, SH | 1 |
| Lee, JL | 2 |
| Nam, SH | 1 |
| Bang, SM | 1 |
| Radić, M | 1 |
| Martinović Kaliterna, D | 1 |
| Radić, J | 1 |
| Hattori, Y | 1 |
| Matsumoto, C | 1 |
| Adams, RA | 1 |
| Coman, WB | 1 |
| Heck, MM | 1 |
| Höppner, M | 1 |
| Horn, T | 1 |
| Thalgott, M | 1 |
| Gschwend, JE | 1 |
| Retz, M | 1 |
| Muslmani, M | 1 |
| Gilson, M | 1 |
| Sudre, A | 1 |
| Juvin, R | 1 |
| Gaudin, P | 1 |
| Moritake, H | 1 |
| Yamada, A | 1 |
| Kimoto, Y | 1 |
| Sawa, D | 1 |
| Shimonodan, H | 1 |
| Nunoi, H | 1 |
| Bruessow, C | 1 |
| Karrer, U | 1 |
| Gubler, J | 1 |
| Pless, M | 1 |
| Rubio-Rivas, M | 1 |
| Gómez-Junyent, J | 1 |
| Simonetti, A | 1 |
| Mitjavila, F | 1 |
| Capdevila, O | 1 |
| Pujol, R | 1 |
| Kalincik, T | 1 |
| Child, N | 1 |
| O'Carroll, M | 1 |
| Berkahn, L | 1 |
| Lota, HK | 1 |
| Dusmet, M | 1 |
| Steele, K | 1 |
| Wells, AU | 1 |
| Hansell, DM | 1 |
| Renzoni, EA | 1 |
| Hommos, M | 1 |
| Sinkey, C | 1 |
| Haynes, WG | 1 |
| Dixon, BS | 1 |
| McKeown, E | 1 |
| Bykerk, VP | 1 |
| De Leon, F | 1 |
| Bonner, A | 1 |
| Thorne, C | 1 |
| Boire, G | 1 |
| Haraoui, B | 1 |
| Ferland, DS | 1 |
| Pope, JE | 1 |
| Lasky, JA | 1 |
| He, XH | 1 |
| Lu, N | 1 |
| Zou, SM | 1 |
| Song, YW | 1 |
| Zheng, S | 1 |
| Dong, M | 1 |
| Zhou, SY | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Feng, FY | 1 |
| Shi, YK | 1 |
| Meulenbeld, HJ | 1 |
| van Werkhoven, ED | 1 |
| Coenen, JL | 1 |
| Creemers, GJ | 1 |
| Loosveld, OJ | 1 |
| de Jong, PC | 1 |
| Ten Tije, AJ | 1 |
| Fosså, SD | 2 |
| Polee, M | 1 |
| Gerritsen, W | 1 |
| Dalesio, O | 1 |
| Pires, C | 1 |
| Foreid, H | 1 |
| Barroso, C | 1 |
| Ferro, JM | 1 |
| d'Amore, F | 1 |
| Relander, T | 1 |
| Jantunen, E | 1 |
| Hagberg, H | 1 |
| Anderson, H | 1 |
| Österborg, A | 1 |
| Merup, M | 1 |
| Brown, P | 1 |
| Kuittinen, O | 1 |
| Erlanson, M | 1 |
| Østenstad, B | 1 |
| Fagerli, UM | 1 |
| Gadeberg, OV | 1 |
| Sundström, C | 1 |
| Ralfkiaer, E | 1 |
| Vornanen, M | 1 |
| Toldbod, HE | 1 |
| Gordon, L | 1 |
| Paietta, E | 1 |
| Forero-Torres, A | 1 |
| Advani, R | 2 |
| Hong, F | 1 |
| Horning, SJ | 3 |
| Tsuji, RK | 1 |
| Bittencourt, AG | 1 |
| Arai, MH | 1 |
| Santiago Gebrim, EM | 1 |
| Silver, B | 1 |
| Nagel, MA | 1 |
| Mahalingam, R | 1 |
| Cohrs, R | 1 |
| Schmid, DS | 1 |
| Gilden, D | 1 |
| van den Broek, M | 1 |
| Kroon, HM | 1 |
| Pasoto, SG | 1 |
| Natalino, RR | 1 |
| Chakkour, HP | 1 |
| Viana, Vdos S | 1 |
| Bueno, C | 1 |
| Leon, EP | 1 |
| Vendramini, MB | 1 |
| Neto, ML | 1 |
| Bonfa, E | 1 |
| Williams, KW | 1 |
| Andrews, AL | 1 |
| Heine, D | 1 |
| Russell, WS | 1 |
| Titus, MO | 1 |
| Uzark, K | 1 |
| King, E | 1 |
| Cripe, L | 1 |
| Spicer, R | 1 |
| Sage, J | 1 |
| Kinnett, K | 1 |
| Pratt, J | 1 |
| Varni, JW | 1 |
| Denlinger, LC | 1 |
| Manthei, DM | 1 |
| Seibold, MA | 1 |
| Ahn, K | 1 |
| Bleecker, E | 1 |
| Boushey, HA | 1 |
| Calhoun, WJ | 1 |
| Castro, M | 1 |
| Chinchili, VM | 1 |
| Fahy, JV | 1 |
| Hawkins, GA | 1 |
| Icitovic, N | 1 |
| Israel, E | 1 |
| Jarjour, NN | 1 |
| King, T | 1 |
| Kraft, M | 1 |
| Lazarus, SC | 1 |
| Lehman, E | 1 |
| Martin, RJ | 1 |
| Meyers, DA | 1 |
| Peters, SP | 1 |
| Sheerar, D | 1 |
| Shi, L | 1 |
| Sutherland, ER | 1 |
| Wechsler, ME | 1 |
| Aaron, SD | 1 |
| Vandemheen, KL | 1 |
| Maltais, F | 1 |
| Field, SK | 1 |
| Sin, DD | 1 |
| Bourbeau, J | 1 |
| Marciniuk, DD | 1 |
| FitzGerald, JM | 1 |
| Mallick, R | 1 |
| Sifuentes Giraldo, WA | 1 |
| de la Puente Bujidos, C | 1 |
| de Blas Beorlegui, G | 1 |
| López San Román, A | 1 |
| Peña Arrebola, A | 1 |
| Yang, DH | 1 |
| Ahn, JS | 1 |
| Byun, BH | 1 |
| Min, JJ | 1 |
| Kweon, SS | 1 |
| Lee, SW | 1 |
| Kim, HW | 1 |
| Jung, SH | 1 |
| Kim, YK | 1 |
| Bom, HS | 1 |
| Ayodele, OE | 1 |
| Okpechi, IG | 1 |
| Swanepoel, CR | 1 |
| Shavit, E | 1 |
| Horev, A | 1 |
| Berman, E | 1 |
| Halevy, S | 1 |
| George, JN | 1 |
| Felman, P | 1 |
| Berger, F | 2 |
| Dumontet, C | 1 |
| Arnaud, P | 1 |
| Hequet, O | 1 |
| Arcache, J | 1 |
| Callet-Bauchu, E | 1 |
| Coiffier, B | 3 |
| Pavesi, G | 1 |
| Cattaneo, L | 1 |
| Marbini, A | 1 |
| Gemignani, F | 1 |
| Mancia, D | 1 |
| Nagao, T | 1 |
| Nagai, S | 1 |
| Hiramoto, Y | 1 |
| Hamada, K | 1 |
| Shigematsu, M | 1 |
| Hayashi, M | 1 |
| Izumi, T | 1 |
| Mishima, M | 1 |
| Saxena, A | 1 |
| Moshynska, O | 1 |
| Sankaran, K | 1 |
| Viswanathan, S | 1 |
| Sheridan, DP | 1 |
| Piso, RJ | 1 |
| Rossi, M | 1 |
| Oehler, T | 1 |
| Nguyen, XM | 1 |
| Täuber, MG | 1 |
| Verrini, A | 1 |
| Cannata, G | 1 |
| Cozzani, E | 1 |
| Terracini, M | 1 |
| Parodi, A | 1 |
| Rebora, A | 1 |
| Modiano, M | 1 |
| Gregurich, M | 1 |
| Asmar, L | 1 |
| Hernández, G | 1 |
| Arriba, L | 1 |
| Jiménez, C | 1 |
| Bagán, JV | 1 |
| Rivera, B | 1 |
| Lucas, M | 1 |
| Moreno, E | 1 |
| Latkany, R | 1 |
| Homel, P | 1 |
| Mazlumzadeh, M | 1 |
| Lowe, VJ | 1 |
| Mullan, BP | 1 |
| Fabry, DA | 1 |
| McDonald, TJ | 1 |
| Gaulke, R | 1 |
| Suppelna, G | 1 |
| Barbón García, JJ | 1 |
| Viña Escalar, C | 1 |
| Menéndez Fernández, CL | 1 |
| Fernández Alvarez, C | 1 |
| Carballo Fernández, C | 1 |
| Villarreal Renedo, PM | 1 |
| Valleala, H | 1 |
| Mandelin, J | 1 |
| Laasonen, L | 1 |
| Koivula, MK | 1 |
| Risteli, J | 1 |
| Konttinen, YT | 1 |
| Sieber, M | 3 |
| Bredenfeld, H | 1 |
| Reineke, T | 1 |
| Rueffer, U | 1 |
| Koch, T | 1 |
| Naumann, R | 1 |
| Boissevain, F | 3 |
| Koch, P | 3 |
| Worst, P | 2 |
| Soekler, M | 1 |
| Eich, H | 1 |
| Franklin, J | 3 |
| Paulus, U | 2 |
| Wolf, J | 3 |
| Weiss, RB | 1 |
| Woolf, SH | 1 |
| Demakos, E | 1 |
| Holland, JF | 1 |
| Berry, DA | 1 |
| Falkson, G | 1 |
| Cirrincione, CT | 1 |
| Robbins, A | 1 |
| Bothun, S | 1 |
| Henderson, IC | 1 |
| Norton, L | 1 |
| Seoane Urgorri, A | 1 |
| Galeras Sadurni, JA | 1 |
| Coll Estrada, S | 1 |
| Solà Lamoglia, R | 1 |
| Bory Ros, F | 1 |
| Pagnoux, C | 2 |
| Hayem, G | 1 |
| Roux, F | 1 |
| Palazzo, E | 1 |
| Meyer, O | 1 |
| Paschal, BR | 1 |
| Dieckmann, K | 1 |
| Pötter, R | 1 |
| Hofmann, J | 1 |
| Heinzl, H | 1 |
| Wagner, W | 1 |
| Schellong, G | 1 |
| Luxon, BA | 1 |
| Amato, L | 1 |
| Mei, S | 1 |
| Gallerani, I | 1 |
| Moretti, S | 1 |
| Fabbri, P | 1 |
| Schiller, P | 1 |
| Herrmann, R | 1 |
| De Wit, M | 1 |
| Mezger, J | 1 |
| Duhmke, E | 3 |
| Willich, N | 1 |
| Muller, RP | 2 |
| Schmidt, BF | 1 |
| Renner, H | 1 |
| Pfistner, B | 2 |
| Loffler, M | 1 |
| Samad, AS | 1 |
| Lindsley, CB | 1 |
| Ernst, DS | 2 |
| Winquist, EW | 1 |
| Venner, PM | 1 |
| Reyno, L | 1 |
| Moore, MJ | 1 |
| Chi, K | 1 |
| Ding, K | 1 |
| Elliott, C | 1 |
| Parulekar, W | 1 |
| Rahman, P | 1 |
| Ibañez, D | 1 |
| Tam, LS | 1 |
| Yamamoto, Y | 1 |
| Teruya, K | 1 |
| Katano, H | 1 |
| Niino, H | 1 |
| Yasuoka, A | 1 |
| Kimura, S | 1 |
| Oka, S | 1 |
| Papapetropoulos, TH | 1 |
| Ellul, J | 1 |
| Tsibri, E | 1 |
| Miller, OF | 1 |
| Smith, LJ | 1 |
| Ferrara, EX | 1 |
| McAleer, IM | 1 |
| Kaplan, GW | 1 |
| Zijlstra, JM | 1 |
| Hoekstra, OS | 1 |
| Raijmakers, PG | 1 |
| Comans, EF | 1 |
| van der Hoeven, JJ | 1 |
| Teule, GJ | 1 |
| Jonkhoff, AR | 1 |
| v Tinteren, H | 1 |
| Lammertsma, AA | 1 |
| Huijgens, PC | 1 |
| Trojet, S | 1 |
| Loukil, I | 1 |
| El Afrit, MA | 1 |
| Mazlout, H | 1 |
| Lamloum, M | 2 |
| Kraiem, A | 1 |
| Alexandrakis, MG | 1 |
| Passam, FH | 1 |
| Sfiridaki, K | 1 |
| Moschandrea, J | 1 |
| Pappa, C | 1 |
| Liapi, D | 1 |
| Petreli, E | 1 |
| Roussou, P | 1 |
| Kyriakou, DS | 1 |
| Mauro, FR | 1 |
| Zinzani, P | 1 |
| Zaja, F | 1 |
| Gentile, M | 2 |
| Vegna, ML | 1 |
| Marin, L | 1 |
| Fanin, R | 1 |
| Tura, S | 1 |
| Mandelli, F | 2 |
| Monsul, NT | 1 |
| Patwa, HS | 1 |
| Knorr, AM | 1 |
| Lesser, RL | 1 |
| Goldstein, JM | 1 |
| Ferrari, TC | 1 |
| Moreira, PR | 1 |
| Cunha, AS | 1 |
| Kloess, M | 1 |
| Schmits, R | 2 |
| Feller, AC | 1 |
| Rudolph, C | 1 |
| Reiser, M | 1 |
| Hossfeld, DK | 2 |
| Rübe, C | 1 |
| Niaudet, P | 1 |
| Vrancken, AF | 1 |
| Notermans, NC | 2 |
| Jansen, GH | 1 |
| Wokke, JH | 2 |
| Said, G | 1 |
| van Everdingen, AA | 2 |
| Siewertsz van Reesema, DR | 2 |
| Jacobs, JW | 2 |
| Bijlsma, JW | 2 |
| Kimby, E | 1 |
| Sverrisdottir, A | 1 |
| Elinder, G | 1 |
| Tumlin, JA | 1 |
| Hennigar, RA | 1 |
| Crovetto, M | 1 |
| Solano, D | 1 |
| Centeno, J | 1 |
| Czaja, AJ | 2 |
| Carpenter, HA | 1 |
| Rubio, E | 1 |
| Acevedo, M | 1 |
| Cohen, Y | 1 |
| Amir, G | 1 |
| Schibi, G | 1 |
| Amariglio, N | 1 |
| Mirsattari, SM | 1 |
| McGinn, GJ | 1 |
| Halliday, WC | 1 |
| Gural, A | 1 |
| Kornberg, A | 1 |
| Spectre, G | 1 |
| Shopen, A | 1 |
| Paltiel, O | 1 |
| Zeidman, LA | 1 |
| Melen, O | 1 |
| Gottardi-Littell, N | 1 |
| Getch, C | 1 |
| Alberts, MJ | 1 |
| Goldstein, L | 1 |
| Bernstein, RA | 1 |
| Cannon, JD | 1 |
| Pullen, RL | 1 |
| Rushing, JD | 1 |
| Lane, M | 1 |
| McBride, J | 1 |
| Archer, J | 1 |
| Jabbour, E | 2 |
| Chalhoub, B | 1 |
| Suzan, F | 1 |
| Aloulou, S | 1 |
| Cainap, C | 2 |
| Toumi, N | 1 |
| Fermé, C | 3 |
| Ribrag, V | 2 |
| Doorduijn, JK | 2 |
| Buijt, I | 1 |
| van der Holt, B | 2 |
| van Agthoven, M | 1 |
| Sonneveld, P | 2 |
| Uyl-de Groot, CA | 1 |
| Acquatella, G | 1 |
| Insausti, CL | 1 |
| Gómez, R | 1 |
| Hernández, M | 1 |
| Carneiro, M | 1 |
| Santos, S | 1 |
| Nouel, A | 1 |
| Adams, AE | 1 |
| Zwicker, J | 1 |
| Curiel, C | 1 |
| Kadin, ME | 1 |
| Falchuk, KR | 1 |
| Drews, R | 1 |
| Kupper, TS | 1 |
| Haran, MZ | 1 |
| Basous, L | 1 |
| Berrebi, A | 1 |
| Lefrère, F | 1 |
| Delmer, A | 1 |
| Levy, V | 2 |
| Varet, B | 1 |
| Hermine, O | 1 |
| Rasquin, FA | 1 |
| Pereleux, AA | 1 |
| Hudson, MM | 1 |
| Krasin, M | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Billups, C | 1 |
| Merchant, TE | 1 |
| Kun, L | 1 |
| Billet, AL | 1 |
| Kaste, S | 1 |
| Tarbell, NJ | 1 |
| Howard, S | 1 |
| Friedmann, AM | 2 |
| Hurwitz, CA | 1 |
| Young, JA | 1 |
| Marcus, KC | 1 |
| Rai, S | 1 |
| Cowan, T | 1 |
| Weinstein, HJ | 1 |
| Katahira, T | 1 |
| Takayama, T | 1 |
| Miyanishi, K | 1 |
| Hayashi, T | 1 |
| Ikeda, T | 1 |
| Takahashi, Y | 1 |
| Takimoto, R | 1 |
| Matsunaga, T | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Ozdemir, F | 1 |
| Aydin, F | 1 |
| Yilmaz, M | 1 |
| Kavgaci, H | 1 |
| Bektas, O | 1 |
| Yavuz, MN | 1 |
| Yavuz, AA | 1 |
| Nakamoto, BK | 1 |
| Dorotheo, EU | 1 |
| Biousse, V | 2 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Newman, NJ | 1 |
| Rabar, D | 1 |
| Issartel, B | 1 |
| Petiot, P | 1 |
| Boibieux, A | 1 |
| Chidiac, C | 1 |
| Peyramond, D | 1 |
| Balwierz, W | 1 |
| Moryl-Bujakowska, A | 1 |
| Depowska, T | 1 |
| Klekawka, T | 1 |
| Stanuch, H | 1 |
| Matysiak, M | 1 |
| Sopyło, B | 1 |
| Kołakowska-Mrozowska, B | 1 |
| Krenke, K | 1 |
| Chybicka, A | 1 |
| Raś, M | 1 |
| Sońta-Jakimczyk, D | 1 |
| Moszant, A | 1 |
| Wachowiak, J | 1 |
| Kaczmarek-Kanold, M | 1 |
| Kowalczyk, J | 1 |
| Odój, T | 1 |
| Balcerska, A | 1 |
| Drozyńska, E | 1 |
| Wysocki, M | 1 |
| Kołtan, A | 1 |
| Krawczuk-Rybak, M | 1 |
| Stolarska, M | 1 |
| Sacks, O | 1 |
| Shulman, M | 1 |
| Banu, E | 1 |
| Voog, E | 1 |
| Dourthe, LM | 1 |
| Hardy-Bessard, AC | 1 |
| Scotté, F | 1 |
| Banu, A | 1 |
| Coscas, Y | 1 |
| Guinet, F | 1 |
| Poupon, MF | 1 |
| Andrieu, JM | 2 |
| Hornberger, JC | 1 |
| Best, JH | 1 |
| Moore, CN | 1 |
| Incalzi, RA | 1 |
| Gambassi, G | 1 |
| Bernabei, R | 1 |
| Bonadonna, G | 2 |
| Bonfante, V | 1 |
| Ward, SE | 1 |
| Loutfy, MR | 1 |
| Blatt, LM | 1 |
| Siminovitch, KA | 1 |
| Hinek, A | 1 |
| Wolff, B | 1 |
| Pham, DH | 1 |
| Deif, H | 1 |
| LaMere, EA | 1 |
| Kain, KC | 1 |
| Farcas, GA | 1 |
| Ferguson, P | 1 |
| Latchford, M | 1 |
| Levy, G | 1 |
| Fung, L | 1 |
| Dennis, JW | 1 |
| Lai, EK | 1 |
| Fish, EN | 1 |
| Feugier, P | 2 |
| Van Hoof, A | 1 |
| Sebban, C | 1 |
| Solal-Celigny, P | 2 |
| Bouabdallah, R | 1 |
| Christian, B | 1 |
| Lepage, E | 2 |
| Bosly, A | 1 |
| Gisselbrecht, C | 1 |
| Reyes, F | 2 |
| Ishikura, S | 2 |
| Ohtsu, A | 2 |
| Nakamura, S | 2 |
| Oda, I | 2 |
| Takagi, T | 1 |
| Mera, K | 2 |
| Kagami, Y | 1 |
| Itoh, K | 1 |
| Tamaki, Y | 1 |
| Suzumiya, J | 2 |
| Taniwaki, M | 1 |
| Yamamoto, S | 1 |
| Gorin, R | 1 |
| Sorin, M | 1 |
| Meyer, A | 1 |
| Batisse, A | 1 |
| Toumieux, MC | 1 |
| Mozziconacci, P | 1 |
| Bariakh, EA | 1 |
| Zvonkov, EE | 1 |
| Kremenetskaia, AM | 1 |
| Kravchenko, SK | 1 |
| Magomedova, AU | 1 |
| Obukhova, TN | 1 |
| Samoĭlova, RS | 1 |
| Vorob'ev, IA | 1 |
| Kaplanskaia, IB | 1 |
| Moiseeva, TN | 1 |
| Zybunova, EE | 1 |
| Lorie, IuIu | 1 |
| Chernova, NG | 1 |
| Mar'in, DS | 1 |
| Egorova, EK | 1 |
| Krasil'nikova, BB | 1 |
| Gabeeva, NG | 1 |
| Vorob'ev, AI | 1 |
| Tatò, F | 1 |
| Rieger, J | 1 |
| Hoffmann, U | 1 |
| Kaufman, DB | 1 |
| Leventhal, JR | 1 |
| Axelrod, D | 1 |
| Gallon, LG | 1 |
| Parker, MA | 1 |
| Stuart, FP | 1 |
| Enschede, SH | 1 |
| Porter, C | 1 |
| Venugopal, P | 1 |
| Gregory, SA | 1 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Balaban, B | 1 |
| Clayton, GH | 1 |
| Carry, T | 1 |
| van Zeben, D | 1 |
| Hazes, JM | 1 |
| Westedt, ML | 1 |
| van Krugten, MV | 1 |
| Bohmeyer, J | 1 |
| Stadler, R | 1 |
| Kremer, A | 1 |
| Nashan, D | 1 |
| Muche, M | 1 |
| Gellrich, S | 1 |
| Luger, T | 1 |
| Sterry, W | 1 |
| Oprea, C | 1 |
| Azoulay, R | 1 |
| Assaf, E | 1 |
| Koscielny, S | 1 |
| Lapusan, S | 1 |
| Vanel, D | 1 |
| Bosq, J | 1 |
| Ghielmini, M | 1 |
| Werner de Castro, GR | 1 |
| Appenzeller, S | 1 |
| Bértolo, MB | 1 |
| Costallat, LT | 1 |
| Galli, M | 1 |
| Nicolucci, A | 1 |
| Valentini, M | 1 |
| Belfiglio, M | 1 |
| Delaini, F | 1 |
| Crippa, C | 1 |
| Barbui, AM | 1 |
| Giussani, U | 1 |
| Barbui, T | 1 |
| Bizzoni, L | 1 |
| Mazzucconi, MG | 1 |
| Santoro, C | 1 |
| Bernasconi, S | 1 |
| Chiarotti, F | 1 |
| Foà, R | 1 |
| Ochiai, A | 1 |
| Yokoi, T | 1 |
| Kitadai, Y | 1 |
| Siman-Tov, T | 1 |
| Meiner, V | 1 |
| Rayón, JM | 1 |
| Berenguer, J | 1 |
| Burton, C | 1 |
| Linch, D | 1 |
| Hoskin, P | 1 |
| Milligan, D | 1 |
| Dyer, MJ | 1 |
| Hancock, B | 1 |
| Mouncey, P | 1 |
| Smith, P | 1 |
| Qian, W | 1 |
| MacLennan, K | 1 |
| Jack, A | 1 |
| Webb, A | 1 |
| Osowo, A | 1 |
| Fetten, J | 1 |
| Navaneethan, S | 1 |
| Klimza, MJ | 1 |
| Sońta-Jakimczyk, DJ | 1 |
| Gielen, GA | 1 |
| Wetzels, JF | 1 |
| Steenbergen, EJ | 1 |
| Mudde, AH | 1 |
| Arlet, JB | 1 |
| Dimitri, D | 1 |
| Boyer, O | 1 |
| Maisonobe, T | 1 |
| Authier, FJ | 1 |
| Bloch-Queyrat, C | 1 |
| Goulvestre, C | 1 |
| Heshmati, F | 1 |
| Atassi, M | 1 |
| Herson, S | 1 |
| Benveniste, O | 1 |
| Knobel, D | 1 |
| Zouhair, A | 1 |
| Tsang, RW | 1 |
| Belkacémi, Y | 1 |
| Bolla, M | 1 |
| Oner, FD | 1 |
| Landmann, C | 1 |
| Castelain, B | 1 |
| Lambotte, O | 1 |
| Khellaf, M | 1 |
| Harmouche, H | 1 |
| Bader-Meunier, B | 1 |
| Manceron, V | 1 |
| Goujard, C | 1 |
| Amoura, Z | 1 |
| Godeau, B | 1 |
| Piette, JC | 3 |
| Delfraissy, JF | 1 |
| Weller, EA | 1 |
| Cassileth, PA | 1 |
| Cohn, JB | 1 |
| Dakhil, SR | 1 |
| Woda, B | 1 |
| Peterson, BA | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Dury, S | 1 |
| Caruso, V | 1 |
| Iacoviello, L | 1 |
| Di Castelnuovo, A | 1 |
| Storti, S | 1 |
| Mariani, G | 1 |
| de Gaetano, G | 1 |
| Donati, MB | 1 |
| Burcheri, S | 1 |
| Arcaini, L | 1 |
| Seo, HY | 1 |
| Seol, HR | 1 |
| Kim, IS | 1 |
| Kim, CY | 1 |
| Jung, KY | 1 |
| Eneli, I | 1 |
| West, M | 1 |
| Sigal, Y | 1 |
| Martel, JN | 1 |
| Lazerson, J | 1 |
| Halthore, SN | 1 |
| LaBeaud, AD | 1 |
| Leonard, EG | 1 |
| McComsey, GA | 1 |
| Seçkin, H | 1 |
| Kazanci, A | 1 |
| Yigitkanli, K | 1 |
| Simsek, S | 1 |
| Kars, HZ | 1 |
| Park, SH | 1 |
| Ko, OB | 1 |
| Koo, JE | 1 |
| Lee, D | 1 |
| Jeong, YP | 1 |
| Kim, SB | 1 |
| Klimm, B | 1 |
| Haverkamp, H | 1 |
| Lohri, A | 1 |
| Trenn, G | 1 |
| Müller-Hermelink, K | 1 |
| Brauner, M | 2 |
| Kambouchner, M | 1 |
| Ferenczi, K | 1 |
| Chang, T | 1 |
| Camouse, M | 1 |
| Han, R | 1 |
| Stern, R | 1 |
| Willis, J | 1 |
| Cooper, KD | 1 |
| Gilliam, AC | 1 |
| Sarkissian, T | 1 |
| Beyene, J | 1 |
| Feldman, B | 1 |
| McCrindle, B | 1 |
| Silverman, ED | 2 |
| Rossignol, E | 1 |
| D'Anjou, G | 1 |
| Lapointe, N | 1 |
| Haddad, E | 1 |
| Vanasse, M | 1 |
| Shatat, IF | 1 |
| Schoeneman, M | 1 |
| Flynn, JT | 1 |
| Woroniecki, RP | 1 |
| Northup, JK | 1 |
| Gadre, SA | 1 |
| Ge, Y | 1 |
| Lockhart, LH | 1 |
| Velagaleti, GV | 1 |
| Williams, KM | 1 |
| Higman, MA | 1 |
| Chen, AR | 1 |
| Schwartz, CL | 1 |
| Wharam, M | 1 |
| Colombani, P | 1 |
| Arceci, RJ | 1 |
| Yoshimi, A | 1 |
| Baumann, I | 1 |
| Führer, M | 1 |
| Bergsträsser, E | 1 |
| Göbel, U | 1 |
| Sykora, KW | 1 |
| Klingebiel, T | 1 |
| Gross-Wieltsch, U | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Fischer, A | 1 |
| Nöllke, P | 1 |
| Grunwald, MH | 1 |
| Amichai, B | 1 |
| Montano Loza, AJ | 1 |
| Simon, Z | 1 |
| Keresztes, K | 1 |
| Miltényi, Z | 1 |
| Ress, Z | 1 |
| Váróczy, L | 1 |
| Vadász, G | 1 |
| Gergely, L | 1 |
| Illés, A | 1 |
| Gassert, DJ | 1 |
| Garcia, H | 1 |
| Tanaka, K | 1 |
| Reinus, JF | 1 |
| Di Mario, A | 1 |
| Garzia, M | 1 |
| d'Alò, F | 1 |
| Rumi, C | 1 |
| Massini, G | 1 |
| Bellesi, S | 1 |
| Zini, G | 1 |
| Cookfair, D | 1 |
| Sella, A | 1 |
| Sternberg, C | 1 |
| Kovel, S | 1 |
| Yarom, N | 1 |
| Skoneczna, I | 1 |
| Case, DC | 1 |
| Desch, CE | 1 |
| Kalman, LA | 1 |
| Vongkovit, P | 1 |
| Mena, RR | 1 |
| Fridman, M | 1 |
| Allen, B | 1 |
| Niermeijer, JM | 1 |
| Eurelings, M | 1 |
| van der Linden, MW | 1 |
| Lokhorst, HM | 1 |
| Franssen, H | 1 |
| Fischer, K | 1 |
| Teunissen, LL | 1 |
| van den Berg, LH | 1 |
| Schobben, F | 1 |
| Abidi, MH | 1 |
| Tove, I | 1 |
| Ibrahim, RB | 1 |
| Maria, D | 1 |
| Peres, E | 1 |
| Cheikhrouhou Abdelmoula, L | 1 |
| Tekaya, R | 1 |
| Ben Hadj Yahia, C | 1 |
| Chaabouni, L | 1 |
| Zouari, R | 1 |
| Dovey, M | 1 |
| Aitken, ML | 2 |
| Emerson, J | 1 |
| McNamara, S | 1 |
| Waltz, DA | 1 |
| Gibson, RL | 1 |
| James, JA | 1 |
| Kim-Howard, XR | 1 |
| Bruner, BF | 1 |
| Jonsson, MK | 1 |
| McClain, MT | 1 |
| Arbuckle, MR | 1 |
| Walker, C | 1 |
| Dennis, GJ | 1 |
| Harley, JB | 1 |
| Maeda, L | 1 |
| Lavori, P | 1 |
| Quon, A | 1 |
| Hoppe, R | 1 |
| Breslin, S | 1 |
| Rosenberg, SA | 1 |
| Gossard, AA | 1 |
| Lindor, KD | 1 |
| Vural, F | 1 |
| Soyer, NA | 1 |
| Tombuloglu, M | 1 |
| Smolej, L | 1 |
| Hrudková, M | 1 |
| Stepánkovd, P | 1 |
| Slykorová, A | 1 |
| Zák, P | 1 |
| Bukac, J | 1 |
| Malý, J | 1 |
| Schwartz, MM | 1 |
| Korbet, SM | 2 |
| Lewis, EJ | 1 |
| Ferguson, AD | 1 |
| Faiman, B | 1 |
| Chavis, PS | 1 |
| Stickler, DE | 1 |
| Walker, A | 1 |
| Oosting-Lenstra, SF | 1 |
| van Marwijk Kooy, M | 1 |
| Trappe, RU | 1 |
| Choquet, S | 1 |
| Reinke, P | 1 |
| Mergenthaler, HG | 1 |
| Jäger, U | 1 |
| Kebelmann-Betzing, C | 1 |
| Jonas, S | 1 |
| Lehmkuhl, H | 1 |
| Anagnostopoulos, I | 1 |
| Leblond, V | 2 |
| Hetzer, R | 1 |
| Dörken, B | 1 |
| Riess, H | 1 |
| Oertel, S | 1 |
| Saliba, M | 1 |
| Pelosse, B | 1 |
| Momtchilova, M | 1 |
| Laroche, L | 1 |
| Deng, HY | 1 |
| Gao, Y | 1 |
| Li, YJ | 1 |
| Zhong, F | 1 |
| Neri, P | 1 |
| Mariotti, C | 1 |
| Mercanti, L | 1 |
| Giovannini, A | 1 |
| Hernández, JM | 1 |
| Gutiérrez, NC | 1 |
| Fuertes, M | 1 |
| Garcia-Sanchez, P | 1 |
| de la Rubia, J | 1 |
| Bargay, J | 1 |
| Ribas, P | 1 |
| Alegre, A | 1 |
| Carrera, D | 1 |
| García-Laraña, J | 1 |
| Prósper, F | 1 |
| Mateo, G | 1 |
| Hiraki, LT | 1 |
| Benseler, SM | 1 |
| Tyrrell, PN | 1 |
| Harvey, E | 1 |
| Zelefsky, JR | 1 |
| Revercomb, CH | 1 |
| Lantos, G | 1 |
| Warren, FA | 1 |
| Garrido, A | 1 |
| Verdejo, C | 1 |
| Márquez, JL | 1 |
| Giráldez, A | 1 |
| Trigo, C | 1 |
| Belda, O | 1 |
| Kalinka-Warzocha, E | 1 |
| Wajs, J | 1 |
| Lech-Maranda, E | 1 |
| Ceglarek, B | 1 |
| Holowiecki, J | 1 |
| Federowicz, I | 1 |
| Czyz, J | 1 |
| Robak, T | 2 |
| Warzocha, K | 1 |
| Goumenos, D | 1 |
| Ahuja, M | 1 |
| Shortland, JR | 1 |
| Brown, CB | 1 |
| Lévy, R | 1 |
| Colonna, P | 1 |
| Tourani, JM | 1 |
| Gastaut, JA | 1 |
| Raphaël, M | 1 |
| Taillan, B | 1 |
| Chan, YM | 1 |
| Adams, DA | 1 |
| Kerr, AG | 1 |
| Bloch, DA | 1 |
| Medsger, TA | 1 |
| Oddis, CV | 1 |
| Malik, IA | 1 |
| Shamsi, Z | 1 |
| Shafquat, A | 1 |
| Aziz, Z | 1 |
| Shaikh, H | 1 |
| Jafri, W | 1 |
| Khan, MA | 1 |
| Khan, AH | 1 |
| Jakacki, RI | 1 |
| Zeltzer, PM | 1 |
| Boyett, JM | 1 |
| Albright, AL | 1 |
| Allen, JC | 1 |
| Geyer, JR | 1 |
| Rorke, LB | 1 |
| Stanley, P | 1 |
| Stevens, KR | 1 |
| Wisoff, J | 1 |
| Roccatello, D | 2 |
| Ferro, M | 2 |
| Coppo, R | 2 |
| Mazzucco, G | 1 |
| Quattrocchio, G | 2 |
| Piccoli, G | 2 |
| Menard, JF | 1 |
| Michaux, JL | 1 |
| Euller-Ziegler, L | 1 |
| Bernard, JF | 1 |
| Grosbois, B | 1 |
| Daragon, A | 1 |
| Courouble, Y | 1 |
| Kaplan, G | 1 |
| Winters, GL | 1 |
| Loh, E | 1 |
| Schoen, FJ | 1 |
| Puścińska, E | 1 |
| Zych, D | 1 |
| Pawlicka, L | 1 |
| Zieliński, J | 1 |
| Dunphy, CH | 1 |
| Kitchen, S | 1 |
| Saravia, O | 1 |
| Velasquez, WS | 1 |
| Haim, N | 1 |
| Leviov, M | 1 |
| Epelbaum, R | 1 |
| Freidin, N | 1 |
| Reshef, R | 1 |
| Ben-Shahar, M | 1 |
| Ciaudo, M | 1 |
| Chauvenet, L | 1 |
| Audouin, J | 1 |
| Rossert, J | 1 |
| Favier, R | 1 |
| Horellou, MH | 1 |
| Bernadou, A | 1 |
| Samama, M | 1 |
| Weh, HJ | 1 |
| Seeger, D | 1 |
| Junge, I | 1 |
| Carson, PJ | 1 |
| Hameed, A | 1 |
| Ahmed, AR | 3 |
| Shaklai, S | 1 |
| Bairey, O | 1 |
| Blickstein, D | 1 |
| Prokocimer, M | 1 |
| Hadar, H | 1 |
| Lahav, M | 1 |
| Sulkes, J | 1 |
| Shaklai, M | 1 |
| Giraudo, G | 1 |
| Hill, ME | 1 |
| MacLennan, KA | 1 |
| Cunningham, DC | 1 |
| Vaughan Hudson, B | 1 |
| Burke, M | 1 |
| Clarke, P | 1 |
| Di Stefano, F | 1 |
| Anderson, L | 1 |
| Vaughan Hudson, G | 1 |
| Mason, D | 1 |
| Selby, P | 1 |
| Linch, DC | 1 |
| Reinhold-Keller, E | 1 |
| De Groot, K | 1 |
| Rudert, H | 1 |
| Nölle, B | 1 |
| Heller, M | 1 |
| Gross, WL | 1 |
| Baqi, N | 1 |
| Moazami, S | 1 |
| Ahmad, H | 1 |
| Balachandra, S | 1 |
| Tejani, A | 1 |
| Macia, J | 1 |
| Gomez, X | 1 |
| Esquerda, A | 1 |
| Perez, B | 1 |
| Callao, V | 1 |
| Marzo, C | 1 |
| Leong, T | 1 |
| Quam, L | 1 |
| Billadeau, D | 1 |
| Greipp, P | 1 |
| Kyle, RA | 4 |
| Oken, MM | 1 |
| Van Ness, B | 1 |
| Sacco, O | 1 |
| Fregonese, B | 1 |
| Picco, P | 1 |
| Faraci, M | 1 |
| Facchetti, P | 1 |
| Pistoia, V | 1 |
| Rossi, GA | 1 |
| Wong, GC | 1 |
| Tan, P | 1 |
| Goh, YT | 1 |
| Ng, HS | 1 |
| Chong, R | 1 |
| Lee, LH | 1 |
| Faedda, R | 1 |
| Pirisi, M | 1 |
| Satta, A | 1 |
| Tanda, F | 1 |
| Bartoli, E | 1 |
| Carrillo-Pacheco, S | 1 |
| Vazquez-Marouschek, MC | 1 |
| Lopez-Checa, F | 1 |
| Sanchez-Roman, J | 1 |
| Bakir, AA | 1 |
| Share, DS | 1 |
| Levy, PS | 1 |
| Arruda, JA | 1 |
| Dunea, G | 1 |
| Kossard, S | 1 |
| Lee, MS | 1 |
| Wilkinson, B | 1 |
| Mont, MA | 1 |
| Fairbank, AC | 1 |
| Hungerford, DS | 1 |
| Aleksic, I | 1 |
| Czer, LS | 1 |
| Freimark, D | 1 |
| Dalichau, H | 1 |
| Takkenberg, JJ | 1 |
| Blanche, C | 1 |
| Nessim, S | 1 |
| Nusser, P | 1 |
| Trento, A | 1 |
| Walser, M | 1 |
| Hill, S | 1 |
| Volgger, B | 1 |
| Marth, C | 1 |
| Zeimet, A | 1 |
| Müller-Holzner, E | 1 |
| Ruth, N | 1 |
| Dapunt, O | 1 |
| Avilés, A | 1 |
| Huerta-Guzmán, J | 1 |
| Delgado, S | 1 |
| Fernández, A | 1 |
| Díaz-Maqueo, JC | 1 |
| Davidge-Pitts, M | 1 |
| Dansey, R | 1 |
| Bezwoda, WR | 1 |
| Wirth, A | 1 |
| Corry, J | 1 |
| Laidlaw, C | 1 |
| Matthews, J | 1 |
| Liew, KH | 1 |
| Mac Manus, MP | 1 |
| Hoppe, RT | 1 |
| Di Martino, V | 1 |
| Saurini, F | 1 |
| Samuel, D | 1 |
| Gigou, M | 1 |
| Dussaix, E | 1 |
| Reynès, M | 1 |
| Bismuth, H | 1 |
| Féray, C | 1 |
| Konstan, MW | 1 |
| Wyser, CP | 1 |
| van Schalkwyk, EM | 1 |
| Alheit, B | 1 |
| Bardin, PG | 1 |
| Joubert, JR | 1 |
| Roberts, TV | 1 |
| Mitchell, P | 1 |
| Dyck, PJ | 2 |
| Bartalena, L | 1 |
| Marcocci, C | 1 |
| Bogazzi, F | 1 |
| Manetti, L | 1 |
| Tanda, ML | 1 |
| Dell'Unto, E | 1 |
| Bruno-Bossio, G | 1 |
| Nardi, M | 1 |
| Bartolomei, MP | 1 |
| Lepri, A | 1 |
| Rossi, G | 1 |
| Martino, E | 1 |
| Pinchera, A | 1 |
| Tehranchi-Nia, Z | 1 |
| Qureshi, TA | 1 |
| Lacki, JK | 1 |
| Mackiewicz, SH | 1 |
| Reich, JM | 1 |
| Rajkumar, SV | 1 |
| Gertz, MA | 2 |
| Bernat, S | 1 |
| Gozalbo, T | 1 |
| García-Boyero, R | 1 |
| Guinot, M | 1 |
| Dighiero, G | 2 |
| Maloum, K | 2 |
| Desablens, B | 2 |
| Cazin, B | 3 |
| Navarro, M | 1 |
| Leblay, R | 1 |
| Leporrier, M | 2 |
| Jaubert, J | 2 |
| Lepeu, G | 1 |
| Dreyfus, B | 2 |
| Binet, JL | 2 |
| Travade, P | 2 |
| Bogomolski-Yahalom, V | 1 |
| Lossos, IS | 1 |
| Okun, E | 1 |
| Sherman, Y | 1 |
| Lossos, A | 1 |
| Usnarska-Zubkiewicz, L | 1 |
| Weinberger, M | 1 |
| Moore, A | 1 |
| Li, A | 1 |
| Figg, WD | 1 |
| Colombat, P | 1 |
| Werfel, U | 1 |
| Rödelsperger, K | 1 |
| Kotter, J | 1 |
| Popp, W | 1 |
| Woitowitz, HJ | 1 |
| Zieger, G | 1 |
| Chapelon Abric, C | 1 |
| Ginsburg, C | 1 |
| Wechsler, B | 1 |
| de Gennes, C | 1 |
| Darbois, Y | 1 |
| Janse Marec, J | 1 |
| Godeau, P | 1 |
| de Courten, C | 1 |
| Bruguera, M | 1 |
| Caballería, L | 1 |
| Parés, A | 1 |
| Rodés, J | 1 |
| Tesch, H | 2 |
| Lathan, B | 1 |
| Rüffer, JU | 1 |
| Sextro, M | 1 |
| Hermann, R | 1 |
| Holmer, L | 1 |
| Stappert-Jahn, U | 1 |
| Winnerlein-Trump, E | 1 |
| Wulf, G | 1 |
| Krause, S | 1 |
| Glunz, A | 1 |
| von Kalle, K | 1 |
| Bischoff, H | 1 |
| Haedicke, C | 1 |
| Georgii, A | 1 |
| Pincus, T | 1 |
| Hwang, JM | 1 |
| Girkin, CA | 1 |
| Perry, JD | 1 |
| Lai, JC | 1 |
| Miller, NR | 1 |
| Altemeier, WA | 1 |
| Tonelli, MR | 1 |
| Lacy, MQ | 1 |
| Chen, MG | 1 |
| Pineda, AA | 1 |
| Gastineau, DA | 1 |
| Greipp, PR | 1 |
| Lust, JA | 1 |
| Tefferi, A | 1 |
| Litzow, MR | 1 |
| Cremer, J | 1 |
| Strüber, M | 1 |
| Wagenbreth, I | 1 |
| Nischelsky, J | 1 |
| Demertzis, S | 1 |
| Graeter, T | 1 |
| Abraham, C | 1 |
| Haverich, A | 1 |
| Katzman, GL | 1 |
| Langford, CA | 1 |
| Sneller, MC | 1 |
| Koby, M | 1 |
| Patronas, NJ | 1 |
| Looney, BD | 1 |
| Hübner, C | 1 |
| Wedding, U | 1 |
| Sträter, J | 1 |
| Limberg, B | 1 |
| Stremmel, W | 1 |
| Campbell, C | 1 |
| Sawka, C | 1 |
| Franssen, E | 1 |
| Osoba, D | 1 |
| Neville, AJ | 1 |
| Tondini, C | 1 |
| Siracusano, L | 1 |
| Giardini, R | 1 |
| Rampinelli, I | 1 |
| Braun, MC | 1 |
| West, CD | 1 |
| Strife, CF | 1 |
| Dumas, JL | 1 |
| Chapelon-Abric, C | 1 |
| Belin, C | 1 |
| Tandjaoui-Lambiotte, H | 1 |
| Goldlust, D | 1 |
| Mullaney, P | 1 |
| Vajsar, J | 1 |
| Smith, R | 1 |
| Buncic, JR | 1 |
| Ezzat, AA | 1 |
| Ibrahim, EM | 1 |
| Stuart, RK | 1 |
| Ajarim, D | 1 |
| Bazarbashi, S | 1 |
| El-Foudeh, MO | 1 |
| Rahal, M | 1 |
| Al-Sayed, A | 1 |
| Berry, J | 1 |
| Meddeb, B | 1 |
| Ben Lakhal, R | 1 |
| Bel Hadj Ali, Z | 1 |
| Ben Abid, H | 1 |
| Hafsia, R | 1 |
| Hafsia, A | 1 |
| Riccardi, A | 1 |
| Mora, O | 1 |
| Tinelli, C | 1 |
| Valentini, D | 1 |
| Brugnatelli, S | 1 |
| Spanedda, R | 1 |
| De Paoli, A | 1 |
| Barbarano, L | 1 |
| Di Stasi, M | 1 |
| Giordano, M | 1 |
| Delfini, C | 1 |
| Nicoletti, G | 1 |
| Bergonzi, C | 1 |
| Rinaldi, E | 1 |
| Piccinini, L | 2 |
| Ascari, E | 1 |
| Dana, BW | 1 |
| Kjeldsberg, C | 1 |
| Forman, JD | 1 |
| Unger, JM | 1 |
| Balcerzak, SP | 1 |
| Gaynor, ER | 1 |
| Roy, V | 1 |
| Miller, T | 1 |
| Spiegel, JR | 1 |
| Sataloff, RT | 1 |
| Hawkshaw, M | 1 |
| Hogg, RJ | 1 |
| Portman, RJ | 1 |
| Milliner, D | 1 |
| Lemley, KV | 1 |
| Eddy, A | 1 |
| Ingelfinger, J | 1 |
| Zeidman, A | 1 |
| Sender, BZ | 1 |
| Yarmolovsky, A | 1 |
| Fradin, Z | 1 |
| Mittelman, M | 1 |
| Roszkowska-Blaim, M | 1 |
| Mizerska-Wasiak, M | 1 |
| Małdyk, J | 1 |
| Weglarska, J | 1 |
| Fiejka, E | 1 |
| Paulus, HE | 1 |
| Di Primeo, D | 1 |
| Sanda, M | 1 |
| Lynch, JM | 1 |
| Schwartz, BA | 1 |
| Sharp, JT | 1 |
| Genant, HK | 1 |
| Weissman, BN | 1 |
| Westby, MD | 1 |
| Wade, JP | 1 |
| Rangno, KK | 1 |
| Berkowitz, J | 1 |
| Halimi, C | 1 |
| Dussaule Md, JC | 1 |
| Cayre-Castel Md, M | 1 |
| Spruit, P | 1 |
| van't Veer, M | 1 |
| Budel, L | 1 |
| Löwenberg, B | 1 |
| Ha, CS | 3 |
| Manning, JT | 1 |
| Hess, M | 1 |
| Cox, JD | 3 |
| Selaru, D | 1 |
| Dragomir, M | 1 |
| Stângu, C | 1 |
| Cohen, BA | 1 |
| Clark, WF | 1 |
| Engel, C | 1 |
| Schmitz, S | 1 |
| Schlembach, PJ | 1 |
| Wilder, RB | 2 |
| Tucker, SL | 2 |
| Hess, MA | 2 |
| Cabanillas, FF | 1 |
| Slee, PH | 1 |
| Brausi, M | 1 |
| Horenblas, S | 1 |
| Hall, RR | 1 |
| Hetherington, JW | 1 |
| Aaronson, N | 1 |
| Collette, L | 1 |
| Biasi, D | 1 |
| Caramaschi, P | 1 |
| Carletto, A | 1 |
| Bambara, LM | 1 |
| Al-Mayouf, SM | 1 |
| Ghonaium, A | 1 |
| Bahabri, S | 1 |
| D'Amico, G | 1 |
| Napodano, P | 1 |
| Ferrario, F | 1 |
| Rastaldi, MP | 1 |
| Arrigo, G | 1 |
| Claudel, CD | 1 |
| Zic, JA | 1 |
| Boyd, AS | 1 |
| Yiu, VW | 1 |
| Kovithavongs, T | 1 |
| McGonigle, LF | 1 |
| Ferreira, P | 1 |
| Pittau, E | 1 |
| Passiu, G | 1 |
| Mathieu, A | 1 |
| Garcia-Porrúa, C | 1 |
| González-Gay, MA | 1 |
| González-Louzao, C | 1 |
| Castro, J | 1 |
| Rivas, MJ | 1 |
| Santos, E | 1 |
| Silfen, ME | 1 |
| Garvin, JH | 1 |
| Hays, AP | 1 |
| Starkman, HS | 1 |
| Aranoff, GS | 1 |
| Levine, LS | 1 |
| Feldstein, NA | 1 |
| Oberfield, SE | 1 |
| Pulte, D | 1 |
| Moin, M | 1 |
| Kersten, RC | 1 |
| Bernardini, F | 1 |
| Kulwin, DR | 1 |
| Souza, CS | 1 |
| Roselino, AM | 1 |
| Figueiredo, F | 1 |
| Foss, NT | 1 |
| Lineberry, TW | 1 |
| Peters, GE | 1 |
| Bostwick, JM | 1 |
| Zajaczkowska, M | 1 |
| Papierkowski, A | 1 |
| Szczepanowska, A | 1 |
| Zinkiewicz, Z | 1 |
| Borzecka, H | 1 |
| Zbarańska, S | 1 |
| Baculard, A | 1 |
| Blanc, N | 1 |
| Boulé, M | 1 |
| Chadelat, K | 1 |
| Boccon-Gibod, L | 1 |
| Tournier, G | 1 |
| Clement, A | 1 |
| Vonmoos, F | 1 |
| Messerli, J | 1 |
| Moser, HR | 1 |
| Prünte, C | 1 |
| Flammer, J | 1 |
| Haefliger, IO | 1 |
| Houman, H | 1 |
| Ben Ghorbel, I | 1 |
| Feki, M | 1 |
| Khanfir, M | 1 |
| Mebazaa, A | 1 |
| Miled, M | 1 |
| Feinstein, L | 1 |
| Sandmaier, B | 1 |
| Maloney, D | 1 |
| McSweeney, PA | 1 |
| Maris, M | 1 |
| Radich, J | 1 |
| Little, MT | 1 |
| Nash, RA | 1 |
| Chauncey, T | 1 |
| Woolfrey, A | 1 |
| Georges, G | 1 |
| Kiem, HP | 1 |
| Blume, KG | 1 |
| Shizuru, J | 1 |
| Niederwieser, D | 1 |
| Storb, R | 1 |
| Chainani-Wu, N | 1 |
| Silverman, S | 1 |
| Lozada-Nur, F | 1 |
| Mayer, P | 1 |
| Watson, JJ | 1 |
| Colin, P | 1 |
| de Kerviler, E | 1 |
| Diviné, M | 2 |
| Bouaffia, F | 1 |
| Kerneis, Y | 1 |
| Blanc, M | 1 |
| Chevalet, P | 1 |
| Barrier, JH | 1 |
| Glémarec, J | 1 |
| el Kouri, D | 1 |
| Hamidou, M | 1 |
| de Wazières, B | 1 |
| Duhamel, E | 1 |
| Jégo, P | 1 |
| Maugars, Y | 1 |
| Planchon, B | 1 |
| Rodat, O | 1 |
| Porcher, R | 1 |
| Fermand, JP | 1 |
| Maloisel, F | 1 |
| Harousseau, JL | 1 |
| Remenieras, L | 1 |
| Guibon, O | 1 |
| Chevret, S | 2 |
| Robak, E | 1 |
| Niewiadomska, H | 1 |
| Bartkowiak, J | 1 |
| Błoński, JZ | 1 |
| Woźniacka, A | 1 |
| Pomorski, L | 1 |
| Sysa-Jedrezejowska, A | 1 |
| Boudjerra, N | 1 |
| Rapp, MJ | 1 |
| Autrand, C | 1 |
| Chastang, C | 1 |
| Villegas, A | 1 |
| Mendoza-Fuentes, A | 1 |
| Moreno-Coutiño, G | 1 |
| Cravioto, MC | 1 |
| Mesina, OM | 1 |
| Romaguera, JE | 2 |
| Sarris, AH | 1 |
| McCarty, C | 1 |
| Morales, M | 1 |
| Gobbi, C | 1 |
| Tosi, C | 1 |
| Städler, C | 1 |
| Merenda, C | 1 |
| Bernasconi, E | 1 |
| Miserocchi, E | 1 |
| Baltatzis, S | 1 |
| Roque, MR | 1 |
| Foster, CS | 1 |
| Artusi, T | 1 |
| Bonacorsi, G | 1 |
| Arigliano, V | 1 |
| Subhash, HS | 1 |
| George, P | 1 |
| Sowmya, G | 1 |
| George, B | 1 |
| Ashwin, I | 1 |
| Cherian, AM | 1 |
| Neki, NS | 1 |
| Sharma, RK | 1 |
| Sharma, N | 1 |
| Multani, LS | 1 |
| Borges, E | 1 |
| Ferry, JA | 1 |
| Cavalli, F | 1 |
| Ahmad, I | 1 |
| Islam, T | 1 |
| Chanan-Khan, A | 1 |
| Hahn, T | 1 |
| Wentling, D | 1 |
| Becker, JL | 1 |
| McCarthy, PL | 1 |
| Alam, AR | 1 |
| Szczech, LA | 1 |
| Edwards, LJ | 1 |
| Sanders, LL | 1 |
| van der Horst, C | 1 |
| Bartlett, JA | 1 |
| Heald, AE | 1 |
| Svetkey, LP | 1 |
| Kirpekar, R | 1 |
| Yorgin, PD | 1 |
| Tune, BM | 1 |
| Kim, MK | 1 |
| Sibley, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma[NCT01796002] | Phase 3 | 421 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| "Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The RECUT-Trial)"[NCT02386735] | 470 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease[NCT01235689] | Phase 3 | 252 participants (Actual) | Interventional | 2011-02-11 | Completed | ||
| A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)[NCT03038399] | Phase 2 | 46 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)[NCT02760277] | Phase 2 | 48 participants (Actual) | Interventional | 2016-07-28 | Completed | ||
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)[NCT02760264] | Phase 2 | 48 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Di[NCT03899337] | Phase 2 | 105 participants (Anticipated) | Interventional | 2019-07-23 | Recruiting | ||
| A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy[NCT02195479] | Phase 3 | 706 participants (Actual) | Interventional | 2014-12-09 | Active, not recruiting | ||
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| Improving Outcomes Assessment in Chronic GVHD[NCT00637689] | 601 participants (Actual) | Observational | 2007-09-30 | Active, not recruiting | |||
| A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate[NCT02116582] | Phase 4 | 215 participants (Actual) | Interventional | 2014-05-23 | Completed | ||
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas[NCT01445535] | Phase 1 | 15 participants (Actual) | Interventional | 2009-01-13 | Completed | ||
| ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia[NCT00430118] | Phase 3 | 4,559 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia[NCT00613457] | Phase 3 | 2,039 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care Unit[NCT03900624] | Phase 4 | 92 participants (Actual) | Interventional | 2019-04-21 | Completed | ||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Personalized Variable Versus Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease[NCT02147015] | 248 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients[NCT04096222] | 42 participants (Anticipated) | Observational | 2021-06-29 | Recruiting | |||
| A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma[NCT00683449] | Phase 2 | 29 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more appropriate dosing scheme for MN-221 in subjects with asthma.) | ||
| A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer[NCT00887198] | Phase 3 | 1,088 participants (Actual) | Interventional | 2009-04-28 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650] | Phase 3 | 873 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.) | ||
| Prednisone in Chronic Rhinosinusitis Without Nasal Polyps. A Double-blind, Randomized, Placebo-controlled Trial[NCT02367118] | Phase 3 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| SinoNasal Microbiota Transfer (SNMT) to Treat Chronic Rhinosinusitis: A Randomized, Double-blind, Placebo-controlled Trial[NCT05454072] | 80 participants (Anticipated) | Interventional | 2022-06-15 | Recruiting | |||
| Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF[NCT00650091] | Phase 3 | 264 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa[NCT05537220] | Phase 3 | 438 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| Biomarkers in Giant Cells Arteritis[NCT02844023] | 100 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to recruitment failure) | |||
| A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Ther[NCT01193257] | Phase 3 | 1,099 participants (Actual) | Interventional | 2010-11-15 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer[NCT01193244] | Phase 3 | 1,560 participants (Actual) | Interventional | 2010-10-01 | Completed | ||
| Phase II Study of Interim PET-CT Scan-guided Response Adapted Therapy in Hodgkin's Lymphoma[NCT01304849] | 50 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy[NCT00683475] | Phase 2 | 138 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.[NCT01051570] | Phase 2 | 26 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects[NCT01091831] | Phase 3 | 389 participants (Actual) | Interventional | 2009-07-31 | Active, not recruiting | ||
| A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma[NCT01336933] | Phase 2 | 34 participants (Actual) | Interventional | 2011-07-06 | Completed | ||
| A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, an[NCT00689936] | Phase 3 | 1,623 participants (Actual) | Interventional | 2008-08-21 | Completed | ||
| A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd)[NCT01237249] | Phase 2 | 250 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course[NCT04204876] | 40 participants (Anticipated) | Observational | 2020-05-28 | Recruiting | |||
| Multimodal Analysis and Electroretinogram in VKH From Acute Onset - a Prospective Study[NCT03811366] | 12 participants (Actual) | Interventional | 2011-06-01 | Completed | |||
| A Phase I Study of Single-centre, Open-label Clinical Trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma[NCT03710915] | Phase 1 | 3 participants (Actual) | Interventional | 2019-01-12 | Terminated (stopped due to Company decision) | ||
| A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer[NCT01188187] | Phase 3 | 1,022 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma[NCT00111319] | Phase 3 | 0 participants | Interventional | 2004-12-31 | Completed | ||
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165] | Phase 2 | 0 participants (Actual) | Interventional | 2012-07-11 | Withdrawn | ||
| A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-31 | Recruiting | ||
| A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min[NCT02424851] | Phase 2 | 31 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma[NCT01484626] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2011-05-05 | Terminated (stopped due to Celgene would no longer supply lenalidomide for the study) | ||
| A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.[NCT01522235] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study[NCT01628315] | 159 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)[NCT00639496] | Phase 3 | 184 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| The Effects of Treatment of Subclinical Rejection on Renal Histology and Graft Function in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil[NCT00885820] | Phase 4 | 240 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036] | Phase 2 | 106 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels[NCT02867020] | Phase 2 | 128 participants (Actual) | Interventional | 2017-10-11 | Completed | ||
| [NCT00284271] | Phase 2 | 65 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)[NCT03576378] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2018-08-08 | Active, not recruiting | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
| Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)[NCT05471427] | 118 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470] | Phase 2 | 74 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919] | 590 participants (Anticipated) | Observational | 2020-01-14 | Recruiting | |||
| An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)[NCT00394329] | Phase 3 | 288 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC[NCT03176381] | 110 participants (Actual) | Observational | 2017-05-05 | Completed | |||
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2013-12-31 | Terminated (stopped due to enrollment default) | ||
| A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-05-31 | Not yet recruiting | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy[NCT00638690] | Phase 3 | 1,195 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma[NCT03145285] | Phase 2 | 10 participants (Anticipated) | Interventional | 2017-04-18 | Active, not recruiting | ||
| Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma in Patients Treated With R-CHOP; Consortium for Improving Survival of Lymphoma (CISL) Study[NCT01266668] | 100 participants (Actual) | Observational | 2010-02-28 | Completed | |||
| Multi-center Phase II Study of the Combination of R-CHOP (RItuximab Plus Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) and Prophylactic Intrathecal Chemotherapy With Methotrexate in Patients With CD20+ Primary Breast Diffuse Large B-cell Ly[NCT01448096] | Phase 2 | 33 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial[NCT05674994] | Phase 3 | 110 participants (Anticipated) | Interventional | 2023-10-26 | Recruiting | ||
| Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial[NCT02460588] | Phase 3 | 120 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial[NCT00789997] | Phase 2/Phase 3 | 81 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid[NCT03492255] | 49 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Significative difference between percentage of renal response (primary outcome) between the two study arms.) | |||
| LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell[NCT02916316] | 127 participants (Actual) | Observational | 2014-02-12 | Active, not recruiting | |||
| A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
| Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)[NCT03136497] | Phase 1 | 10 participants (Actual) | Interventional | 2017-09-05 | Active, not recruiting | ||
| Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.[NCT00140595] | Phase 3 | 380 participants (Anticipated) | Interventional | 2003-12-31 | Completed | ||
| Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)[NCT00144807] | Phase 2 | 128 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)[NCT00140660] | Phase 3 | 223 participants (Actual) | Interventional | 2003-12-31 | Terminated (stopped due to Low acrual) | ||
| Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.[NCT00144755] | Phase 3 | 600 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random[NCT02428751] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2017-11-06 | Active, not recruiting | ||
| Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial[NCT02000336] | Phase 3 | 395 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy[NCT02087696] | Phase 4 | 122 participants (Anticipated) | Interventional | 2014-05-31 | Recruiting | ||
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in Patients With Active Rheumatoid Arthritis (BACH)[NCT04985435] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-05-12 | Recruiting | ||
| Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1[NCT00898157] | 1,600 participants (Actual) | Observational | 2007-09-24 | Completed | |||
| Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma[NCT00003150] | Phase 3 | 630 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus[NCT06151990] | 102 participants (Anticipated) | Observational | 2023-12-31 | Recruiting | |||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)[NCT02647255] | Phase 2/Phase 3 | 10 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Due to the rarity and rapid progressive course of the disease, patients were less likely to participate in randomization.) | ||
| Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy[NCT00188149] | Phase 4 | 300 participants | Interventional | 2000-05-31 | Recruiting | ||
| Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
| HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA[NCT00002630] | Phase 2 | 50 participants (Anticipated) | Interventional | 1993-06-30 | Completed | ||
| Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System[NCT02235857] | 35 participants (Anticipated) | Interventional | 2015-05-03 | Recruiting | |||
| Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial With Immunohistochemical Analysis[NCT05882864] | Phase 4 | 28 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity. A negative change from Baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | -6.4 |
| Tight Control Management | -7.7 |
"The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, from 0 (not at all) to 4 (very much). The FACIT-Fatigue score ranges from 0 to 52, with higher scores denoting lower levels of fatigue.~A positive change from Baseline score indicates an improvement.~." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | 7.6 |
| Tight Control Management | 13.0 |
The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression. A negative change from Baseline score indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | -3.6 |
| Tight Control Management | -5.6 |
The IBDQ measures the effects of inflammatory bowel disease on daily function and quality of life. The IBDQ consists of 32 questions which address symptoms as a result of Crohn's disease, feeling in general, and mood. Each question is answered on a scale from 1 (all of the time) to 7 ( none of the time); the total score ranges from 7 (worst) to 224 (best). A positive change from baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) |
|---|---|
| Clinically Driven Management | 31.2 |
| Tight Control Management | 41.9 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 37 |
| Tight Control Management | 25 |
Any hospitalization with an overnight stay in hospital/clinic related to Crohn's disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 29 |
| Tight Control Management | 14 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | emergency hospitalizations (Number) |
|---|---|
| Clinically Driven Management | 11 |
| Tight Control Management | 4 |
The total number of CD-related surgical procedures included major CD-related surgery, debridement, perineal related surgery - abscess drainage, seton placement, fistulotomy, and TPN. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | surgical procedures (Number) |
|---|---|
| Clinically Driven Management | 9 |
| Tight Control Management | 7 |
"Major Crohn's disease-related intra-abdominal surgery included:~bowel resection~ostomy~by-pass~strictureplasty~drainage of abdominal or pelvic abscess (surgical drainage or percutaneous drainage by interventional radiology).~The following were excluded:~debridement~exploration laparotomy~abdominal surgery for other reason~perineal related surgery~abscess drainage~placement of setons~fistulotomy~Total parental nutrition (TPN) use" (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | surgeries (Number) |
|---|---|
| Clinically Driven Management | 3 |
| Tight Control Management | 6 |
"Biologic remission was defined as high sensitivity C-reactive protein (hs-CRP) < 5 mg/L, fecal Calprotectin < 250 μg/g, and CDEIS < 4 at 48 weeks after randomization.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 15.6 |
| Tight Control Management | 29.5 |
"Deep remission was defined as CDAI < 150, discontinuation from steroids for at least 8 weeks, absence of draining fistula, CDEIS < 4 and no deep ulcerations.~CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing data 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 23.0 |
| Tight Control Management | 36.9 |
"Complete mucosal healing was defined as CDEIS = 0. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 16.4 |
| Tight Control Management | 18.0 |
"Endoscopic response was defined as a decrease CDEIS > 5 points. CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 40.2 |
| Tight Control Management | 50.8 |
"Percentage of participants with mucosal healing (defined as a CDEIS < 4) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 30.3 |
| Tight Control Management | 45.9 |
"Percentage of participants with mucosal healing (defined as CDEIS < 4) and CDEIS < 4 in every segment on ileocolonoscopy at 48 weeks after randomization. The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon. The range of the score is from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing values 48 weeks after randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 23.8 |
| Tight Control Management | 29.5 |
"Percentage of participants with mucosal healing (defined as Crohn's disease endoscopy Index of severity [CDEIS] < 4) and no deep ulcerations on ileocolonoscopy (defined as the absence of all deep ulcerations in all segments explored in CDEIS) at 48 weeks after randomization (48 weeks after the 1st Key visit). The ileocolonoscopies were evaluated by the site.~CDEIS is an index for determining the severity of Crohn's disease. The CDEIS considers deep ulcerations, superficial ulcerations, ulcerated and non-ulcerated surface, and the presence of ulcerated/non-ulcerated stenosis evaluated in 5 pre-defined segments of the colon (ileum, ascending colon, transverse colon, descending colon and sigmoid loop, and rectum). The score ranges from 0 to 44 where higher scores indicate more severe endoscopic activity.~Participants with missing data 48 weeks after Randomization were counted as non-responders." (NCT01235689)
Timeframe: 48 weeks after Randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Clinically Driven Management | 30.3 |
| Tight Control Management | 45.9 |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Clinical remission was defined as CDAI < 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI scores generally range from 0 to 600 where higher scores indicate more severe disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | 78 |
| Tight Control Management | 43 |
Time to Crohn's disease flare, where flare is defined as an increase in CDAI ≥ 70 points compared to Week 8 or Early Randomization CDAI, and a CDAI > 220. (NCT01235689)
Timeframe: From Randomization to 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic. Hospitalization due to emergency was defined as a hospitalization admitted through the emergency department. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Crohn's disease-related hospitalization was defined as a visit to hospital/clinic resulting in admission and overnight stay in hospital/clinic for reasons related to Crohn's disease (CD). Hospitalization for adverse events relating to study medication, i.e., prednisone, azathioprine or adalimumab, were according to Investigator's clinical judgment. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | NA |
| Tight Control Management | NA |
Steroid-free remission was defined as CDAI < 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease. (NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Median) |
|---|---|
| Clinically Driven Management | 162 |
| Tight Control Management | 159 |
The total dose of prednisone each participant received during both the run-in phase and post-randomization treatment phase. (NCT01235689)
Timeframe: From Baseline through 48 weeks after Randomization
| Intervention | mg (Mean) |
|---|---|
| Clinically Driven Management | 1505.7 |
| Tight Control Management | 1369.8 |
(NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Mean) |
|---|---|
| Clinically Driven Management | 40.2 |
| Tight Control Management | 50.1 |
(NCT01235689)
Timeframe: From Randomization through 48 weeks after Randomization
| Intervention | days (Mean) |
|---|---|
| Clinically Driven Management | 9.8 |
| Tight Control Management | 15.8 |
The Crohn's Disease Activity Index (CDAI) is a research tool used to quantify the symptoms of patients with Crohn's disease. Participants were asked to record the frequency of stools, abdominal pain and general well-being on a daily basis. In addition to the diary data, the investigator assessed the following for the calculation of CDAI: presence of complications (arthritis/arthralgia, iritis/uveitis, erythema nodosum/pyoderma gangrenosum/aphthous stomatitis, anal fissure/fistula/abscess, other fistula, and fever), the use of antidiarrheal medicines, presence of an abdominal mass, hematocrit, and body weight. The CDAI is the sum of the products of each item multiplied by a weighting factor and generally ranges from 0 up to 600, where remission of Crohn's disease is defined as CDAI < 150, and severe disease is defined as CDAI > 450. A negative change from Baseline indicates improvement. (NCT01235689)
Timeframe: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | units on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 of Prednisone Run-in | Week 8 of Prednisone Run-in | 2 Weeks After Randomization | 6 Weeks After Randomization | 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | -78.3 | -64.2 | -80.2 | -93.1 | -103.5 | -71.1 | -69.9 | -143.3 | -71.8 | -47.9 | -140.4 | -60.8 | -76.8 | -146.2 |
| Tight Control Management | -90.9 | -105.5 | -110.1 | -130.8 | -141.0 | -101.2 | -112.0 | -154.1 | -135.7 | -143.8 | -166.4 | -132.8 | -107.4 | -175.8 |
High sensitivity C-reactive protein was analyzed by a central laboratory. (NCT01235689)
Timeframe: Baseline and 8 weeks during the prednisone run-in, and 11, 23, 35, and 48 weeks after Randomization.
| Intervention | mg/L (Mean) | ||||
|---|---|---|---|---|---|
| Week 8 of Prednisone Run-in | 11 Weeks After Randomization | 23 Weeks After Randomization | 35 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | -10.3 | -14.6 | -15.1 | -11.0 | -12.3 |
| Tight Control Management | -9.2 | -15.9 | -14.7 | -14.0 | -13.2 |
"The Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).~The physical component summary (PCS) score summarizes the subscales physical functioning, role-physical, bodily pain, and general health. The mental component summary (MCS) score summarizes the subscales vitality, social functioning, role-emotional, and mental health. Each score ranges from 0 to 100 where higher scores indicate a better quality of life. A positive change from Baseline score indicates an improvement." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Physical Component Summary Score | Mental Component Summary Score | |
| Clinically Driven Management | 6.3 | 5.8 |
| Tight Control Management | 9.2 | 9.3 |
"The WPAI:CD questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease. The self-administered questionnaire consisted of 6 questions.~Work time missed was defined as the percentage of time absent from work due to Crohn's disease in the past week.~Impairment while working is the participant's assessment of the degree to which Crohn's disease affected productivity while working in the past 7 days.~Total work productivity impairment takes into account both hours missed due to Crohn's disease symptoms and the patient's assessment of the degree to which Crohn's disease affected their productivity while working.~Total activity impairment is the percent impairment of non-work related activities due to Crohn's disease.~WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. A negative change from Baseline indicates improvement." (NCT01235689)
Timeframe: Baseline and 48 weeks after Randomization
| Intervention | percent impairment (Mean) | |||
|---|---|---|---|---|
| Work time missed | Impairment while working | Overall work impairment | Activity impairment | |
| Clinically Driven Management | -12.8 | -17.5 | -21.7 | -19.2 |
| Tight Control Management | -17.6 | -25.8 | -29.2 | -27.7 |
"Clinical remission was defined as CDAI < 150. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~Participants with missing data at each time point were counted as non-responders." (NCT01235689)
Timeframe: Baseline and 4 and 8 weeks during the prednisone run-in, and 2, 6, 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 4 of Prednisone Run-in | Week 8 of Prednisone Run-in | 2 Weeks After Randomization | 6 Weeks After Randomization | 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | 24.6 | 14.8 | 23.8 | 32.8 | 41.8 | 8.2 | 9.0 | 50.8 | 4.1 | 3.3 | 45.1 | 4.1 | 4.1 | 43.4 |
| Tight Control Management | 30.3 | 22.1 | 41.0 | 47.5 | 62.3 | 6.6 | 8.2 | 65.6 | 20.5 | 23.0 | 59.8 | 9.0 | 7.4 | 59.8 |
"Steroid-free remission was defined as CDAI < 150 and discontinuation from steroids for at least 8 weeks. CDAI is a tool used to quantify the symptoms of patients with Crohn's disease. The score includes the frequency of stools, abdominal pain and general well-being as well as the presence of complications, use of antidiarrheals, presence of abdominal mass, hematocrit and weight. CDAI generally ranges from 0 to 600 where higher scores indicate more severe disease.~Participants with missing data at each time point were counted as non-responders." (NCT01235689)
Timeframe: 11, 14, 18, 23, 26, 30, 35, 38, 42, and 48 weeks after Randomization.
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Weeks After Randomization | 14 Weeks After Randomization | 18 Weeks After Randomization | 23 Weeks After Randomization | 26 Weeks After Randomization | 30 Weeks After Randomization | 35 Weeks After Randomization | 38 Weeks After Randomization | 42 Weeks After Randomization | 48 Weeks After Randomization | |
| Clinically Driven Management | 23.8 | 4.1 | 3.3 | 45.1 | 2.5 | 0.8 | 42.6 | 4.1 | 4.1 | 39.3 |
| Tight Control Management | 39.3 | 4.9 | 7.4 | 63.1 | 18.9 | 21.3 | 59.0 | 9.0 | 7.4 | 59.8 |
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- month Treatment Period, in boys ages 4-7 years with DMD; Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination); (NCT03038399)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level Group 1 | 4 |
| Dose Level Group 2 | 14 |
| Dose Level Group 3 | 29 |
| Dose Level Group 4 | 1 |
| Dose Level Group 5 | 39 |
To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24-month Treatment Period, in boys ages 4-7 years with DMD. Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). (NCT03038399)
Timeframe: 24 Months
| Intervention | Events (Number) | |
|---|---|---|
| Total Number of AEs | Total Number of TEAEs | |
| Dose Level Group 1 | 15 | 14 |
| Dose Level Group 2 | 34 | 34 |
| Dose Level Group 3 | 203 | 202 |
| Dose Level Group 4 | 5 | 5 |
| Dose Level Group 5 | 302 | 300 |
"Summary of BMI Z-score of Safety Population.~Please note 0 is the mean. A negative result indicates a response that is many standard deviations below the mean, and a positive result indicates a response that is many standard deviations above the mean. In this case, the closer the group mean BMI Z-score is to 0 is more favorable." (NCT02760277)
Timeframe: 002 Baseline, 003 Week 12, Week 24
| Intervention | z score (Mean) | ||||
|---|---|---|---|---|---|
| 002 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 1.165 | 1.103 | -0.062 | 1.004 | -0.161 |
| Dose Level Group 2 | 0.703 | 0.494 | -0.209 | 0.493 | -0.210 |
| Dose Level Group 3 | 1.200 | 1.261 | 0.062 | 1.242 | 0.043 |
| Dose Level Group 4 | 0.695 | 1.011 | 0.174 | 1.330 | 0.493 |
To compare the efficacy, as measured by the Time to Stand Test (TTSTAND), of vamorolone administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. untreated DMD historical controls in boys ages 4-7 years with DMD (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 12, Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | Rises/Second (Mean) | |||||
|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 0.18 | 0.15 | 0.18 | -0.01 | 0.18 | -0.01 |
| Dose Level Group 2 | 0.24 | 0.22 | 0.23 | 0.00 | 0.24 | 0.00 |
| Dose Level Group 3 | 0.22 | 0.24 | 0.24 | 0.02 | 0.26 | 0.05 |
| Dose Level Group 4 | 0.19 | 0.22 | 0.22 | 0.02 | 0.24 | 0.04 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by North Star Ambulatory Assessment (NSAA) in boys ages 4-7 years with DMD. ***Total NSAA score is being reported. The score can range from 0 to 32. Higher scores (approaching 32) indicate a better outcome assessing functional mobility. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 19.0 | 20.1 | 19.3 | 0.3 | 19.8 | 0.8 |
| Dose Level Group 2 | 20.5 | 20.8 | 21.2 | 0.7 | 21.6 | 1.1 |
| Dose Level Group 3 | 20.0 | 21.7 | 21.0 | 1.0 | 22.3 | 2.3 |
| Dose Level Group 4 | 19.7 | 20.4 | 20.4 | 0.5 | 22.3 | 2.5 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Climb Test (TTCLIMB) in boys ages 4-7 years with DMD. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | tasks/ second (Mean) | |||||
|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 0.20 | 0.20 | 0.21 | 0.01 | 0.20 | 0.00 |
| Dose Level Group 2 | 0.29 | 0.29 | 0.34 | 0.05 | 0.30 | 0.01 |
| Dose Level Group 3 | 0.29 | 0.31 | 0.31 | 0.02 | 0.34 | 0.04 |
| Dose Level Group 4 | 0.24 | 0.25 | 0.26 | 0.02 | 0.29 | 0.05 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by Time to Run/Walk Test (TTRW) in boys ages 4-7 years with DMD. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | meters/ second (Mean) | |||||
|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 1.60 | 1.57 | 1.54 | -0.06 | 1.55 | -0.05 |
| Dose Level Group 2 | 1.77 | 1.78 | 1.77 | 0.00 | 1.84 | 0.06 |
| Dose Level Group 3 | 1.84 | 1.86 | 1.97 | 0.13 | 1.90 | 0.06 |
| Dose Level Group 4 | 1.64 | 1.72 | 1.88 | 0.26 | 1.89 | 0.27 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period, on muscle strength, mobility and functional exercise capacity vs. historical controls as measured by 6-minute Walk Test (6MWT) in boys ages 4-7 years with DMD. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 12, 003 Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | Meters (Mean) | |||||
|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 316.2 | 294.3 | 312.9 | 6.0 | 306.2 | -11.6 |
| Dose Level Group 2 | 331.5 | 332.2 | 358.7 | 20.8 | 350.4 | 18.9 |
| Dose Level Group 3 | 353.9 | 341.1 | 393.7 | 39.8 | 383.1 | 29.2 |
| Dose Level Group 4 | 336.8 | 335.1 | 369.9 | 27.6 | 372.6 | 43.9 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD. (NCT02760277)
Timeframe: 24 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Subjects with Any TEAE | Subjects with Any Drug Related TEAE | Subjects with Any CTCAE Grade 3 or Higher TEAE | Discontinuation of Study Drug due to TEAE | Subjects with Any Serious TEAE | Death | |
| Dose Level Group 1 | 10 | 1 | 0 | 0 | 0 | 0 |
| Dose Level Group 2 | 10 | 2 | 0 | 0 | 1 | 0 |
| Dose Level Group 3 | 11 | 4 | 0 | 0 | 0 | 0 |
| Dose Level Group 4 | 11 | 5 | 2 | 0 | 2 | 0 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | 003 Week 26-29 | 003 Week 26-29 Change from 002 Baseline | |
| Dose Level Group 1 | 18.3 | 15.9 | 13.0 | -5.3 | 12.2 | -6.2 | 19.8 | 0.6 | 9.5 | -7.8 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | pg/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 2 | 18.0 | 18.6 | 7.1 | -10.5 | 9.0 | -9.1 | 14.0 | -4.0 |
| Dose Level Group 3 | 21.1 | 18.2 | 7.8 | -13.3 | 9.0 | -12.0 | 15.7 | -5.4 |
| Dose Level Group 4 | 19.3 | 18.4 | 6.5 | -13.5 | 9.0 | -12.2 | 11.3 | -6.3 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | pg/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | 003 Week 26-29 | 003 Week 26-29 Change from 002 Baseline | |
| Dose Level Group 1 | 871.0 | 915.9 | 897.1 | 26.1 | 885.4 | -2.6 | 1109.3 | 212.3 | 1059.3 | 569.5 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | pg/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 2 | 935.8 | 964.4 | 933.3 | -31.6 | 912.8 | -46.3 | 1235.6 | 295.6 |
| Dose Level Group 3 | 936.8 | 949.8 | 928.3 | -8.5 | 939.8 | 3.0 | 1248.7 | 346.5 |
| Dose Level Group 4 | 889.3 | 989.2 | 825.5 | -59.6 | 953.7 | 102.3 | 1237.0 | 321.4 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 12, 003 Week 24
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| 002 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 87.5 | 81.5 | -6.8 | 80.8 | -6.3 |
| Dose Level Group 2 | 88.9 | 81.7 | -7.6 | 80.8 | -9.0 |
| Dose Level Group 3 | 89.3 | 84.3 | -5.1 | 81.3 | -8.1 |
| Dose Level Group 4 | 92.3 | 86.5 | -5.2 | 84.6 | -7.8 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 12, 003 Week 24
| Intervention | uIU/mL (Mean) | ||||
|---|---|---|---|---|---|
| 002 Baseline | 003 Week 12 | 003 Week 12 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 1 | 5.54 | 4.17 | -1.13 | 4.23 | -1.67 |
| Dose Level Group 2 | 3.09 | 2.97 | -0.14 | 3.12 | 0.34 |
| Dose Level Group 3 | 3.40 | 3.89 | 0.49 | 4.82 | 1.36 |
| Dose Level Group 4 | 3.96 | 6.97 | 2.97 | 7.21 | 3.26 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29
| Intervention | % change (Mean) | ||
|---|---|---|---|
| 003 Week 8 % Change from 002 Baseline | 003 Week 16 % Change from 002 Baseline | 003 Week 24 % Change from 002 Baseline | |
| Dose Level Group 2 | 2.28 | 2.72 | 0.08 |
| Dose Level Group 3 | 1.79 | 1.30 | -1.27 |
| Dose Level Group 4 | 0.02 | 1.03 | -0.33 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29
| Intervention | % change (Mean) | |||
|---|---|---|---|---|
| 003 Week 8 % Change from 002 Baseline | 003 Week 16 % Change from 002 Baseline | 003 Week 24 % Change from 002 Baseline | 003 Week 26-29 % Change from 002 Baseline | |
| Dose Level Group 1 | 0.06 | 1.70 | -1.89 | -1.25 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29
| Intervention | % of HbA1c (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 2 | 5.22 | 5.33 | 0.12 | 5.35 | 0.14 | 5.22 | 0.00 |
| Dose Level Group 3 | 5.19 | 5.28 | 0.09 | 5.26 | 0.07 | 5.13 | -0.07 |
| Dose Level Group 4 | 5.23 | 5.25 | 0.00 | 5.31 | 0.05 | 5.24 | -0.02 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29
| Intervention | % of HbA1c (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | 003 Week 26-29 | 003 Week 26-29 Change from 002 Baseline | |
| Dose Level Group 1 | 5.18 | 5.18 | 0.00 | 5.26 | 0.08 | 5.15 | -0.10 | 5.07 | -0.07 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | ng/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | 003 Week 26-29 | 003 Week 26-29 Change from 002 Baseline | |
| Dose Level Group 1 | 37.94 | 39.20 | 36.21 | -1.60 | 39.01 | 1.07 | 38.80 | -1.34 | 40.10 | -1.23 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 2 | 35.66 | 41.84 | 41.78 | 6.13 | 42.23 | 6.57 | 51.41 | 15.75 |
| Dose Level Group 3 | 41.17 | 47.91 | 44.45 | 3.28 | 44.60 | 3.43 | 51.98 | 10.81 |
| Dose Level Group 4 | 44.36 | 42.81 | 41.55 | -2.01 | 39.39 | -4.17 | 49.08 | 5.29 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | ng/mL (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | 003 Week 26-29 | 003 Week 26-29 Change from 002 Baseline | |
| Dose Level Group 1 | 555.8 | 573.9 | 511.6 | -20.3 | 481.9 | -73.8 | 457.1 | -30.8 | 619.0 | -152.0 |
To investigate the effects of vamorolone, administered orally at daily doses up to 6.0 mg/kg over a 24-week Treatment Period vs. prednisone-treated historical controls, on serum pharmacodynamic (PD) biomarkers of safety (insulin resistance, adrenal axis suppression, and bone turnover). SomaScan aptamer panels testing 1,200 serum proteins were used to discover a candidate set of prednisone-responsive biomarkers, with a subset of these validating in a longitudinal sample set (individual DMD patients pre/post steroid treatment). These PD biomarkers were assigned to a safety panel or efficacy panel based on comparison to normal controls and information concerning the function of each protein. (NCT02760277)
Timeframe: 002 Baseline, 003 Baseline, 003 Week 8, 003 Week 16, 003 Week 24, 003 Week 26-29 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
| Intervention | ng/mL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 002 Baseline | 003 Baseline | 003 Week 8 | 003 Week 8 Change from 002 Baseline | 003 Week 16 | 003 Week 16 Change from 002 Baseline | 003 Week 24 | 003 Week 24 Change from 002 Baseline | |
| Dose Level Group 2 | 480.7 | 489.3 | 459.8 | -22.9 | 431.8 | -42.4 | 471.1 | 2.1 |
| Dose Level Group 3 | 508.2 | 492.0 | 485.2 | -23.0 | 455.7 | -52.5 | 565.5 | 57.3 |
| Dose Level Group 4 | 511.5 | 566.3 | 402.7 | -105.6 | 488.5 | -19.8 | 526.2 | 8.7 |
Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug; To evaluate the long-term safety and tolerability of vamorolone, administered orally at daily doses up to 6.0 mg/kg/day over a 24- week Treatment Period, in boys ages 4-7 years with DMD. (NCT02760277)
Timeframe: 24 weeks
| Intervention | Events (Number) | |
|---|---|---|
| Total Number of AEs | Total Number of TEAEs | |
| Dose Level Group 1 | 48 | 48 |
| Dose Level Group 2 | 44 | 44 |
| Dose Level Group 3 | 54 | 54 |
| Dose Level Group 4 | 73 | 72 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Week 2 (pre-dose)
| Intervention | mcg/dL (Mean) |
|---|---|
| Dose Level Group 1 | 10.425 |
| Dose Level Group 2 | 9.755 |
| Dose Level Group 3 | 7.321 |
| Dose Level Group 4 | 3.010 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Week 2
| Intervention | Week 2 % change from Baseline (Mean) |
|---|---|
| Dose Level Group 1 | -1.8 |
| Dose Level Group 2 | -4.2 |
| Dose Level Group 3 | 0.8 |
| Dose Level Group 4 | -1.2 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Week 2
| Intervention | Week 2 % change from Baseline (Mean) |
|---|---|
| Dose Level Group 1 | -5.54 |
| Dose Level Group 2 | 26.07 |
| Dose Level Group 3 | 42.85 |
| Dose Level Group 4 | 83.55 |
A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites. (NCT02760264)
Timeframe: Week 2 (Day 14)
| Intervention | % of total drug related exposure (Mean) | |||||
|---|---|---|---|---|---|---|
| M1 | M2 | M3 | M4 | M5 | Vamorolone | |
| Dose Level Group 3 | 34.42 | 1.16 | 1.21 | 37.84 | 2.73 | 22.64 |
"Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug.~Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group" (NCT02760264)
Timeframe: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
| Intervention | Number of Events (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total Number of Adverse Events | Total Number of Treatment Emergent Adverse Events | Any Treatment Emergent Adverse Events | Any Drug Related Treatment Emergent Adverse Events | Any CTCAE Grade 3 or Higher TEAE | Discontinuation of Study Drug due to TEAE | Any Serious Treatment Emergent Adverse Events | Death | |
| Dose Level Group 1 | 16 | 13 | 7 | 1 | 0 | 0 | 0 | 0 |
| Dose Level Group 2 | 18 | 13 | 6 | 2 | 0 | 0 | 0 | 0 |
| Dose Level Group 3 | 13 | 11 | 8 | 2 | 0 | 0 | 0 | 0 |
| Dose Level Group 4 | 11 | 9 | 7 | 3 | 0 | 0 | 0 | 0 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity. (NCT02760264)
Timeframe: Day 1, Week 2
| Intervention | [(hr)(ng)/mL] (Mean) | |
|---|---|---|
| Day 1 | Week 2 | |
| Dose Level Group 1 | 118 | 164 |
| Dose Level Group 2 | 379 | 544 |
| Dose Level Group 3 | 761 | 1138 |
| Dose Level Group 4 | 3279 | 3606 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay (NCT02760264)
Timeframe: Day 1, Week 2
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 1 | Week 2 | |
| Dose Level Group 1 | 22.9 | 32.2 |
| Dose Level Group 2 | 75.9 | 124.7 |
| Dose Level Group 3 | 199 | 252.2 |
| Dose Level Group 4 | 855.6 | 970 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum. (NCT02760264)
Timeframe: Day 1, Week 2
| Intervention | hour (Mean) | |
|---|---|---|
| Day 1 | Week 2 | |
| Dose Level Group 1 | 3.6 | 3.8 |
| Dose Level Group 2 | 4.6 | 3.8 |
| Dose Level Group 3 | 2.5 | 2.8 |
| Dose Level Group 4 | 2.7 | 2.3 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay (NCT02760264)
Timeframe: Day 1, Week 2
| Intervention | ml/hr/kg (Mean) | |
|---|---|---|
| Day 1 | Week 2 | |
| Dose Level Group 1 | 2459 | 1828 |
| Dose Level Group 2 | 2285 | 1509 |
| Dose Level Group 3 | 2697 | 2047 |
| Dose Level Group 4 | 2320 | 1777 |
Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life. (NCT02760264)
Timeframe: Day 1, Week 2
| Intervention | hour (Mean) | |
|---|---|---|
| Day 1 | Week 2 | |
| Dose Level Group 1 | 2.1 | 1.9 |
| Dose Level Group 2 | 1.8 | 2.1 |
| Dose Level Group 3 | 1.9 | 1.9 |
| Dose Level Group 4 | 1.9 | 1.4 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline Day 1 Week 2 Week 4
| Intervention | ng/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 1 Change from Baseline | Week 2 | Week 2 Change from Baseline | Week 4 | Week 4 Change from Baseline | |
| Dose Level Group 1 | 555.8 | 474.0 | -81.8 | 443.8 | -112.0 | 573.8 | 18.1 |
| Dose Level Group 2 | 480.7 | 443.7 | -34.5 | 407.8 | -70.6 | 496.7 | 21.3 |
| Dose Level Group 3 | 508.2 | 417.1 | -91.1 | 346.6 | -161.6 | 492.0 | -16.2 |
| Dose Level Group 4 | 511.5 | 475.2 | -36.5 | 303.7 | -207.8 | 566.3 | 54.8 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Day 1, Week 2, Week 4
| Intervention | % change from Baseline (Mean) | ||
|---|---|---|---|
| Day 1 Percent Change from Baseline | Week 2 Percent Change from Baseline | Week 4 Percent Change from Baseline | |
| Dose Level Group 1 | -12.2 | -17.5 | 2.8 |
| Dose Level Group 2 | -5.4 | -11.2 | 7.8 |
| Dose Level Group 3 | -17.4 | -30.9 | -1.4 |
| Dose Level Group 4 | -5.7 | -39.9 | 11.8 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Day 1, Week 4
| Intervention | % change from Baseline (Mean) | ||
|---|---|---|---|
| Day 1 Percent Change from Baseline | Week 2 Percent Change from Baseline | Week 4 Percent Change from Baseline | |
| Dose Level Group 1 | 9.9 | 11.9 | 3.6 |
| Dose Level Group 2 | 2.7 | 2.2 | 6.8 |
| Dose Level Group 3 | -8.0 | -22.5 | 2.7 |
| Dose Level Group 4 | -6.7 | -27.7 | 14.5 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Day 1, Week 4
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 1 Change from Baseline | Week 2 | Week 2 Change from Baseline | Week 4 | Week 4 Change from Baseline | |
| Dose Level Group 1 | 871.0 | 974.8 | 72.4 | 963.7 | 85.0 | 915.9 | 17.4 |
| Dose Level Group 2 | 935.8 | 940.8 | -12.9 | 903.3 | -19.9 | 983.5 | 34.8 |
| Dose Level Group 3 | 936.8 | 838.3 | -98.5 | 710.4 | -226.4 | 949.8 | 12.9 |
| Dose Level Group 4 | 889.3 | 786.8 | -115.7 | 625.7 | -263.7 | 989.2 | 99.8 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Week 2
| Intervention | mg/ dL (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 2 Change from Baseline | |
| Dose Level Group 1 | 87.5 | 85.3 | -2.2 |
| Dose Level Group 2 | 88.9 | 83.1 | -5.8 |
| Dose Level Group 3 | 89.3 | 89.5 | 0.2 |
| Dose Level Group 4 | 92.3 | 89.2 | -1.3 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline , Week 2
| Intervention | µIU/mL (Mean) | ||
|---|---|---|---|
| Baseline | Week 2 | Week 2 Change from Baseline | |
| Dose Level Group 1 | 5.54 | 5.29 | -0.65 |
| Dose Level Group 2 | 3.09 | 3.22 | 0.34 |
| Dose Level Group 3 | 3.40 | 3.87 | 0.47 |
| Dose Level Group 4 | 3.96 | 6.73 | 2.78 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Day 1, Week 2, Week 4
| Intervention | % change from Baseline (Mean) | ||
|---|---|---|---|
| Day 1 Percent Change from Baseline | Week 2 Percent Change from Baseline | Week 4 Percent Change from Baseline | |
| Dose Level Group 1 | 3.95 | 2.48 | 2.72 |
| Dose Level Group 2 | 1.41 | -0.07 | 20.91 |
| Dose Level Group 3 | -12.63 | -7.81 | 18.74 |
| Dose Level Group 4 | -25.05 | -33.87 | -2.43 |
Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-< 7 years with DMD. (NCT02760264)
Timeframe: Baseline, Day 1, Week 2, Week 4
| Intervention | ng/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 1 | Day 1 Change from Baseline | Week 2 | Week 2 Change from Baseline | Week 4 | Week 4 Change from Baseline | |
| Dose Level Group 1 | 37.94 | 39.37 | 1.43 | 38.53 | 0.58 | 39.20 | 1.26 |
| Dose Level Group 2 | 35.66 | 35.89 | 0.23 | 35.10 | -0.56 | 42.24 | 6.58 |
| Dose Level Group 3 | 41.17 | 34.93 | -6.23 | 37.51 | -3.66 | 47.91 | 6.74 |
| Dose Level Group 4 | 44.36 | 33.52 | -11.37 | 29.04 | -15.32 | 42.81 | -1.55 |
DOR: participants with a confirmed response (PR or better) as time between first documentation of response and disease progression, IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase>=0.5 g/dL); Urine M-component (absolute increase>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase >10 mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%>=10%); Bone marrow PC's %: absolute%>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02195479)
Timeframe: Up to 2.4 years
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 21.3 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (>=) 50 percentage(%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, >=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was >=30%, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 73.9 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 90.9 |
Overall Survival (OS) was defined as the number of days the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method. (NCT02195479)
Timeframe: From randomization to death (up to approximately 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 24.4 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 42.6 |
The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR). (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 6.2 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 22.3 |
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; <5% plasma cells (PCs) in bone marrow. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 9.3 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 20.3 |
VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response[sCR]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or >= 90% reduction in serum M-protein plus urine M-protein level less than (<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and < 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry. (NCT02195479)
Timeframe: From randomization to disease progression (up to 2.4 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 49.7 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 71.1 |
PFS- duration from date of randomization to Progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum and urine M-component (absolute increase >=0.5 gram per deciliter [g/dL] and >=200 milligram [mg]/24 hours respectively); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase>10 mg/dL); Only participants without measurable serum and urine M-protein levels,without measurable disease by FLC levels,bone marrow Plasma cells (PC) %(absolute % >=10%);Bone marrow PC%: absolute% >10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to the PC proliferative disorder. (NCT02195479)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 18.14 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment. (NCT02195479)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum and urine M-component (absolute increase >=0.5 gram per deciliter [g/dL] and >=200 mg/24 hours respectively); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase >10 milligram per deciliter [mg/dL]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % >=10%); Bone marrow PC %: absolute % >10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to the PC proliferative disorder. (NCT02195479)
Timeframe: From randomization to either disease progression or death due to PD whichever occurs first (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 19.35 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Time to next treatment is defined as the time from randomization to the start of the next-line treatment. (NCT02195479)
Timeframe: Approximately up to 2.4 years
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | NA |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | NA |
Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: >=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to <200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, >=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was >=30%. (NCT02195479)
Timeframe: From randomization to first documented PR or better (up to 2.4 years)
| Intervention | Months (Median) |
|---|---|
| Velcade, Melphalan and Prednisone (VMP) | 0.82 |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 0.79 |
"The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from 1-not at all to 4-very much to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values indicate deterioration in quality of life or functioning and positive values indicate improvement." (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 8.8 | 10.6 | 11.1 | 12.6 | 11.4 |
| Velcade, Melphalan and Prednisone (VMP) | 9.4 | 10.5 | 11.9 | 11 | 12.7 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm. (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 0.57 | 0.12 | 0.13 | 0.16 | 0.17 | 0.13 |
| Velcade, Melphalan and Prednisone (VMP) | 0.59 | 0.09 | 0.12 | 0.16 | 0.15 | 0.13 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. (NCT02195479)
Timeframe: Baseline, Months 3, 6, 9, 12 and 18
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | Month 18 | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 57.90 | 9.28 | 10.83 | 12.50 | 10.79 | 12.04 |
| Velcade, Melphalan and Prednisone (VMP) | 60.33 | 4.20 | 7.40 | 9.89 | 10.80 | 7.65 |
Percentage of participants with Best M- protein response of 100% reduction and >=90% to < 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC). (NCT02195479)
Timeframe: Approximately up to 2.4 years
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Best M-protein response in serum: 100% reduction | Best M-protein response in serum:>= 90 to < 100% | Best M-protein response in urine:100% reduction | Best M-protein response in urine:>=90 to < 100% | Best response in dFLC:100% reduction | Best response in dFLC: >=90% to < 100% reduction | |
| Daratumumab, Velcade, Melphalan and Prednisone (D-VMP) | 58.5 | 15.2 | 90.5 | 7.1 | 0 | 100.0 |
| Velcade, Melphalan and Prednisone (VMP) | 38.7 | 14.6 | 69.4 | 13.9 | 0 | 77.8 |
OS was defined as the time from first dose to death from any cause. All events of death were included. If patients discontinued study drug before the analysis data cut-off point, only OS status was assessed every 12 weeks until the data cut-off point date or until death, whichever occurred first. For patients who were alive at the time of the analysis data cut-off point, the OS time was censored on the last date the patient was known to be alive. Death from any cause was included, regardless of whether the event occurred while the patient was still taking study drug or after the patient discontinued study drug. OS median was estimated using the KM method. A 2-sided 95% CI was provided for this estimate using the BC method. (NCT02116582)
Timeframe: From the first dose of study drug administration up to the data cut-off date of 08 May 2016; up to 2 years.
| Intervention | Months (Median) |
|---|---|
| Enzalutamide | NA |
PSA response was defined as at least a 50% decrease from baseline in PSA, and was a binary variable for achieving this criteria (or not) based on the lowest PSA value observed postbaseline. Participants with no postbaseline PSA value were regarded as non-responders. 95% CI for PSA response rate was computed using the Clopper-Pearson method based on the exact binomial distribution. (NCT02116582)
Timeframe: From the first dose of study drug administration up to the data cut-off date for end-of-study completion 29 Sep 2017; the median duration of treatment was 5.7 months.
| Intervention | Percentage of participants (Number) |
|---|---|
| Enzalutamide | 22.0 |
Radiographic PFS, was defined as the time from first dose to the first objective evidence of radiographic disease progression or death from any cause, whichever occurred first. For patients with no documented progression event, it was censored on the date of the last disease assessment performed prior to the analysis data cut-off point. Radiographic progression (RP) for soft tissue disease was defined by Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria. RP for bone disease was determined according to the consensus guidelines of a modification of the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) guidelines. The 50th percentile of Kaplan-Meier (KM) estimates was used as the estimate of the rPFS median. A 2-sided 95% Confidence Interval (CI) was provided for this estimate using the Brookmeyer & Crowley (BC) method. (NCT02116582)
Timeframe: From the first dose of study drug administration up to treatment discontinuation or the data cut-off date of 08 May 2016, whichever occurred first; the median duration of treatment was 5.7 months.
| Intervention | Months (Median) |
|---|---|
| Enzalutamide | 8.1 |
The time to PSA progression was calculated as the time interval from the date of first dose to the date of first observation of PSA progression. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 μg/L (i.e., 2 ng/mL or more) above the nadir or above the baseline value for patients who did not have a decline in PSA postbaseline values, and which was confirmed by a second consecutive value obtained at least 3 or more weeks later (i.e., a confirmed rising trend) (PCWG2 criteria). The 50th percentile of KM estimates was used as the estimate of the time to PSA progression median. A 2-sided 95% CI was provided for this estimate using the BC method. (NCT02116582)
Timeframe: From the first dose of study drug administration up to the data cut-off date of 08 May 2016; the median duration of treatment was 5.7 months.
| Intervention | Months (Median) |
|---|---|
| Enzalutamide | 5.7 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03). (NCT02116582)
Timeframe: From the first dose of study drug administration up to data cut-off date for end-of-study completion (29 Sep 2017); the median duration of treatment was 5.7 months.
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | NCI-CTCAE Grade ≥3 | Study Drug-Related | Study Drug-Related NCI-CTCAE Grade ≥3 | TEAEs with Death as an Outcome | Serious Adverse Event (SAE) | Study Drug-related SAE | TEAEs Leading to Study Drug Discontinuation | Study Drug-Related TEAEs Leading to Drug Disc. | |
| Enzalutamide | 199 | 95 | 127 | 18 | 22 | 82 | 8 | 76 | 23 |
A classic 3+3 dose-escalation design was used to assess the MTD of siplizumab in combination with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R). If 2 of 6 patients experienced a dose-limiting toxicity (DLT) at a particular dose level, the MTD has been exceeded. The preceding dose level will be the MTD, provided 6 patients have been entered at this level and no more than one has experienced a DLT. DLTs for siplizumab was defined as infusional grade 3 non-hematologic toxicity lasting longer than 6 hours after the infusion, any grade 4 non-hematologic toxicity, or the development of an Epstein Barr Virus (EBV)-related lymphoproliferative disorder (LPD). Expected toxicities of dose-adjusted EPOCH-R and grade 3 laboratory adverse events (AEs) were not considered to be DLTs. (NCT01445535)
Timeframe: First 30 days after treatment initiation.
| Intervention | mg/kg (Number) |
|---|---|
| All Participants | 15 |
DLTs for siplizumab was defined as infusional grade 3 non-hematologic toxicity lasting longer than 6 hours after the infusion, any grade 4 non-hematologic toxicity, or the development of an EBV-related lymphoproliferative disorder (LPD). Expected toxicities of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) and grade 3 laboratory AEs were not considered to be DLTs. (NCT01445535)
Timeframe: First 30 days after treatment initiation.
| Intervention | Dose Limiting Toxicities (Number) |
|---|---|
| Cohort 1 - 3.4 mg/kg | 0 |
| Cohort 2 - 4.8 mg/kg | 0 |
| Cohort 3 - 8.5 mg/kg | 0 |
| Cohort 4 - 15 mg/kg | 0 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01445535)
Timeframe: Date treatment consent signed until 30 days after removal from study treatment or until off study, whichever comes first, approximately 22 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - 3.4 mg/kg | 3 |
| Cohort 2 - 4.8 mg/kg | 3 |
| Cohort 3 - 8.5 mg/kg | 3 |
| Cohort 4 - 15 mg/kg | 5 |
Progression was assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma. Progression is defined as ≥50% increase from nadir in the sum of the products of the perpendicular diameters (SPD) of any previously identified abnormal nodes for Partial Response's or non-responders. Progression-free survival (PFS) was determined from the on-study date until date of progression or last follow-up. The probability of PFS as a function of time was estimated by the Kaplan-Meier method. (NCT01445535)
Timeframe: On-study date until date of progression or last follow up, approximately 7 months.
| Intervention | Months (Median) |
|---|---|
| All Participants | 6.8 |
Overall survival was determined from the on-study date until date of progression or last follow up. The probability of OS as a function of time was estimated by the Kaplan-Meier method. (NCT01445535)
Timeframe: On study date until date of death or last follow up, approximately 12 months.
| Intervention | Months (Median) |
|---|---|
| All Participants | 12.1 |
Response was assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma. Complete Remission was defined as the disappearance of all detectable clinical and radiographic evidence of disease, disappearance of all disease related symptoms if present before therapy, and normalization of those biochemical abnormalities (for example lactate dehydrogenase (LDH)) definitely assignable to the lymphoma. Complete response unconfirmed was defined as a residual node greater than 1.5 cm, with a decrease by greater than 75 percent in the sum of the products of the perpendicular diameters (SPD) of all measured lymph nodes. Partial Response was defined as a ≥ 50% decreased in SPD of 6 largest dominant nodes or nodal masses. Relapsed disease was defined as the appearance of any new lesion or increase by ≥50% in the size of the previously identified sites. Progressive disease was defined as a ≥50% increase from nadir in the SPD. (NCT01445535)
Timeframe: Response assessments were performed after the fourth and sixth cycle of therapy, at therapy completion, and every 3 months for year 1, four months for year 2, 6 months for years 3-5, and annually thereafter, up to 5 years.
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Remission | Complete Response Unconfirmed | Partial Response | Relapsed Disease | Progressive Disease | Stable Disease | Not Evaluable | |
| Cohort 1 - 3.4 mg/kg | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Cohort 2 - 4.8 mg/kg | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Cohort 3 - 8.5 mg/kg | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
| Cohort 4 - 15 mg/kg | 4 | 0 | 0 | 0 | 0 | 0 | 2 |
Duration (in days) of continuous nebulized albuterol. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | days (Median) |
|---|---|
| Methylprednisolone Arm - Standard Care | 1 |
| Dexamethasone Arm - Interventional Arm | 0.8 |
Hospital length of stay measured in days. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | days (Mean) |
|---|---|
| Methylprednisolone Arm - Standard Care | 2.9 |
| Dexamethasone Arm - Interventional Arm | 2.9 |
"Number of participants receiving an adjunctive therapy:~use of non-invasive ventilation (NIV)~terbutaline~inhaled helium~inhaled anesthetic gas~mechanical ventilation~extracorporeal life support" (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Methylprednisolone Arm - Standard Care | 41 |
| Dexamethasone Arm - Interventional Arm | 16 |
Rates of known corticosteroid-related adverse events including clinically-relevant gastrointestinal bleeding, gastritis, ventilator associated pneumonia, necrotizing enterocolitis, hypertension, hyperglycemia, altered mentation (including hallucinations and delirium), and adrenal insufficiency observed prior to hospital discharge. (NCT03900624)
Timeframe: From enrollment through hospital discharge, up to 1 week
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hyperglycemia | Hypertension | Adrenal insufficiency | Altered mentation | Clinically-relevant gastrointestinal bleeding | Gastritis | Necrotizing enterocolitis | Ventilator associated pneumonia | |
| Dexamethasone Arm | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Methylprednisolone Arm | 7 | 1 | 2 | 2 | 0 | 0 | 0 | 0 |
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
The primary efficacy summary was change from Baseline in FEV1 (percent predicted), at Hour 2. Baseline was defined as FEV1 (percent predicted) after two doses of albuterol (5 mg each) and ipratropium (0.5 mg each) and FEV1 (percent predicted) FEV1 at Hour 2 was defined as the FEV1 (percent predicted) at 2 hours after the start of the infusion of MN-221 or placebo. Change from Baseline in FEV1 (percent predicted), was summarized by treatment group at Hour 2. (NCT00683449)
Timeframe: Baseline and Hour 2
| Intervention | FEV1 (percent of predicted) (Mean) |
|---|---|
| 240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes | 16.57 |
| MN-221 Placebo i.v. Infusion | 3.88 |
| 1,000-1,080 μg MN-221 i.v. | 3.03 |
| 450 μg MN-221 i.v. for 15 Minutes | 4.27 |
| 1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes | -0.82 |
FEV1 (L) was determined over time using a spirometer. Measure the mean change in FEV1 (L) from Baseline. (NCT00683449)
Timeframe: Baseline to Hour 2
| Intervention | liters per second (Mean) |
|---|---|
| MN-221 at 16.0 μg/Min for 15 Min (Total 240 μg) | 0.60 |
| Placebo Administered Intravenously | 0.10 |
| 450 μg MN-221 Given i.v. | 0.12 |
| 1,000-1,080 μg MN-221 Given i.v. for 15 Minutes | 0.10 |
| 1,995 MN-221 Administered i.v. for 15 Minutes and 25 Minutes | -0.02 |
After a patient in the emergency department (ED) presents with an acute exacerbation of asthma, the hospital proceeds with SOC procedures for this condition. Despite treatment in the ED, it is sometimes necessary to admit the patient into the hospital. In the study described here, the rate of hospital admissions was recorded. (NCT00683449)
Timeframe: Hour -1.5 through Hour 5
| Intervention | participants (Number) |
|---|---|
| 240 μg MN-221 i.v. (Intravenous) Infusion for 15 Minutes | 0 |
| MN-221 Placebo i.v. Infusion | 7 |
| 1,000-1,080 μg MN-221 i.v. | 0 |
| 450 μg MN-221 i.v. for 15 Minutes | 3 |
| 1,995 μg MN-221 i.v. Over 15 Minutes and 25 Minutes | 1 |
Overall survival is defined as the time from randomization to date of death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to end of study (Month 60)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 34.66 |
| Placebo | 30.29 |
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | NA |
| Placebo | 8.28 |
The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 12.29 |
| Placebo | 10.87 |
The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 25.17 |
| Placebo | 16.82 |
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first opiate use or end of study (Month 60)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 33.38 |
| Placebo | 23.39 |
The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)
| Intervention | Months (Median) |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 11.07 |
| Placebo | 5.55 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. (NCT00887198)
Timeframe: From first dose of study drug up to 30 days after the last dose of study drug
| Intervention | Participants (Number) | |
|---|---|---|
| With Treatment-Emergent Adverse Events | With Treatment-Emergent Serious Adverse Events | |
| Abiraterone Acetate + Prednisone (AAP) | 541 | 208 |
| Placebo | 524 | 148 |
| Placebo to Abiraterone Acetate | 93 | 39 |
OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months
| Intervention | months (Median) |
|---|---|
| Sunitinib and Prednisone | 13.1 |
| Placebo and Prednisone | 11.8 |
OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Sunitinib and Prednisone | 6.1 |
| Placebo and Prednisone | 1.8 |
PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks
| Intervention | weeks (Median) |
|---|---|
| Sunitinib and Prednisone | 24.1 |
| Placebo and Prednisone | 17.9 |
"The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions:~1. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax." (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | events (Number) |
|---|---|
| N-Acetylcysteine | 3 |
| Placebo | 3 |
"The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression.~The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline." (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | percentage of participants (Number) |
|---|---|
| N-Acetylcysteine | 27.1 |
| Placebo | 26.5 |
Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline. (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | participants (Number) |
|---|---|
| N-Acetylcysteine | 29 |
| Placebo | 35 |
Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters) (NCT00650091)
Timeframe: Measured as the estimated change from baseline to Week 60
| Intervention | liters (Mean) |
|---|---|
| N-Acetylcysteine | -0.18 |
| Placebo | -0.19 |
(NCT00650091)
Timeframe: Measured at Week 60
| Intervention | events (Number) |
|---|---|
| N-Acetylcysteine | 6 |
| Placebo | 6 |
Change from Baseline in Forced Vital Capacity at 15, 30, 45, and 60 weeks (units in liters) (NCT00650091)
Timeframe: Baseline, 15, 30, 45, 60 week
| Intervention | liters (Mean) | |||
|---|---|---|---|---|
| 15 week | 30 week | 45 week | 60 week | |
| N-Acetylcysteine | -0.07 | -0.07 | -0.15 | -0.16 |
| Placebo | -0.04 | -0.08 | -0.15 | -0.15 |
(NCT01193257)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
| Intervention | participants (Number) |
|---|---|
| Placebo + Prednisone | 345 |
| Orteronel + Prednisone | 719 |
(NCT01193257)
Timeframe: Cycle 59 Day 58
| Intervention | participants (Number) |
|---|---|
| Placebo + Prednisone | 1 |
| Orteronel + Prednisone | 3 |
(NCT01193257)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
| Intervention | participants (Number) |
|---|---|
| Placebo + Prednisone | 0 |
| Orteronel + Prednisone | 1 |
Best pain response was evaluated in participants who had a pain response across the entire study were summarized by treatment group. The pain response was defined as a >=2-point reduction from baseline in BPI-SF worst pain score without an increase in analgesic use, or a 25% or more reduction in analgesic use from baseline without an increase in worst pain score from baseline. (NCT01193257)
Timeframe: Baseline until disease progression or death, whichever occurred first (approximately up to 4.5 years)
| Intervention | participants (Number) |
|---|---|
| Placebo + Prednisone | 72 |
| Orteronel + Prednisone | 166 |
Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier. (NCT01193257)
Timeframe: Baseline until death (approximately up to 4.5 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone | 15.3 |
| Orteronel + Prednisone | 17.1 |
The PSA50 was defined as the percentage of participants who had a PSA decline of at least 50 percent (%) from baseline. (NCT01193257)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone | 9.9 |
| Orteronel + Prednisone | 24.9 |
The PSA90 was defined as the percentage of participants who had a PSA decline of at least 90% from baseline. (NCT01193257)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone | 2.83 |
| Orteronel + Prednisone | 9.66 |
The global health status or quality of life (QOL) was measured as the HRQOL response rate at 12 weeks using the 2-item global health status index of the european organization for research and treatment of cancer-quality of life questionnaire-C30 (EORTC QLQ-C30) instrument. HRQOL response was defined as a 17-point increase from the baseline assessment on the QOL index, after the score had been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30: included 5 functional scales (physical, role, cognitive, emotional, and social), 1 global health status, 3 symptom scales (fatigue, pain, nausea/vomiting) and 6 single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score representing better level of functioning or greater degree of symptoms. (NCT01193257)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone | 9.9 |
| Orteronel + Prednisone | 8.7 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. The overall objective response was defined as a complete response (CR) or partial response (PR). A complete response (CR) was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to <10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter(s) or short axis of lymph nodes. (NCT01193257)
Timeframe: Baseline until disease progression or death, whichever occurred first (approximately up to 4.5 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone | 2.7 |
| Orteronel + Prednisone | 17.1 |
Pain response was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: A greater than or equal to (>=) 2 point reduction from baseline in BPI-SF worst pain score without an increase in analgesic use; or a 25 percent (%) or more reduction in analgesic use from baseline without an increase in worst pain score from baseline. (NCT01193257)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone | 9.0 |
| Orteronel + Prednisone | 12.1 |
rPFS was defined as the time from randomization until radiographic disease progression or death due to any cause, whichever occurred first. Radiographic disease progression was defined as the occurrence of 1 or more of the following: The appearance of 2 or more new lesions on radionuclide bone scan as defined by prostate cancer working group (PCWG)2; Should 2 or more new bone lesions be evident at the first assessment (8-week assessment) on treatment, 2 or more additional new lesions must have been evident on a confirmatory assessment at least 6 weeks later; One or more new soft tissue/visceral organ lesions identified by computed tomography (CT)/magnetic resonance imaging (MRI); Progression as defined by response evaluation criteria in solid tumors (RECIST) 1.1 criteria. (NCT01193257)
Timeframe: Baseline until disease progression or death, whichever occurred first (approximately up to 4.5 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone | 5.7 |
| Orteronel + Prednisone | 8.3 |
Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was >= 4 with a >= 2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was >= 4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was <= 3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. (NCT01193257)
Timeframe: Baseline until EOT visit or until end of short term follow-up, whichever occurred later (approximately up to 4.5 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone | 22.0 |
| Orteronel + Prednisone | 24.2 |
Time to pain response was defined as the time from randomization until first pain response. Pain response was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: A >= 2 point reduction from baseline in BPI-SF worst pain score without an increase in analgesic use, or a 25% or more reduction in analgesic use from baseline without an increase in worst pain score from baseline. The analysis was performed by Kaplan-Meier method. (NCT01193257)
Timeframe: Baseline until disease progression or death, whichever occurred first (approximately up to 4.5 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone | NA |
| Orteronel + Prednisone | NA |
Time to PSA progression was defined as time from randomization to a PSA increase of 25% and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, above the baseline PSA. (NCT01193257)
Timeframe: Baseline until the final on treatment assessment or until end of short term follow-up following discontinuation of treatment, whichever occurred later (approximately up to 4.5 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone | 2.9 |
| Orteronel + Prednisone | 5.5 |
A favorable CTC count was defined as less than (<) 5 counts per (/) 7.5 mililiter (mL) in whole blood. An unfavorable CTC count was defined as >=5 counts/7.5 mL in whole blood. (NCT01193257)
Timeframe: Baseline and EOT (Cycle 59 Day 58)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Baseline: Favorable; EOT: Favorable | Baseline: Favorable; EOT: Unfavorable | Baseline: Unfavorable; EOT: Favorable | Baseline: Unfavorable; EOT: Unfavorable | |
| Orteronel + Prednisone | 63 | 40 | 23 | 141 |
| Placebo + Prednisone | 27 | 30 | 8 | 92 |
(NCT01193257)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Digestive enzymes | Renal function analyses | Liver function analyses | Tissue enzyme analyses NEC | Coagulation and bleeding analyses | Mineral and electrolyte analyses | White blood cell analyses | Carbohydrate tolerance analyses-including diabetes | Urinary tract function analyses NEC | Platelet analyses | Cholesterol analyses | Red blood cell analyses | Protein analyses not elsewhere classified (NEC) | Vascular tests NEC (including blood pressure) | Adrenal cortex tests | Metabolism tests NEC | Skeletal and cardiac muscle analyses | Triglyceride analyses | Urinalysis NEC | Vitamin analyses | |
| Orteronel + Prednisone | 140 | 41 | 38 | 30 | 17 | 9 | 8 | 8 | 5 | 4 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Placebo + Prednisone | 9 | 13 | 14 | 16 | 1 | 5 | 4 | 0 | 1 | 3 | 1 | 2 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
(NCT01193257)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hypertension | Hypotension | Pyrexia | |
| Orteronel + Prednisone | 83 | 31 | 51 |
| Placebo + Prednisone | 21 | 8 | 18 |
(NCT01193257)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
| Intervention | participants (Number) | |
|---|---|---|
| Weight decreased | Weight increased | |
| Orteronel + Prednisone | 107 | 6 |
| Placebo + Prednisone | 32 | 7 |
ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50% of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period. (NCT01193257)
Timeframe: Baseline up to End-of-treatment (EOT) (Cycle 59 Day 58)
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: 0; Overall: 0 | Baseline: 0; Overall: 1 | Baseline: 0; Overall: 2 | Baseline: 0; Overall: 3 | Baseline: 0; Overall: 4 | Baseline: 1; Overall: 0 | Baseline: 1; Overall: 1 | Baseline: 1; Overall: 2 | Baseline: 1; Overall: 3 | Baseline: 1; Overall: 4 | Baseline: 2; Overall: 1 | Baseline: 2; Overall: 2 | Baseline: 2; Overall: 3 | Baseline: 2; Overall: 4 | |
| Orteronel + Prednisone | 112 | 121 | 47 | 18 | 3 | 10 | 179 | 113 | 39 | 11 | 6 | 25 | 18 | 3 |
| Placebo + Prednisone | 56 | 70 | 13 | 5 | 1 | 3 | 103 | 53 | 22 | 7 | 0 | 10 | 10 | 0 |
The PSA50 was defined as the percentage of participants who had a PSA decline of at least 50% from baseline. (NCT01193257)
Timeframe: Cycle: 4, 7, 10, 13, 16, 19, 22, and 25
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cycle 4 (n= 283; 559) | Cycle 7 (n= 163; 403) | Cycle 10 (n= 102; 267) | Cycle 13 (n= 55; 171) | Cycle 16 (n= 34; 107) | Cycle 19 (n= 24; 68) | Cycle 22 (n= 14; 36) | Cycle 25 (n= 8; 16) | |
| Orteronel + Prednisone | 32.74 | 38.21 | 36.70 | 40.94 | 44.86 | 42.65 | 52.78 | 62.50 |
| Placebo + Prednisone | 12.72 | 18.40 | 22.55 | 23.64 | 23.53 | 20.83 | 28.57 | 25.00 |
The PSA90 was defined as the percentage of participants who had a PSA decline of at least 90% from baseline. (NCT01193257)
Timeframe: Cycle: 7, 10, 13, 16, 19, 22, and 25
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 7 (n=163; 403) | Cycle 10 (n=102; 267) | Cycle 13 (n=55; 171) | Cycle 16 (n=34; 107) | Cycle 19 (n=24; 68) | Cycle 22 (n=14; 36) | Cycle 25 (n=8; 16) | |
| Orteronel + Prednisone | 14.89 | 14.23 | 15.20 | 19.63 | 23.53 | 27.78 | 43.75 |
| Placebo + Prednisone | 4.91 | 6.86 | 7.27 | 5.88 | 4.17 | 0.00 | 0.00 |
(NCT01193244)
Timeframe: Baseline up to EOT (Cycle 61 Day 58)
| Intervention | participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 130 |
| Orteronel 400 mg + Prednisone 5 mg | 163 |
Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier. (NCT01193244)
Timeframe: Baseline until death (up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 29.5 |
| Orteronel 400 mg + Prednisone 5 mg | 29.9 |
The PSA50 is defined as a decline of at least 50 percent (%) from baseline. (NCT01193244)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 24.6 |
| Orteronel 400 mg + Prednisone 5 mg | 42.6 |
The PSA90 is defined as a decline of PSA by 90 percent from baseline. (NCT01193244)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 5.4 |
| Orteronel 400 mg + Prednisone 5 mg | 16.7 |
A favorable CTC count was defined as less than <5 counts per 7.5 milliliter (mL) in whole blood. An unfavorable CTC count was defined as greater than or equal to (>=) 5 counts/7.5 mL in whole blood. (NCT01193244)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 9.1 |
| Orteronel 400 mg + Prednisone 5 mg | 15.4 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1. A CR was defined as the disappearance of all target lesions determined by computerized tomography (CT) or MRI. Any pathological lymph nodes (whether target or non-target) must have had reduction in short axis to <10 millimetre (mm). A PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of longest diameters of non-lymph node lesions and of the short diameter or short axis of lymph nodes. (NCT01193244)
Timeframe: Baseline until disease progression or death, whichever occurred first (approximately up to 4.7 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 15.2 |
| Orteronel 400 mg + Prednisone 5 mg | 34.7 |
Skeletal related (SRE) event is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence. (NCT01193244)
Timeframe: Baseline up to EOT (approximately up to 4.7 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Prednisone 5 mg | 10.9 |
| Orteronel 400 mg + Prednisone 5 mg | 8.6 |
rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment. (NCT01193244)
Timeframe: Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 8.7 |
| Orteronel 400 mg + Prednisone 5 mg | 13.8 |
Global health status deterioration is defined as a drop greater than 16 points from the baseline assessment, confirmed at least 3 weeks later, on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core Module 30 (EORTC QLQ-C30) index after the score has been linearly transformed to a 0 to 100 scale. EORTC QLQ-C30 consists of 30 questions, where question 1 to 28 can be answered with 1: Not at all, 2: A little, 3: Quite a bit, 4: Very much and question 29 to 30 with 1: Very poor to 7: Excellent. For subscales a high score from 0-100 indicates: high global quality of life, high level of functioning (physical, role, emotional, cognitive, social) or a high level of symptoms (fatigue, nausea, pain, dyspnea, insomnia, appetite loss, constipation, diarrhoea, financial difficulties). (NCT01193244)
Timeframe: Baseline until EOT (approximately up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 10.7 |
| Orteronel 400 mg + Prednisone 5 mg | 8.3 |
Time to docetaxel based chemotherapy is defined as the time from randomization to the start of docetaxel based chemotherapy for prostate cancer, regardless of whether the participant received concurrent orteronel or not. Deaths due to disease progression prior to Docetaxel based chemotherapy were considered as events. (NCT01193244)
Timeframe: Baseline until start of docetaxel chemotherapy (up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 19.0 |
| Orteronel 400 mg + Prednisone 5 mg | 23.0 |
Time to pain progression was defined as the time from participant randomization to the first assessment date of pain progression. Pain progression was defined as the occurrence of 1 of the following and confirmed by an additional assessment, at least 3 weeks but not more than 5 weeks later: The brief pain inventory-short form (BPI-SF) worst pain score was >=4 with a >=2 point increase over baseline in BPI-SF worst pain score with stable or increased analgesic use; The BPI-SF worst pain score was >=4 but not less than baseline with new or increased (relative to baseline) Step II or Step III analgesic use; The BPI-SF worst pain score was <=3 but not less than baseline with new or increased (relative to baseline) Step III analgesic use. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 100 with lower scores being indicative of less pain or pain interference. (NCT01193244)
Timeframe: Baseline until End of treatment (EOT) (approximately up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | NA |
| Orteronel 400 mg + Prednisone 5 mg | NA |
Time to PSA progression was defined as time from randomization to a PSA increase of 25 percent and PSA rise of at least 2 nanogram per milliliter (ng/mL) above the lowest value observed post baseline or, if no PSA decline occurred post baseline, compared to baseline PSA. (NCT01193244)
Timeframe: Baseline until the final on treatment assessment or until end of short term follow-up following discontinuation of treatment, whichever occurred later (approximately up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 5.59 |
| Orteronel 400 mg + Prednisone 5 mg | 8.3 |
Time to SRE is defined as the time from randomization to SRE, or death due to any cause, whichever comes first. SRE is defined as a fracture or spinal cord compression or the need for radiation or surgery at the site of a prostate cancer metastatic lesion that is substantiated by radiographic or pathologic evidence. (NCT01193244)
Timeframe: Baseline up to EOT (Cycle 61 Day 58)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 9.0 |
| Orteronel 400 mg + Prednisone 5 mg | 13.9 |
Time to subsequent antineoplastic therapy is defined as the time from randomization to the start of any alternate antineoplastic therapy for prostate cancer. Deaths due to disease progression prior to antineoplastic therapy for prostate cancer are considered as events. Otherwise, time to next therapy is censored at the date of death or the last date the participant was known to be alive or the data cutoff date, whichever is earlier. (NCT01193244)
Timeframe: Baseline until start of subsequent antineoplastic therapy (up to 4.7 years)
| Intervention | months (Median) |
|---|---|
| Placebo + Prednisone 5 mg | 13.9 |
| Orteronel 400 mg + Prednisone 5 mg | 17.2 |
Worst change was defined as the worst overall change that occurred in cardiac ejection fraction at any measured time point. (NCT01193244)
Timeframe: Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)
| Intervention | percent ejection fraction (Mean) |
|---|---|
| Placebo + Prednisone 5 mg | -3.8 |
| Orteronel 400 mg + Prednisone 5 mg | -4.8 |
(NCT01193244)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
| Intervention | participants (Number) | |
|---|---|---|
| TEAE | Serious Adverse Events (SAE) | |
| Orteronel 400 mg + Prednisone 5 mg | 769 | 380 |
| Placebo + Prednisone 5 mg | 733 | 321 |
(NCT01193244)
Timeframe: Baseline up to 30 days or EOT whichever is later (approximately up to Cycle 61 Day 58)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Investigations | Blood and lymphatic system disorders | Metabolism and nutrition disorders | |
| Orteronel 400 mg + Prednisone 5 mg | 399 | 107 | 336 |
| Placebo + Prednisone 5 mg | 215 | 114 | 204 |
(NCT01193244)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hypertension | Pyrexia | Hypotension | |
| Orteronel 400 mg + Prednisone 5 mg | 98 | 41 | 26 |
| Placebo + Prednisone 5 mg | 76 | 26 | 12 |
(NCT01193244)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
| Intervention | participants (Number) | |
|---|---|---|
| Weight decreased | Weight increased | |
| Orteronel 400 mg + Prednisone 5 mg | 119 | 10 |
| Placebo + Prednisone 5 mg | 47 | 36 |
Grade 3 (Severe) events=unacceptable or intolerable events, significantly interrupting usual daily activity, require systemic drug therapy/other treatment. Grade 4 (Life-threatening) events caused participant to be in imminent danger of death. Grade 5 (Death) events=death related to an AE. (NCT01193244)
Timeframe: Baseline up to 30 days after last dose of study drug (Cycle 61 Day 58)
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 or higher TEAE | Grade 5 (Death) | |
| Orteronel 400 mg + Prednisone 5 mg | 537 | 77 |
| Placebo + Prednisone 5 mg | 405 | 78 |
ECOG assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50 percent of waking hours [hrs]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50 percent of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. Worst change was defined as the worst overall change that occurred in ECOG status at any measured time point during the treatment period. (NCT01193244)
Timeframe: Baseline until EOT (approximately up to 4.7 years)
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: 0; Overall: 0 | Baseline: 0; Overall: 1 | Baseline: 0; Overall: 2 | Baseline: 0; Overall: 3 | Baseline: 0; Overall: 4 | Baseline: 1; Overall: 0 | Baseline: 1; Overall: 1 | Baseline: 1; Overall: 2 | Baseline: 1; Overall: 3 | Baseline: 1; Overall: 4 | Baseline: 2; Overall: 2 | |
| Orteronel 400 mg + Prednisone 5 mg | 200 | 237 | 66 | 15 | 7 | 6 | 147 | 60 | 26 | 6 | 1 |
| Placebo + Prednisone 5 mg | 251 | 177 | 47 | 22 | 7 | 6 | 162 | 57 | 28 | 2 | 1 |
The PSA50 is defined as a decline of PSA by 50 percent from baseline. (NCT01193244)
Timeframe: Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 4 (n= 687, 672) | Cycle 7 (n= 541, 540) | Cycle 10 (n= 438, 450) | Cycle 13 (n= 344, 382) | Cycle 16 (n= 286, 303) | Cycle 19 (n= 228, 272) | Cycle 22 (n= 184, 211) | Cycle 25 (n= 109, 119) | Cycle 28 (n= 67, 77) | Cycle 31 (n= 35, 39) | Cycle 34 (n= 22, 18) | Cycle 37 (n= 7, 5) | |
| Orteronel 400 mg + Prednisone 5 mg | 49.70 | 54.81 | 56.00 | 53.14 | 54.13 | 52.94 | 54.03 | 46.22 | 48.05 | 48.72 | 38.89 | 40.00 |
| Placebo + Prednisone 5 mg | 28.09 | 34.94 | 36.99 | 37.21 | 34.27 | 37.72 | 33.15 | 35.78 | 44.78 | 34.29 | 36.36 | 71.43 |
The PSA90 is defined as a decline of PSA by 90 percent from baseline. (NCT01193244)
Timeframe: Cycle: 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 4 (n= 687, 672) | Cycle 7 (n= 541, 540) | Cycle 10 (n= 438, 450) | Cycle 13 (n= 344, 382) | Cycle 16 (n= 286, 303) | Cycle 19 (n= 228, 272) | Cycle 22 (n= 184, 211) | Cycle 25 (n= 109, 119) | Cycle 28 (n= 67, 77) | Cycle 31 (n= 35, 39) | Cycle 34 (n= 22, 18) | Cycle 37 (n= 7, 5) | |
| Orteronel 400 mg + Prednisone 5 mg | 16.67 | 22.22 | 26.44 | 26.18 | 25.74 | 26.10 | 28.44 | 21.01 | 27.27 | 12.82 | 22.22 | 20.00 |
| Placebo + Prednisone 5 mg | 5.39 | 8.69 | 11.64 | 12.79 | 12.24 | 12.72 | 10.87 | 11.01 | 16.42 | 8.57 | 4.55 | 14.29 |
"Defined as the median time from randomization to the earliest of:~Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST);~Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of >=2 new lesions;~New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression)~Symptomatic progression (for participants without measurable disease);~Other clinical events attributable to prostate cancer that require major interventions; or~Death from any cause~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: Randomization to composite progressive disease, up to 23.4 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 4.1 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 6.7 |
"Data presented are the percentage of participants without disease progression at 12 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 12.4 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 20.0 |
"Data presented are the percentage of participants without disease progression at 6 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 37.2 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 59.2 |
"Data presented are the percentage of participants without disease progression at 9 months.~Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: 9 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 20.7 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 35.9 |
"Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions.~Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100." (NCT00683475)
Timeframe: Baseline to date of progressive disease or death up to 36.3 months
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 15.2 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 31.6 |
Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive. (NCT00683475)
Timeframe: First dose to death due to any cause up to 36.3 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 10.8 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 13.0 |
PSA response rate is defined as the percentage of participants with a decrease in PSA >= 50 percent from baseline. (NCT00683475)
Timeframe: Baseline up to data cut-off date (up to 36.3 months)
| Intervention | percentage of participants (Number) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 18.5 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 21.4 |
"Time between date of randomization and earliest date of radiographic progression defined as either:~Tumor progression by RECIST;~Evidence of progression by bone scan;~New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression).~Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy." (NCT00683475)
Timeframe: Randomization to date of radiographic progression, up to 36.3 months
| Intervention | months (Median) |
|---|---|
| IMC-A12 + Mitoxantrone + Prednisone | 7.5 |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 10.2 |
Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section. (NCT00683475)
Timeframe: Randomization to 36.3 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| A12/1121B Related TEAE | A12/1121B Related Serious TEAE | A12/1121B Related Grade >= 3 TEAE | TEAE Leading to Dose Modification of A12/1121B | TEAE Leading to Discontinuation of A12/1121B | |
| IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone | 63 | 16 | 31 | 35 | 25 |
| IMC-A12 + Mitoxantrone + Prednisone | 64 | 22 | 35 | 35 | 18 |
Overall Survival as measured by the Kaplan-Meier method (NCT01051570)
Timeframe: After treatment, participants will be contacted every 3 months up to 4 years
| Intervention | months (Median) |
|---|---|
| Carboplatin, RAD 001 & Prednisone | 12.5 |
Using a limited sampling model (i.e., AUC = 0.52 × C2.75h + 0.92) (Sorensen et al., 1993), observed carboplatin AUC was estimated based on the concentration in the 2.75-h sample. (NCT01051570)
Timeframe: Samples were collected Cycle 2, Day 1
| Intervention | mg/ml*min (Mean) |
|---|---|
| Carboplatin, RAD 001 & Prednisone | 5.8 |
PSA response rate with response defined as => a 30% reduction in PSA (NCT01051570)
Timeframe: Day 1 of each cycle (every 21 days), through study completion, an average of 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Carboplatin, RAD 001 & Prednisone | 15 |
Progression defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT01051570)
Timeframe: Up to 63 days while on treatment, then up 90 days thereafter. From date of registration to date of progressive disease.
| Intervention | months (Median) |
|---|---|
| Carboplatin, RAD 001 & Prednisone | 2.5 |
PSA response defined as a decrease of 30% or more will be tabled against mTOR, pAKT, and p70S6 (1+, 2+, 3+ vs ND) (NCT01051570)
Timeframe: Archival tissue will be collected if available. Optional biopsies pre-treatment and 24 hours after first everolimus and carboplatin dose
| Intervention | participants (Number) | ||
|---|---|---|---|
| pAKT(ND) vs Responder | mTOR(ND) vs Responder | p70S6(ND) vs Responder | |
| Carboplatin, RAD 001 & Prednisone | 1 | 0 | 1 |
Number of Participants with Grade 3/4 Toxicity as measured by NCI CTCAE v3.0 criteria (NCT01051570)
Timeframe: Day 1 of each cycle (every 21 days), through study completion, an average of 6 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Thrombocytopenia | Lymphopenia | Leukopenia | Infection without neutropenia | Hypophosphatemia | Neutropenia | Dehydration | Hyperglycemia | Hyponatremia | Pulmonary embolism | Fatigue | Hypercholesterolemia | Rash | AST | Hypomagnesemia | Hypokalemia | |
| Carboplatin, RAD 001 & Prednisone | 10 | 9 | 6 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
"Complete Response Rate (CR) was reported at the end of the CEOP-P (6 courses for patients not receiving transplant and 4-6 courses for patients receiving transplant). Response assessment was performed by computerized tomography (CT) or positron emission tomography (PET)/CT based on the investigator's preference after cycles 2, 4 and 6. Response was assessed by the treating physician according to the Cheson Revised response criteria (Cheson et al,, 2007) or International Harmonization Project criteria (Cheson, 2007), based on imaging modality used.~Complete Response Definition: Disappearance of all evidence of disease Nodal Masses: (a) [18F]fluorodeoxyglucose(FDG)-avid or PET positive prior to therapy; mass of any size permitted if PETnegative (b) Variably FDG-avid or PET negative; regression to normal size on CT Spleen, Liver: Not palpable, nodules disappeared Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative" (NCT01336933)
Timeframe: 168 days - 252 days (4-6 courses; 42 days per course)
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Treatment (Chemotherapy and Enzyme Inhibitor Therapy) | 52 |
Estimated 2-year Event Free Survival (EFS), as well as plots of EFS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for EFS. Event-free survival is defined as time from therapy until relapse, progression, or death from any cause. (NCT01336933)
Timeframe: 2 years
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Treatment (Chemotherapy and Enzyme Inhibitor Therapy) | 39 |
"Every patient who fulfills all aspects of patient eligibility who receives at least 2 complete courses of chemotherapy will be evaluable for the response endpoint. Response rates will be descriptively summarized using percentages and 95% confidence intervals.~Complete Response Definition: Defined in Primary Objective Partial Response Definition: Regression of measurable disease and no new sites, Nodal Masses: > 50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes~FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site~Variably FDG-avid or PET negative; regression on CT Spleen, Liver:> 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified" (NCT01336933)
Timeframe: 2 years
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Treatment (Chemotherapy and Enzyme Inhibitor Therapy) | 70 |
Estimated 2-year Overall Survival (OS), as well as plots of OS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for OS. Overall survival is defined as time from the first chemotherapy administered on trial until death from any cause. (NCT01336933)
Timeframe: 2 years
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Treatment (Chemotherapy and Enzyme Inhibitor Therapy) | 60 |
Percentage of patients who received consolidation with high dose therapy and autologous stem cell rescue (HDT/SCR). (NCT01336933)
Timeframe: 168-252 days (4 courses up to 6 courses of treatment)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 15 |
Adverse events will be summarized using patient level incidence rates so that a patient contributes once to any adverse event. The number and percentage of patients with any adverse event will be summarized for each course. Serious adverse events will be analyzed similarly. (NCT01336933)
Timeframe: 22 months
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Grade 3-4 anaemia | Grade 3-4 thrombocoytopenia | Grade 3-4 febrile neutropenia | Grade 3-4 mucositis | Grade 3-4 sepsis | Grade 3-4 increased creatinine | Grade 3-4 liver transaminases | |
| Treatment (Chemotherapy and Enzyme Inhibitor Therapy) | 27 | 12 | 18 | 18 | 15 | 12 | 12 |
Time to second-line anti-myeloma therapy was defined as time from randomization to the start of another non-protocol anti-myeloma therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 39.1 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median follow-up for responders was 19.9 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 31.5 |
| Lenalidomide and Dexamethasone Rd18 | 21.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.1 |
Duration of response was defined as the duration from the time when the response criteria were first met for CR or VGPR or PR based on IMWG criteria until the first date the response criteria were met for progressive disease or until the participant died from any cause, whichever occurred first. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median follow-up for responders was 20.1 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 35.0 |
| Lenalidomide and Dexamethasone Rd18 | 22.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 22.3 |
Overall survival was defined as the time between randomization and death. Participants, who died, regardless of the cause of death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the participant was known to be alive. (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 48.3 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 59.1 |
| Lenalidomide and Dexamethasone Rd18 | 62.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 49.1 |
Time to second-line anti-myeloma therapy is defined as time from randomization to the start of another non-protocol anti-myeloma therapy. Those who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of date 21 January 2016; median follow-up for all participants was 23.0 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 36.7 |
| Lenalidomide and Dexamethasone Rd18 | 28.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | 26.7 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by IRAC based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off of 24 May 2013; median follow-up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
TTF is defined as the time between the randomization and discontinuation of study treatment for any reason, including disease progression (determined by the investigators assessment based on the IMWG response criteria), treatment toxicity, start of another anti-myeloma therapy (AMT) or death. (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 21 January 2016; median follow up for all participants was 16.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 16.9 |
| Lenalidomide and Dexamethasone Rd18 | 17.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 14.1 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 26.0 |
| Lenalidomide and Dexamethasone Rd18 | 21.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.9 |
PFS was calculated as the time from randomization to the first documented PD or death due to any cause during the study, which ever occurred first based on the International Myeloma Working Group Uniform Response criteria (IMWG). Those who withdrew for any reason or received another anti-myeloma therapy without documented PD were censored on the date of their last response assessment, prior to receiving any other anti-myeloma therapy. Censoring rules for PFS: - No baseline assessments and no progression or death documented within the 2 scheduled assessments; Death within the lst two assessments without any adequate response assessment; Progression documented between scheduled assessments; Death between adequate assessments; no progression; study discontinuations for reasons other than PD or death; new anti-myeloma started prior to PD; death or PD after an extended lost to follow-up time period (2 or more missed scheduled assessment's). (NCT00689936)
Timeframe: From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 25.5 |
| Lenalidomide and Dexamethasone Rd18 | 20.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 21.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 70.0 |
| Lenalidomide and Dexamethasone Rd18 | 69.7 |
| Melphalan + Prednisone + Thalidomide (MPT) | 58.2 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 81.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 70.6 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of particpants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.4 |
| Lenalidomide and Dexamethasone Rd18 | 74.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 61.0 |
Participants were placed in adverse and non-adverse cytogenetic risk categories at baseline and response rates evaluated. Adverse Risk: t(4;14), t(14;16), del(13q) or monosomy 13, del(17p), 1q gain Favorable Hyperdiploidy: : t(11;14), gains of 5/9/15; Normal: a normal result, gains other than 5/9/15, IgH deletion Uncertain risk: probes used for analysis cannot place participant in any of the other risk categories. Objective response = best overall response including CR, VGPR or PR based on the IRAC Review; A CR is negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPRis serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 60.5 |
| Lenalidomide and Dexamethasone Rd18 | 76.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 57.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment; data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 46.2 |
| Lenalidomide and Dexamethasone Rd18 | 53.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 45.7 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined s: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 80.7 |
| Lenalidomide and Dexamethasone Rd18 | 78.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 67.5 |
Objective response according to IMWG Uniform Response Criteria was defined as a best overall response including a complete response (CR), very good partial response (VGPR) or partial response (PR) based on the IRAC Review. A CR is defined as: negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in BM; A VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; A PR is: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 75.1 |
| Lenalidomide and Dexamethasone Rd18 | 73.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 62.3 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria assessed by the investigator. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 21 January 2016; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The time to first myeloma response was defined as the time from randomization to the time when the response criteria for at least a PR was first met based on the IMWG criteria. (NCT00689936)
Timeframe: Disease response was assessed every 28 days until end of treatment or the data cut-off date of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 |
| Lenalidomide and Dexamethasone Rd18 | 1.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Appetite Loss Scale is scored between 0 and 100, with a high score indicating a higher level of appetite loss. Negative change from Baseline values indicate improvement in appetite and positive values indicate worsening of appetite. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.9 | -3.3 | -8.6 | -6.4 | -5.1 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.3 | -5.9 | -9.8 | -7.3 | -8.1 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | -6.2 | -13.5 | -10.5 | -12.2 | -2.6 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Cognitive Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1, (Baseline) then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.7 | 1.8 | 0.9 | -1.2 | -2.8 | -2.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.2 | -0.7 | -0.9 | -1.6 | -2.2 | -4.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.8 | -1.5 | -0.3 | -0.6 | -0.7 | -7.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Constipation Scale is scored between 0 and 100, with a high score indicating a higher level of constipation. Negative change from Baseline values indicate improvement in constipation and positive values indicate worsening of constipation. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 6.3 | 0.0 | -5.1 | -5.2 | -5.9 | -7.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 8.3 | 1.8 | -2.4 | -2.4 | -4.5 | -7.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 18.4 | 13.9 | 6.8 | 3.7 | 0.0 | -2.2 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Diarrhea Scale is scored between 0 and 100, with a high score indicating a higher level of diarrhea. Negative change from Baseline values indicate improvement in diarrhea and positive values indicate worsening of diarrhea. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 2.3 | 3.4 | 6.0 | 9.1 | 10.9 | 6.4 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 3.8 | 3.7 | 8.2 | 11.8 | 14.8 | 10.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.6 | -2.4 | -2.2 | -2.5 | -1.7 | -0.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnoea Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.6 | -1.9 | -2.9 | -1.6 | 2.9 | 0.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.9 | -0.8 | -2.3 | -3.5 | -1.8 | -1.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.2 | 2.0 | 0.1 | -1.6 | 0.4 | 7.8 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 0.1 | 3.9 | 5.8 | 4.9 | 3.1 | 3.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.6 | 3.8 | 4.6 | 4.6 | 5.8 | 2.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 2.1 | 5.5 | 5.1 | 5.1 | -0.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.4 | -3.4 | -5.9 | -2.3 | 0.1 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.6 | -2.5 | -3.7 | -4.3 | -3.1 | 0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | 2.8 | -1.8 | -4.5 | -3.9 | -4.3 | 2.7 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Financial Difficulties Scale is scored between 0 and 100, with a high score indicating a higher level of financial difficulties. Negative change from Baseline values indicate improvement in financial difficulties and positive values indicate worsening of financial difficulties. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.3 | -0.4 | -0.3 | 1.6 | 1.8 | 0.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 1.9 | 1.4 | 0.4 | 2.0 | 1.9 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.5 | 1.9 | 0.7 | 1.1 | 0.4 | 5.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Insomnia Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.2 | -1.3 | -1.9 | 1.1 | 1.4 | -1.6 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.1 | 0.2 | -1.2 | -1.0 | -0.5 | -5.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -10.5 | -8.9 | -11.6 | -9.6 | -6.0 | -4.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Nausea/Vomiting Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.5 | -2.5 | -4.0 | -3.6 | -2.7 | -4.2 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 1.8 | -1.1 | -1.3 | -2.2 | -2.3 | 0.4 |
| Melphalan + Prednisone + Thalidomide (MPT) | 4.0 | -1.2 | -3.9 | -3.9 | -3.9 | 1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate improvement in symptoms and positive values indicate worsening symptoms. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.4 | -13.1 | -16.1 | -14.7 | -12.4 | -7.9 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -5.4 | -13.4 | -14.4 | -14.0 | -14.4 | -8.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | -7.8 | -12.1 | -13.4 | -14.3 | -14.7 | -6.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.4 | 4.7 | 7.6 | 7.4 | 6.8 | 3.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -1.7 | 3.4 | 4.7 | 5.0 | 6.9 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | -0.9 | 2.2 | 5.3 | 6.9 | 8.3 | -0.1 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Role Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.6 | 6.3 | 8.6 | 9.4 | 9.1 | 3.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -2.7 | 2.4 | 6.3 | 7.8 | 8.0 | -0.3 |
| Melphalan + Prednisone + Thalidomide (MPT) | -2.4 | 4.1 | 8.2 | 11.8 | 14.5 | -1.0 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Social Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -2.2 | 2.0 | 5.2 | 3.8 | 3.2 | 2.7 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.3 | 0.7 | 4.0 | 2.9 | 4.2 | -1.2 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.4 | 2.4 | 3.4 | 5.8 | 6.0 | -3.5 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Study discontinuation | |
| Lenalidomide and Dexamethasone Rd18 | -1.3 | 4.7 | 5.4 | 3.2 | 5.7 | 5.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.4 | 4.8 | 5.9 | 4.8 | 6.4 | -0.1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 1.0 | 4.3 | 6.1 | 6.5 | 4.8 | 0.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the body image scale, a higher score indicates a better body image. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -1.5 | 0.8 | 1.5 | -0.4 | -0.3 | 1.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.5 | -1.7 | -1.4 | -1.4 | -2.3 | -5.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | -1.6 | -3.0 | -2.8 | -2.6 | -1.1 | -5.6 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score indicates more severe disease symptom(s). (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -4.1 | -10.0 | -9.9 | -8.7 | -6.2 | -4.5 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | -4.0 | -9.1 | -8.8 | -7.8 | -8.7 | -3.5 |
| Melphalan + Prednisone + Thalidomide (MPT) | -4.4 | -7.0 | -7.9 | -6.5 | -7.9 | -3.7 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; for the future perspective scale, a higher score indicates a better perspective of the future. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 3.9 | 9.2 | 12.3 | 12.1 | 11.7 | 8.8 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 4.7 | 8.5 | 9.8 | 10.8 | 12.7 | 5.8 |
| Melphalan + Prednisone + Thalidomide (MPT) | 3.3 | 6.3 | 8.0 | 10.0 | 9.5 | 3.2 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used a 4-point scale (from 1 'Not at All' to 4 'Very Much'). Scores were averaged, and transformed to a 0-100 scale; a higher score represents a more severe overall side effect of treatment. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | 4.0 | 1.2 | -0.4 | 1.2 | 2.3 | -1.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 2.5 | 1.0 | 1.7 | 1.9 | 2.2 | 0.6 |
| Melphalan + Prednisone + Thalidomide (MPT) | 5.6 | 3.5 | 2.9 | 4.7 | 4.3 | 3.8 |
EQ-5D is a self-administered questionnaire that assesses health-related quality of life. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where higher EQ-5D scores represent better health status. A positive change from baseline score indicates improvement in health status and better health state. (NCT00689936)
Timeframe: Cycle 1 Day 1 (Baseline), then Months 1, 3, 6, 12, 18 and Discontinuation visit
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Discontinuation Visit | |
| Lenalidomide and Dexamethasone Rd18 | -0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
A TEAE is any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. (NCT00689936)
Timeframe: From first dose of study drug through 28 days following the discontinuation visit from active treatment phase; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 adverse event (AE) | ≥ 1 grade (Gr) 3 or 4 AE | ≥ 1 grade (Gr) 5 AE | ≥ 1 serious adverse event (SAE) | ≥ 1 AE related to Lenalidomide/Dex/Mel/Pred/Thal | ≥ 1 AE related to Lenalidomide | ≥ 1 AE related to dexamethasone | ≥ 1 AE related to melphalan | ≥ 1 AE related to prednisone | ≥ 1 AE related to thalidomide | ≥1 AE related to Lenalidomide/Dex or Mel/Pred/Thal | ≥ 1 Gr 3 or 4 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 grade 3 or 4 AE related to Lenalidomide | ≥ 1 grade 3 or 4 AE related to dexamethasone | ≥ 1 grade 3 or 4 AE related to melphalan | ≥ 1 grade 3 or 4 AE related to prednisone | ≥ 1 grade 3 or 4 AE related to Thalidomide | ≥1Gr 3 or 4 AE related to Len/Dex or Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Len/Dex/Mel/Pred/Thal | ≥ 1 Grade 5 AE related to Lenalidomide | ≥ 1 Grade 5 AE related to Dexamethasone | ≥ 1 Grade 5 AE related to melphalan | ≥ 1 Grade 5 AE related to prednisone | ≥ 1 Grade 5 AE related to Thalidomide | ≥1 Grade 5 AE related to Len/Dex or Mel/Pred/Thal | ≥1 SAE related to Len/Dex/Mel/Pred/Thal | ≥1 SAE related to Lenalidomide | ≥1 SAE related to dexamethasone | ≥1 SAE related to melphalan | ≥1 SAE related to prednisone | ≥1 SAE related to thalidomide | ≥1 SAE related to Len/Dex or Mel/Pred/Thal | ≥1AE leading to Len/Dex/Mel/Pred/Thal Withdrawal | ≥1 AE leading to Lenalidomide withdrawal | ≥1 AE leading to dexamethasone withdrawal | ≥1 AE leading to melphalan withdrawal | ≥1 AE leading to prednisone withdrawal | ≥1 AE leading to Thalidomide withdrawal | ≥1AE leading to Len/DexOR Mel/Pred/Thal Withdrawal | ≥1AE leading to Len/Dex/Mel/Pred/Thal reduction | ≥1 AE leading to Lenalidomide reduction | ≥1 AE leading to dexamethasone reduction | ≥1 AE leading to melphalan reduction | ≥1 AE leading to prednisone reduction | ≥1 AE leading to thalidomide reduction | ≥1AE leading to Len/Dex or Mel/Pred/Thal reduction | ≥1 AE leading to Rd or MPT interruption | ≥1 AE leading to Lenalidomide interruption | ≥1 AE leading to dexamethasone interruption | ≥1 AE leading to melphalan interruption | ≥1 AE leading to prednisone interruption | ≥1 AE leading to Thalidomide interruption | ≥1 AE leading to Len and Dex or MPT interruption | |
| Lenalidomide and Dexamethasone Rd18 | 536 | 433 | 36 | 308 | 501 | 481 | 410 | 0 | 0 | 0 | 269 | 326 | 290 | 177 | 0 | 0 | 0 | 104 | 11 | 9 | 7 | 0 | 0 | 0 | 5 | 158 | 130 | 97 | 0 | 0 | 0 | 64 | 109 | 93 | 104 | 0 | 0 | 0 | 84 | 214 | 155 | 118 | 0 | 0 | 0 | 20 | 321 | 301 | 280 | 0 | 0 | 0 | 241 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 529 | 453 | 50 | 359 | 506 | 482 | 429 | 0 | 0 | 0 | 269 | 373 | 342 | 229 | 0 | 0 | 0 | 131 | 17 | 12 | 16 | 0 | 0 | 0 | 11 | 195 | 165 | 130 | 0 | 0 | 0 | 95 | 157 | 109 | 152 | 0 | 0 | 0 | 96 | 279 | 203 | 170 | 0 | 0 | 0 | 30 | 368 | 353 | 319 | 0 | 0 | 0 | 290 |
| Melphalan + Prednisone + Thalidomide (MPT) | 539 | 480 | 38 | 270 | 527 | 0 | 0 | 441 | 326 | 493 | 145 | 423 | 0 | 0 | 307 | 118 | 316 | 49 | 10 | 0 | 0 | 6 | 5 | 5 | 2 | 142 | 0 | 0 | 75 | 62 | 94 | 27 | 153 | 0 | 0 | 83 | 78 | 146 | 71 | 348 | 0 | 0 | 199 | 47 | 254 | 2 | 419 | 0 | 0 | 328 | 324 | 388 | 249 |
Neutrophil counts was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline Grade | Grade 4 Baseline to Grade 1 postbaseline Grade | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline Grade to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 133 | 85 | 109 | 71 | 30 | 6 | 11 | 15 | 30 | 4 | 0 | 1 | 11 | 18 | 5 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 103 | 96 | 121 | 70 | 21 | 7 | 8 | 17 | 25 | 9 | 1 | 1 | 14 | 18 | 9 | 0 | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Melphalan + Prednisone + Thalidomide (MPT) | 37 | 79 | 128 | 141 | 45 | 2 | 2 | 11 | 20 | 21 | 0 | 1 | 7 | 21 | 10 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Renal function was assessed for participants from baseline to the most extreme value in creatinine clearance calculated using the Cockcroft-Gault estimation. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CrCl< 30 mL/min to CrCl< 30 mL/min | CrCl < 30 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl < 30 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl< 30 mL/min to ≥ 80 mL/min | CrCl≥ 30 but < 50 mL/min to < 30 mL/min | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 30 but < 50 mL | CrCl ≥ 30 but < 50 mL/min to CrCl ≥ 50 but < 80 mL | CrCl ≥ 30 but < 50 mL/min to ≥ 80 mL/min | CrCl ≥ 50 but < 80 mL to CrCl< 30 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 50 but < 80 mL to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 50 but < 80 mL to ≥ 80 mL/min | CrCl ≥ 80 mL/min to CrCl< 30 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 30 but < 50 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 50 but < 80 mL/min | CrCl ≥ 80 mL/min to CrCl ≥ 80 mL/min | |
| Lenalidomide and Dexamethasone Rd18 | 17 | 14 | 8 | 2 | 2 | 41 | 55 | 12 | 0 | 1 | 130 | 99 | 1 | 0 | 10 | 114 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 15 | 18 | 7 | 2 | 1 | 37 | 67 | 9 | 0 | 4 | 112 | 107 | 0 | 0 | 6 | 109 |
| Melphalan + Prednisone + Thalidomide (MPT) | 19 | 19 | 5 | 0 | 0 | 41 | 65 | 2 | 0 | 4 | 102 | 97 | 0 | 0 | 9 | 121 |
Hemoglobin was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade 1 Baseline to Normal postbaseline | Grade 1 Baseline to Grade 1 postbaseline | Grade1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | Grade 4 Baseline to Normal postbaseline | Grade 4 Baseline to Grade 1 postbaseline | Grade 4 Baseline to Grade 2 postbaseline | Grade 4 Baseline to Grade 3 postbaseline | Grade 4 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 10 | 30 | 8 | 1 | 0 | 0 | 126 | 123 | 17 | 5 | 0 | 12 | 135 | 41 | 9 | 0 | 1 | 4 | 8 | 3 | 0 | 0 | 0 | 1 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 6 | 39 | 8 | 0 | 0 | 0 | 106 | 128 | 25 | 2 | 0 | 8 | 125 | 48 | 4 | 0 | 0 | 12 | 10 | 5 | 0 | 0 | 0 | 0 | 1 |
| Melphalan + Prednisone + Thalidomide (MPT) | 9 | 25 | 4 | 1 | 0 | 0 | 110 | 123 | 20 | 4 | 0 | 14 | 133 | 47 | 11 | 0 | 0 | 10 | 10 | 2 | 0 | 0 | 1 | 0 | 2 |
Improvement in platelets was assessed for participants from baseline grade to most extreme severity grade using the NCI CTCAE v 3.0 grading scale. (NCT00689936)
Timeframe: Randomization to end of treatment or the data cut off of 24 May 2013; median duration of treatment was 80.2 weeks in the Rd arm; 72 weeks in the Rd18 arm and 67.1 weeks in the MPT arm
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Baseline Grade to Normal Postbaseline Grade | Normal Baseline Grade to Grade 1 postbaseline | Normal Baseline Grade to Grade 2 postbaseline | Normal Baseline Grade to Grade 3 postbaseline | Normal Baseline Grade to Grade 4 postbaseline | Grade1 Baseline to Normal postbaseline Grade | Grade 1 Baseline to Grade 1 postbaseline | Grade 1 Baseline to Grade 2 postbaseline | Grade 1 Baseline to Grade 3 postbaseline | Grade 1 Baseline to Grade 4 postbaseline | Grade 2 Baseline to normal postbaseline Grade | Grade 2 Baseline to Grade 1 postbaseline | Grade 2 Baseline to Grade 2 postbaseline | Grade 2 Baseline to Grade 3 postbaseline | Grade 2 Baseline to Grade 4 postbaseline | Grade 3 Baseline to Normal postbaseline Grade | Grade 3 Baseline to Grade 1 postbaseline | Grade 3 Baseline to Grade 2 postbaseline | Grade 3 Baseline to Grade 3 postbaseline | Grade 3 Baseline to Grade 4 postbaseline | |
| Lenalidomide and Dexamethasone Rd18 | 197 | 211 | 30 | 12 | 5 | 3 | 38 | 19 | 12 | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lenalidomide and Low-Dose Dexamethasone (Rd) | 197 | 216 | 24 | 15 | 4 | 1 | 34 | 15 | 10 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 2 |
| Melphalan + Prednisone + Thalidomide (MPT) | 165 | 208 | 27 | 31 | 11 | 6 | 51 | 7 | 10 | 1 | 0 | 2 | 1 | 2 | 2 | 0 | 0 | 1 | 1 | 0 |
(NCT02424851)
Timeframe: End of week 6 (after receiving two cycles of therapy)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 13 |
| Arm B (BTD) | 3 |
(NCT02424851)
Timeframe: 1 month post end of treatment and 1 year post randomisation
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (BBD) | 9 |
| Arm B (BTD) | 13 |
(NCT02424851)
Timeframe: End of weeks 3, 6, 9, 12 (after receiving 4 cycles of therapy), 30 days after final treatment and 12 months after randomisation
| Intervention | Events (Number) | |
|---|---|---|
| Serious adverse events | Adverse events | |
| Arm A (BBD) | 2 | 3 |
| Arm B (BTD) | 0 | 6 |
"The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is scored on a scale of 1 to 3: 1 (no problems), 2 (some problems), and 3 (extreme problems). Higher score equates to a worse outcome.~As stated in the official EQ-5D user guide, patient responses to the 5 questions were converted into a single index value as per Dolan P (1997). Modeling valuations for EuroQol health states. Med Care 35(11):1095-108. These index values, with country specific value sets, facilitate the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions. In the UK, the values range from -0.594 to +1." (NCT02424851)
Timeframe: Baseline and 1 month follow up
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | 1 month FU | |
| Arm A (BBD) | 0.72 | 0.69 |
| Arm B (BTD) | 0.69 | 0.80 |
(NCT02424851)
Timeframe: End of 2nd treatment cycle, week 6
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Partial response | Minor response | No repsonse | |
| Arm A (BBD) | 2 | 9 | 4 |
| Arm B (BTD) | 0 | 7 | 6 |
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. (NCT01522235)
Timeframe: Baseline and 6 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIg Group | 42.5 |
| Placebo Group | -12.3 |
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). (NCT01522235)
Timeframe: 6 weeks and 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| IVIG Group | -26 |
| Placebo Group | -7.6 |
"To determine the change in autonomic symptoms (measured by the composite autonomic severity score [CASS]) measured at baseline and 6 weeks in individuals receiving IVIg.~Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 0.5 |
| Placebo Group | 0 |
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score [COMPASS] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | -5 |
| Placebo Group | -0.33 |
"To determine the change in quality of life (measured by the EuroQol [EQ-5D]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| IVIg Group | 15 |
| Placebo Group | 9.3 |
"To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60.~Higher values represent worse outcome. We are reporting the total score." (NCT01522235)
Timeframe: Baseline, 6 weeks
| Intervention | units (Mean) |
|---|---|
| Group A | -9 |
| Group B | 12 |
Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days
| Intervention | proportion (Number) |
|---|---|
| EPOCH + Concurrent Rituximab | 0.69 |
| EPOCH Followed by Rituximab | 0.53 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
(NCT00394329)
Timeframe: Rescue albuterol puffs were measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | count of the number of puffs per day (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.26 |
| B: Daily ICS | 0.24 |
| C: Rescue ICS | 0.26 |
| D: Placebo | 0.18 |
(NCT00394329)
Timeframe: An asthma control day was determined daily during each of the 44-week treatment periods. The primary analysis constructed the change between week 14 and week 0.
| Intervention | proportion of asthma control days (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | -0.006 |
| B: Daily ICS | -0.021 |
| C: Rescue ICS | -0.064 |
| D: Placebo | -0.034 |
The ACT consisted of five questions, each ranging from 1 (worst) to 5 (best). The five questions were summed to yield an overall score that ranged from 5 (worst) to 25 (best). (NCT00394329)
Timeframe: The ACT was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.17 |
| B: Daily ICS | -0.15 |
| C: Rescue ICS | -0.57 |
| D: Placebo | -0.76 |
The asthma-specific quality of life scale ranged from 1 (worst) to 7 (best) (NCT00394329)
Timeframe: The asthma-specific quality of life assessment was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.15 |
| B: Daily ICS | 0.07 |
| C: Rescue ICS | 0.05 |
| D: Placebo | -0.03 |
(NCT00394329)
Timeframe: Evening PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 16.2 |
| B: Daily ICS | 14.9 |
| C: Rescue ICS | 12.9 |
| D: Placebo | 20.6 |
(NCT00394329)
Timeframe: eNO was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | parts per billion (Least Squares Mean) |
|---|---|
| Daily ICS + Rescue ICS | -0.08 |
| Daily ICS | 0.07 |
| Rescue ICS | 0.58 |
| Placebo | 0.34 |
(NCT00394329)
Timeframe: Morning PEFR was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters per minute (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 17.7 |
| B: Daily ICS | 16.3 |
| C: Rescue ICS | 16.5 |
| D: Placebo | 21.1 |
(NCT00394329)
Timeframe: Pre-bronchodilator FEV1 was measured on seven occasions during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | liters (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.104 |
| B: Daily ICS | 0.113 |
| C: Rescue ICS | 0.097 |
| D: Placebo | 0.063 |
PEFR variability represents the relative change between the evening and morning PEFR measurements, so it could be a positive or negative number. It was measured daily during the 44-week treatment period. Specifically, the PEFR variability on a specific day is defined as 100% x (evening PEFR - morning PEFR)/{0.5*(evening PEFR + morning PEFR)} (NCT00394329)
Timeframe: PEFR variability was measured daily during the 44-week treatment period. The primary analysis constructed the change between week 44 and week 0.
| Intervention | relative change (AM and PM peak flow) (Least Squares Mean) |
|---|---|
| A: Daily ICS + Rescue ICS | 0.836 |
| B: Daily ICS | -0.043 |
| C: Rescue ICS | 0.098 |
| D: Placebo | 0.894 |
(NCT00394329)
Timeframe: Measured during the 44-week treatment period
| Intervention | participants (Number) |
|---|---|
| A: Daily ICS + Rescue ICS | 22 |
| B: Daily ICS | 20 |
| C: Rescue ICS | 25 |
| D: Placebo | 36 |
A prostate-specific antigen (PSA) response was defined as a >=50% decline from baseline. (NCT00638690)
Timeframe: Up to 12 months
| Intervention | Participants (Number) |
|---|---|
| Abiraterone Acetate | 232 |
| Placebo | 22 |
Overall survival is defined as the time interval from the date of randomization to the date of death from any cause. (NCT00638690)
Timeframe: Up to 60 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 450.0 |
| Placebo | 332.0 |
Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be >=2.0 cm to be considered a target lesion; progression on bone scans with >=2 new lesions not consistent with tumor flare, confirmed on a second scan >=6 weeks later that shows >=1 additional new lesion. (NCT00638690)
Timeframe: Up to 11 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 171.0 |
| Placebo | 110.0 |
The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart. (NCT00638690)
Timeframe: Up to 12 months
| Intervention | Days (Median) |
|---|---|
| Abiraterone Acetate | 309.0 |
| Placebo | 200.0 |
"FEV1 was obtained using calibrated spirometers at approximately the same time of day at all visits throughout the study. The highest acceptable FEV1 and the highest FVC measurement each obtained on any of three blows (even if not from the same curve) meeting the American Thoracic Society criteria constituted the data for that test set.~Not all participants had Day 14 FEV1 measures collected" (NCT00789997)
Timeframe: Day 0 to Day 14
| Intervention | percentage of change in FEV1 (Mean) |
|---|---|
| Etanercept | 15.2 |
| Prednisone | 20.1 |
In the etanercept group 16/40 (40%) failed treatment compared with 12/38 (32%) in the prednisone group. (NCT00789997)
Timeframe: Day 0 to Day 90
| Intervention | participants (Number) |
|---|---|
| Etanercept | 16 |
| Prednisone | 12 |
Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | Percentage of Positive Fibers (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 1.95 |
| Cohort 2 | 1.72 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | ng/mg total protein (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 12 |
| Cohort 2 | 14.6 |
(NCT03333590)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 0 |
| Cohort 2 | 0 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts
| Intervention | meters (Number) | |
|---|---|---|
| Day 90 (Cohort 2) /Day 120 (Cohort 1) | Day 180 | |
| Cohort 1 (Minimal Efficacious Dose) | 320 | 324 |
| Cohort 2 (Minimal Efficacious Dose) | 405 | 416 |
The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | score on a scale (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 1 (Minimal Efficacious Dose) | 16 | 14 | 10 | 6 | 2 |
| Cohort 2 | 21 | 23 | 23 | 23 | 23 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | kg (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 90/Day 120-Right Knee Extension | Day 90/Day 120-Right Knee Flexion | Day 90/Day 120- Left Knee Extension | Day 90/Day 120-Left Knee Flexion | Day 180-Right Knee Extension | Day 180-Right Knee Flexion | Day 180-Left Knee Extension | Day 180-Left Knee Flexion | Month 12-Right Knee Extension | Month 12-Right Knee Flexion | Month 12-Left Knee Extension | Month 12-Left Knee Flexion | Month 18-Right Knee Extension | Month 18-Right Knee Flexion | Month 18-Left Knee Extension | Month 18-Left Knee Flexion | Month 24-Right Knee Extension | Month 24-Right Knee Flexion | Month 24-Left Knee Extension | Month 24-Left Knee Flexion | |
| Cohort 1 (Minimal Efficacious Dose) | 7.42 | 6.06 | 8.78 | 6.12 | 7.13 | 6.1 | 8.66 | 6.69 | 7.49 | 5.67 | 7.5 | 5.32 | 4.55 | 6.11 | 4.96 | 6.26 | 5.06 | 4.41 | 6.93 | 4.17 |
| Cohort 2 | 7.04 | 8.12 | 5.9 | 8.4 | 9.73 | 4.24 | 8.19 | 5.25 | 9.85 | 5.85 | 8.02 | 5.12 | 7.67 | 6.89 | 7.34 | 6.08 | 9.81 | 5.04 | 5.21 | 4.87 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | |||
|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | |
| Cohort 1 (Minimal Efficacious Dose) | 98.2 | 110.9 | 144.5 | 167.8 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 2 | 56.1 | 44.9 | 44.7 | 65.6 | 48.4 |
91 reviews available for prednisone and Disease Exacerbation
| Article | Year |
|---|---|
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
Topics: Anti-Inflammatory Agents; Child; Disease Progression; Humans; Male; Multicenter Studies as Topic; Mu | 2020 |
Aggressive B-cell lymphoma: chasing the target.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; | 2020 |
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survi | 2020 |
Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus.
Topics: Administration, Oral; Disease Progression; Dose-Response Relationship, Drug; Drug Tapering; Female; | 2020 |
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, | 2020 |
Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Fluorodeoxygl | 2020 |
Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Disease Progression; Drug Resistan | 2020 |
An update for Richter syndrome - new directions and developments.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2017 |
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Daca | 2017 |
Delayed Treatment Response in a Neonate with Multisystem Langerhans Cell Histiocytosis Case report and review of literature.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Biopsy; Delayed Diagnosis; Disease Prog | 2017 |
Treatment of mantle cell lymphoma in older adults.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2018 |
Glucocorticoid-Induced Myopathy in a Patient with Systemic Lupus Erythematosus (SLE): A Case Report and Review of the Literature.
Topics: Administration, Oral; Adult; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Femal | 2018 |
Cryoglobulinemic Glomerulonephritis Associated With Nodal and Renal Infiltration by T-Cell Lymphoma of T-Follicular Helper Phenotype: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Cryoglobulinemia | 2018 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease P | 2018 |
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; | 2018 |
How can we define low disease activity in systemic lupus erythematosus?
Topics: Disease Progression; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Prednisone; Re | 2019 |
Infliximab for the treatment of refractory polyarteritis nodosa.
Topics: Cyclophosphamide; Disease Progression; Humans; Immunosuppressive Agents; Infliximab; Patient Safety; | 2019 |
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone.
Topics: Androstenes; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Pulmonary function and clinical correlation in DMD.
Topics: Disease Progression; Glucocorticoids; Humans; Morpholinos; Muscular Dystrophy, Duchenne; Oxadiazoles | 2019 |
Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Europe; | 2013 |
[Treatment of giant cell arteritis].
Topics: Antibodies, Monoclonal, Humanized; Biomarkers; Disease Progression; Giant Cell Arteritis; Glucocorti | 2013 |
Adult-onset Still's disease and pregnancy: about ten cases and review of the literature.
Topics: Adult; Cohort Studies; Disease Progression; Female; Glucocorticoids; Humans; Prednisone; Pregnancy; | 2014 |
Common variable immunodeficiency-associated granulomatous and interstitial lung disease.
Topics: Common Variable Immunodeficiency; Comorbidity; Disease Progression; Granuloma, Respiratory Tract; Hu | 2013 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherap | 2013 |
[Three cases of bullous lupus erythematosus].
Topics: Adult; Arthralgia; Autoantibodies; Blister; Collagen; Diagnosis, Differential; Disease Progression; | 2013 |
Nonoperative management of pneumatosis intestinalis and pneumoperitoneum in mixed connective tissue disease.
Topics: Abdominal Pain; Aged; Disease Progression; Enteral Nutrition; Female; Follow-Up Studies; Humans; Met | 2014 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2013 |
[Hemophagocytic lymphohistiocytosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy P | 2014 |
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pro | 2014 |
Recognizing and managing the immunologic reactions in leprosy.
Topics: Biopsy, Needle; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Erythema Nodo | 2014 |
Is dexamethasone an effective alternative to oral prednisone in the treatment of pediatric asthma exacerbations?
Topics: Administration, Oral; Anti-Inflammatory Agents; Asthma; Child; Dexamethasone; Disease Progression; G | 2014 |
Glucocorticoid treatment in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Therapy, Combination; Glucoco | 2014 |
[Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio | 2014 |
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis | 2014 |
Progressive multifocal leukoencephalopathy in patients with a hematological malignancy: review of therapeutic options.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain; | 2014 |
Anti-glomerular basement membrane antibodies.
Topics: Anti-Glomerular Basement Membrane Disease; Autoantibodies; Cyclophosphamide; Disease Progression; Gl | 2014 |
The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph | 2015 |
Richter syndrome: an aggressive transformation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphami | 2015 |
Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.
Topics: Adult; Aged; Autoantibodies; Dermatomyositis; Disease Progression; Female; Glucocorticoids; Humans; | 2016 |
CD 30-positive transformed follicular lymphoma: two case reports and literature review.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell T | 2015 |
COPD exacerbations: 5 days of corticosteroid therapy.
Topics: Administration, Intravenous; Administration, Oral; Adrenal Cortex Hormones; Disease Progression; Dru | 2014 |
Pyoderma Gangrenosum:Recognition and Management.
Topics: Anti-Infective Agents; Contraindications; Debridement; Diagnosis, Differential; Disease Progression; | 2016 |
Langerhans Cell Histiocytosis: Emerging Insights and Clinical Implications.
Topics: Animals; Antigens, CD; Disease Progression; Enzyme Activation; Histiocytosis, Langerhans-Cell; Human | 2016 |
Treating and preventing acute exacerbations of COPD.
Topics: Acidosis, Respiratory; Acute Disease; Administration, Inhalation; Albuterol; Anti-Bacterial Agents; | 2016 |
Microscopic Polyangiitis with Spinal Cord Involvement: A Case Report and Review of the Literature.
Topics: Adult; Aged; Biopsy; Cerebral Hemorrhage; Disease Progression; Fatal Outcome; Female; Glucocorticoid | 2016 |
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclop | 2016 |
Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2016 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2017 |
Idiopathic sensorineural hearing disorders in adults--a pragmatic approach.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Autoantibodies; Comorbidity; Disease Progression; He | 2009 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Management of infantile parotid gland hemangiomas: a 40-year experience.
Topics: Combined Modality Therapy; Disease Progression; Glucocorticoids; Hemangioma; Humans; Infant; Interfe | 2010 |
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
Topics: Child; Disease Progression; Drug Administration Schedule; Humans; Male; Muscular Dystrophy, Duchenne | 2010 |
[MALT B cell lymphoma with kidney damage and monoclonal gammopathy: a case study and literature review].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2010 |
[Plasmacytoid dendritic cell tumor].
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Bone | 2011 |
CD5-positive follicular lymphoma: a case report and literature review.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CD5 Antigens | 2011 |
Mooren's-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review.
Topics: Amnion; Antibodies, Monoclonal; Aza Compounds; Conjunctiva; Corneal Perforation; Corneal Ulcer; Derm | 2011 |
Drug-induced vasculitis: a clinical and pathological review.
Topics: Antibodies, Antineutrophil Cytoplasmic; Diagnosis, Differential; Disease Progression; Drug Hypersens | 2012 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin | 2002 |
Autoimmune hepatitis. Making sense of all those antibodies.
Topics: Adult; Algorithms; Anti-Inflammatory Agents; Antibodies, Antinuclear; Asialoglycoprotein Receptor; A | 2003 |
Presentation of idiopathic retroperitoneal fibrosis in the pediatric population.
Topics: Autoimmune Diseases; Azathioprine; Blood Sedimentation; Child; Combined Modality Therapy; Creatinine | 2003 |
[Lipoid nephrosis in childhood].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Anti-Inflammatory Agents; Biopsy; Child; Cyclosporins; | 2003 |
Progressive idiopathic axonal neuropathy--a comparative clinical and histopathological study with vasculitic neuropathy.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Disease Progression; Female; Humans; Male; Middle Age | 2004 |
Managing the patient with amyloidosis.
Topics: Amyloidosis; Anti-Inflammatory Agents; Causality; Diagnosis, Differential; Disease Progression; Huma | 2004 |
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease Progress | 2004 |
Progressive outer retinal necrosis presenting with isolated optic neuropathy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infection | 2004 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agon | 2005 |
Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Do | 2005 |
The best treatment for diffuse large B-cell lymphoma: a German perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free | 2005 |
Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Acute dermatomyositis with subcutaneous generalized edema.
Topics: Acute Disease; Adult; Dermatomyositis; Disease Progression; Edema; Fatal Outcome; gamma-Globulins; H | 2006 |
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents, Hormonal; Asparaginase; Child; Child, Preschool; | 2006 |
Chronic subdural hematoma in patients with idiopathic thrombocytopenic purpura: A case report and review of the literature.
Topics: Adolescent; Adult; Aged; Brain; Cerebral Veins; Child; Disease Progression; Female; Glucocorticoids; | 2006 |
[Interstitial lung disease in systemic sclerosis].
Topics: Anti-Inflammatory Agents; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; | 2006 |
Current therapy for autoimmune hepatitis.
Topics: Adult; Age Factors; Aged; Azathioprine; Biopsy, Needle; Disease Progression; Drug Therapy, Combinati | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; | 2007 |
Immunosuppressive or surgical treatment for ocular Myasthenia Gravis.
Topics: Combined Modality Therapy; Disease Progression; Eye Diseases; Humans; Immunosuppressive Agents; Myas | 2007 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease P | 2008 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Acute myelofibrosis terminating in acute lymphoblastic leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Bone Marrow; Chro | 1996 |
Influence of treatment on the clinical course of pemphigus vulgaris.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Contraindicatio | 1996 |
Overview of treatment of localized low-grade lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; California; Chemotherap | 1997 |
Treatment of airway inflammation in cystic fibrosis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Anti-Inf | 1996 |
[Dose-effects and chemotherapy dose intensity of aggressive non-Hodgkin's lymphomas in the adult].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-R | 1998 |
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1998 |
Aggressive treatment of early rheumatoid arthritis to prevent joint damage.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Manage | 1998 |
The treatment of primary focal segmental glomerulosclerosis.
Topics: Anti-Inflammatory Agents; Disease Progression; Glomerulosclerosis, Focal Segmental; Humans; Immunosu | 2000 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; | 2001 |
Management of patients with multiple myeloma: emphasizing the role of high-dose therapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2001 |
Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Clinical Trials, Phase III | 2000 |
185 trials available for prednisone and Disease Exacerbation
| Article | Year |
|---|---|
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2021 |
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Cyc | 2022 |
Effect of pulsed intravenous methylprednisolone with alternative low-dose prednisone on high-risk IgA nephropathy: a 18-month prospective clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Disease Progression; Drug Tapering; Drug T | 2022 |
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
Topics: Disease Progression; Double-Blind Method; Humans; Prednisone; Protein Kinase Inhibitors; Radiation P | 2023 |
Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial.
Topics: Clinical Trials, Phase II as Topic; Disease Progression; Glucocorticoids; Humans; Immunoglobulins, I | 2023 |
Three-dimensional facial swelling evaluation of pre-operative single-dose of prednisone in third molar surgery: a split-mouth randomized controlled trial.
Topics: Adult; Disease Progression; Female; Humans; Male; Molar, Third; Mouth; Pain; Prednisone; Retrospecti | 2023 |
Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial).
Topics: Administration, Oral; Adrenal Cortex Hormones; Ambulatory Care; Disease Progression; Double-Blind Me | 2019 |
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Disease Progression; Drug | 2020 |
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adrenocorticotropic Hormone; Adult; Anti-Inflammatory Agents; Autoantibodies; Autoimmune Diseases; B | 2020 |
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2020 |
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2020 |
The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Disease Progression; Drug Therapy, Combinat | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Disease Progression; Glucocorticoids; Humans; Male | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Dise | 2020 |
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Pr | 2021 |
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
Topics: Abiraterone Acetate; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineopl | 2017 |
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; Drug Resistan | 2017 |
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
Topics: Adult; Aged; Calcineurin Inhibitors; Chronic Disease; Disease Progression; Endpoint Determination; F | 2017 |
Predictors of re-exacerbation after an index exacerbation of chronic obstructive pulmonary disease in the REDUCE randomised clinical trial.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Disease Progression; Dyspnea; Female; Glucocorticoids; | 2017 |
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Ben | 2018 |
Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Administration S | 2017 |
Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Disease Progression | 2018 |
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Randomized Trial of Dexamethasone Versus Prednisone for Children with Acute Asthma Exacerbations.
Topics: Acute Disease; Administration, Oral; Adolescent; Anti-Asthmatic Agents; Asthma; Child; Child, Presch | 2017 |
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2018 |
The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2018 |
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; | 2018 |
Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2018 |
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progre | 2018 |
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progress | 2019 |
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2019 |
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Male | 2013 |
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Male | 2013 |
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Male | 2013 |
Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Male | 2013 |
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Topics: Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic | 2014 |
Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Disease Progression; Female; Humans; Hyperglyc | 2014 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Com | 2013 |
Albuterol administration is commonly associated with increases in serum lactate in patients with asthma treated for acute exacerbation of asthma.
Topics: Adult; Albuterol; Asthma; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Ther | 2014 |
[5 days of systemic steroids in COPD exacerbation are adequate].
Topics: Administration, Oral; Adult; Disease Progression; Drug Administration Schedule; Drug Therapy, Combin | 2013 |
CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic C | 2013 |
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherap | 2013 |
Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.
Topics: Absorptiometry, Photon; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Disease Progressi | 2015 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxe | 2014 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di | 2014 |
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2014 |
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2014 |
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2014 |
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2014 |
Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy.
Topics: Adult; Biomarkers; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Glomerulone | 2014 |
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Dise | 2014 |
[Recruiting participants - study of therapy of CRPC].
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Biomarkers, Tumor; Disease Progression; Drug Ther | 2014 |
Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Foot Joints; | 2015 |
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2015 |
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehy | 2015 |
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy:
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; D | 2015 |
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Cytochrome P- | 2015 |
Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamid | 2015 |
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromatography, | 2015 |
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2015 |
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dis | 2015 |
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progressi | 2015 |
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosph | 2015 |
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2016 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexameth | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug | 2016 |
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Di | 2016 |
Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study.
Topics: Administration, Inhalation; Administration, Intravenous; Aged; Aged, 80 and over; Albuterol; Broncho | 2015 |
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Thera | 2016 |
Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2016 |
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2016 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherap | 2017 |
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dise | 2017 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
Topics: Acute Disease; Aged; Analysis of Variance; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, | 2009 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2008 |
Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; A | 2009 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2008 |
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Topics: Adult; Atrophy; Azathioprine; Brain; Cerebral Ventricles; Disease Progression; Drug Therapy, Combina | 2009 |
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2009 |
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Atrophy; Azathioprine; Brain; Disability Evaluation; | 2009 |
Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregio
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 2010 |
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P | 2009 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dis | 2009 |
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2009 |
Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil.
Topics: Adult; Biopsy; Cadaver; Disease Progression; Female; Fibrosis; Graft Rejection; HLA Antigens; Humans | 2009 |
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2010 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Prot | 2010 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Prot | 2010 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Prot | 2010 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Prot | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug R | 2010 |
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2010 |
Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis.
Topics: Absorptiometry, Photon; Adult; Aged; Antibodies, Monoclonal; Arthritis, Rheumatoid; Bone Density; Di | 2010 |
A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; C-Reactive Prot | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progressi | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2011 |
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Bi | 2011 |
Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Calcineurin Inhibitors; Chi-Square Distribution; Cyclosporine | 2010 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progress | 2011 |
Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Adolescent; Albuterol; Anti-Asthmatic Agents; Anti-Inflammatory Agents; | 2011 |
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progressio | 2011 |
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Chemotherapy, Adj | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Abiraterone and increased survival in metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera | 2011 |
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2011 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antin | 2012 |
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2011 |
Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progre | 2011 |
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Brain; Cohort Stud | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com | 2012 |
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 2012 |
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2012 |
Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Cluster Analysis; | 2012 |
TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Double-Blind Method; Etanercept; | 2013 |
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2002 |
Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Arthrography; Collagen Type I; Disease Progression; Dose-Respons | 2003 |
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphami | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymph
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 2003 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre | 2003 |
Development of generalized myasthenia gravis in patients with ocular myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Disease Progression; Eye Disea | 2003 |
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease Progression; Dr | 2003 |
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progres | 2004 |
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progres | 2004 |
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progres | 2004 |
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progres | 2004 |
The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Di | 2004 |
Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cycl | 2004 |
Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Disease Progres | 2004 |
Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphami | 2004 |
Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2004 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2005 |
Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2005 |
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2005 |
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 2004 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Arthrography; Disease Progressi | 2005 |
Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Deri | 2005 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyc | 2006 |
[Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Disease-Free Sur | 2005 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2007 |
Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Atrophy; Azathioprine; Brain; Cerebral Ventricles; Diseas | 2008 |
Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Topics: Activities of Daily Living; Aged; Cross-Over Studies; Cyclophosphamide; Dexamethasone; Disease Progr | 2007 |
Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
Topics: Adult; Cystic Fibrosis; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; | 2007 |
The prognosis and pathogenesis of severe lupus glomerulonephritis.
Topics: Administration, Oral; Adult; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic | 2008 |
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease Progression; F | 2008 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Treatment of rapidly progressive IgA nephropathy.
Topics: Antibodies, Antineutrophil Cytoplasmic; Arteritis; Autoantibodies; Biopsy; Combined Modality Therapy | 1995 |
Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 1995 |
Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 1996 |
Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease.
Topics: Adult; Aged; Disease Progression; Female; Granulomatosis with Polyangiitis; Humans; Immunosuppressiv | 1996 |
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; C | 1996 |
Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Diabetic Nephropath | 1997 |
Improved outcome in solitary bone plasmacytomata with combined therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chem | 1996 |
The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Adult; Anti-Inflammatory Agents; Cohort Studies; Disability Evaluation; Disease Progression; Female; | 1997 |
Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial.
Topics: Adult; Bronchoalveolar Lavage Fluid; Cyclosporine; Disease Progression; Drug Therapy, Combination; F | 1997 |
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithyroid Agents; Combined Modality Therapy; Disease P | 1998 |
[The effect of low dose methotrexate on the course of rheumatoid arthritis--four years of observation].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1997 |
Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambuci | 1998 |
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease P | 1998 |
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Multivariate Analysis; Pre | 1998 |
[Autoimmune hepatitis. Clinical characteristics and response to treatment in a series of 49 spanish patients].
Topics: Adult; Disease Progression; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver C | 1998 |
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1998 |
Progression of steroid-associated osteoporosis after heart transplantation.
Topics: Adult; Anti-Inflammatory Agents; Bone Density; Calcitonin; Disease Progression; Double-Blind Method; | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2000 |
[Results of a prospective protocol for the treatment of adult Hodgkin's disease].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease Progression; D | 1999 |
Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; | 2000 |
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2000 |
Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Arthrography; Disease Progression; Dose-Response Rel | 2000 |
A randomized controlled trial to evaluate the effectiveness of an exercise program in women with rheumatoid arthritis taking low dose prednisone.
Topics: Arthritis, Rheumatoid; Bone Density; Disease Progression; Dose-Response Relationship, Drug; Exercise | 2000 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Ma | 2000 |
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Platelets; | 2000 |
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Disease Progression; Europe; Flutamide; | 2001 |
Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Disease Progression; Female; Humans; Immunosuppressive Agents; Lymphocyte Cou | 2000 |
[Influence of glucocorticoid steroid therapy on gastric and duodenal mucosa and Helicobacter pylori infection in children with nephrotic syndrome].
Topics: Adolescent; Child; Child, Preschool; Disease Progression; Duodenitis; Female; Gastric Mucosa; Gastri | 2001 |
Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease Progression; Doxorubicin; | 2001 |
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cy | 2001 |
Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; F | 2002 |
Summaries for patients. Prednisone for rheumatoid arthritis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; F | 2002 |
477 other studies available for prednisone and Disease Exacerbation
| Article | Year |
|---|---|
A 51-Year-Old Man With a Large Posterior Mediastinal Mass.
Topics: Cough; Cytoreduction Surgical Procedures; Decompression, Surgical; Disease Progression; Dyspnea; For | 2021 |
Stridor Due to Cranial Nerve X Palsy Progressing to Polyneuropathy in a Teenager With COVID-19.
Topics: Acute Disease; Adolescent; Combined Modality Therapy; COVID-19; Deglutition Disorders; Diagnosis, Di | 2021 |
Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Card | 2021 |
Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Down-Regulati | 2022 |
Archetypal analysis of visual fields in optic neuritis reveals functional biomarkers associated with outcome and treatment response.
Topics: Biomarkers; Disease Progression; Humans; Methylprednisolone; Optic Neuritis; Prednisone; Retrospecti | 2022 |
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Topics: Antimalarials; Disease Progression; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, S | 2022 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
Topics: Adolescent; Disease Progression; Humans; Longitudinal Studies; Male; Muscular Dystrophy, Duchenne; P | 2023 |
HIGH LONG-TERM DRUG-FREE REMISSION RATE FOR ACUTE VOGT-KOYANAGI-HARADA DISEASE WITH AN APPROPRIATE IMMUNOSUPPRESSIVE REGIMEN.
Topics: Acute Disease; Disease Progression; Glucocorticoids; Humans; Immunosuppressive Agents; Prednisone; R | 2023 |
Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19.
Topics: COVID-19; Dexamethasone; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Prednisone; Res | 2023 |
[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].
Topics: Adolescent; Child; Disease Progression; Histiocytosis, Langerhans-Cell; Humans; Molecular Targeted T | 2023 |
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclop | 2023 |
Factors associated with acute exacerbations of myasthenia gravis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Disease P | 2019 |
Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
Topics: Adult; Age of Onset; Aged; Blepharoptosis; Cholinesterase Inhibitors; Cohort Studies; Deglutition Di | 2019 |
Infliximab for Refractory Cardiac Sarcoidosis.
Topics: Antirheumatic Agents; Cardiomyopathies; Disease Progression; Dose-Response Relationship, Drug; Femal | 2019 |
Vasculitis Mimicking Pseudo Erysipelas in Systemic Lupus Erythematosus.
Topics: Adult; Biopsy, Needle; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Erys | 2019 |
Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Topics: Adrenal Cortex Hormones; Adult; China; Disease Progression; Female; Glomerular Filtration Rate; Glom | 2020 |
Response to treatment in pediatric ocular myasthenia gravis.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Fe | 2020 |
Idiopathic granulomatous mastitis responding to oral prednisone.
Topics: Adult; Breast Feeding; Cutaneous Fistula; Disease Progression; Female; Glucocorticoids; Granulomatou | 2020 |
Natural course of diffuse large B cell lymphoma-a manifestation in buccal mucosa.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxoru | 2019 |
Obstructive uropathy associated with rheumatoid arthritis successfully treated with steroids and immunosuppressive therapy: A case report.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Progression; Female; Hematuria; Humans; Hyd | 2019 |
Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Topics: Abnormal Karyotype; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase | 2020 |
Extrapulmonary Sarcoidosis in the Orbit, Brain, and Heart.
Topics: Aged; Antirheumatic Agents; Brain Diseases; Cardiac Pacing, Artificial; Cardiomyopathies; Diagnostic | 2020 |
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2020 |
Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.
Topics: Adult; Anti-Inflammatory Agents; Bayes Theorem; Cohort Studies; Disease Progression; Female; Humans; | 2020 |
Case of anti-MDA-5 positive dermatomyositis with rapidly progressive interstitial lung disease.
Topics: Autoantibodies; Computed Tomography Angiography; Dermatomyositis; Diagnosis, Differential; Disease P | 2020 |
Subcutaneous Masses as an Unusual Manifestation of Relapse in a Case of Atypical Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation and Complex Karyotype: A Diagnostic Dilemma and Treatment Challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorub | 2020 |
Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Dis | 2020 |
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2020 |
Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Comorbidity; Disease Progression; Female; Huma | 2020 |
Tuberculous pericarditis
Topics: Antitubercular Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Humans; Lymph Nodes; | 2020 |
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cycl | 2020 |
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined | 2020 |
Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT.
Topics: Disease Progression; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lysine; Male; Middle Aged; Posi | 2020 |
Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center.
Topics: Adrenergic beta-Agonists; Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Asthma; Biologic | 2020 |
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Topics: Aged; Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Asthma; Disease Progression; Drug Th | 2020 |
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Disease Progres | 2020 |
The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ch | 2020 |
Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments of mdx mice?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Disease Models, Animal; | 2020 |
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and | 2021 |
Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Examination; Cyclop | 2020 |
ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; | 2021 |
Corticosteroid Exposure in the Treatment of Severe COPD Exacerbations.
Topics: Adrenal Cortex Hormones; Disease Progression; Glucocorticoids; Humans; Prednisone; Pulmonary Disease | 2022 |
Liver transplant in a recently COVID-19 positive child with hepatoblastoma.
Topics: Child, Preschool; COVID-19; COVID-19 Testing; Disease Progression; Hepatoblastoma; Humans; Immunoglo | 2021 |
Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anti-Inflammatory Agents; Antirheumatic Age | 2021 |
Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
Topics: Adult; Aged; Aged, 80 and over; Anti-Asthmatic Agents; Asthma; Biological Products; Disease Progress | 2021 |
Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; Fe | 2021 |
Benralizumab for Prednisone-Dependent Eosinophilic Asthma Associated With Novel STAT3 Loss of Function Mutation.
Topics: Anti-Asthmatic Agents; Antibodies, Monoclonal, Humanized; Asthma; Disease Progression; DNA; DNA Muta | 2021 |
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2021 |
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease | 2021 |
Diarrhea in a Patient With Combined Kidney-Pancreas Transplant.
Topics: Caliciviridae Infections; Diabetes Mellitus, Type 1; Diagnosis, Differential; Diarrhea; Disease Prog | 2021 |
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; B | 2021 |
Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2021 |
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; Crohn Disease; Disease Progressio | 2017 |
Serum Bilirubin Concentrations in Patients With Takayasu Arteritis.
Topics: Adult; Anti-Inflammatory Agents; Bilirubin; Biomarkers; C-Reactive Protein; Disease Progression; Fem | 2017 |
Reduction of nitric oxide and DNA/RNA oxidation products are associated with active disease in systemic lupus erythematosus patients.
Topics: Adult; Antioxidants; Biomarkers; Case-Control Studies; Disease Progression; DNA; Female; Glucocortic | 2017 |
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bio | 2017 |
[Idiopathic nephrotic syndrome (INS) in children in Dakar: about 40 cases].
Topics: Azathioprine; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Female; Glucocorticoid | 2017 |
Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Sedimentation; Disease Progression; E | 2017 |
Warfarin-induced skin necrosis accompanied by aggravation of vasculitis in a patient with cutaneous arteritis.
Topics: Anticoagulants; Biopsy, Needle; Disease Progression; Erythema; Female; Humans; Immunohistochemistry; | 2017 |
miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Bone Marrow; Child; | 2017 |
The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Biomarkers; Disease Progression; Drug Admini | 2017 |
Tongue Involvement in Parry-Romberg Syndrome.
Topics: Adolescent; Atrophy; Child, Preschool; Disease Progression; Facial Hemiatrophy; Female; Glucocortico | 2017 |
Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
Topics: Adult; Anti-Inflammatory Agents; Cohort Studies; Disease Progression; Female; Follow-Up Studies; His | 2017 |
Adult Langerhans cell histiocytosis with pulmonary and colorectoanal involvement: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Colonic Diseases; Colonoscopy; | 2017 |
Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Topics: Adult; Anti-Inflammatory Agents; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hum | 2018 |
Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.
Topics: Acute Disease; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Disease Prog | 2018 |
[Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal, Humanized; Complement C3; | 2018 |
A case of peripheral T-cell lymphoma, not otherwise specified, with rapid progression to erythroderma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Dermatitis, | 2018 |
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2018 |
Acne fulminans.
Topics: Acne Vulgaris; Adolescent; Arthralgia; Disease Progression; Fever; Glucocorticoids; Humans; Male; Ne | 2017 |
Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Cysts; Disease Progression; | 2018 |
Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Black or African American; Disease Progres | 2018 |
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis].
Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resista | 2018 |
Editorial Comment.
Topics: Abiraterone Acetate; Disease Progression; Humans; Male; Prednisone; Prostate-Specific Antigen; Prost | 2018 |
Editorial Comment.
Topics: Abiraterone Acetate; Disease Progression; Humans; Male; Prednisone; Prostate-Specific Antigen; Prost | 2018 |
Acute exacerbation of staphylococcal catarrhal infiltration associated with treatment for Pseudomonas aeruginosa keratitis: A case report.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Ceftazidime; Contact Lenses, Hydrophilic; Disease Progre | 2018 |
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic D | 2019 |
The use of a standardized order set reduces systemic corticosteroid dose and length of stay for individuals hospitalized with acute exacerbations of COPD: a cohort study.
Topics: Aged; Disease Progression; Electronic Health Records; Female; Glucocorticoids; Hospitalization; Huma | 2018 |
Systemic Corticosteroid and Antibiotic Use in Hospitalized Patients With Chronic Obstructive Pulmonary Disease Exacerbation.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Disease Progression; Female; Glucocorticoids; Hospitali | 2019 |
Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus.
Topics: Adult; Canada; Cross-Sectional Studies; Disease Progression; Female; Follow-Up Studies; Humans; Line | 2019 |
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2018 |
Progressive multifocal leukoencephalopathy unmasked by antiretroviral therapy for HIV.
Topics: Anti-Retroviral Agents; Disease Progression; Glucocorticoids; HIV Infections; Humans; Immune Reconst | 2018 |
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progres | 2019 |
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bren | 2019 |
Outcomes for Pediatric Asthmatic Inpatients After Implementation of an Emergency Department Dexamethasone Treatment Protocol.
Topics: Adolescent; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Clinical Protocols; Dexametha | 2019 |
Neoplasia de celulas dendriticasblastica plasmocitoide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back; Cyclophosphamide; Dendritic Cells; Disea | 2018 |
Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort.
Topics: Adult; Cohort Studies; Disease Progression; Female; Humans; Immunosuppressive Agents; Lupus Erythema | 2019 |
Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease P | 2019 |
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2019 |
The Burden of Sarcoidosis Symptoms from a Patient Perspective.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cost of Illness; Cross-Sectional Studies; Disease | 2019 |
Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Disease P | 2019 |
Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Promising new combination therapy for non-GCB DLBCL.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclop | 2019 |
Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naïve Patients with Duchenne Muscular Dystrophy.
Topics: Adolescent; Child; Disease Progression; Glucocorticoids; Humans; Male; Muscular Dystrophy, Duchenne; | 2019 |
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2019 |
Thirty Years of Followup in 3 Patients with Familial Polyarteritis Nodosa due to Adenosine Deaminase 2 Deficiency.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Disease Progression; Etanercept; Female; Humans; | 2019 |
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lu | 2019 |
R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Detection of COPD Exacerbations and compliance with patient-reported daily symptom diaries using a smart phone-based information system [corrected].
Topics: Adult; Aged; Anti-Bacterial Agents; Cell Phone; Disease Progression; Female; Glucocorticoids; Humans | 2013 |
Treatment of rheumatoid arthritis with methotrexate in Congolese patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Democratic Republic of the Congo; Disease | 2013 |
Histopathological insights into hair loss in Cronkhite-Canada syndrome: diffuse anagen-telogen conversion precedes clinical hair loss progression.
Topics: Alopecia; Antineoplastic Agents, Hormonal; Disease Progression; Female; Hair Follicle; Humans; Hypoa | 2014 |
Histologic transformation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, | 2013 |
Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2013 |
[Achilles heel of COPD].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Diagnosis, Di | 2013 |
Lymphotoxin alpha (LTA) polymorphism is associated with prognosis of non-Hodgkin's lymphoma in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Protei | 2013 |
Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cohort Studies; Disease Progression; Dose-Response Relationshi | 2013 |
Numbness over the distribution of trigeminal nerve--trigeminal trophic syndrome or viral neuritis: a diagnostic dilemma!
Topics: Adult; Diagnosis, Differential; Disease Progression; Female; Humans; Hypesthesia; Lost to Follow-Up; | 2013 |
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androstadienes; Disease Progression; Docetaxel; Fol | 2013 |
Severe exacerbation of Crohn's disease during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; G | 2014 |
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.
Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Magnetic Resonance Imaging; Methylprednisolon | 2013 |
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Treatment-resistant Churg-Strauss syndrome: progression after five years using rituximab.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Biopsy; Churg-Strauss Syndrome; Combined Modality Ther | 2013 |
[Acute neutrophilic dermatosis (pustular dermatitis) associated with aggressive transformed mycosis fungoides].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Depsipept | 2013 |
Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Disease Progression; Female; Follow | 2014 |
Langerhans cell sarcoma of the nasopharynx: a rare case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cladribine; Cytarabine; Disease Pr | 2013 |
[Transition from pemphigus vulgaris to pemphigus foliaceus: a case report].
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Autoantigens; Desmoglein 1; Desmoglein 3; Di | 2013 |
Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculit | 2014 |
Pulmonary hemorrhage in a patient initially presenting with discoid lupus.
Topics: Adult; Anti-Bacterial Agents; Biopsy; Bronchopneumonia; Diagnostic Errors; Disease Progression; Dysp | 2013 |
Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Survival of patients with transformed lymphoma in the rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Biomarkers, Tumo | 2014 |
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T | 2014 |
Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Topics: Acute Disease; Adult; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Disease Progression; | 2014 |
Clinico-pathological features and outcomes of patients with propylthiouracil-associated ANCA vasculitis with renal involvement.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculi | 2014 |
The fate of chronic rhinosinusitis sufferers after maximal medical therapy.
Topics: Administration, Oral; Adult; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Humans | 2014 |
The fate of chronic rhinosinusitis sufferers after maximal medical therapy.
Topics: Administration, Oral; Adult; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Humans | 2014 |
The fate of chronic rhinosinusitis sufferers after maximal medical therapy.
Topics: Administration, Oral; Adult; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Humans | 2014 |
The fate of chronic rhinosinusitis sufferers after maximal medical therapy.
Topics: Administration, Oral; Adult; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Humans | 2014 |
Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2015 |
Short communication: spectrum of non-Hodgkin lymphoma in an urban Ryan White-funded clinic in the established antiretroviral era.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antibodies, Monoclonal, Murine-De | 2014 |
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation.
Topics: Age Factors; Aged; Analysis of Variance; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Huma | 2014 |
Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.
Topics: Adolescent; Antirheumatic Agents; Child; Child, Preschool; Dermatomyositis; Disease Progression; Dru | 2014 |
Primary cutaneous CD4/CD8-/- TCRαβ T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Blotting, Southern; CD4 A | 2015 |
The intricate relationship of histoplasmosis and sarcoidosis: a case report.
Topics: Disease Progression; Histoplasmosis; Humans; Immunocompromised Host; Immunosuppressive Agents; Lymph | 2014 |
Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy.
Topics: Adult; CD4 Antigens; Cells, Cultured; Cytokines; Disease Progression; Female; Follow-Up Studies; Glo | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Proto | 2014 |
Recurrent right atrial thrombosis due to Behçet disease.
Topics: Anticoagulants; Azathioprine; Behcet Syndrome; Disease Progression; Heart Atria; Heart Diseases; Hum | 2014 |
Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.
Topics: Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug | 2014 |
Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 2014 |
A case of an adult Langerhans cell sarcoma.
Topics: Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Etoposide; Fatal Outcome; Female; Hu | 2016 |
Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2014 |
Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Disease Progression; Female; Histiocy | 2014 |
Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
Topics: Adrenal Cortex Hormones; Age of Onset; Child; Disease Progression; Follow-Up Studies; Humans; Longit | 2015 |
A case of rupioid psoriasis exacerbated by systemic glucocorticosteroids.
Topics: Disease Progression; Drug Eruptions; Female; Glucocorticoids; Humans; Middle Aged; Prednisone; Psori | 2015 |
Polyarticular Gout Flare Masquerading as Sepsis.
Topics: Arthritis; Arthritis, Gouty; Blood Chemical Analysis; Diagnosis, Differential; Disease Progression; | 2015 |
A 41-year-old woman with shortness of breath and history of rash and recurrent laryngeal edema.
Topics: Adult; Azathioprine; Complement System Proteins; Disease Progression; Dyspnea; Female; Glucocorticoi | 2015 |
Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri | 2015 |
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T | 2015 |
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Diseas | 2015 |
Case 216: hypertrophic spinal pachymeningitis.
Topics: Combined Modality Therapy; Contrast Media; Diagnosis, Differential; Disease Progression; Dura Mater; | 2015 |
Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
Topics: Adolescent; Adult; Age Factors; Child; Disease Progression; Fibrosis; Glucocorticoids; Heart; Humans | 2015 |
Predictors of longterm changes in body mass index in rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Cohort Studi | 2015 |
Organizing pneumonia appearing in B-cell chronic leukemia malignancy progression - a case report.
Topics: Aged; Cryptogenic Organizing Pneumonia; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, | 2015 |
Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Topics: Adolescent; Adult; Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients.
Topics: Anti-Inflammatory Agents; Creatine Kinase; Dermatomyositis; Disease Progression; Female; Humans; Imm | 2015 |
[A case of neurolymphomatosis presenting extended involvement of spinal nerve roots].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cerebrospina | 2015 |
Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Behcet Syndrome; Dis | 2017 |
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Arrhythmias, Cardiac; Diagnosis, Differential | 2015 |
Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxoru | 2015 |
ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cohort Studies; Cyclophosph | 2015 |
Predictors of Outcome in Ulcerative Colitis.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Aged; Anti-Inflammatory Agents; Antibodies, Antineutro | 2015 |
Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents; Asthma; | 2015 |
[Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer].
Topics: Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Neoplasm Grading; Prednisone; Pr | 2015 |
Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2016 |
The long-term outlook to final outcome and steroid treatment results in children with idiopathic nephrotic syndrome.
Topics: Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; | 2015 |
Uncovering the diagnosis.
Topics: Cardiac Tamponade; Diagnosis, Differential; Disease Progression; Dyspnea; Electrocardiography; Femal | 2015 |
An Unusual Cause of Abdominal Pain: Lupus Enteritis.
Topics: Abdomen; Abdominal Pain; Acute Kidney Injury; Administration, Intravenous; Adult; Anti-Inflammatory | 2016 |
Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2016 |
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Tri | 2016 |
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study.
Topics: Aged; Aged, 80 and over; Biopsy; Disease Progression; Female; Fever; Follow-Up Studies; Giant Cell A | 2016 |
Malfunctioned cardiac resynchronization therapy attributed to acute exacerbation of cardiac sarcoidosis.
Topics: Adult; Cardiac Resynchronization Therapy; Cardiomyopathies; Disease Progression; Fluorodeoxyglucose | 2016 |
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2016 |
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Aged; Alleles; Antineoplastic Agents; Disease Progression; Genotype; Humans; Ka | 2016 |
Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Blood Cel | 2016 |
First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2016 |
Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplast | 2016 |
Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopho | 2016 |
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Child; Disease Progression; Drug Therapy, Co | 2017 |
Cardiac sarcoidosis - silent destroyer.
Topics: Cardiomyopathies; Disease Progression; Female; Glucocorticoids; Heart Failure; Humans; Magnetic Reso | 2016 |
Comparative Long-Term Evaluation of Patients With Juvenile Inflammatory Myopathies.
Topics: Adolescent; Child; Child, Preschool; Disease Progression; Humans; Immunosuppressive Agents; Myositis | 2016 |
Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Disease Progression; Drug Therapy, Combinati | 2017 |
Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Topics: Adult; Arthritis; Cataract; Cohort Studies; Diabetes Mellitus; Disease Progression; Female; Glucocor | 2017 |
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progress | 2017 |
Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2017 |
Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries.
Topics: Child; Disease Progression; Drug Therapy, Combination; Europe; Glucocorticoids; Humans; Immunosuppre | 2017 |
Hypereosinophilic syndrome and mepolizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Disease Progression; Drug Therapy, Combin | 2008 |
[Pyoderma gangrenosum--an interdisciplinary diagnostic problem].
Topics: Cyclosporine; Disease Progression; Female; Humans; Middle Aged; Prednisone; Pyoderma Gangrenosum; Re | 2008 |
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
A clinicopathological study of lupus nephritis in children.
Topics: Adolescent; Biopsy; Child; Cyclophosphamide; Disease Progression; Female; Humans; Iran; Kidney; Kidn | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Huma | 2008 |
Obstructive jaundice in a patient with mycosis fungoides metastatic to the pancreas. EUS findings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograde; Cyc | 2008 |
Stromal gene signatures in large-B-cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Microenvironmental protection in diffuse large-B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Acute retinal necrosis caused by herpes simplex virus type 2 in a 3-year-old Japanese boy.
Topics: Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Child, Preschool; Disease Progression; Drug T | 2009 |
Therapeutic vignette: old and new drugs in mixed connective tissue disease.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Comorbidity; Disease Progression; Drug Therapy, Combin | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Di | 2008 |
Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up.
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Cataract; Cataract Extraction; Corneal Ulcer | 2009 |
[Elephantiasic pretibial myxoedema: study of five cases].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antithyroid Agents; Biopsy; Di | 2007 |
A paradoxical reaction during antituberculosis therapy for congenital tuberculosis.
Topics: Antitubercular Agents; Disease Progression; Female; Glucocorticoids; Humans; Infant, Newborn; Mycoba | 2009 |
Antibody titers predict clinical features of autoimmune autonomic ganglionopathy.
Topics: Adult; Autoantibodies; Autoantigens; Autoimmune Diseases of the Nervous System; Constipation; Diseas | 2009 |
Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Inflammatory Agents; Choroid; Disease Progression; | 2010 |
Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
Adult nemaline myopathy with trabecular muscle fibers.
Topics: Biopsy; Disease Progression; Humans; Immunosuppressive Agents; Inclusion Bodies; Male; Middle Aged; | 2009 |
Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy.
Topics: Adolescent; Age Factors; Age of Onset; Akathisia, Drug-Induced; Anti-Inflammatory Agents; Child; Chi | 2009 |
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Subacute inflammatory polyradiculopathy associated with Sjögren's syndrome.
Topics: Aged; Disease Progression; Electrodiagnosis; Female; Humans; Immunosuppressive Agents; Magnetic Reso | 2009 |
Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child; Child, Pr | 2009 |
Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
Topics: Adult; Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2009 |
Clinical spectrum of vulva metastatic Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Colon; Colonoscopy; Crohn Disease; Disease Progression; | 2009 |
ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
Topics: Antibodies; Desmoglein 1; Desmoglein 2; Disease Progression; Drug Therapy, Combination; Enzyme-Linke | 2009 |
Paraneoplastic pemphigus associated with systemic mastocytosis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Disease Progres | 2009 |
Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents; Asthma; Child; Child, Preschool; Dexamet | 2009 |
[Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
Topics: Adolescent; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Increased plasma myeloperoxidase levels in systemic lupus erythematosus.
Topics: Adult; Age of Onset; Antimalarials; Arthritis; Azathioprine; Biomarkers; Cross-Sectional Studies; Cy | 2010 |
Development of classic dermatomyositis rash years after diagnosis of juvenile polymyositis.
Topics: Anti-Inflammatory Agents; Child; Dermatomyositis; Disease Progression; Drug Therapy, Combination; Ex | 2009 |
Improved survival for patients with large B-cell lymphoma after introduction of rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
Epstein-Barr virus negative large B-cell lymphoma during long term immunomodulatory therapy for T-cell large granular lymphocytic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Disease Progression; | 2010 |
[Therapeutic management of central nervous system lymphomas in a single hematological institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2010 |
Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Azathioprine; Chi-Square Distribution; Cyclospor | 2010 |
Cutaneous natural killer (NK) / T-cell lymphoma: nasal type with extensive facial destruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; | 2009 |
Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Topics: Adolescent; Azathioprine; Child; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy | 2009 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; De | 2009 |
Myasthenia gravis and return to flying status.
Topics: Adult; Aerospace Medicine; Cholinesterase Inhibitors; Disease Progression; Glucocorticoids; Health S | 2010 |
Higher levels of CCL20 expression on peripheral blood mononuclear cells of chinese patients with inflammatory bowel disease.
Topics: Adult; Aged; Biomarkers; Biomarkers, Pharmacological; C-Reactive Protein; Chemokine CCL20; China; Di | 2010 |
28-year-old woman with rapidly progressive shortness of breath. Diagnosis: CSS.
Topics: Adult; Anti-Inflammatory Agents; Asthma; Biopsy; Churg-Strauss Syndrome; Diagnosis, Differential; Di | 2010 |
Ring and nodular multiple sclerosis lesions: a retrospective natural history study.
Topics: Adult; Anti-Inflammatory Agents; Contrast Media; Disability Evaluation; Disease Progression; Encepha | 2010 |
Evolution of clinically amyopathic dermatomyositis despite aggressive immunosuppression with cyclophosphamide and prednisone.
Topics: Cyclophosphamide; Dermatomyositis; Disease Progression; Humans; Immunosuppressive Agents; Lung Disea | 2010 |
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Syringomyelia in the Cavalier King Charles spaniel (CKCS) dog.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arnold-Chiari Malformation; Breeding; Cyclohe | 2010 |
Bolus methylprednisolone efficacy for uncontrolled exacerbation of cystic fibrosis in children.
Topics: Anti-Inflammatory Agents; Bronchiectasis; Child; Combined Modality Therapy; Cystic Fibrosis; Disease | 2010 |
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?
Topics: Adrenal Cortex Hormones; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Drug Therapy | 2010 |
Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin | 2010 |
[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2010 |
Therapeutic options for systemic sclerosis related interstitial lung diseases.
Topics: Cyclophosphamide; Disease Progression; Humans; Immunosuppressive Agents; Injections, Intravenous; Lu | 2010 |
[Sweet syndrome in underlying malignancy].
Topics: Aged; Carcinoma, Renal Cell; Disease Progression; Follow-Up Studies; Humans; Kidney Neoplasms; Male; | 2010 |
Cardiac tamponade as a rare form of presentation of rheumatic carditis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antihypertensive Agents; Captopril; Cardiac Tampona | 2010 |
Vasculitis of the gastrointestinal tract in chronic periaortitis.
Topics: Administration, Oral; Adult; Aged; Angiography; Biopsy; Disease Progression; Female; Gastrointestina | 2011 |
Chlorambucil in indolent mantle cell lymphoma--just another old drug for a new disease?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Disease Progressio | 2011 |
Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study.
Topics: Adjuvants, Immunologic; Adult; Anti-Inflammatory Agents; Apolipoprotein E4; Atrophy; Azathioprine; B | 2010 |
[Maxillary T/NK lymphoma. Case report].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Ant | 2011 |
[Radiological deterioration in a patient with cavitary lung lesion].
Topics: Adult; Azathioprine; Blood Vessel Prosthesis Implantation; Breast Implantation; Disease Progression; | 2011 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients.
Topics: Adult; Anti-Inflammatory Agents; Body Mass Index; Confidence Intervals; Diet; Dietary Fiber; Disease | 2011 |
Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2011 |
Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2011 |
Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2012 |
Early versus later onset childhood-onset systemic lupus erythematosus: Clinical features, treatment and outcome.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents; Child; Cohort Studies; Cyclophosphamide; Disease | 2011 |
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2012 |
Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous Syste | 2011 |
Beta agonist use during asthma exacerbations: how much is too much?
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; And | 2011 |
Preliminary prospective explanatory observation on the impact of 3-month steroid therapy on the objective measures of sleep-disordered breathing.
Topics: Anti-Inflammatory Agents; Body Size; Body Weight; Disease Progression; Dose-Response Relationship, D | 2012 |
Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Consolidation | 2011 |
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant | 2012 |
Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosph | 2012 |
Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Combined Modality Therapy; Cy | 2011 |
Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Der | 2012 |
Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive | 2012 |
Clinical features and outcomes of 98 children and adults with dense deposit disease.
Topics: Adolescent; Adult; Age of Onset; Anti-Inflammatory Agents; Child; Child, Preschool; Chronic Disease; | 2012 |
[Renal failure in sarcoidosis].
Topics: Adult; Anti-Inflammatory Agents; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hum | 2011 |
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; C | 2011 |
Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Sudden death associated with spontaneous cerebrospinal fluid leak: a case report.
Topics: Adult; Anti-Bacterial Agents; Cerebrospinal Fluid Rhinorrhea; Death, Sudden; Disease Progression; Hu | 2011 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2012 |
[Lyme disease with hepatitis and corticosteroids: a case report].
Topics: Adrenal Cortex Hormones; Aged; Disease Progression; Hepatitis; Humans; Lyme Disease; Male; Methotrex | 2012 |
Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Biomarkers, Tumor; Cytarabine; Cytokines; Disease Progr | 2012 |
Homonymous hemianopsia in a patient with Hodgkin's lymphoma in remission after BEACOPP chemotherapy.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; | 2012 |
[Proliferative mesangial lupus nephritis: description of a cohort of 27 patients].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Disease Progression; Drug Administration Schedule; Drug | 2012 |
Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Combined Modality Therapy; | 2012 |
A rapidly growing lung mass with air crescent formation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2013 |
Membranous nephropathy with renal salt wasting: role of neurohumoral factors in sodium retention.
Topics: Blood Chemical Analysis; Creatinine; Cyclosporine; Disease Progression; Drug Therapy, Combination; E | 2012 |
Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
Topics: Arthritis, Rheumatoid; Bone Density Conservation Agents; Calcium; Cohort Studies; Databases, Factual | 2012 |
R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2012 |
Rapidly progressive dementia due to leukocytoclastic vasculitis of the central nervous system.
Topics: Aged; Biopsy; Cerebral Angiography; Dementia; Diagnosis, Differential; Disease Progression; Glucocor | 2011 |
Cochleovestibular nerve involvement in multifocal fibrosclerosis.
Topics: Azathioprine; Biopsy; Diagnosis, Differential; Disease Progression; Female; Glucocorticoids; Humans; | 2012 |
Varicella zoster virus vasculopathy: a treatable form of rapidly progressive multi-infarct dementia after 2 years' duration.
Topics: Acyclovir; Aged; Antiviral Agents; Apraxias; Basal Ganglia Cerebrovascular Disease; Cyclophosphamide | 2012 |
EBV reactivation serological profile in primary Sjögren's syndrome: an underlying trigger of active articular involvement?
Topics: Adult; Antibodies, Antinuclear; Antibodies, Viral; Antigens, Viral; Biomarkers; Case-Control Studies | 2013 |
Parental preference for short- versus long-course corticosteroid therapy in children with asthma presenting to the pediatric emergency department.
Topics: Asthma; Attitude; Child; Child, Preschool; Dexamethasone; Disease Management; Disease Progression; E | 2013 |
Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.
Topics: Activities of Daily Living; Adolescent; Age Factors; Anti-Inflammatory Agents; Child; Child, Prescho | 2012 |
P2X7-regulated protection from exacerbations and loss of control is independent of asthma maintenance therapy.
Topics: Adrenal Cortex Hormones; Adult; Albuterol; Asthma; Black or African American; Case-Control Studies; | 2013 |
Herpes zoster motor neuropathy in a patient with previous motor paresis secondary to Vogt-Koyanagi-Harada disease.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Disease Progression; Electromyography; Female; Herpes Zost | 2013 |
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2013 |
Long-term renal outcome and complications in South Africans with proliferative lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Blood Pressure; Creatinine; Cyclophosphamide; Disease | 2013 |
[Cutaneous polyarteritis nodosa--is it really benign?].
Topics: Amputation, Surgical; Arteries; Azathioprine; Biopsy; Disease Progression; Fatal Outcome; Female; Fl | 2012 |
Idiopathic thrombocytopenic purpura and myelodysplastic syndrome: distinct entities or overlapping syndromes?
Topics: Aged; Autoimmune Diseases; Bone Marrow; Clone Cells; Diagnosis, Differential; Disease Progression; D | 2002 |
Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.
Topics: Axons; Azathioprine; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Hu | 2002 |
Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Cohort Studies; Disease Progression; Female; Humans; Lung Dis | 2002 |
Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance.
Topics: 5' Untranslated Regions; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ba | 2002 |
Fatal sepsis in an AIDS patient during therapy for Pneumocystis carinii pneumonia.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptococcosis; Disease Progression; Drug Therapy, Com | 2002 |
A patient with immunological features of paraneoplastic pemphigus in the absence of a detectable malignancy.
Topics: Aged; Autoantibodies; Autoantigens; Azathioprine; Cytoskeletal Proteins; Desmoplakins; Disease Progr | 2002 |
Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient.
Topics: Carcinoma, Squamous Cell; Disease Progression; Humans; Immunosuppression Therapy; Immunosuppressive | 2003 |
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodi | 2003 |
The utility of positron emission tomography in the evaluation of autoimmune hearing loss.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies; Autoimmune Diseases; Cochlea; Disease Progression | 2003 |
[Solitary tumorous muscular sarcoidosis (granulomatous myopathy) of the forearm extensors].
Topics: Adult; Biopsy; Diagnosis, Differential; Disease Progression; Fingers; Follow-Up Studies; Humans; Mag | 2003 |
[Uveal lymphoid infiltration with systemic extension].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Choroid Diseases; Choroid Neoplas | 2003 |
[Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bronchopneumonia; Combined Modality T | 2003 |
[Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis].
Topics: Abdominal Pain; Age Factors; Anti-Inflammatory Agents; Biopsy, Needle; Cholagogues and Choleretics; | 2003 |
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2003 |
Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pres | 2003 |
A case of chronic herpes gestationis: persistent disease or conversion to bullous pemphigoid?
Topics: Adult; Chronic Disease; Diagnosis, Differential; Disease Progression; Female; Fluorescent Antibody T | 2003 |
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
Topics: Adolescent; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Hemorrhage; H | 2003 |
Accrual of organ damage over time in patients with systemic lupus erythematosus.
Topics: Adult; Age of Onset; Chi-Square Distribution; Cohort Studies; Confidence Intervals; Disease Progress | 2003 |
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2003 |
[Bilateral optic neuropathy in a case of primary Gougerot Sjögren's syndrome].
Topics: Anti-Inflammatory Agents; Biopsy; Blood Flow Velocity; Diagnosis, Differential; Disease Progression; | 2003 |
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; | 2004 |
Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
Topics: Disease Progression; Drug Administration Schedule; Humans; Immunosuppressive Agents; Myasthenia Grav | 2004 |
The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Topics: Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2004 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2003 |
Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antiplatyhelmintic Agents; Biopsy; Child; Child, | 2004 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplast | 2004 |
Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chi-Square Distribution; Cyclophosphamide; Disease Progres | 2004 |
[Recurrent polychondritis: apropos of a case].
Topics: Aspirin; Autoimmune Diseases; Azathioprine; Biopsy; Carcinoma, Squamous Cell; Conjunctivitis; Cyclos | 2003 |
Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.
Topics: Disease Progression; Female; Follow-Up Studies; Glucocorticoids; Hepatitis, Autoimmune; Humans; Live | 2004 |
[Rapidly progressive glomerulonephritis in a 68-year-old man].
Topics: Acute Kidney Injury; Aged; Antibodies, Antineutrophil Cytoplasmic; Autoantigens; Autoimmune Diseases | 2004 |
Rapidly progressive diffuse large B-cell lymphoma with initial clinical presentation mimicking seronegative Wegener's granulomatosis.
Topics: Adult; Biopsy; Complementarity Determining Regions; Cyclophosphamide; Diagnosis, Differential; Disea | 2004 |
Neuro-Behcet disease with predominant involvement of the brainstem.
Topics: Adult; Atrophy; Autoimmune Diseases of the Nervous System; Behcet Syndrome; Brain; Brain Stem; Cyclo | 2004 |
Prolonged fever of unknown origin and hemophagocytosis evolving into acute lymphoblastic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Susac syndrome with transient inverted vision.
Topics: Adult; Autoimmune Diseases; Cerebral Infarction; Cyclophosphamide; Disease Progression; Dysarthria; | 2004 |
Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis.
Topics: Acetazolamide; Adult; Amphotericin B; Antifungal Agents; Arachnoiditis; Cerebral Infarction; Dexamet | 2004 |
Aggressive cutaneous T-cell lymphomas after TNFalpha blockade.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Cyclophospha | 2004 |
Multiple myeloma associated with CD4+ large granular lymphocytic leukemia: a possible causal relationship.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; CD4 Antigens; CD4 Lymphocyte Count; C | 2004 |
Long term follow-up of birdshot chorioretinopathy.
Topics: Adrenal Cortex Hormones; Chorioretinitis; Cyclosporine; Disease Progression; Drug Administration Sch | 2004 |
Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disea | 2004 |
[Tuberculoma and tuberculous meningeal-radiculitis with paradoxical progression during treatment].
Topics: Aged; Anti-Inflammatory Agents; Antitubercular Agents; Confusion; Disease Progression; Drug Therapy, | 2005 |
[Influence of age on treatment results in children and adolescents with Hodgkin's disease].
Topics: Adolescent; Age Distribution; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2004 |
Steroid dementia: an overlooked diagnosis?
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Bipolar Disorder; Brain; Dementia; Diagnosis, Dif | 2005 |
Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2005 |
Ruffled hair and fever in an old woman with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Cognition; Disease Progression | 2005 |
Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Dacarbazine; Disea | 2005 |
Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Antiviral Agents; Chemokine CCL5; Chemokine CX | 2005 |
[Kawasaki's cutaneo-mucosal and lymph node syndrome. A case complicated by multiple aneurysms].
Topics: Aneurysm; Angiocardiography; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aortic Aneurysm, Abdom | 1978 |
[Treatment of adult Berkitt-like lymphoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; C | 2005 |
Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab.
Topics: Adalimumab; Administration, Cutaneous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2005 |
An aggressive extranodal NK-cell lymphoma arising from indolent NK-cell lymphoproliferative disorder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorub | 2005 |
Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Topics: Adolescent; Anti-Inflammatory Agents; Body Height; Body Weight; Disease Progression; Dose-Response R | 2005 |
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combine | 2003 |
Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2005 |
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combin | 2005 |
Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients.
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Disease Progression; Drug Evaluation; Female; Hemorrha | 2006 |
Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cyclophosphamide; Disease Prog | 2006 |
Could steroids mask the diagnosis of cerebrotendinous xanthomatosis?
Topics: Achilles Tendon; Adult; Brain; Chenodeoxycholic Acid; Cholestanetriol 26-Monooxygenase; Cholestanol; | 2006 |
Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
Topics: Adult; Aged; Biopsy; Cohort Studies; Cyclosporine; Disease Progression; Dose-Response Relationship, | 2006 |
Idiopathic hypereosinophilic syndrome: a rare but fatal condition presenting with common symptoms.
Topics: Administration, Oral; Aged, 80 and over; Biopsy; Bone Marrow; Diagnosis, Differential; Disease Progr | 2006 |
Fibrillary glomerulonephritis in a patient with type 2 diabetes mellitus.
Topics: Biopsy; Contraindications; Diabetes Mellitus, Type 2; Diagnosis, Differential; Disease Progression; | 2006 |
Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Ant | 2006 |
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
Topics: Actuarial Analysis; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap | 2006 |
Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome.
Topics: Adolescent; Adult; C-Reactive Protein; Child; Cyclophosphamide; Cyclosporine; Disease Progression; E | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
[Treatment of idiopathic pulmonary fibrosis].
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Cyclopho | 2006 |
A paraumbilical lymphomatous mass.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxoru | 2006 |
Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo | 2006 |
Index of suspicion.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Bronchial Diseases; Diagnosis, Differential; | 2006 |
A case of Churg-Strauss syndrome associated with antiphospholipid antibodies.
Topics: Antibodies, Antiphospholipid; Azathioprine; Biopsy, Needle; Churg-Strauss Syndrome; Disease Progress | 2007 |
Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus.
Topics: Adolescent; Adult; Atherosclerosis; Child; Child, Preschool; Cohort Studies; Disease Progression; Do | 2007 |
Evolution and treatment of childhood chronic inflammatory polyneuropathy.
Topics: Acute Disease; Adolescent; Azathioprine; Child; Child, Preschool; Disease Progression; Female; Gluco | 2007 |
Association of steroid and cyclosporin resistance in focal segmental glomerulosclerosis.
Topics: Adolescent; Child; Child, Preschool; Cyclosporine; Disease Progression; Drug Resistance, Multiple; F | 2007 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
Immunosuppressive therapy with anti-thymocyte globulin and cyclosporine A in selected children with hypoplastic refractory cytopenia.
Topics: Antilymphocyte Serum; Blood Transfusion; Child; Combined Modality Therapy; Cyclosporine; Disease Pro | 2007 |
Nudulo-cystic eruption with musculoskeletal pain.
Topics: Acne Vulgaris; Adolescent; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2007 |
[Our experiences in treating patients with Hodgkin disease in the last decade].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Ad | 2007 |
Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis.
Topics: Antibodies, Antinuclear; Biopsy; Disease Progression; Female; Follow-Up Studies; Glucocorticoids; He | 2007 |
Rapid leukaemic evolution in a cutaneous blastic NK-cell lymphoma initially diagnosed as pseudolymphoma.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; CD | 2007 |
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dise | 2007 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2007 |
[Adult onset Still's disease: about 11 cases].
Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Arthritis; Disease Progression; Female; Fever; G | 2007 |
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibody Specificity; Autoantibodies; Disease Progre | 2007 |
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease Progression; Doxorubicin; | 2007 |
Development of autoimmune hepatitis in primary biliary cirrhosis.
Topics: Adult; Alanine Transaminase; Anti-Inflammatory Agents; Aspartate Aminotransferases; Azathioprine; Ch | 2007 |
Primary testicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; | 2007 |
Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma--a single-center, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2007 |
Rhinocerebral mucormycosis acquired after a short course of prednisone therapy.
Topics: Aged; Amphotericin B; Antifungal Agents; Brain Diseases; Comorbidity; Diabetes Mellitus; Disease Pro | 2007 |
Failure of CHOP with rituximab for lymphomatoid granulomatosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2007 |
[Susac syndrome and ocular manifestation in a 14-year-old girl].
Topics: Adolescent; Brain; Brain Ischemia; Cognition Disorders; Diagnosis, Differential; Disease Progression | 2007 |
[Antineutrophil cytoplasmic autoantibody-associated rapidly progressive glomerulonephritis in children].
Topics: Adolescent; Antibodies, Antineutrophil Cytoplasmic; Biopsy; Child; Child, Preschool; Disease Progres | 2008 |
Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil.
Topics: Adult; Anti-Inflammatory Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Imm | 2009 |
Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study.
Topics: Adolescent; Age of Onset; Antimalarials; Autoantibodies; Azathioprine; Central Nervous System Diseas | 2008 |
Isolated lymphoma of the anterior visual pathway diagnosed by optic nerve biopsy.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Biomarke | 2008 |
[Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Celiac Disease; Cyclophosphamide; Diarrhea; | 2008 |
Can immunosuppressive drugs slow the progression of IgA nephropathy?
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Disease Progression; Female; Glomerulonephritis, IGA; | 1995 |
Syphilitic labyrinthitis--an update.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Ampicillin; Anti-Inflammatory Agents; Deafness; Disease Pr | 1995 |
A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis.
Topics: Adult; Aged; Cohort Studies; Dermatomyositis; Disability Evaluation; Disabled Persons; Disease Progr | 1995 |
Clinicopathological features and management of immunoproliferative small intestinal disease and primary small intestinal lymphoma in Pakistan.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Prog | 1995 |
Prognostic factors in low tumour mass asymptomatic multiple myeloma: a report on 91 patients. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
Topics: Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Cyclophosphamide; Disease Progression; Female; | 1995 |
Natural history of focal moderate cardiac allograft rejection. Is treatment warranted?
Topics: Azathioprine; Biopsy; Cyclosporine; Disease Progression; Endocardium; Female; Graft Rejection; Heart | 1995 |
[Recurrence of pulmonary sarcoidosis].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Disease Progression; Female; Follow-Up Stu | 1995 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cy | 1995 |
Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, H | 1996 |
Report on intensive treatment of extracapillary glomerulonephritis with focus on crescentic IgA nephropathy.
Topics: Adolescent; Adult; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; | 1995 |
Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosome | 1996 |
Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 1996 |
Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkins lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cyclo | 1996 |
Common variable immunodeficiency presenting in a girl as lung infiltrates and mediastinal adenopathies leading to severe "superior vena caval" syndrome.
Topics: Anti-Inflammatory Agents; Azathioprine; Child; Common Variable Immunodeficiency; Diagnosis, Differen | 1996 |
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carrier State; Chronic Disea | 1996 |
Immunosuppressive treatment of the nephrotic syndrome due to mesangial lesions.
Topics: Adult; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up S | 1996 |
Progressive outer retinal necrosis in an immunocompetent patient.
Topics: Acyclovir; Administration, Oral; Adolescent; Antibodies, Anti-Idiotypic; Antibodies, Viral; Antivira | 1996 |
Focal segmental glomerulosclerosis in adult African Americans.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Cyclophosphamide; Diseas | 1996 |
Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Antimalarials; Biopsy; Chloroquine; Dermato | 1997 |
Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Cross-Sectional Studies; Decompression, Surgical; Disea | 1997 |
Heart transplantation in patients with diabetic end-organ damage before transplantation.
Topics: Actuarial Analysis; Case-Control Studies; Contraindications; Coronary Disease; Diabetic Angiopathies | 1996 |
Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman.
Topics: Adult; Azathioprine; Carcinogens; Carcinoma in Situ; Carcinoma, Squamous Cell; Condylomata Acuminata | 1997 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1997 |
Salvage radiotherapy for Hodgkin's disease following chemotherapy failure.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Di | 1997 |
Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation.
Topics: Adult; Disease Progression; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; Hepa | 1997 |
Acute posterior multifocal placoid pigment epitheliopathy: a long-term study.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Disease Progression; Female; Fluorescein Ang | 1997 |
A case-control and nerve biopsy study of CREST multiple mononeuropathy.
Topics: Aged; Antirheumatic Agents; Biopsy; Case-Control Studies; CREST Syndrome; Disease Progression; Drug | 1997 |
Pemphigus vulgaris in older adults.
Topics: Age Distribution; Age of Onset; Aged; Disease Progression; Female; Glucocorticoids; Humans; Male; Pe | 1998 |
Corticosteroid therapy and relapse in sarcoidosis.
Topics: Adrenal Cortex Hormones; Black People; Disease Progression; Female; Glucocorticoids; Humans; Male; P | 1998 |
Primary systemic amyloidosis with delayed progression to multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Disease Progr | 1998 |
[Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progressio | 1998 |
Intravascular lymphomatosis--an indolent or aggressive entity?
Topics: Aged; Arthritis, Rheumatoid; Asthma; Blood Sedimentation; Bone Marrow; Brain Neoplasms; Disease Prog | 1998 |
Sarcoid granulomatosis after zirconium exposure with multiple organ involvement.
Topics: Disease Progression; Female; Follow-Up Studies; Granuloma; Humans; Lung; Microscopy, Electron, Scann | 1998 |
[Sarcoidosis and pregnancy. A retrospective study of 11 cases].
Topics: Abortion, Induced; Abortion, Spontaneous; Abortion, Therapeutic; Adult; Anti-Inflammatory Agents; Di | 1998 |
Potential role of computerized visual field testing for the appraisal and follow-up of birdshot chorioretinopathy.
Topics: Adult; Chorioretinitis; Cyclosporine; Disease Progression; Drug Therapy, Combination; Fluorescein An | 1998 |
Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment.
Topics: Administration, Oral; Aged; Blindness; Disease Progression; Eye; Female; Giant Cell Arteritis; Human | 1999 |
Pseudomonal pericarditis complicating cystic fibrosis.
Topics: Adult; Anti-Inflammatory Agents; Cystic Fibrosis; Disease Progression; Drainage; Fatal Outcome; Huma | 1999 |
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carm | 1999 |
Pituitary involvement by Wegener's granulomatosis: a report of two cases.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Diabetes Insipidus; Disease Progression; Female; Granul | 1999 |
Unilateral proptosis resulting from giant-cell arteritis.
Topics: Administration, Oral; Aged; Chronic Disease; Disease Progression; Exophthalmos; Follow-Up Studies; G | 1999 |
Clinical stable systemic mastocytosis with interferon alpha-2b therapy.
Topics: Antineoplastic Agents; Disease Progression; Drug Therapy, Combination; Glucocorticoids; Humans; Inte | 1997 |
Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disea | 1999 |
Diffuse large-cell lymphoma of the testis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Pr | 1999 |
Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen.
Topics: Child; Complement C3; Creatinine; Disease Progression; Drug Administration Schedule; Female; Glomeru | 1999 |
Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy.
Topics: Adult; Brain; Brain Diseases; Contrast Media; Demyelinating Diseases; Disease Progression; Female; F | 2000 |
The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Topics: Adolescent; Blepharoptosis; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; | 2000 |
Prolonged ulcerative laryngitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clarithromycin; Disease Progression; Female; | 2000 |
Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and eliminati
Topics: Child; Disease Progression; Glucocorticoids; Humans; Immunization; Kidney; Nephrotic Syndrome; Predn | 2000 |
Severe amyloidosis with mild multiple myeloma--an unusual course.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Colchicine; Disease Progression; Fatal | 2000 |
[Index of histopathological changes in rapidly progressive glomerulonephritis: a preliminary report].
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Azathioprine; Biopsy; Child; Chronic Dise | 2000 |
Brachial plexopathy associated with diffuse edematous scleroderma.
Topics: Anti-Inflammatory Agents; Brachial Plexus Neuropathies; Cyclophosphamide; Disease Progression; Drug | 2000 |
Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2000 |
[Serpiginous choroiditis--the diagnostic problems].
Topics: Anti-Inflammatory Agents; Choroiditis; Dexamethasone; Diagnosis, Differential; Disease Progression; | 2000 |
Pauci-immune renal vasculitis: natural history, prognostic factors, and impact of therapy.
Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Creatinine; C | 2000 |
Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2000 |
Hypergammaglobulinaemic purpura associated with IgG subclass imbalance and recurrent infection.
Topics: Child, Preschool; Disease Progression; Humans; Hydroxychloroquine; Immunoglobulin G; Infections; Mal | 2000 |
Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Capillaries; Cyclophosphamide; Disease Prog | 2001 |
Idiopathic leukonychia totalis and partialis in a 12-year-old patient.
Topics: Asthma; Child; Chronic Disease; Disease Progression; Follow-Up Studies; Humans; Hypopigmentation; Ma | 2001 |
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.
Topics: Azathioprine; Child; Combined Modality Therapy; Disease Progression; Female; Humans; Neurologic Exam | 2001 |
Remitting asymmetrical pitting oedema in systemic lupus erythematosus: two cases studied with magnetic resonance imaging.
Topics: Adult; Ankle; Cyclosporine; Disease Progression; Drug Therapy, Combination; Edema; Female; Functiona | 2000 |
Uncommon arthritis as presenting manifestation of silent Crohn's disease.
Topics: Adult; Arthritis; Crohn Disease; Disease Progression; Female; Humans; Prednisone; Sulfasalazine; Tre | 2000 |
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyta | 2001 |
Celiac disease and diffuse T-cell lymphoma of the colon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Celiac Disease; Colonic Neoplasms; C | 2001 |
Destructive eyelid lesions in sarcoidosis.
Topics: Adult; Cicatrix; Disease Progression; Drug Therapy, Combination; Entropion; Humans; Immunosuppressiv | 2001 |
Lucio's phenomenon: clinical and therapeutic aspects.
Topics: Aged; Anti-Inflammatory Agents; Brazil; Disease Progression; Endothelium, Vascular; Fatal Outcome; F | 2000 |
Bupropion-induced erythema multiforme.
Topics: Administration, Oral; Adult; Aftercare; Anti-Inflammatory Agents; Antidepressive Agents, Second-Gene | 2001 |
Pulmonary sarcoidosis in children: a follow-up study.
Topics: Adolescent; Blood Gas Analysis; Bronchoalveolar Lavage; Cell Count; Child; Child, Preschool; Disease | 2001 |
Immunosuppressive therapy in serpiginous choroiditis--case report and brief review of the literature.
Topics: Adult; Azathioprine; Choroiditis; Cyclosporine; Disease Progression; Drug Therapy, Combination; Fluo | 2001 |
Prolactin levels in Behçet's disease: no correlation with disease manifestations and activity.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Behcet Syndrome; Case-Control Studies; Colchicine; Dise | 2001 |
Oral lichen planus: patient profile, disease progression and treatment responses.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Squamous Ce | 2001 |
[Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose].
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Biopsy; Disease Progression; Drug Administration Schedu | 2001 |
Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biopsy; Disease Progression; Female; Humans; Immunohistochemi | 2001 |
Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Chloroquine; Cohort Studies; Disease Progression; Em | 2001 |
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2001 |
Allergic bronchopulmonary aspergillosis. A complicated case of asthma.
Topics: Aged; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Asthma; Disease Progression; Fema | 2001 |
Recurrent myelitis associated with herpes simplex virus type 2.
Topics: Acyclovir; Aged; Disease Progression; Drug Therapy, Combination; Female; Herpes Genitalis; Herpesvir | 2001 |
The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Azathi | 2002 |
Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality | 2002 |
Progressive dilated cardiomyopathy in a patient with hypereosinophilic syndrome despite prednisone induced hematological remission.
Topics: Adolescent; Cardiomyopathy, Dilated; Disease Progression; Echocardiography; Follow-Up Studies; Human | 2001 |
Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clinical Trials as Topic | 2002 |
Multiple myeloma presenting as proptosis and sixth nerve palsy.
Topics: Abducens Nerve Diseases; Adult; Antineoplastic Combined Chemotherapy Protocols; Cranial Nerve Neopla | 2001 |
Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; D | 2002 |
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Protease inhibitors are associated with a slowed progression of HIV-related renal diseases.
Topics: Adult; AIDS-Associated Nephropathy; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Disease Pr | 2002 |
Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy.
Topics: Anti-Inflammatory Agents; Biopsy, Needle; Child; Disease Progression; Drug Administration Schedule; | 2002 |